aspirin has been researched along with Coronary Artery Disease in 1202 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| "THEMIS is a double-blind, randomized trial of 19,220 patients with diabetes mellitus and stable coronary artery disease (CAD) comparing ticagrelor to placebo, in addition to aspirin." | 9.69 | External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Hea ( Abtan, J; Bhatt, DL; Bueno, H; Ducrocq, G; Eagle, KA; Elbez, Y; Fox, K; Goto, S; Harrington, RA; Leiter, LA; Lev, E; Mehta, SR; Ohman, EM; Pais, P; Petrov, I; Simon, T; Sinnaeve, PR; Smith, SC; Steg, PG; Wilson, P, 2023) |
| "To conduct a health economic evaluation of ticagrelor in patients with type 2 diabetes and coronary artery disease (CAD) from a multinational payer perspective." | 9.51 | Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial. ( Andersson, M; Bhatt, DL; Bueno, H; Darlington, O; De Luca, L; Fox, KM; Harrington, RA; Himmelmann, A; Hoskin, L; James, SK; Leiter, LA; McEwan, P; Mehta, SR; Mellström, C; Ridderstråle, W; Simon, T; Steg, PG; Tank, A, 2022) |
| "In patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in The Cardiovascular Outcomes for People Using Anticoagulation Strategies trial, the effects of rivaroxaban 2." | 9.51 | Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. ( Bhatt, DL; Bosch, J; Connolly, SJ; Eikelboom, JW; Fox, KAA; Hori, M; Liang, Y; Maggioni, A; Yusuf, S; Zhu, J, 2022) |
| "The aim of this study was to investigate the safety and efficacy of dabigatran dual therapy (110 or 150 mg twice daily, plus clopidogrel or ticagrelor) versus warfarin triple therapy in patients with atrial fibrillation and STEMI." | 9.41 | Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial. ( Bhatt, DL; Cannon, CP; Gabor Kiss, R; Hohnloser, SH; Leiva, O; Lip, GYH; Miede, C; Navarro Estrada, J; Nickenig, G; Nordaby, M; Oldgren, J; Ongen, Z; Oude Ophuis, T; Steg, PG; Ten Berg, JM; Zeymer, U, 2021) |
| "In the AFIRE trial, rivaroxaban monotherapy was noninferior to combination therapy with rivaroxaban and an antiplatelet agent for thromboembolic events or death, and superior for major bleeding in patients with atrial fibrillation (AF) and stable coronary artery disease." | 9.41 | Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis. ( Akao, M; Ako, J; Hagiwara, N; Hirayama, A; Kaikita, K; Kimura, K; Matoba, T; Matsui, K; Miyauchi, K; Nakamura, M; Ogawa, H; Yasuda, S, 2021) |
| "5 mg twice daily rivaroxaban and aspirin in patients with polyvascular disease (coronary artery disease, peripheral arterial disease or both), the underlying mechanism of which is not clearly understood." | 9.34 | Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy. ( Bafford, R; Cummings, C; Gonze, M; Gurbel, P; Mackrell, P; Rout, A; Sukhi, A; Tantry, U; Ulloa, K, 2020) |
| "The REDUAL PCI trial (Evaluation of Dual Therapy With Dabigatran vs Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting) demonstrated that, in patients with atrial fibrillation following percutaneous coronary intervention, bleeding risk was lower with dabigatran plus clopidogrel or ticagrelor (dual therapy) than warfarin plus clopidogrel or ticagrelor and aspirin (triple therapy)." | 9.34 | Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial. ( Berry, NC; Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Mauri, L; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2020) |
| "5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events and mortality and increased bleeding." | 9.30 | Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. ( Berkowitz, SD; Bhatt, DL; Bosch, JJ; Cairns, JA; Connolly, SJ; Cook Bruns, N; Dagenais, GR; Diaz, R; Eikelboom, JW; Fox, KAA; Hart, RG; Leong, DP; Maggioni, AP; Muehlhofer, E; O'Donnell, M; Shestakovska, O; Tasto, C; Yusuf, S, 2019) |
| "In RE-DUAL PCI, 2,725 patients with atrial fibrillation (993 with diabetes) who had undergone PCI were assigned to warfarin triple therapy (warfarin, clopidogrel or ticagrelor, and aspirin) or dabigatran dual therapy (dabigatran 110 mg or 150 mg twice daily and clopidogrel or ticagrelor)." | 9.30 | Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes. ( Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Maeng, M; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2019) |
| "The benefits of both dabigatran 110 mg and 150 mg dual therapy compared with warfarin triple therapy in reducing bleeding risks were consistent across subgroups of patients with or without ACS, and patients treated with ticagrelor or clopidogrel." | 9.30 | Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. ( Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2019) |
| " The COMMANDER HF randomized clinical trial evaluated the effects of adding low-dose rivaroxaban to antiplatelet therapy in patients with recent worsening of chronic HF with reduced ejection fraction, coronary artery disease (CAD), and sinus rhythm." | 9.30 | Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. ( Anker, SD; Byra, WM; Cleland, JGF; Deng, H; Fu, M; Greenberg, B; La Police, DA; Lam, CSP; Mehra, MR; Neaton, JD; Nessel, CC; Spiro, TE; van Veldhuisen, DJ; Vanden Boom, CM; Zannad, F, 2019) |
| "In patients with chronic coronary artery disease or peripheral artery disease and a history of mild or moderate HF, combination rivaroxaban and aspirin compared with aspirin alone produces similar relative but larger absolute benefits than in those without HF." | 9.30 | Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. ( Avezum, A; Bhatt, DL; Bosch, J; Branch, KR; Cheng, RK; Connolly, SJ; Eikelboom, JW; Fox, KAA; Maggioni, AP; Probstfield, JL; Shestakovska, O; Yusuf, S, 2019) |
| "In this 8 years' follow-up study, we evaluated the long-term outcomes of the addition of clopidogrel to aspirin during the first year after coronary artery bypass grafting, versus aspirin plus placebo, with respect to survival, major adverse cardiac, or major cerebrovascular events, including revascularization, functional status, graft patency, and native coronary artery disease progression." | 9.27 | Eight-year follow-up of the Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) trial. ( Chow, B; Erthal, F; Farkouh, M; Fortier, J; Glineur, D; Hage, A; Ko, G; Kulik, A; Larose, É; LeMay, M; Mesana, TG; Ruel, M; Tremblay, H; Une, D; Voisine, P, 2018) |
| "In patients with stable coronary artery disease, addition of rivaroxaban to aspirin lowered major vascular events, but increased major bleeding." | 9.27 | Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. ( Anand, SS; Avezum, AA; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Connolly, SJ; Cook Bruns, N; Dagenais, G; Dans, AL; Dyal, L; Eikelboom, JW; Felix, C; Fox, KAA; Guzik, TJ; Ha, JW; Hori, M; Keltai, K; Lanas, F; Lisheng, L; Lonn, E; Maggioni, AP; Metsarinne, K; O'Donnell, M; Parkhomenko, AN; Torp-Pedersen, C; Varigos, JD; Widimsky, P; Yusoff, K; Yusuf, S, 2018) |
| "The Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis (TARGET) study is a multi-center double-blind randomized controlled trial enrolling patients who have undergone multi-vessel CABG with at least one saphenous vein graft." | 9.27 | Impact of ticagrelor versus aspirin on graft patency after CABG: Rationale and design of the TARGET (ticagrelor antiplatelet therapy to reduce graft events and thrombosis) randomized controlled trial (NCT02053909). ( Abreu, AM; Boronat, V; Kouchoukos, NT; Kulik, A; Ruel, M, 2018) |
| "The aim of the study was to assess ticagrelor's effects on inhibition of platelet aggregation (IPA), P2Y12 reaction units (PRU, measure of platelet P2Y12 receptor blockade), pharmacokinetic (PK) parameters and safety in Chinese patients with stable coronary artery disease (CAD)." | 9.22 | Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. ( Carlson, GF; Guo, J; Li, H; Teng, R, 2016) |
| "In the PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54), ticagrelor reduced the risk of major adverse cardiovascular events when added to low-dose aspirin in stable patients with prior myocardial infarction, resulting in the approval of ticagrelor 60 mg twice daily for long-term secondary prevention." | 9.22 | Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm ( Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Dalby, AJ; Goodrich, E; Goto, S; Held, P; Hu, D; Jensen, E; Mauri, L; Morrow, DA; Ophuis, TO; Ruda, M; Sabatine, MS; Seung, KB; Špinar, J; Steg, PG; Storey, RF, 2016) |
| " The aim of this prospective, randomised, study was to compare the PD effects of standard-dose prasugrel [60 mg loading dose (LD)/10 mg daily maintenance dose (MD)] with high-dose clopidogrel (900 mg LD/150 mg daily MD) in non-diabetic obese [body mass index (BMI) ≥30 kg/m²] patients, with coronary artery disease (CAD) on aspirin therapy." | 9.19 | Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. ( Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Patel, R; Rollini, F; Tello-Montoliu, A; Ueno, M, 2014) |
| " We verified if the pharmacodynamic effects of CYP3A4-metabolized statins (atorvastatin) and non-CYP3A4-metabolized statins (pitavastatin) differ in patients with coronary artery disease (CAD) treated with DAPT." | 9.19 | Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy. ( Franzoni, F; Gaudio, C; Greco, C; Marazzi, G; Pelliccia, F; Polacco, M; Rosano, G; Speziale, G; Spoletini, I; Vitale, C, 2014) |
| " In this study we verified the idea that plasma homocysteine (Hcy) contributes to 'aspirin-resistance' in patients with coronary artery disease (CAD) and with or without type 2 diabetes mellitus (T2DM)." | 9.17 | Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study. ( Drzewoski, J; Kamysz, W; Karafova, A; Karolczak, K; Watala, C, 2013) |
| "This is a post-hoc analysis derived from patients (n = 79) enrolled in a prospective, randomized, double-blind, double-dummy, crossover study comparing cilostazol with placebo in stable coronary artery disease patients on aspirin and clopidogrel therapy." | 9.17 | Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. ( Angiolillo, DJ; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Rollini, F; Tello-Montoliu, A; Ueno, M, 2013) |
| " The present study was conducted in healthy individuals (n = 50) and in outpatients with coronary artery disease (CAD) at a distance from the acute ischemic episode (aspirin group, n = 71; aspirin/clopidogrel group, n = 106)." | 9.16 | Description of response to aspirin and clopidogrel in outpatients with coronary artery disease using multiple electrode impedance aggregometry. ( Baccouche, H; Bandi, A; Chaari, M; Elalamy, I; Galea, V; Gerotziafas, GT; Mossialos, L; Sassi, M; Tsinopoulos, G; Zarifis, J, 2012) |
| " Patients with severe Kawasaki disease were randomly assigned by a minimisation method to receive either intravenous immunoglobulin (2 g/kg for 24 h and aspirin 30 mg/kg per day) or intravenous immunoglobulin plus prednisolone (the same intravenous immunoglobulin regimen as the intravenous immunoglobulin group plus prednisolone 2 mg/kg per day given over 15 days after concentrations of C-reactive protein normalised)." | 9.16 | Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. ( Arakawa, H; Fukazawa, R; Furuno, K; Fuse, S; Hamaoka, K; Hara, S; Hara, T; Ichida, F; Kato, T; Kobayashi, T; Miura, M; Morikawa, A; Nakamura, T; Nomura, Y; Ogawa, C; Ogawa, S; Otani, T; Saji, T; Seki, M; Takatsuki, S; Takeuchi, K; Tokunaga, H, 2012) |
| "Aspirin resistance and chronic renal failure are both potentially important clinical issues in coronary artery disease." | 9.16 | Renal function and aspirin resistance in patients with coronary artery disease. ( Blann, AD; Kuzniatsova, N; Lip, GY; Velu, S, 2012) |
| "In a population of diabetic patients with coronary artery disease and a high risk of time-dependent aspirin resistance, aspirin divided twice per day can significantly decrease the rate of biological loss of efficacy at trough level." | 9.16 | Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. ( Bal dit Sollier, C; Dillinger, JG; Drissa, A; Drouet, L; Henry, P; Logeart, D; Manzo Silberman, S; Sideris, G; Voicu, S, 2012) |
| "Platelet responsiveness to aspirin was evaluated in 11 stable coronary artery disease patients on chronic aspirin therapy before and 1, 3, 8, and 24h after observed ingestion of 80-mg enteric-coated aspirin." | 9.15 | Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. ( Diodati, JG; Lordkipanidzé, M; Palisaitis, DA; Pharand, C; Schampaert, E, 2011) |
| "Aspirin dosing regimens are associated with different pharmacodynamic effects in platelets from T2DM patients and stable coronary artery disease, with a twice-daily, low-dose aspirin administration resulting in greater platelet inhibition than once-daily administration as assessed by aspirin-sensitive assays and a dose-dependent effect on serum TXB(2) levels." | 9.15 | Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Patel, A; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011) |
| "Aspirin is widely used in the secondary prevention of coronary artery diseases, including myocardial infarction, stroke, and vascular related deaths." | 9.15 | Effect of polymorphism and type II diabetes on aspirin resistance in patients with unstable coronary artery disease. ( Gao, F; Men, JL; Ren, J; Wang, ZX; Wei, MX, 2011) |
| "Adjunctive treatment with pentoxifylline is not associated with increased platelet inhibitory effects in DM patients with coronary artery disease receiving DAPT." | 9.15 | Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011) |
| " One hundred and seventy-two coronary artery disease patients who had taken aspirin only or combinations with aspirin and clopidogrel for over 7 days were included." | 9.14 | Comparison of laboratory detection methods of aspirin resistance in coronary artery disease patients. ( Cha, KS; Goh, RY; Han, JY; Kim, KE; Kim, MH; Quan, ML; Woo, KS, 2010) |
| "Adding clopidogrel to aspirin beyond 4 weeks post PCI is not associated with a significant increase in the overall rate of major or minor bleeding, although it is associated with an increase in major gastrointestinal bleeding in the year after a PCI." | 9.14 | Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. ( Aronow, HD; Berger, PB; Brennan, DM; Steinhubl, SR; Topol, EJ, 2009) |
| "In a laboratory substudy of the PRAGUE-8 trial, the influences of nonmodifiable (age and sex) and modifiable (body mass index and tobacco smoke) factors, comorbidity (hypertension, hyperlipidemia, diabetes mellitus, and renal insufficiency) and cotherapy (statin, aspirin, and heparin), on the course of clopidogrel efficacy were investigated in 105 patients pretreated with clopidogrel >or=6 hours before coronary angiography +/- percutaneous coronary intervention." | 9.14 | Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox". ( Bilkova, D; Kala, P; Marinov, I; Motovska, Z; Petr, R; Simek, S; Widimsky, P, 2009) |
| "We studied patients with stable coronary artery disease on chronic aspirin therapy randomised to addition of clopidogrel 75 mg/d (n = 30) or continuation of aspirin 100 mg/d (n = 30) for 4 weeks." | 9.14 | Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin. ( Branicka, A; Stepień, E; Tracz, W; Undas, A; Wołkow, P; Zmudka, K, 2009) |
| "In a multicenter, randomized, double-blind study, 123 patients with stable coronary artery disease who were taking aspirin therapy (75 to 100 mg/d) received ticagrelor (180-mg load, 90-mg BID maintenance dose [n=57]), clopidogrel (600-mg load, 75-mg/d maintenance dose [n=54]), or placebo (n=12) for 6 weeks." | 9.14 | Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. ( Antonino, MJ; Bliden, KP; Butler, K; Gesheff, T; Gurbel, PA; Karunakaran, A; Kereiakes, DJ; Ledley, GS; Parris, C; Patil, SB; Purdy, D; Storey, RF; Tantry, US; Teng, R; Wei, C; Wilson, V, 2009) |
| "The aim of this pilot study was to compare the effect of two different regimens of aspirin dosage on platelet of coronary artery disease (CAD) diabetic patients." | 9.14 | Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. ( Abderazek, F; Addad, F; Chakroun, T; Chouchene, S; Dridi, Z; Elalamy, I; Gamra, H; Gerotziafas, GT; Hassine, M; Hatmi, M, 2010) |
| " The Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) study was undertaken to evaluate whether the addition of clopidogrel to aspirin inhibits SVG disease after coronary artery bypass grafting, as assessed at 1 year by intravascular ultrasound." | 9.14 | Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. ( Delarochelliere, R; Kulik, A; Le May, MR; Mesana, TG; Naidoo, S; Ruel, M; Tardif, JC; Voisine, P; Wells, GA, 2010) |
| "The aim of this study was to evaluate the relationship between reticulated platelets (RPs), platelet size, and platelet function in patients with stable coronary artery disease (CAD) taking aspirin and clopidogrel." | 9.13 | Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. ( Alviar, CL; Arikan, M; DeLao, T; Dong, JF; Granada, JF; Guthikonda, S; Kleiman, NS; Lev, EI; Tellez, A; Vaduganathan, M, 2008) |
| " One hundred consecutive patients with coronary artery disease (CAD) on combined acetylsalicylic acid and clopidogrel treatment (75 mg/d) and 33 patients on aspirin only were screened for platelet ADP-induced signalling by conventional aggregometry, platelet P-selectin expression and the platelet reactivity index (PRI)." | 9.13 | ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. ( Bauersachs, J; Eigenthaler, M; Ertl, G; Flierl, U; Schäfer, A; Störk, S; Walter, U; Weinberger, S, 2008) |
| " One hundred ten aspirin-treated patients with stable coronary artery disease were randomized to a loading dose (LD, day 1)/ maintenance dose (MD, days 2-29) of prasugrel 60 mg/10 mg or clopidogrel 600 mg/75 mg." | 9.13 | Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. ( Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Johnell, M; Siegbahn, A; Varenhorst, C; Wallentin, L; Winters, KJ, 2008) |
| " Aspirin-treated subjects with coronary artery disease were randomized to double-blind treatment with clopidogrel 600 mg loading dose (LD) followed by daily 75 mg maintenance dose (MD) or prasugrel 60 mg LD and daily 10 mg MD for 28 days." | 9.13 | Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. ( Ernest, CS; Rohatagi, S; Salazar, DE; Small, DS; Wallentin, L; Winters, KJ; Wrishko, RE, 2008) |
| "The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade." | 9.13 | The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. ( Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G, 2008) |
| "In aspirin-treated subjects with coronary artery disease, prasugrel 60/10 mg provides faster onset and greater inhibition of P2Y(12) receptor-mediated platelet aggregation than clopidogrel 600/75 mg, because of greater and more efficient generation of the active metabolite." | 9.13 | Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. ( Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Siegbahn, A; Sugidachi, A; Varenhorst, C; Wallentin, L; Winters, KJ, 2008) |
| "To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the authors studied consecutive patients during a 29-month period." | 9.13 | Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. ( Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M, 2008) |
| "We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)." | 9.13 | Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008) |
| "Aspirin inhibits platelet activation and reduces major vascular events in patients with stable coronary artery disease." | 9.13 | Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study. ( Allal, J; Christiaens, L; Macchi, L; Mergy, J; Ragot, S, 2008) |
| "To compare the efficacy of low-dose or no aspirin with conventional high-dose aspirin for the initial treatment in the acute-phase of Kawasaki disease (KD)." | 9.12 | Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review. ( Chiang, MH; Liu, HE; Wang, JL, 2021) |
| "This study was designed to compare the degree of inhibition of platelet aggregation (IPA) of prasugrel with that of clopidogrel in stable aspirin-treated patients with coronary artery disease (CAD)." | 9.12 | Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. ( Brandt, JT; Darstein, C; Jakubowski, JA; Jernberg, T; Naganuma, H; Payne, CD; Siegbahn, A; Wallentin, L; Winters, KJ, 2006) |
| " Whether this polymorphism affects response to aspirin in patients with coronary artery disease is not known." | 9.12 | Antithrombotic effects of aspirin based on PLA1/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease. ( Dropinski, J; Musial, J; Nizankowski, R; Sanak, M; Szczeklik, A; Wegrzyn, W, 2007) |
| "Clopidogrel improves endothelial nitric oxide bioavailability and diminishes biomarkers of oxidant stress and inflammation in patients with symptomatic coronary artery disease, suggesting that beyond inhibition of platelet aggregation, adenosine phosphate receptor blockade may also have promising vasoprotective effects." | 9.12 | Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. ( Baldus, S; Böger, R; Heitzer, T; Karstens, M; Meinertz, T; Ortak, M; Rudolph, V; Schwedhelm, E; Sydow, K; Tschentscher, P, 2006) |
| "Aspirin resistance may increase the risk of major adverse cardiac events (MACE) more than threefold in patients with stable coronary artery disease (CAD)." | 9.12 | Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). ( Mercanoglu, F; Meric, M; Nisanci, Y; Oflaz, H; Oncul, A; Onur, I; Ozcan, M; Pamukcu, B; Umman, B, 2007) |
| "We searched for additional anti-platelet effects of clopidogrel in coronary artery disease (CAD) patients treated with aspirin." | 9.12 | The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin. ( Biernat, M; Dropinski, J; Dziedzina, S; Jakiela, B; Plutecka, H; Sanak, M; Szczeklik, A; Wegrzyn, W, 2007) |
| " We investigated if adding clopidogrel to aspirin treatment could attenutate stress-induced platelet activation and myocardial ischemia in patients with coronary artery disease (CAD)." | 9.12 | Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease. ( Hjemdahl, P; Hofman-Bang, C; Ivert, T; Li, N; Perneby, C; Tornvall, P; Wallén, NH, 2007) |
| "The purpose of the present study was to study the concept of aspirin resistance or non-responsiveness by investigating the response to long-term aspirin therapy in patients with a former acute myocardial infarction (AMI)." | 9.10 | Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. ( Andersen, K; Arnesen, H; Hurlen, M; Seljeflot, I, 2002) |
| "We sought to assess how one tablet of non-enteric coated aspirin (325 mg) affects human platelets in subjects with risk factors for coronary artery disease." | 9.10 | Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. ( Atar, D; Callahan, KP; Malinin, AI; McKenzie, ME; Serebruany, VL, 2003) |
| "The aim of this study was to determine whether selective cyclooxygenase-2 (COX-2) inhibition with rofecoxib can modulate endothelial dysfunction and levels of circulating inflammatory markers in patients with established coronary artery disease (CAD)." | 9.10 | Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. ( Giddens, K; McInerney, MM; McQueen, MJ; Nassar, BA; Title, LM, 2003) |
| "Heightened platelet reactivity may affect the occurrence of ischemic events in patients with coronary artery disease on aspirin therapy." | 9.10 | The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy. ( Bliden, KP; Gurbel, PA, 2003) |
| "The results of the THEMIS trial, conducted in DM patients with stable coronary artery disease and no prior stroke or myocardial infarction, showed that although ticagrelor in addition to aspirin reduced the risk of ischemic events, this was associated with a parallel increase in bleeding complications." | 9.05 | An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus. ( Angiolillo, DJ; Calderone, D; Capodanno, D, 2020) |
| "The aim of this study was to investigate the association among the PlA1/A2 gene polymorphism, laboratory aspirin resistance and adverse clinical outcomes in coronary artery disease (CAD) patients who were on aspirin maintainance therapy." | 9.01 | Association among PlA1/A2 gene polymorphism, laboratory aspirin resistance and clinical outcomes in patients with coronary artery disease: An updated meta-analysis. ( Bai, J; Chen, J; Gong, X; Kong, D; Li, C; Liu, J; Meng, H; Wang, F; Wang, J; Xu, K; Zhou, Y, 2019) |
| "Although aspirin (ASA) is the mainstay of treatment for the prevention of recurrent ischemic stroke, the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial showed ASA monotherapy to be inferior to clopidogrel in preventing recurrent adverse cardiovascular outcomes in patients with high cardiac risks." | 9.01 | Aspirin Versus Clopidogrel Monotherapy for the Treatment of Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis. ( Ding, J; Xu, GM; Yuan, J, 2019) |
| " Whether aspirin ameliorates this risk in patients with established coronary artery disease undergoing cardiac or noncardiac surgery is unknown." | 8.95 | Clinical outcomes associated with per-operative discontinuation of aspirin in patients with coronary artery disease: A systematic review and meta-analysis. ( Cooper, CJ; Husnain, M; Kanjwal, Y; Khan, AR; Khan, MS; Khuder, SA; Luni, FK; Riaz, H; Riaz, IB; Riaz, T; Taleb, M, 2017) |
| "Aspirin is indicated for primary and secondary prevention of cardiovascular diseases (CVD) by major guidelines." | 8.95 | Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. ( Bliden, K; Chaudhary, R; Gurbel, PA; Sharma, T; Tantry, U, 2017) |
| "Aspirin is still the mainstay of antiplatelet therapy in the secondary prevention of coronary artery disease." | 8.89 | Aspirin and aspirin resistance in coronary artery disease. ( Apostolakis, S; Kasmeridis, C; Lip, GY, 2013) |
| "For many years clopidogrel was the 'gold standard' ADP receptor antagonist in patients with coronary artery disease in combination with acetylsalicylic acid, i." | 8.88 | Clopidogrel in coronary artery disease: update 2012. ( Huber, K, 2012) |
| "The role of aspirin in patients with coronary artery disease (CAD) is well established, yet patients happen to discontinue aspirin according to physician's advice or unsupervised." | 8.83 | A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. ( Abbate, A; Agostoni, P; Biondi-Zoccai, GG; Burzotta, F; Fusaro, M; Lotrionte, M; Sangiorgi, G; Sheiban, I; Testa, L, 2006) |
| "To provide a diagnostic strategy for evaluating and treating patients with aspirin sensitivity, with additional consideration for issues specific to patients with coronary artery disease (CAD)." | 8.82 | Aspirin sensitivity: implications for patients with coronary artery disease. ( Gollapudi, RR; Simon, RA; Stevenson, DD; Teirstein, PS, 2004) |
| "Dual pathway inhibition (DPI) with low-dose rivaroxaban and aspirin in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD) reduces the occurrence of cardiovascular (CV) events; however, the underlying mechanisms explaining these latter CV benefits are not clearly understood." | 8.31 | Dual Pathway Inhibition with Rivaroxaban and Aspirin Reduces Inflammatory Biomarkers in Atherosclerosis. ( Attena, E; Cotticelli, C; D'Alterio, G; D'Onofrio, A; Fabiani, D; Golino, P; Leonardi, S; Maione, B; Nigro, G; Rago, A; Russo, V; Sarpa, S, 2023) |
| " A total of 477 patients receiving double antiaggregation therapy with aspirin and clopidogrel, after suffering a first event, were followed for 1 year to record relapse, as a surrogate end point to measure their therapeutic response, as defined by presenting with an acute coronary event (unstable angina, ST-segment-elevation myocardial infarction, or non-ST-segment-elevation myocardial infarction), stent thrombosis/restenosis, or cardiac mortality." | 8.12 | Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome. ( Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A, 2022) |
| " The COMPASS trial has shown that in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD), low-dose rivaroxaban (2." | 8.12 | [ANMCO Position paper: Evidence and practical indications for the use of low-dose rivaroxaban in stable coronary artery disease and peripheral artery disease]. ( Altamura, V; Bianco, M; Caldarola, P; Ceravolo, R; Cipriani, M; Colivicchi, F; De Luca, L; Di Fusco, SA; Francese, GM; Gabrielli, D; Gulizia, MM; Lucà, F; Nardi, F; Navazio, A; Oliva, F; Riccio, C; Rizzello, V; Scicchitano, P; Valente, S, 2022) |
| "Patients with diabetes and no obstructive coronary artery disease (CAD) as assessed by coronary angiography (CAG) are frequently treated with aspirin and statins." | 8.12 | Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Registry. ( Bøtker, HE; Heide-Jørgensen, U; Maeng, M; Olesen, KKW; Sørensen, HT; Thim, T; Thomsen, RW, 2022) |
| "Ticagrelor plus aspirin could reduce the risks of major adverse cardiac events in diabetic patients with stable coronary artery disease (SCD), and yet it also increases bleeding risk." | 8.02 | Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease. ( Shi, L; Wu, B, 2021) |
| "This study aimed to investigate the cost-effectiveness of low-dose rivaroxaban plus aspirin versus aspirin alone for patients with stable cardiovascular diseases in the Taiwan setting." | 8.02 | Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases. ( Chang, WT; Chen, ZC; Chou, CC; Lee, MC; Liao, CT; Strong, C; Toh, HS; Wu, WS; Yu, T, 2021) |
| "Dual antiplatelet therapy with aspirin and clopidogrel is commonly used for coronary artery disease (CAD) patients undergoing percutaneous coronary intervention to prevent stent thrombosis and ischemic events." | 8.02 | Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease. ( Chen, XP; Du, YX; Li, MP; Ma, QL; Peng, LM; Song, PY; Zhu, KX, 2021) |
| "To determine whether pre-hospitalization use of aspirin is associated with all-cause mortality in coronavirus disease 2019 (COVID-19) patients with coronary artery disease (CAD)." | 8.02 | Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease. ( Chen, C; Chen, P; Li, H; Wang, DW; Wang, F; Yuan, S, 2021) |
| "Clopidogrel is widely used for antiplatelet therapy in patients with coronary artery disease (CAD), but clopidogrel resistance (CR) is relatively common in these patients." | 8.02 | The expression profile of platelet-derived miRNA in coronary artery disease patients with clopidogrel resistance. ( Chen, R; Chen, X; Cheng, J; Hu, H; Hu, Y; Lin, S; Xu, X, 2021) |
| " We conducted a network meta-analysis to compare ticagrelor with other receptor antagonists (P2Y12) inhibitors and aspirin in monotherapy or combination in the treatment of patients with high risk for cardiovascular or cerebrovascular disease, defined as coronary artery disease, acute coronary syndrome, stroke or transient ischemic attack, or peripheral artery disease." | 8.02 | Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events. ( Bálint, A; El Alaoui El Abdallaoui, O; Komócsi, A; Kupó, P; Tornyos, D, 2021) |
| "Aspirin is indispensable in secondary prevention of ischemic events in patients with coronary artery disease (CAD)." | 7.96 | Enhanced Platelet Reactivity under Aspirin Medication and Major Adverse Cardiac and Cerebrovascular Events in Patients with Coronary Artery Disease. ( Ayhan, A; Dannenberg, L; Helten, C; Hohlfeld, T; Kelm, M; Knoop, B; Konsek, D; Levkau, B; Metzen, D; Mourikis, P; Naguib, D; Petzold, T; Pöhl, M; Polzin, A; Trojovsky, K; Veulemans, V; Zako, S; Zeus, T, 2020) |
| "Patients treated with ticagrelor and aspirin usually suffer from bleeding events, especially mild bleeding which is one of the main factors reducing patients' adherence to ticagrelor." | 7.96 | Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischemic risk compared with 75-100 mg aspirin daily in coronary artery disease patients: insights from the TIFU (Ticagrelor in Fuwai Hospital) study. ( Chen, R; Chen, Y; Li, J; Liu, C; Sheng, Z; Song, L; Tan, Y; Yan, H; Zhao, H; Zhou, J; Zhou, P, 2020) |
| " Despite long-term antiplatelet therapy with aspirin, recurrent cardiovascular events remain common in patients with coronary artery disease (CAD)." | 7.96 | Imbalance between Fibrin Clot Formation and Fibrinolysis Predicts Cardiovascular Events in Patients with Stable Coronary Artery Disease. ( Ajjan, RA; Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S, 2020) |
| "To evaluate whether initial treatment with low-dose compared with high-dose aspirin in children with KD is associated with an increase in fever recrudescence." | 7.96 | Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin. ( Belarski, E; Carroll, AE; John, CC; Manaloor, J; Ofner, S; Platt, B; Wood, JB, 2020) |
| "The RE-DUAL PCI trial reported that dabigatran dual therapy (110/150 mg twice daily, plus clopidogrel or ticagrelor) reduced bleeding events versus warfarin triple therapy (warfarin plus aspirin and clopidogrel or ticagrelor) in patients with atrial fibrillation who underwent percutaneous coronary intervention, with noninferiority in composite thromboembolic events." | 7.96 | Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percut ( Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Kimura, T; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2020) |
| " Among current therapies, low-dose aspirin has been shown to reduce cardiovascular thrombosis." | 7.96 | A Pathophysiologic Primary Prevention Review of Aspirin Administration to Prevent Cardiovascular Thrombosis. ( Burchiel, S; Eaton, RP; Schade, DS, 2020) |
| "To identify whether lymphocyte hydrogen sulfide production is a potential biomarker for predicting coronary artery lesions (CAL) in children with Kawasaki disease (KD)." | 7.96 | Lymphocyte Hydrogen Sulfide Production Predicts Coronary Artery Lesions in Children with Kawasaki Disease: A Preliminary, Single-Center Study. ( Jiao, F; Lin, J; Ma, L; Wang, W; Zhao, H, 2020) |
| "To evaluate the effect of prestroke aspirin (PA) use on initial stroke severity, early neurologic deterioration (END), stroke recurrence, hemorrhagic transformation (HT), and functional outcome in patients with ischemic stroke (IS)." | 7.91 | Prestroke Aspirin Use is Associated with Clinical Outcomes in Ischemic Stroke Patients with Atherothrombosis, Small Artery Disease, and Cardioembolic Stroke. ( Han, Z; Lin, J; Luo, H; Yi, X; Zhou, J; Zhou, Q, 2019) |
| "BackgroundHigh-dose aspirin (HDA) is used with intravenous immunoglobulin (IVIg) in Kawasaki disease (KD)." | 7.88 | Duration of high-dose aspirin therapy does not affect long-term coronary artery outcomes in Kawasaki disease. ( Binstadt, BA; Braunlin, EA; Migally, K; Zhang, L, 2018) |
| "Seventy patients with stable coronary artery disease, supplemented with aspirin, participated in this pilot study." | 7.85 | MMP-2, MMP-9, and TIMP-4 and Response to Aspirin in Diabetic and Nondiabetic Patients with Stable Coronary Artery Disease: A Pilot Study. ( Bil-Lula, I; Gąsior, M; Kaczmarski, J; Kuliczkowski, W; Mysiak, A; Negrusz-Kawecka, M; Radomski, M; Urbaniak, J, 2017) |
| "This study is the largest to investigate platelet aggregation in stable coronary artery disease patients receiving aspirin as single antithrombotic therapy." | 7.85 | Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S; Würtz, M, 2017) |
| "Elderly, hospitalized coronary artery disease patients on regular aspirin treatment were enrolled from January 2014 to September 2016." | 7.85 | Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease. ( Chen, XH; Feng, XR; Fu, SW; He, XQ; Liang, WY; Liu, ML; Liu, WW; McCaffrey, TA; Zhang, JW, 2017) |
| "The combined use of aspirin and oral anticoagulant therapy in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) has been questioned due to an increased risk of major bleeding with little to no benefit in preventing ischemic events." | 7.85 | Combined aspirin and anticoagulant therapy in patients with atrial fibrillation. ( Eckman, MH; So, CH, 2017) |
| "There are limited data on aspirin (ASA) desensitization for patients with coronary artery disease." | 7.85 | Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease). ( Angiolillo, DJ; Anzuini, A; Bianco, M; Bossi, I; Capodanno, D; Colombo, P; Dossena, C; Iorio, A; Leonardi, S; Lettieri, C; Musumeci, G; Pozzi, R; Rigattieri, S; Rossini, R; Senni, M, 2017) |
| "In this hypothesis generating pilot analysis, dipyrone medication in aspirin treated coronary artery disease patients is associated with an increased cumulative incidence of death, MI or stroke as well as all-cause mortality and ischemic events." | 7.85 | Analgesic medication with dipyrone in patients with coronary artery disease: Relation to MACCE. ( Achilles, A; Dannenberg, L; Hohlfeld, T; Kelm, M; Levkau, B; Mohring, A; Piayda, K; Polzin, A; Zeus, T, 2017) |
| "Aspirin is the cornerstone of antiplatelet therapy in patients with coronary artery disease (CAD)." | 7.83 | Prevalence of aspirin resistance in Asian-Indian patients with stable coronary artery disease. ( Arun, SS; Chadha, DS; Jayaprasad, V; Karthikeyan, G; Sumana, B, 2016) |
| " Our results suggest that this strategy is not beneficial as compared to aspirin alone in terms of ischaemic or bleeding events." | 7.83 | Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study). ( Bauters, C; Caudmont, S; Ketelers, R; Lamblin, N; Lemaire, N; Lemesle, G; Meurice, T; Philias, A; Schurtz, G; Tricot, O, 2016) |
| "No aspirin resistance was detected among patients with stable coronary artery disease." | 7.83 | The lack of aspirin resistance in patients with coronary artery disease. ( Balogh, L; Bereczky, Z; Édes, I; Haramura, G; Homoródi, N; Katona, É; Kiss, RG; Kovács, EG; Leé, S; Muszbek, L; Péterfy, H; Shemirani, AH; Szőke, G, 2016) |
| "Aspirin is recommended in stable coronary artery disease based on myocardial infarction and stroke studies." | 7.81 | Impact of aspirin according to type of stable coronary artery disease: insights from a large international cohort. ( Bavry, AA; Cooper-DeHoff, RM; Gong, Y; Handberg, EM; Pepine, CJ, 2015) |
| "We sought to examine the risk of mortality associated with nonobstructive coronary artery disease (CAD) and to determine the impact of baseline statin and aspirin use on mortality." | 7.81 | Prognostic and therapeutic implications of statin and aspirin therapy in individuals with nonobstructive coronary artery disease: results from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter registry) re ( Achenbach, S; Al-Mallah, M; Berman, DS; Budoff, MJ; Cademartiri, F; Callister, TQ; Chang, HJ; Chen, L; Cheng, VY; Chinnaiyan, K; Chow, BJ; Cury, R; Delago, A; Dunning, A; Feuchtner, G; Hadamitzky, M; Hausleiter, J; Karlsberg, RP; Kaufmann, PA; Kim, YJ; LaBounty, T; Leipsic, J; Lin, F; Maffei, E; McPherson, R; Min, JK; Raff, GL; Shaw, LJ; Small, G; Villines, TC; Yam, Y, 2015) |
| "Aspirin is a cornerstone in management of coronary artery disease (CAD)." | 7.81 | Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S; Würtz, M, 2015) |
| "Presence of non-obstructive coronary artery disease (CAD) is associated with increased prescription of cardiovascular preventive medications including aspirin." | 7.81 | Association between Aspirin Therapy and Clinical Outcomes in Patients with Non-Obstructive Coronary Artery Disease: A Cohort Study. ( Hwang, IC; Jeon, JY; Kim, HK; Kim, HM; Kim, Y; Kim, YJ; Lee, SP; Sohn, DW; Sung, J; Yoon, YE, 2015) |
| " The aim of our study was to compare between two established methods of aspirin response, urinary 11-dehydrothromboxane B2 (11dhTXB2) and platelet Light Transmission Aggregometry (LTA) assays in elderly Chinese patients with coronary artery disease (CAD), and to investigate the clinical significance of both methods in predicting cardiovascular events." | 7.81 | Comparison between urinary 11-dehydrothromboxane B2 detection and platelet Light Transmission Aggregometry (LTA) assays for evaluating aspirin response in elderly patients with coronary artery disease. ( Chen, X; Feng, X; Fu, SW; Liu, M; Liu, T; McCaffrey, TA; Zhang, J, 2015) |
| "Dual antiplatelet therapy with clopidogrel and aspirin is the current standard of care in the management of patients with coronary artery disease (CAD) and acute coronary syndrome (ACS)." | 7.81 | Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease. ( Arya, V; Bhargava, M; Mahajan, P; Mohanty, A; Saraf, A; Sawhney, JP, 2015) |
| "To elucidate the correlation between urinary 11-dehydro-thromboxane B2 (11dhTxB2) and clinical efficacy of aspirin treatment in patients with type 2 diabete and coronary artery disease (CAD)." | 7.81 | [Correlation between the level of the urinary 11-dehydrothromboxane B2 and the clinical efficacy of aspirin in patients with type 2 diabetes and coronary artery disease]. ( Bai, ZS; Chen, XH; Feng, XR; Liu, ML; Liu, TF; Zhang, JW, 2015) |
| "Aspirin and statin therapy are mainstay treatments in patients with coronary artery disease (CAD)." | 7.80 | Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin. ( Bliden, KP; Ens, G; Franzese, CJ; Gesheff, MG; Gurbel, PA; Guyer, K; Singh, M; Singla, A; Stapleton, D; Tabrizchi, A; Tantry, US; Toth, PP, 2014) |
| "Patients (DM, n = 30; non-DM, n = 30) with stable coronary artery disease taking aspirin 81 mg/day and P2Y12 antagonist naive were enrolled." | 7.80 | Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. ( Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Franchi, F; Guzman, LA; Jakubowski, JA; Moser, BA; Rollini, F; Sugidachi, A; Tello-Montoliu, A; Ueno, M, 2014) |
| "The effects of dual antiplatelet therapy with aspirin and clopidogrel on the progression of native coronary artery disease after coronary artery bypass grafting are unknown." | 7.80 | Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial. ( Al-Atassi, T; Kulik, A; Le May, M; Ruel, M; Une, D; Voisine, P, 2014) |
| " We examined whether plasma L5 levels are elevated in patients with ST-segment elevation myocardial infarction (STEMI) and whether aspirin provides epigenetic protection of human coronary artery ECs (HCAECs) exposed to L5." | 7.79 | Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: a novel cytoprotective role of aspirin in acute myocardial infarction. ( Chang, FH; Chang, PY; Chang, SF; Chen, CH; Chen, YJ; Huang, WH; Lee, YT; Lu, J; Lu, SC; Yang, TC, 2013) |
| " Limited data are available exploring the age dependency of ex vivo aspirin response in young and old patients with stable coronary artery disease." | 7.79 | Relation of aspirin response to age in patients with stable coronary artery disease. ( Bental, T; Kornowski, R; Lev, EI; Solodky, A; Vaduganathan, M; Vaturi, M, 2013) |
| " To assess the efficacy and safety of aspirin desensitisation in Chinese patients with coronary artery disease." | 7.79 | Aspirin desensitisation for Chinese patients with coronary artery disease. ( Chan, HL; Chan, KK; Chau, CH; Cheung, CY; Cheung, GS; Choi, MC; Lee, JK; Li, SK; Tsui, KL; Wu, KL, 2013) |
| "Patients with established coronary artery disease (CAD) are likely to receive a combination of aspirin, a statin, and blood pressure (BP)-lowering agents." | 7.79 | The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease. ( Bots, ML; Grobbee, DE; Lafeber, M; Nathoe, H; Spiering, W; van der Graaf, Y; Visseren, FL, 2013) |
| "This study sought to assess the usefulness of clopidogrel-pathway genotyping and on-treatment platelet reactivity (OTR) testing in predicting major adverse cardiac events (MACE) in stable coronary artery disease (CAD) patients receiving drug-eluting stents (DES) under dual antiplatelet (clopidogrel plus aspirin) therapy." | 7.79 | Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. ( Briguori, C; Condorelli, G; De Micco, F; Focaccio, A; Latronico, MV; Pagnotta, P; Papa, L; Roncarati, R; Visconti, G; Viviani Anselmi, C, 2013) |
| "Variability in the response to aspirin (sometimes known as aspirin resistance) in modulating platelet activity is a potentially important clinical issue in coronary artery disease (CAD), but may be also be important in other areas of pathophysiology." | 7.79 | Vascular and platelet responses to aspirin in patients with coronary artery disease. ( Blann, AD; Kuzniatsova, N; Lip, GY, 2013) |
| "To characterize the clinical presentation of a cohort of patients with coronary artery disease (CAD) and aspirin reactions." | 7.79 | Characterization of aspirin allergies in patients with coronary artery disease. ( Feng, CH; Stevenson, DD; White, AA, 2013) |
| "A 73-year-old woman was admitted to our hospital with anterior acute myocardial infarction due to subacute thrombosis after coronary stenting with a zotarolimus-eluting stent (ZES), which is a newly developed drug-eluting stent that has been widely used since May 2009 in Japan." | 7.78 | A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent. ( Arima, M; Matsuda, A; Nitta, M; Shimizu, M; Yoshida, K, 2012) |
| "The widespread use of aspirin-driven vascular prevention strategies does not impede the occurrence of first and recurrent ischemic strokes in numerous subjects." | 7.78 | Ischemic stroke in patients receiving aspirin. ( Ameriso, S; Ameriso, SF; Povedano, GP; Pujol Lereis, VA, 2012) |
| "Platelet reactivity was assessed by the light transmission aggregometry and TxB(2) assay in 423 patients with coronary artery disease (CAD) on aspirin." | 7.78 | P2RY1 and P2RY12 polymorphisms and on-aspirin platelet reactivity in patients with coronary artery disease. ( Aung, PP; Barnard, J; Bhatt, DL; Gaussem, P; Kottke-Marchant, K; Murugesan, G; Silverstein, RL; Timur, AA; Wang, QK; Zhang, L, 2012) |
| "Aspirin is the most commonly used antiplatelet agent in patients with coronary artery disease (CAD)." | 7.78 | Aspirin sensitivity and coronary artery disease: implications for the practicing cardiologist. ( Das, P; Lieberman, P; Pattanaik, D, 2012) |
| "We hypothesized that single-nucleotide polymorphisms (SNPs) associated with heightened in vitro platelet function during aspirin exposure (which we define as "laboratory aspirin resistance") would be associated with greater risk for death, myocardial infarction (MI) or stroke among patients with coronary artery disease regularly using aspirin." | 7.77 | Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use. ( Horton, J; Newby, LK; Shah, SH; Shaw, LK; Voora, D, 2011) |
| "The aim of this study was to assess the association between "aspirin non responsiveness" in patients with coronary artery diseases (CAD) and the risk of major adverse cardiovascular events (MACE)." | 7.76 | Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease. ( Abderazek, F; Addad, F; Ben-Farhat, M; Chakroun, T; Dridi, Z; Elalamy, I; Gamra, H; Hamdi, S; Hassine, M; Samama, MM, 2010) |
| "To evaluate the effect of proton pump inhibitors (PPIs) on the platelet response to aspirin in patients with coronary artery disease (CAD)." | 7.76 | The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Würtz, M, 2010) |
| "This study sought to evaluate the platelet response to aspirin and the immature platelet fraction in patients with previous stent thrombosis (ST)." | 7.76 | Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. ( Grove, EL; Hvas, AM; Jensen, LO; Kaltoft, AK; Kristensen, SD; Tilsted, HH; Wulff, LN; Würtz, M, 2010) |
| "7% male) at risk for coronary artery disease (CAD) before and after low dose aspirin." | 7.75 | Leukocyte count is associated with increased platelet reactivity and diminished response to aspirin in healthy individuals with a family history of coronary artery disease. ( Becker, DM; Becker, LC; Faraday, N; Herrera-Galeano, JE; Kral, B; Moy, TF; Qayyum, R; Vaidya, D; Yanek, LR, 2009) |
| "Aspirin reduces cardiovascular events in patients with coronary artery disease (CAD), but studies report a highly variable response to aspirin, often referred to as 'aspirin low-responsiveness'." | 7.75 | Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. ( Daví, G; Grove, EL; Hedegaard, SS; Hvas, AM; Kristensen, SD; Refsgaard, J; Rocca, B, 2009) |
| "Aspirin chemoprophylaxis for coronary artery disease (CAD) is recommended for persons with the metabolic syndrome." | 7.75 | Native platelet aggregation and response to aspirin in persons with the metabolic syndrome and its components. ( Becker, DM; Becker, LC; Faraday, N; Moy, TF; Vaidya, D; Yanek, LR, 2009) |
| " A patient suffering from coronary artery disease and taking metoprolol and aspirin was stung by wasps and developed cutaneous allergic signs including rash, urticaria and orbital oedema." | 7.74 | Hymenoptera sting-induced Kounis syndrome: effects of aspirin and beta-blocker administration. ( Ioannidis, TI; Karpeta, MZ; Kounis, GN; Kounis, NG; Mazarakis, A; Notaras, SP; Rallis, DG; Tsintoni, AC, 2007) |
| "To determine whether patients with documented myocardial infarction (MI) while on aspirin therapy (cases) were more likely to be aspirin resistant than were patients with coronary artery disease (CAD) who had no history of MI (controls) and to assess clinical predictors of aspirin resistance in patients with stable CAD." | 7.74 | Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. ( Colby, E; Dorsch, MP; Dunn, SP; Lee, JS; Lynch, DR; Montague, D; Rodgers, JE; Schwartz, T; Smyth, SS, 2007) |
| "Silent myocardial ischemia (SMI) is a relatively common complication in patients with coronary artery disease (CAD) under aspirin therapy presenting with upper gastrointestinal hemorrhage (UGIH)." | 7.74 | A risk score to predict silent myocardial ischemia in patients with coronary artery disease under aspirin therapy presenting with upper gastrointestinal hemorrhage. ( Chen, CC; Chong, CF; Kuo, CD; Wang, TL, 2007) |
| "Recent studies have suggested that low-dose aspirin has preserved benefit with less bleeding compared with standard-dose aspirin when given with or without clopidogrel in patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACSs)." | 7.74 | Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative. ( Cannon, CP; Gibler, WB; Milford-Beland, S; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Tickoo, S, 2007) |
| "We sought to compare the results obtained from six major platelet function tests in the assessment of the prevalence of aspirin resistance in patients with stable coronary artery disease." | 7.74 | A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. ( Diodati, JG; Lordkipanidzé, M; Palisaitis, DA; Pharand, C; Schampaert, E; Turgeon, J, 2007) |
| "We sought to determine the clinical significance of aspirin resistance measured by a point-of-care assay in stable patients with coronary artery disease (CAD)." | 7.74 | Aspirin resistance and adverse clinical events in patients with coronary artery disease. ( Chen, WH; Cheng, X; Kwok, JY; Lau, CP; Lee, PY; Ng, W; Tse, HF, 2007) |
| " Therefore, we investigated the effects of these polymorphisms on platelet aggregation in aspirin-treated patients with coronary artery disease (CAD)." | 7.74 | P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease. ( Bierend, A; Böger, RH; Maas, R; Rau, T; Schwedhelm, E, 2008) |
| "In our study, endothelial dysfunction was found in all the patients with stable coronary artery disease, without any association of its presence and severity with aspirin resistance." | 7.74 | [The relationship between aspirin resistance and endothelial dysfunction in patients with stable coronary artery disease]. ( Buğra, Z; Elitok, A; Nişanci, Y; Oflaz, H; Onür, I; Pamukçu, B, 2008) |
| "Between September 1999 and April 2002, a total of 1,236 patients hospitalized for acute coronary syndrome (ACS) were questioned in order to determine whether aspirin intake had been interrupted." | 7.73 | Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. ( Benhamou, M; Cerboni, P; Ferrari, E; Marcel, B, 2005) |
| "To study the discontinuation of aspirin therapy as a risk factor for ischemic stroke (IS)." | 7.73 | Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. ( Bezerra, DC; Bogousslavsky, J; Maulaz, AB; Michel, P, 2005) |
| "We sought to determine patterns of aspirin use and the relationship between aspirin prescription and outcomes in patients with coronary artery disease (CAD) and heart failure (HF)." | 7.73 | Aspirin use in older patients with heart failure and coronary artery disease: national prescription patterns and relationship with outcomes. ( Foody, JM; Havranek, EP; Krumholz, HM; Masoudi, FA; Rathore, SS; Wolfe, P, 2005) |
| "A total of 991 patients with coronary artery disease (CAD) on low-dose aspirin were prospectively followed-up for two years for the occurrence and clinical features of first hospitalized episode of UGIB." | 7.73 | Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease. ( Chen, WH; Cheng, X; Lai, KC; Lam, KF; Lau, CP; Lee, PY; Li, SW; Ng, M; Ng, W; Tse, HF; Wong, WM, 2006) |
| "The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes." | 7.72 | Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004) |
| "Acetylsalicylic acid, or aspirin, is widely used in secondary prevention of coronary artery diseases, but the inhibition of platelet aggregation is not uniform in all individuals." | 7.71 | Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. ( Allal, J; Brizard, A; Christiaens, L; Coisne, D; Duplantier, C; Herpin, D; Macchi, L; Mauco, G, 2002) |
| "Despite substantial evidence that antiplatelet therapy saves lives and reduces adverse events in patients with coronary artery disease (CAD), use of the most widely available and lowest cost antiplatelet agent, aspirin, continues to be disappointingly low." | 7.71 | Underuse of aspirin in a referral population with documented coronary artery disease. ( Califf, RM; Chen, A; DeLong, ER; Hammill, BG; Kramer, JM; LaPointe, NA; McCants, CB; Muhlbaier, LH; Ostbye, T, 2002) |
| "We report the prevalence of use of aspirin, beta blockers, angiotensin-converting enzyme (ACE) inhibitors or angiotensin II type 1 receptor blockers, statins, and calcium channel blockers in older persons with coronary artery disease (CAD) in an academic nursing home." | 7.71 | Underutilization of aspirin, beta blockers, angiotensin-converting enzyme inhibitors, and lipid-lowering drugs and overutilization of calcium channel blockers in older persons with coronary artery disease in an academic nursing home. ( Aronow, WS; Ghosh, S; Ziesmer, V, 2002) |
| "Dabigatran is a direct acting (anti-II) oral anticoagulant which does not interfere with CYP and has favourable safety and efficacy profiles compared with VKAs." | 6.82 | Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study. ( Ajjan, RA; Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Franchi, F; Guzman, LA; King, R; Phoenix, F; Rollini, F; Tello-Montoliu, A; Zenni, MM, 2016) |
| "CAD patients with type 2 diabetes had higher platelet aggregation (all p-values <0." | 6.80 | The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin. ( Gregersen, S; Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S, 2015) |
| " We sought to evaluate platelet reactivity during loading and maintenance dosing of ticagrelor versus clopidogrel, and the pharmacokinetic profile of ticagrelor and its metabolite AR-C124910XX, in black patients with stable CAD taking low-dose aspirin (acetylsalicylic acid)." | 6.80 | Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study. ( Angiolillo, DJ; Caplan, RJ; Carlson, GF; Ferdinand, KC; Maya, J; Teng, R; Waksman, R, 2015) |
| " However, the effects of EV-077 on pharmacodynamic (PD) profiles in patients with DM and coronary artery disease (CAD) while on antiplatelet therapy is poorly explored and represented the aim of this in vitro pilot investigation." | 6.79 | Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation. ( Angiolillo, DJ; Bender, N; Darlington, A; Desai, B; Franchi, F; Muñiz-Lozano, A; Patel, R; Rollini, F; Sakariassen, KS; Tello-Montoliu, A; Wilson, RE, 2014) |
| " At the end of the dosing interval on day 28, mean final-extent IPA was 10." | 6.79 | Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. ( Emanuelsson, H; Hiasa, Y; Teng, R, 2014) |
| "Ozone treatment significantly (P<0." | 6.77 | Effects of ozone therapy on haemostatic and oxidative stress index in coronary artery disease. ( Delgado-Roche, L; Díaz-Batista, A; Martínez-Sánchez, G; Pérez-Davison, G; Re, L, 2012) |
| " The aim of this study was to perform serial pharmacodynamic assessments of prasugrel with high-dose clopidogrel in patients with DM." | 6.76 | A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. ( Angiolillo, DJ; Badimon, JJ; Baker, BA; Effron, MB; Frelinger, AL; Jakubowski, JA; Michelson, AD; Ojeh, CK; Saucedo, JF; Zhu, B, 2011) |
| "Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition compared with non-diabetics following P2Y(12) receptor blockade." | 6.73 | A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. ( Angiolillo, DJ; Aslam, M; Bass, TA; Box, LC; Capranzano, P; Charlton, RK; Desai, B; Goto, S; Guzman, LA; Shoemaker, SB; Suzuki, Y; Zenni, MM, 2008) |
| " Decision to increase clopidogrel dosage may vary on the basis of the assay used, thus highlighting the need for unambiguous guidelines with respect to assay selection, as platelet function assays are not interchangeable." | 6.73 | Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. ( Diodati, JG; Lordkipanidzé, M; Nguyen, TA; Palisaitis, DA; Pharand, C; Schampaert, E, 2008) |
| " Additional controlled studies are warranted to confirm this observation and determine whether long-term use of low-dose colchicine can improve clinical outcomes in patients with advanced vascular disease." | 6.73 | Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. ( Nidorf, M; Thompson, PL, 2007) |
| "Aspirin has been widely prescribed over the last several decades as part of primary CAD prevention strategy." | 6.72 | Aspirin for Primary Prevention of Coronary Artery Disease. ( Aronow, WS; Bandyopadhyay, D; Deedwania, P; Ghosh, RK; Gupta, M; Jain, V; Kapadia, S; Lavie, CJ; Qamar, A; Ujjawal, A, 2021) |
| "Aspirin therapy has been proven to decrease mortality and major adverse cardiovascular events in patients with CAD." | 6.53 | The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. ( Hernandez, AF; Johnston, A; Jones, WS, 2016) |
| " Ongoing studies are challenging the current one-size-fits-all dosing strategy, but the preceding evaluation of platelet function assays has not been adequate." | 6.48 | Antiplatelet effect of aspirin in patients with coronary artery disease. ( Grove, EL, 2012) |
| "Future advances in the treatment of coronary artery disease will likely occur as we further refine the role of these established antiplatelet drugs and develop agents that bind to novel targets in the thrombotic cascade." | 6.42 | The expanding role of antiplatelet agents in coronary artery disease. A current review of aspirin, glycoprotein IIb/IIIa inhibitors, and the thienopyridines. ( Bhatt, DL; Hostetter, JC, 2003) |
| "The mainstay of treatment for unstable coronary artery disease (UCAD) currently consists of antithrombotic therapy with aspirin plus unfractionated heparin (UFH), together with anti-ischemic treatment with beta blockers and nitrates." | 6.19 | Long-term management--the way forward? ( Wallentin, L, 2000) |
| " This study intends to carry out an evaluation of whether combining rivaroxaben with aspirin will be effective and safe in treating patients experiencing chronic CAD." | 5.72 | Evaluation of efficacy and safety of rivaroxaban combined with aspirin in patients with chronic coronary artery disease: A protocol for systematic review and meta-analysis. ( Li, X; Wang, H; Wu, H; Wu, X; Xie, G, 2022) |
| "THEMIS is a double-blind, randomized trial of 19,220 patients with diabetes mellitus and stable coronary artery disease (CAD) comparing ticagrelor to placebo, in addition to aspirin." | 5.69 | External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Hea ( Abtan, J; Bhatt, DL; Bueno, H; Ducrocq, G; Eagle, KA; Elbez, Y; Fox, K; Goto, S; Harrington, RA; Leiter, LA; Lev, E; Mehta, SR; Ohman, EM; Pais, P; Petrov, I; Simon, T; Sinnaeve, PR; Smith, SC; Steg, PG; Wilson, P, 2023) |
| "In this prospective, open-label, multi-centre, 2 × 2 factorial, randomized, controlled study, 1,800 patients with diabetes mellitus and multi-vessel disease (inclusion criteria similar to FREEDOM trial) with indication for coronary revascularization will be randomly assigned to Supraflex Cruz or Xience stents and also to ticagrelor- or prasugrel- based antiplatelet strategies." | 5.69 | Rationale and design of the TUXEDO-2 India study: Ultra-Thin strUt Supraflex Cruz versus XiencE in a Diabetic pOpulation with multi-vessel disease-2. ( Abhaichand, R; Agrawal, DK; Arambam, P; Bangalore, S; Banker, D; Chandra, S; Garg, R; Kaul, U; Khan, A; Koduganti, SC; Mody, R; Moorthy, N; Parida, AK; Reddy, KMK; Sarma, PR; Sharma, R; Sinha, SK, 2023) |
| "In patients undergoing drug-eluting stent implantation for non-complex lesions, the benefits of 1-month DAPT followed by aspirin monotherapy for a composite of ischaemic and bleeding outcomes were found in patients with stable CAD, but not in those with ACS." | 5.51 | Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial. ( Ahn, CM; Cho, JY; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Lee, YJ; Yun, KH, 2022) |
| "To conduct a health economic evaluation of ticagrelor in patients with type 2 diabetes and coronary artery disease (CAD) from a multinational payer perspective." | 5.51 | Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial. ( Andersson, M; Bhatt, DL; Bueno, H; Darlington, O; De Luca, L; Fox, KM; Harrington, RA; Himmelmann, A; Hoskin, L; James, SK; Leiter, LA; McEwan, P; Mehta, SR; Mellström, C; Ridderstråle, W; Simon, T; Steg, PG; Tank, A, 2022) |
| "5 mg twice daily plus aspirin, and to report their clinical outcomes and bleeding rates in clinical practice compared to the COMPASS randomized trial, which provided the basis for using DPI in this patient population." | 5.51 | Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry. ( Aboyans, V; Anand, SS; Bosch, J; Cowie, MR; Debus, ES; Fox, KAA; Gay, A; Patel, M; Vogtländer, K; Welsh, RC; Zeymer, U, 2022) |
| "In patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in The Cardiovascular Outcomes for People Using Anticoagulation Strategies trial, the effects of rivaroxaban 2." | 5.51 | Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. ( Bhatt, DL; Bosch, J; Connolly, SJ; Eikelboom, JW; Fox, KAA; Hori, M; Liang, Y; Maggioni, A; Yusuf, S; Zhu, J, 2022) |
| "Previously, in the ESCAPE study, a randomized controlled trial, we found that 12 months of cilostazol administration significantly decreased coronary artery stenosis and the noncalcified plaque component compared with aspirin." | 5.51 | Cilostazol treatment for preventing adverse cardiovascular events in patients with type 2 diabetes and coronary atherosclerosis: Long-term follow-up of the ESCAPE study. ( Chun, EJ; Lim, S; Sohn, M, 2022) |
| "Aspirin is a key player in the management and prevention of stroke and myocardial infarction in patients with atherothrombosis." | 5.43 | A study into the genetic basis of aspirin resistance in Pakistani patients with coronary artery disease. ( Akhtar, N; Junaid, A; Mohyuddin, A; Mukarram, O, 2016) |
| " We investigated if the effect of aspirin declined during the 24-hour dosing interval in patients with coronary artery disease and type 2 diabetes, and whether this correlated with increased platelet turnover." | 5.42 | Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes. ( Christensen, KH; Grove, EL; Hvas, AM; Kristensen, SD; Würtz, M, 2015) |
| " Antiplatelet drugs such as aspirin and P2Y12 inhibitors are commonly used to reduce the risk of thrombotic events, including myocardial infarction, stroke, and stent thrombosis." | 5.41 | Personalised antiplatelet therapies for coronary artery disease: what the future holds. ( Angiolillo, DJ; Capodanno, D, 2023) |
| "Aspirin is the only antiplatelet agent with a Class I recommendation for long-term prevention of cardiovascular events in patients with coronary artery disease (CAD)." | 5.41 | P2Y ( Arnesen, H; Bhatt, DL; Calabrò, P; Cao, D; Chiarito, M; Franzone, A; Gragnano, F; Kang, J; Kastrati, A; Kim, HS; McFadden, EP; Mehran, R; Park, KW; Pettersen, AR; Pirondini, L; Pocock, S; Schunkert, H; Seljeflot, I; Steg, PG; Valgimigli, M; von Scheidt, M; Windecker, S; Woodward, M; Zhao, Q; Zhu, Y, 2023) |
| " The aspirin plus low-dose rivaroxaban group had a lower incidence of ischemic stroke compared to the aspirin group (OR = 0." | 5.41 | Comparison of Different Chronic Maintenance Antithrombotic Strategies in Patients with Coronary Artery Disease: A Systematic Review and Network Meta-Analysis. ( Cai, Y; Chen, Z; He, Y; Li, C; Zhang, J, 2023) |
| "5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events (MACE) in patients with chronic coronary artery disease or peripheral artery disease by 24% during a mean follow-up of 23 months." | 5.41 | Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. ( Anand, SS; Berkowitz, SD; Bosch, J; Connolly, SJ; Dagenais, GR; Eikelboom, JW; Fox, KA; Guzik, TJ; Keller, L; Liang, Y; Liu, L; Muehlhofer, E; O'Donnell, M; Shestakovska, O; Yusuf, S; Zhu, J, 2021) |
| "The aim of this study was to investigate the safety and efficacy of dabigatran dual therapy (110 or 150 mg twice daily, plus clopidogrel or ticagrelor) versus warfarin triple therapy in patients with atrial fibrillation and STEMI." | 5.41 | Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial. ( Bhatt, DL; Cannon, CP; Gabor Kiss, R; Hohnloser, SH; Leiva, O; Lip, GYH; Miede, C; Navarro Estrada, J; Nickenig, G; Nordaby, M; Oldgren, J; Ongen, Z; Oude Ophuis, T; Steg, PG; Ten Berg, JM; Zeymer, U, 2021) |
| "In the AFIRE trial, rivaroxaban monotherapy was noninferior to combination therapy with rivaroxaban and an antiplatelet agent for thromboembolic events or death, and superior for major bleeding in patients with atrial fibrillation (AF) and stable coronary artery disease." | 5.41 | Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis. ( Akao, M; Ako, J; Hagiwara, N; Hirayama, A; Kaikita, K; Kimura, K; Matoba, T; Matsui, K; Miyauchi, K; Nakamura, M; Ogawa, H; Yasuda, S, 2021) |
| "5 mg rivaroxaban twice daily and 100 mg aspirin once daily compared with 100 mg aspirin once daily reduces major adverse cardiovascular (CV) events in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD)." | 5.41 | Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. ( Anand, SS; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Connolly, SJ; Dagenais, GR; Eikelboom, JW; Félix, C; Fox, KAA; Guzik, TJ; Hart, RG; Maggioni, AP; Muehlhofer, E; Sharma, M; Shestakovska, O; Yusuf, S, 2021) |
| "Aspirin resistance was detected in 22 (16." | 5.40 | Hypertension as a risk factor for aspirin and clopidogrel resistance in patients with stable coronary artery disease. ( Akturk, IF; Caglar, FN; Caglar, IM; Erturk, M; Surgit, O; Tuncer, N; Uzun, F; Yalcın, AA, 2014) |
| "Fibrinogen levels were elevated in T2DM (p< 0." | 5.40 | The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease. ( Ajjan, RA; Grant, PJ; Grove, EL; Hvas, AM; Kristensen, SD; Kurdee, Z; Larsen, SB; Neergaard-Petersen, S; Phoenix, F, 2014) |
| "Inflammation has been proposed to modify platelet function." | 5.39 | Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB, 2013) |
| "Diabetes mellitus is an independent predictor of adverse clinical events after drug-eluting stent implantation." | 5.39 | Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study. ( Chen, X; Han, Y; Jiang, T; Jing, Q; Li, Y; Liu, H; Ma, Y; Wang, G; Wang, S; Wang, X; Yan, G; Yang, L; Zhang, L; Zhu, G, 2013) |
| "Aspirin resistance was detected in 27 patients (16." | 5.38 | [The frequency of aspirin resistance by a modified thrombelastography method and its relationship with clinical and laboratory parameters in patients with stable coronary artery disease]. ( Caylı, M; Demirtaş, M; Kanadaşı, M; Karaarslan, O; Koç, M; Sahin, DY; Uysal, OK, 2012) |
| " If cigarette smoking is associated with a dose-response effect on pharmacodynamic measures in clopidogrel-treated patients is unknown." | 5.38 | Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012) |
| "Diabetic patients with CAD had significantly higher levels of both platelet aggregation and activation compared to non-diabetic patients with CAD despite treatment with the same dosage of aspirin." | 5.36 | Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Mortensen, SB, 2010) |
| "Aspirin resistance was defined as an ARU (aspirin reaction units) > or =550, and clopidogrel resistance was defined as platelet inhibition <20%." | 5.35 | Prevalence and risk factors for aspirin and clopidogrel resistance in patients with coronary artery disease or ischemic cerebrovascular disease. ( Han, K; Jeon, HK; Kim, H; Lee, HK, 2009) |
| "Aspirin resistance was defined as a closure time (CT) <186 s with Col/Epi cartridges, despite regular aspirin therapy." | 5.35 | Relationship between the serum sCD40L level and aspirin-resistant platelet aggregation in patients with stable coronary artery disease. ( Midilli, K; Nisanci, Y; Oflaz, H; Onur, I; Pamukcu, B; Yilmaz, E; Yilmaz, G, 2008) |
| "5 mg twice daily rivaroxaban and aspirin in patients with polyvascular disease (coronary artery disease, peripheral arterial disease or both), the underlying mechanism of which is not clearly understood." | 5.34 | Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy. ( Bafford, R; Cummings, C; Gonze, M; Gurbel, P; Mackrell, P; Rout, A; Sukhi, A; Tantry, U; Ulloa, K, 2020) |
| "The REDUAL PCI trial (Evaluation of Dual Therapy With Dabigatran vs Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting) demonstrated that, in patients with atrial fibrillation following percutaneous coronary intervention, bleeding risk was lower with dabigatran plus clopidogrel or ticagrelor (dual therapy) than warfarin plus clopidogrel or ticagrelor and aspirin (triple therapy)." | 5.34 | Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial. ( Berry, NC; Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Mauri, L; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2020) |
| " Methods and Results Healthy volunteers and patients with stable coronary artery disease receiving aspirin received escalating doses of RUC-4 or placebo in a sentinel-dose, randomized, blinded fashion." | 5.34 | First Human Use of RUC-4: A Nonactivating Second-Generation Small-Molecule Platelet Glycoprotein IIb/IIIa (Integrin αIIbβ3) Inhibitor Designed for Subcutaneous Point-of-Care Treatment of ST-Segment-Elevation Myocardial Infarction. ( Bentur, O; Carlson, M; Coller, BS; DeMaria, AN; Garza, D; Gibson, CM; Henry, TD; Kereiakes, DJ; Martin, LH; Meek, T; Midkiff, J; Mueller, M; Seng Yue, C, 2020) |
| "Aspirin resistance was defined when epinephrine closure time <174 s." | 5.34 | Prevalence and biologic profile of aspirin resistance in patients with angiographically proven coronary artery disease. ( de Lafuente, JP; Iriarte, JA; Lafita, M; Molinero, E; Monica, S; Narvaez, I; Saez, Y; Sagastagoitia, JD; Vacas, M, 2007) |
| "Aspirin non-response was defined as: 1) slope steeper than 12%/min in AA-aggregations, and 2) by closure time shorter than 170 s in PFA-100." | 5.33 | Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. ( Backman, JT; Kankuri, E; Karhunen, PJ; Lassila, R; Lepäntalo, A; Mikkelsson, J; Reséndiz, JC; Viiri, L, 2006) |
| "Aspirin treatment with 300 mg o." | 5.33 | Aspirin reduces anticardiolipin antibodies in patients with coronary artery disease. ( Andreotti, F; Ikonomidis, I; Kremastinos, DT; Lekakis, J; Loizou, S; Nihoyannopoulos, P; Revela, I; Vamvakou, G, 2006) |
| "In patients with stable coronary artery disease and diabetes without a history of myocardial infarction or stroke, those who received ticagrelor plus aspirin had a lower incidence of ischemic cardiovascular events but a higher incidence of major bleeding than those who received placebo plus aspirin." | 5.30 | Ticagrelor in Patients with Stable Coronary Disease and Diabetes. ( Andersson, M; Bhatt, DL; Corbalán, R; Cornel, JH; Fox, K; Ge, J; Harrington, RA; Held, C; Himmelmann, A; Leiter, LA; Leonsson-Zachrisson, M; Liu, Y; Mehta, SR; Nicolau, JC; Opolski, G; Ridderstråle, W; Simon, T; Steg, PG; Widimský, P; Zateyshchikov, D, 2019) |
| "5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events and mortality and increased bleeding." | 5.30 | Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. ( Berkowitz, SD; Bhatt, DL; Bosch, JJ; Cairns, JA; Connolly, SJ; Cook Bruns, N; Dagenais, GR; Diaz, R; Eikelboom, JW; Fox, KAA; Hart, RG; Leong, DP; Maggioni, AP; Muehlhofer, E; O'Donnell, M; Shestakovska, O; Tasto, C; Yusuf, S, 2019) |
| "In RE-DUAL PCI, 2,725 patients with atrial fibrillation (993 with diabetes) who had undergone PCI were assigned to warfarin triple therapy (warfarin, clopidogrel or ticagrelor, and aspirin) or dabigatran dual therapy (dabigatran 110 mg or 150 mg twice daily and clopidogrel or ticagrelor)." | 5.30 | Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes. ( Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Maeng, M; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2019) |
| "Triflusal has demonstrated an efficacy similar to aspirin in the prevention of vascular events in patients with acute myocardial infarction (ΜΙ) and ischaemic stroke but with less bleeding events." | 5.30 | Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial. ( Adamopoulos, D; Asimakopoulos, C; Bourdakis, A; Chantzichristos, VG; Darmanis, P; Dimitriadou, A; Gkiokas, S; Goudevenos, JA; Ipeirotis, K; Kalantzi, KI; Kitikidou, K; Klonaris, I; Kostaki, A; Logothetis, D; Mainas, K; Mais, T; Maragiannis, A; Martiadou, K; Mavronasos, K; Michelongonas, I; Mitropoulos, D; Ntalas, IV; Panagiotakos, DB; Papadimitriou, G; Papadopoulos, A; Papaioakeim, M; Sofillas, K; Stabola, S; Stefanakis, E; Stergiou, D; Thoma, M; Tselepis, AD; Tsoumani, ME; Zenetos, A; Zisekas, S, 2019) |
| "Strokes were significantly reduced by the combination of rivaroxaban plus aspirin in comparison with aspirin in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies)." | 5.30 | Stroke Outcomes in the COMPASS Trial. ( Aboyans, V; Alings, M; Berkowitz, SD; Bhatt, DL; Bosch, J; Bruns, NC; Catanese, L; Connolly, SJ; Eikelboom, JW; Fox, K; Ha, JW; Hart, RG; Keltai, K; Maggioni, A; Ng, KKH; O'Donnell, M; Sharma, M; Shestakovska, O; Tonkin, A; Varigos, J; Yusuf, S, 2019) |
| " In patients with prior coronary artery disease or peripheral arterial disease the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial revealed that compared with acetylsalicylic acid alone, dual pathway inhibition with low-dose rivaroxaban (2." | 5.30 | Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. ( Coppens, M; Eikelboom, JWA; Weitz, JI, 2019) |
| "In the setting of prior myocardial infarction, the oral antiplatelet ticagrelor added to aspirin reduced the risk of recurrent ischemic events, especially, in those with diabetes mellitus." | 5.30 | Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. ( Andersson, M; Bhatt, DL; Fox, K; Harrington, RA; Held, C; Himmelmann, A; Leiter, LA; Mehta, SR; Ridderstråle, W; Simon, T; Steg, PG, 2019) |
| "The benefits of both dabigatran 110 mg and 150 mg dual therapy compared with warfarin triple therapy in reducing bleeding risks were consistent across subgroups of patients with or without ACS, and patients treated with ticagrelor or clopidogrel." | 5.30 | Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. ( Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2019) |
| "5%), an independent adjudication process of reported and unreported potential endpoints, using standardised CEC procedures, in order to assess whether 23-month ticagrelor monotherapy (90 mg twice daily) after 1-month DAPT is non-inferior to a standard regimen of DAPT for 12 months followed by aspirin monotherapy for the primary efficacy endpoint of death, non-fatal myocardial infarction, non-fatal stroke or urgent target vessel revascularisation and superior for the primary safety endpoint of type 3 or 5 bleeding according to the Bleeding Academic Research Consortium criteria." | 5.30 | Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY). ( Aminian, A; Benit, E; Bolognese, L; Bryniarski, K; Buszman, P; Dominici, M; Ferrario, M; Franzone, A; Garg, S; Hamm, C; Heg, D; Huber, K; Janssens, L; Juni, P; Leonardi, S; Liebetrau, C; McFadden, E; Naber, C; Petrov, I; Piccolo, R; Prokopczuk, J; Serruys, P; Slagboom, T; Steg, G; Tumscitz, C; Valgimigli, M; van Geuns, RJ; Vranckx, P; Vrolix, M; Windecker, S; Zurakowski, A, 2019) |
| " The COMMANDER HF randomized clinical trial evaluated the effects of adding low-dose rivaroxaban to antiplatelet therapy in patients with recent worsening of chronic HF with reduced ejection fraction, coronary artery disease (CAD), and sinus rhythm." | 5.30 | Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. ( Anker, SD; Byra, WM; Cleland, JGF; Deng, H; Fu, M; Greenberg, B; La Police, DA; Lam, CSP; Mehra, MR; Neaton, JD; Nessel, CC; Spiro, TE; van Veldhuisen, DJ; Vanden Boom, CM; Zannad, F, 2019) |
| "5 mg bd plus aspirin), versus aspirin alone, are preserved in patients with moderate renal dysfunction without evidence of an excess hazard of bleeding." | 5.30 | Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. ( Connolly, SJ; Eikelboom, JW; Fox, KAA; Metsarinne, KP; Shestakovska, O; Yusuf, S, 2019) |
| "In patients with chronic coronary artery disease or peripheral artery disease and a history of mild or moderate HF, combination rivaroxaban and aspirin compared with aspirin alone produces similar relative but larger absolute benefits than in those without HF." | 5.30 | Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. ( Avezum, A; Bhatt, DL; Bosch, J; Branch, KR; Cheng, RK; Connolly, SJ; Eikelboom, JW; Fox, KAA; Maggioni, AP; Probstfield, JL; Shestakovska, O; Yusuf, S, 2019) |
| "In this 8 years' follow-up study, we evaluated the long-term outcomes of the addition of clopidogrel to aspirin during the first year after coronary artery bypass grafting, versus aspirin plus placebo, with respect to survival, major adverse cardiac, or major cerebrovascular events, including revascularization, functional status, graft patency, and native coronary artery disease progression." | 5.27 | Eight-year follow-up of the Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) trial. ( Chow, B; Erthal, F; Farkouh, M; Fortier, J; Glineur, D; Hage, A; Ko, G; Kulik, A; Larose, É; LeMay, M; Mesana, TG; Ruel, M; Tremblay, H; Une, D; Voisine, P, 2018) |
| "In patients with stable coronary artery disease, addition of rivaroxaban to aspirin lowered major vascular events, but increased major bleeding." | 5.27 | Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. ( Anand, SS; Avezum, AA; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Connolly, SJ; Cook Bruns, N; Dagenais, G; Dans, AL; Dyal, L; Eikelboom, JW; Felix, C; Fox, KAA; Guzik, TJ; Ha, JW; Hori, M; Keltai, K; Lanas, F; Lisheng, L; Lonn, E; Maggioni, AP; Metsarinne, K; O'Donnell, M; Parkhomenko, AN; Torp-Pedersen, C; Varigos, JD; Widimsky, P; Yusoff, K; Yusuf, S, 2018) |
| "The topic of aspirin (acetylsalicylic acid, ASA) use in coronary artery disease patients planned for coronary artery bypass grafting during perioperative period is among the most disputed issues in cardiac surgery." | 5.27 | Effect of Sustained Use of Aspirin until the Time of Surgery on Outcomes following Coronary Artery Bypass Grafting: A Randomized Clinical Trial. ( Ghandi, Y; Kamali, A; Sharifi, M, 2018) |
| "This trial aims to determine whether the addition of GXNT will further improve prognosis without increasing bleeding risk for patients with coronary artery disease who have switched from DAPT to aspirin alone after PCI." | 5.27 | Guanxinning tablet for patients who switch from dual antiplatelet therapy to aspirin alone after percutaneous coronary intervention: study protocol for a cluster randomized controlled trial. ( Chen, Z; Gao, R; Ju, J; Li, J; Liu, J; Lu, F; Xu, H, 2018) |
| "The Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis (TARGET) study is a multi-center double-blind randomized controlled trial enrolling patients who have undergone multi-vessel CABG with at least one saphenous vein graft." | 5.27 | Impact of ticagrelor versus aspirin on graft patency after CABG: Rationale and design of the TARGET (ticagrelor antiplatelet therapy to reduce graft events and thrombosis) randomized controlled trial (NCT02053909). ( Abreu, AM; Boronat, V; Kouchoukos, NT; Kulik, A; Ruel, M, 2018) |
| " Patients undergoing percutaneous coronary intervention with a biolimus A9-eluting stent for stable coronary artery disease or acute coronary syndromes were randomly assigned (1:1) to 75-100 mg aspirin daily plus 90 mg ticagrelor twice daily for 1 month, followed by 23 months of ticagrelor monotherapy, or standard dual antiplatelet therapy with 75-100 mg aspirin daily plus either 75 mg clopidogrel daily (for patients with stable coronary artery disease) or 90 mg ticagrelor twice daily (for patients with acute coronary syndromes) for 12 months, followed by aspirin monotherapy for 12 months." | 5.27 | Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la ( Benit, E; Chichareon, P; Dominici, M; Ferrario, M; Hamm, C; Heg, D; Huber, K; Janssens, L; Jüni, P; McFadden, EP; Möllmann, H; Moschovitis, A; Onuma, Y; Serruys, PW; Slagboom, T; Steg, PG; Valgimigli, M; van Es, GA; Van Geuns, RJ; van Meijeren, C; Vranckx, P; Windecker, S; Zurakowski, A, 2018) |
| "The DAPT (Dual Antiplatelet Therapy) study randomized 11,648 patients free from ischemic and bleeding events 12 months after coronary stenting to continued thienopyridine plus aspirin therapy for an additional 18 months versus aspirin therapy alone." | 5.24 | Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. ( Apruzzese, PK; Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017) |
| "The ITALIC (Is There a Life for DES After Discontinuation of Clopidogrel) trial showed that rates of bleeding and thrombotic events at 1 year were much the same with 6 versus 12 months of DAPT after percutaneous coronary intervention with second-generation drug-eluting stents." | 5.24 | 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel). ( Armengaud, J; Barragan, P; Ben Amer, H; Berlan, J; Blanchard, D; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Didier, R; Druelles, P; Dupouy, P; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J, 2017) |
| "Tranexamic acid reduces the risk of bleeding among patients undergoing cardiac surgery, but it is unclear whether this leads to improved outcomes." | 5.24 | Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. ( Bussières, JS; Byrne, K; Chan, MT; Cooper, DJ; Forbes, A; Jayarajah, M; Landoni, G; Marasco, S; McGuinness, S; McNeil, J; Myles, PS; Painter, T; Silbert, B; Smith, JA; Wallace, S, 2017) |
| "8 years with 10-75% coronary artery stenosis, as assessed by coronary computed tomography angiography, were randomly assigned to sarpogrelate 300 mg/day plus aspirin 100 mg/day (SPG + ASA group) or aspirin 100 mg/day alone (ASA group) for 6 months." | 5.24 | Effect of sarpogrelate, a selective 5-HT ( Chun, EJ; Han, SJ; Hur, JH; Jang, HC; Kang, DK; Kim, HJ; Kim, KM; Lee, DH; Lee, JE; Lim, S; Min, SH; Oh, TJ, 2017) |
| "To perform a systematic literature review and indirect treatment comparison (ITC) to identify, summarize and quantify randomized controlled trial (RCT) evidence evaluating combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone for the prevention of atherothrombotic events in patients with stable coronary artery disease (CAD) and/or peripheral artery disease (PAD)." | 5.22 | Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease. ( Baker, WL; Bookhart, B; Coleman, CI; Kharat, AA, 2022) |
| "In EES-treated subjects, significant reductions in stent thrombosis and MI and an increase in bleeding were observed with continued thienopyridine beyond 1 year compared with aspirin alone." | 5.22 | Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. ( Cohen, DJ; Cutlip, DE; Hermiller, JB; Hsieh, WH; Kereiakes, DJ; Krucoff, MW; Massaro, JM; Mauri, L; Steg, PG; Windecker, S; Yeh, RW, 2016) |
| "The aim of the study was to assess ticagrelor's effects on inhibition of platelet aggregation (IPA), P2Y12 reaction units (PRU, measure of platelet P2Y12 receptor blockade), pharmacokinetic (PK) parameters and safety in Chinese patients with stable coronary artery disease (CAD)." | 5.22 | Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. ( Carlson, GF; Guo, J; Li, H; Teng, R, 2016) |
| "In the PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54), ticagrelor reduced the risk of major adverse cardiovascular events when added to low-dose aspirin in stable patients with prior myocardial infarction, resulting in the approval of ticagrelor 60 mg twice daily for long-term secondary prevention." | 5.22 | Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm ( Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Dalby, AJ; Goodrich, E; Goto, S; Held, P; Hu, D; Jensen, E; Mauri, L; Morrow, DA; Ophuis, TO; Ruda, M; Sabatine, MS; Seung, KB; Špinar, J; Steg, PG; Storey, RF, 2016) |
| "Rates of bleeding and thrombotic events were not significantly different according to 6- versus 24-month DAPT after PCI with new-generation DES in good aspirin responders." | 5.20 | 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. ( Armengaud, J; Barragan, P; Benamer, H; Berland, J; Blanchard, D; Boschat, J; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Druelles, P; Dupouy, P; Endresen, K; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J, 2015) |
| "We have recently shown that dipyrone (metamizole), a non-opioid analgesic, can nullify aspirin (acetylsalicylic acid; ASA) antiplatelet effects in patients with coronary artery disease (CAD)." | 5.20 | Prevention of dipyrone (metamizole) induced inhibition of aspirin antiplatelet effects. ( Hohlfeld, T; Kelm, M; Merx, MW; Polzin, A; Rassaf, T; Richter, S; Schrör, K; Zeus, T, 2015) |
| " The aim of this prospective, randomised, study was to compare the PD effects of standard-dose prasugrel [60 mg loading dose (LD)/10 mg daily maintenance dose (MD)] with high-dose clopidogrel (900 mg LD/150 mg daily MD) in non-diabetic obese [body mass index (BMI) ≥30 kg/m²] patients, with coronary artery disease (CAD) on aspirin therapy." | 5.19 | Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. ( Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Patel, R; Rollini, F; Tello-Montoliu, A; Ueno, M, 2014) |
| " We verified if the pharmacodynamic effects of CYP3A4-metabolized statins (atorvastatin) and non-CYP3A4-metabolized statins (pitavastatin) differ in patients with coronary artery disease (CAD) treated with DAPT." | 5.19 | Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy. ( Franzoni, F; Gaudio, C; Greco, C; Marazzi, G; Pelliccia, F; Polacco, M; Rosano, G; Speziale, G; Spoletini, I; Vitale, C, 2014) |
| " Subjects with coronary artery disease treated with aspirin were randomly assigned to clopidogrel 75 mg daily or prasugrel 10 mg daily for 7 days." | 5.19 | Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification. ( Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Price, MJ, 2014) |
| "In a randomized study with a factorial design, 82 stable coronary artery disease patients treated with 75 mg clopidogrel MD and aspirin were assigned to receive in a double blind fashion lansoprazole (30 mg/day) or placebo and to receive in an open fashion 150 mg clopidogrel MD or 10 mg prasugrel MD." | 5.19 | Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. ( Abtan, J; Anzaha, G; Barthélémy, O; Beygui, F; Brugier, D; Cayla, G; Charland, SL; Collet, JP; Galier, S; Gallois, V; Hulot, JS; Kerneis, M; Montalescot, G; O'Connor, SA; Silvain, J; Stanek, EJ, 2014) |
| "PARADOX was a prospective, randomized, double-blind, double-dummy, placebo-controlled, crossover study of objectively assessed nonsmokers (n = 56) and smokers (n = 54) with stable coronary artery disease receiving aspirin therapy." | 5.17 | The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. ( Angiolillo, DJ; Bailey, WL; Baker, BA; Bliden, KP; Gurbel, PA; Jakubowski, JA; Jeong, YH; Kereiakes, DJ; Lasseter, KC; Logan, DK; Maa, JF; Nolin, TD; Ojeh, CK; Tantry, US; White, A, 2013) |
| " In this study we verified the idea that plasma homocysteine (Hcy) contributes to 'aspirin-resistance' in patients with coronary artery disease (CAD) and with or without type 2 diabetes mellitus (T2DM)." | 5.17 | Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study. ( Drzewoski, J; Kamysz, W; Karafova, A; Karolczak, K; Watala, C, 2013) |
| "To verify the hypothesis that erythrocytes play a role in suboptimal blood platelet response to acetylsalicylic acid (ASA, aspirin) in subjects with coronary artery disease (CAD)." | 5.17 | Aspirin dose increase from 75 to 150 mg suppresses red blood cell contribution to suboptimal platelet response to aspirin in patients with CAD. ( Drzewoski, J; Karolczak, K; Kasznicki, J; Pietruszynski, R; Watala, C, 2013) |
| " Eligible patients were those with stable coronary artery disease or history of low-risk acute coronary syndrome (ACS) undergoing PCI with zotarolimus-eluting stents." | 5.17 | Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. ( Abizaid, A; Abizaid, AS; Bhatt, DL; Botelho, RV; Castello, HJ; Costa, JR; Costa, RA; de Castro, JP; de Paula, JE; Devito, FS; Feres, F; Gusmão, M; King, SB; Labrunie, A; Leon, MB; Liu, M; Mangione, JA; Marin-Neto, JA; Meireles, GX; Negoita, M; Nicolela, EL; Perin, MA; Salvadori, D; Staico, R, 2013) |
| "This is a post-hoc analysis derived from patients (n = 79) enrolled in a prospective, randomized, double-blind, double-dummy, crossover study comparing cilostazol with placebo in stable coronary artery disease patients on aspirin and clopidogrel therapy." | 5.17 | Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. ( Angiolillo, DJ; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Rollini, F; Tello-Montoliu, A; Ueno, M, 2013) |
| " This study investigated the influence of renal function and platelet turnover on the antiplatelet effect of aspirin in patients with coronary artery disease." | 5.16 | Influence of renal function and platelet turnover on the antiplatelet effect of aspirin. ( Grove, EL; Hvas, AM; Kristensen, SD; Wulff, LN; Würtz, M, 2012) |
| " The present study was conducted in healthy individuals (n = 50) and in outpatients with coronary artery disease (CAD) at a distance from the acute ischemic episode (aspirin group, n = 71; aspirin/clopidogrel group, n = 106)." | 5.16 | Description of response to aspirin and clopidogrel in outpatients with coronary artery disease using multiple electrode impedance aggregometry. ( Baccouche, H; Bandi, A; Chaari, M; Elalamy, I; Galea, V; Gerotziafas, GT; Mossialos, L; Sassi, M; Tsinopoulos, G; Zarifis, J, 2012) |
| " Patients with severe Kawasaki disease were randomly assigned by a minimisation method to receive either intravenous immunoglobulin (2 g/kg for 24 h and aspirin 30 mg/kg per day) or intravenous immunoglobulin plus prednisolone (the same intravenous immunoglobulin regimen as the intravenous immunoglobulin group plus prednisolone 2 mg/kg per day given over 15 days after concentrations of C-reactive protein normalised)." | 5.16 | Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. ( Arakawa, H; Fukazawa, R; Furuno, K; Fuse, S; Hamaoka, K; Hara, S; Hara, T; Ichida, F; Kato, T; Kobayashi, T; Miura, M; Morikawa, A; Nakamura, T; Nomura, Y; Ogawa, C; Ogawa, S; Otani, T; Saji, T; Seki, M; Takatsuki, S; Takeuchi, K; Tokunaga, H, 2012) |
| "Hospitalized patients with coronary artery disease discharged on aspirin, β-blocker, and statin who used a participating pharmacy were randomized to usual care or intervention." | 5.16 | Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial. ( Allen LaPointe, NM; Anstrom, KJ; Calvert, SB; Kaltenbach, LA; Kramer, JM; Stafford, JA, 2012) |
| " Blood from patients with known coronary artery disease who were treated with aspirin but no other antithrombotic agent was spiked in vitro with rivaroxaban alone or in combination with a direct acting P2Y12 antagonist (cangrelor)." | 5.16 | Effects on platelet function of a direct acting antagonist of coagulation factor Xa. ( Dibattiste, PM; Ringwala, SM; Schneider, DJ, 2012) |
| "This randomized, double-blind, parallel-group, single-center trial involved patients with stable coronary artery disease who were assigned to receive either 300 mg of aspirin or placebo the night before coronary bypass surgery." | 5.16 | Effects of preoperative aspirin in coronary artery bypass grafting: a double-blind, placebo-controlled, randomized trial. ( Deja, MA; Domaradzki, W; Gaszewska-Żurek, E; Gocoł, R; Kargul, T; Mazur, W; Pytel, A; Stącel, T; Wojakowski, W; Woś, S; Żurek, P, 2012) |
| "Aspirin resistance and chronic renal failure are both potentially important clinical issues in coronary artery disease." | 5.16 | Renal function and aspirin resistance in patients with coronary artery disease. ( Blann, AD; Kuzniatsova, N; Lip, GY; Velu, S, 2012) |
| "In a population of diabetic patients with coronary artery disease and a high risk of time-dependent aspirin resistance, aspirin divided twice per day can significantly decrease the rate of biological loss of efficacy at trough level." | 5.16 | Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. ( Bal dit Sollier, C; Dillinger, JG; Drissa, A; Drouet, L; Henry, P; Logeart, D; Manzo Silberman, S; Sideris, G; Voicu, S, 2012) |
| "Platelet responsiveness to aspirin was evaluated in 11 stable coronary artery disease patients on chronic aspirin therapy before and 1, 3, 8, and 24h after observed ingestion of 80-mg enteric-coated aspirin." | 5.15 | Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. ( Diodati, JG; Lordkipanidzé, M; Palisaitis, DA; Pharand, C; Schampaert, E, 2011) |
| "Any bleeding and TIMI major bleeding complications increase in patients aged ≥75 years treated with clopidogrel in addition to aspirin." | 5.15 | Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study. ( Aydogdu, S; Balbay, Y; Cagirci, G; Cay, S; Demir, AD; Erbay, AR; Maden, O; Sen, N, 2011) |
| "Aspirin dosing regimens are associated with different pharmacodynamic effects in platelets from T2DM patients and stable coronary artery disease, with a twice-daily, low-dose aspirin administration resulting in greater platelet inhibition than once-daily administration as assessed by aspirin-sensitive assays and a dose-dependent effect on serum TXB(2) levels." | 5.15 | Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Patel, A; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011) |
| "The goal of this study was to investigate whether omega-3 polyunsaturated fatty acids (n-3 PUFA) are able to alter plasma fibrin clot properties and reduce thrombin formation in stable coronary artery disease patients undergoing percutaneous coronary intervention (PCI)." | 5.15 | Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot). ( Gajos, G; Nessler, J; Piwowarska, W; Rostoff, P; Undas, A; Zalewski, J, 2011) |
| " For over a decade, aspirin has been prescribed for primary prevention of cardiovascular disease and for patients with the coronary artery disease risk equivalents; yet, there is no substantial evidence of an appropriate risk-benefit ratio to support this practice." | 5.15 | Reconsidering low-dose aspirin therapy for cardiovascular disease: a study protocol for physician and patient behavioral change. ( Folks, B; Leblanc, WG; Pace, WD; Staton, EW, 2011) |
| "Aspirin is widely used in the secondary prevention of coronary artery diseases, including myocardial infarction, stroke, and vascular related deaths." | 5.15 | Effect of polymorphism and type II diabetes on aspirin resistance in patients with unstable coronary artery disease. ( Gao, F; Men, JL; Ren, J; Wang, ZX; Wei, MX, 2011) |
| "Adjunctive treatment with pentoxifylline is not associated with increased platelet inhibitory effects in DM patients with coronary artery disease receiving DAPT." | 5.15 | Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011) |
| " One hundred and seventy-two coronary artery disease patients who had taken aspirin only or combinations with aspirin and clopidogrel for over 7 days were included." | 5.14 | Comparison of laboratory detection methods of aspirin resistance in coronary artery disease patients. ( Cha, KS; Goh, RY; Han, JY; Kim, KE; Kim, MH; Quan, ML; Woo, KS, 2010) |
| "Adding clopidogrel to aspirin beyond 4 weeks post PCI is not associated with a significant increase in the overall rate of major or minor bleeding, although it is associated with an increase in major gastrointestinal bleeding in the year after a PCI." | 5.14 | Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. ( Aronow, HD; Berger, PB; Brennan, DM; Steinhubl, SR; Topol, EJ, 2009) |
| "In a laboratory substudy of the PRAGUE-8 trial, the influences of nonmodifiable (age and sex) and modifiable (body mass index and tobacco smoke) factors, comorbidity (hypertension, hyperlipidemia, diabetes mellitus, and renal insufficiency) and cotherapy (statin, aspirin, and heparin), on the course of clopidogrel efficacy were investigated in 105 patients pretreated with clopidogrel >or=6 hours before coronary angiography +/- percutaneous coronary intervention." | 5.14 | Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox". ( Bilkova, D; Kala, P; Marinov, I; Motovska, Z; Petr, R; Simek, S; Widimsky, P, 2009) |
| "This multicenter registry documents satisfactory safety and efficacy profiles, as evidenced by low rates of major adverse cardiac events and stent thrombosis up to 18 months, for the Excel biodegradable polymer-based sirolimus-eluting stent when used with 6 months of dual antiplatelet therapy in a "real-world" setting." | 5.14 | Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. ( Chen, X; Gao, R; Han, Y; Jiang, T; Jing, Q; Li, H; Li, Y; Li, Z; Liu, H; Liu, Y; Qiu, J; Shang, X; Xu, B; Yang, L; Zhang, H, 2009) |
| "We screened 1277 patients to enroll 93 aspirin, 147 clopidogrel, and 23 dual poor responders, based on a point-of-care assay, who underwent elective coronary angioplasty at 10 European sites for stable or low-risk unstable coronary artery disease." | 5.14 | Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho ( Angiolillo, DJ; Brugaletta, S; Campo, G; Colangelo, S; de Cesare, N; Ferrari, R; Furgieri, A; Hamon, M; Meliga, E; Parrinello, G; Percoco, G; Repetto, A; Sabatè, M; Valgimigli, M; Vranckx, P, 2009) |
| "We studied patients with stable coronary artery disease on chronic aspirin therapy randomised to addition of clopidogrel 75 mg/d (n = 30) or continuation of aspirin 100 mg/d (n = 30) for 4 weeks." | 5.14 | Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin. ( Branicka, A; Stepień, E; Tracz, W; Undas, A; Wołkow, P; Zmudka, K, 2009) |
| "In a multicenter, randomized, double-blind study, 123 patients with stable coronary artery disease who were taking aspirin therapy (75 to 100 mg/d) received ticagrelor (180-mg load, 90-mg BID maintenance dose [n=57]), clopidogrel (600-mg load, 75-mg/d maintenance dose [n=54]), or placebo (n=12) for 6 weeks." | 5.14 | Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. ( Antonino, MJ; Bliden, KP; Butler, K; Gesheff, T; Gurbel, PA; Karunakaran, A; Kereiakes, DJ; Ledley, GS; Parris, C; Patil, SB; Purdy, D; Storey, RF; Tantry, US; Teng, R; Wei, C; Wilson, V, 2009) |
| "Patients (n = 485) with stable coronary artery disease taking low-dose aspirin (75 to 162 mg) for at least 1 week were screened for aspirin response with the VerifyNow Aspirin assay (Accumetrics, San Diego, California)." | 5.14 | Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation. ( Assali, A; Battler, A; Brosh, D; Harel, N; Kleiman, NS; Kornowski, R; Lev, EI; Mager, A; Roller, M; Solodky, A, 2010) |
| "Acetylsalicylic acid (aspirin) is widely used in the secondary prevention of coronary artery disease." | 5.14 | Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting. ( Jannati, M; Khalili, A; Kojuri, J; Mahboodi, A; Mahmoody, Y; Zangbar Sabegh, B, 2010) |
| "The aim of this pilot study was to compare the effect of two different regimens of aspirin dosage on platelet of coronary artery disease (CAD) diabetic patients." | 5.14 | Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. ( Abderazek, F; Addad, F; Chakroun, T; Chouchene, S; Dridi, Z; Elalamy, I; Gamra, H; Gerotziafas, GT; Hassine, M; Hatmi, M, 2010) |
| "CYP2C19 (*1, *2, *3, *4, *5, *6, *7, *8, *17) genotyping was performed in patients with coronary artery disease treated with ticagrelor (180-mg load, 90 mg BID) (n=92) or clopidogrel (600-mg load, 75 mg/d) (n=82)." | 5.14 | First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. ( Armstrong, M; Bliden, KP; Butler, K; Gurbel, PA; Storey, RF; Tantry, US; Wei, C, 2010) |
| " The Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) study was undertaken to evaluate whether the addition of clopidogrel to aspirin inhibits SVG disease after coronary artery bypass grafting, as assessed at 1 year by intravascular ultrasound." | 5.14 | Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. ( Delarochelliere, R; Kulik, A; Le May, MR; Mesana, TG; Naidoo, S; Ruel, M; Tardif, JC; Voisine, P; Wells, GA, 2010) |
| "The effects of therapy with aspirin 300 mg/day and with combined aspirin 100 mg/day plus clopidogrel 75 mg/day on platelet function were compared in patients with diabetes mellitus and coronary artery disease and impaired antiplatelet responses to aspirin 100 mg/day." | 5.13 | Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin. ( Aygul, N; Duzenli, MA; Ozdemir, K; Soylu, A; Tokac, M, 2008) |
| "The aim of this study was to evaluate the relationship between reticulated platelets (RPs), platelet size, and platelet function in patients with stable coronary artery disease (CAD) taking aspirin and clopidogrel." | 5.13 | Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. ( Alviar, CL; Arikan, M; DeLao, T; Dong, JF; Granada, JF; Guthikonda, S; Kleiman, NS; Lev, EI; Tellez, A; Vaduganathan, M, 2008) |
| " Eleven patients had a history of documented coronary artery disease, all patients were on aspirin, and 18 were on statins." | 5.13 | Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. ( Blombery, P; Bobik, A; Dart, AM; Kanellakis, P; Lyon, S; Mukhamedova, N; Murphy, A; Shaw, JA; Sviridov, D; Woollard, K, 2008) |
| " One hundred consecutive patients with coronary artery disease (CAD) on combined acetylsalicylic acid and clopidogrel treatment (75 mg/d) and 33 patients on aspirin only were screened for platelet ADP-induced signalling by conventional aggregometry, platelet P-selectin expression and the platelet reactivity index (PRI)." | 5.13 | ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. ( Bauersachs, J; Eigenthaler, M; Ertl, G; Flierl, U; Schäfer, A; Störk, S; Walter, U; Weinberger, S, 2008) |
| " One hundred ten aspirin-treated patients with stable coronary artery disease were randomized to a loading dose (LD, day 1)/ maintenance dose (MD, days 2-29) of prasugrel 60 mg/10 mg or clopidogrel 600 mg/75 mg." | 5.13 | Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. ( Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Johnell, M; Siegbahn, A; Varenhorst, C; Wallentin, L; Winters, KJ, 2008) |
| " Aspirin-treated subjects with coronary artery disease were randomized to double-blind treatment with clopidogrel 600 mg loading dose (LD) followed by daily 75 mg maintenance dose (MD) or prasugrel 60 mg LD and daily 10 mg MD for 28 days." | 5.13 | Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. ( Ernest, CS; Rohatagi, S; Salazar, DE; Small, DS; Wallentin, L; Winters, KJ; Wrishko, RE, 2008) |
| "The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade." | 5.13 | The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. ( Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G, 2008) |
| "The present study suggested benefit of tailored antiplatelet therapy during elective PCI with GP IIb/IIIa antagonist for clopidogrel nonresponders without increased bleeding risk." | 5.13 | Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. ( Alessi, MC; Bali, L; Bonnet, JL; Cuisset, T; Frere, C; Lambert, M; Morange, PE; Moro, PJ; Mouret, JP; Quilici, J, 2008) |
| "1% male) patients receiving 300 mg daily enteric coated aspirin for at least 7 days with documented coronary artery disease were included in the study." | 5.13 | Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions. ( Aydinalp, A; Ertan, C; Gulmez, O; Kaynar, G; Konas, D; Muderrisoglu, H; Ozin, B; Yildirir, A, 2008) |
| "In aspirin-treated subjects with coronary artery disease, prasugrel 60/10 mg provides faster onset and greater inhibition of P2Y(12) receptor-mediated platelet aggregation than clopidogrel 600/75 mg, because of greater and more efficient generation of the active metabolite." | 5.13 | Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. ( Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Siegbahn, A; Sugidachi, A; Varenhorst, C; Wallentin, L; Winters, KJ, 2008) |
| "To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the authors studied consecutive patients during a 29-month period." | 5.13 | Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. ( Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M, 2008) |
| "We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)." | 5.13 | Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008) |
| "Aspirin inhibits platelet activation and reduces major vascular events in patients with stable coronary artery disease." | 5.13 | Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study. ( Allal, J; Christiaens, L; Macchi, L; Mergy, J; Ragot, S, 2008) |
| "We evaluated the safety, tolerability, and pharmacodynamic profile of REG1 in a randomized, double-blind, placebo-controlled study, assigning 50 subjects with coronary artery disease taking aspirin and/or clopidogrel to 4 dose levels of RB006 (15, 30, 50, and 75 mg) and RB007 (30, 60, 100, and 150 mg)." | 5.13 | Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. ( Aberle, LG; Alexander, JH; Becker, RC; Chan, MY; Chronos, N; Cohen, MG; Dyke, CK; Gilchrist, IC; Harrington, RA; Kleiman, NS; Lin, M; Melloni, C; Myles, SK; Rusconi, CP; Steinhubl, SR; Tonkens, RM; Vorchheimer, DA; Walder, J, 2008) |
| "Patients with coronary artery disease (CAD) presenting with acute coronary syndrome or undergoing coronary stenting are indicated to treatment with dual antiplatelet therapy (DAPT) combining aspirin with a P2Y12 receptor inhibitor." | 5.12 | Complexity of Antiplatelet Therapy in Coronary Artery Disease Patients. ( Costa, F; Fischman, D; Sabouret, P; Savage, MP, 2021) |
| "To compare the efficacy of low-dose or no aspirin with conventional high-dose aspirin for the initial treatment in the acute-phase of Kawasaki disease (KD)." | 5.12 | Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review. ( Chiang, MH; Liu, HE; Wang, JL, 2021) |
| "This study was designed to compare the degree of inhibition of platelet aggregation (IPA) of prasugrel with that of clopidogrel in stable aspirin-treated patients with coronary artery disease (CAD)." | 5.12 | Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. ( Brandt, JT; Darstein, C; Jakubowski, JA; Jernberg, T; Naganuma, H; Payne, CD; Siegbahn, A; Wallentin, L; Winters, KJ, 2006) |
| " Whether this polymorphism affects response to aspirin in patients with coronary artery disease is not known." | 5.12 | Antithrombotic effects of aspirin based on PLA1/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease. ( Dropinski, J; Musial, J; Nizankowski, R; Sanak, M; Szczeklik, A; Wegrzyn, W, 2007) |
| "Clopidogrel improves endothelial nitric oxide bioavailability and diminishes biomarkers of oxidant stress and inflammation in patients with symptomatic coronary artery disease, suggesting that beyond inhibition of platelet aggregation, adenosine phosphate receptor blockade may also have promising vasoprotective effects." | 5.12 | Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. ( Baldus, S; Böger, R; Heitzer, T; Karstens, M; Meinertz, T; Ortak, M; Rudolph, V; Schwedhelm, E; Sydow, K; Tschentscher, P, 2006) |
| " To obtain a better understanding of platelet function in coronary artery disease in the setting of aspirin therapy, we performed platelet functional testing in patients with ACS and compared results to patients without CAD." | 5.12 | Evaluation of platelet function in aspirin treated patients with CAD. ( Bush, DE; Kickler, TS; Ng'alla, LS; Vaidya, D; Williams, MS, 2006) |
| "Aspirin resistance may increase up to more then threefold the risk of major cardiovascular events (MACE) in patients with stable coronary artery disease." | 5.12 | The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. ( Mercanoglu, F; Meric, M; Nisanci, Y; Oflaz, H; Oncul, A; Ozcan, M; Pamukcu, B; Umman, B, 2006) |
| "Aspirin resistance may increase the risk of major adverse cardiac events (MACE) more than threefold in patients with stable coronary artery disease (CAD)." | 5.12 | Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). ( Mercanoglu, F; Meric, M; Nisanci, Y; Oflaz, H; Oncul, A; Onur, I; Ozcan, M; Pamukcu, B; Umman, B, 2007) |
| "Treatment of acute Kawasaki disease with intravenous immune globulin and aspirin reduces the risk of coronary-artery abnormalities and systemic inflammation, but despite intravenous immune globulin therapy, coronary-artery abnormalities develop in some children." | 5.12 | Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. ( Atz, AM; Baker, AL; Colan, SD; Gersony, W; Klein, GL; Li, JS; McCrindle, BW; Minich, LL; Mitchell, PD; Newburger, JW; Sleeper, LA; Sundel, RP; Takahashi, M; Vetter, VL, 2007) |
| "We searched for additional anti-platelet effects of clopidogrel in coronary artery disease (CAD) patients treated with aspirin." | 5.12 | The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin. ( Biernat, M; Dropinski, J; Dziedzina, S; Jakiela, B; Plutecka, H; Sanak, M; Szczeklik, A; Wegrzyn, W, 2007) |
| " We investigated if adding clopidogrel to aspirin treatment could attenutate stress-induced platelet activation and myocardial ischemia in patients with coronary artery disease (CAD)." | 5.12 | Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease. ( Hjemdahl, P; Hofman-Bang, C; Ivert, T; Li, N; Perneby, C; Tornvall, P; Wallén, NH, 2007) |
| "To evaluate whether aspirin reduces the incidence and frequency of daily life myocardial ischaemia in a cohort of patients with chronic stable coronary artery disease." | 5.11 | Reduction of daily life ischaemia by aspirin in patients with angina: underlying link between thromboxane A2 and macrophage colony stimulating factor. ( Andreotti, F; Ikonomidis, I; Nihoyannopoulos, P, 2004) |
| "The purpose of the present study was to study the concept of aspirin resistance or non-responsiveness by investigating the response to long-term aspirin therapy in patients with a former acute myocardial infarction (AMI)." | 5.10 | Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. ( Andersen, K; Arnesen, H; Hurlen, M; Seljeflot, I, 2002) |
| "We sought to assess how one tablet of non-enteric coated aspirin (325 mg) affects human platelets in subjects with risk factors for coronary artery disease." | 5.10 | Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. ( Atar, D; Callahan, KP; Malinin, AI; McKenzie, ME; Serebruany, VL, 2003) |
| "The aim of this study was to determine whether selective cyclooxygenase-2 (COX-2) inhibition with rofecoxib can modulate endothelial dysfunction and levels of circulating inflammatory markers in patients with established coronary artery disease (CAD)." | 5.10 | Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. ( Giddens, K; McInerney, MM; McQueen, MJ; Nassar, BA; Title, LM, 2003) |
| "Heightened platelet reactivity may affect the occurrence of ischemic events in patients with coronary artery disease on aspirin therapy." | 5.10 | The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy. ( Bliden, KP; Gurbel, PA, 2003) |
| " However, it is still not clear, how aspirin affects expression of major platelet receptors in chronic drug users with coronary artery disease, especially those recovering in the methadone clinic maintenance program." | 5.09 | Paradoxical activation of major platelet receptors in the methadone-maintained patients after single pill of aspirin. ( Callahan, KP; Malinin, AI; Serebruany, VL, 2001) |
| " In addition, among HBR patients, (i) new recommendations prefer direct oral anticoagulants (DOAC) over vitamin K antagonists in DOAC-eligible patients with atrial fibrillation and coronary artery disease; (ii) measures to minimize bleedings while on DAPT should be pursued, including de-escalation of P2Y12 receptor inhibitor therapy; and (iii) new studies are testing reversal strategies for short DAPT regimens, with early discontinuation of aspirin." | 5.05 | [Short dual antiplatelet therapy: how, when and why]. ( Carrozzi, C; Ditali, V; Leonardi, S, 2020) |
| "In this review, the role of the rivaroxaban-plus-aspirin approach (dual pathway inhibition - DPI) in patients with chronic coronary syndrome (CCS) and to perform practical recommendations about its use was updated." | 5.05 | Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition. ( Almendro-Delia, M; Bellmunt-Montoya, S; Cosín-Sales, J; García-Alegría, J; García-Moll, X; Gómez-Doblas, JJ; González-Juanatey, JR; Hernández, JL; Lozano, FS; Riambau, V; Suarez Fernández, C, 2020) |
| "The COMPASS trial demonstrated that rivaroxaban and aspirin reduce myocardial infarction, stroke, and cardiovascular death in patients with coronary artery disease, without a demonstrated effect on bypass graft patency in the first postoperative year." | 5.05 | The COMPASS trial: practical considerations for application after coronary artery bypass surgery. ( Arora, RC; Eikelboom, R; Lodewyks, C; Muller Moran, HR; Yan, W; Zelentsov, I, 2020) |
| "The results of the THEMIS trial, conducted in DM patients with stable coronary artery disease and no prior stroke or myocardial infarction, showed that although ticagrelor in addition to aspirin reduced the risk of ischemic events, this was associated with a parallel increase in bleeding complications." | 5.05 | An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus. ( Angiolillo, DJ; Calderone, D; Capodanno, D, 2020) |
| "The aim of this study was to investigate the association among the PlA1/A2 gene polymorphism, laboratory aspirin resistance and adverse clinical outcomes in coronary artery disease (CAD) patients who were on aspirin maintainance therapy." | 5.01 | Association among PlA1/A2 gene polymorphism, laboratory aspirin resistance and clinical outcomes in patients with coronary artery disease: An updated meta-analysis. ( Bai, J; Chen, J; Gong, X; Kong, D; Li, C; Liu, J; Meng, H; Wang, F; Wang, J; Xu, K; Zhou, Y, 2019) |
| "Aspirin plays a pivotal role in the management of patients with Coronary Artery Disease (CAD) with well-recognised benefits of reducing recurrent myocardial infarction and minimising the risk of stent thrombosis for those undergoing Percutaneous Coronary Intervention (PCI)." | 5.01 | Aspirin Hypersensitivity in Patients Undergoing Percutaneous Coronary Intervention. What Should We be Doing? ( Alexopoulos, D; Kassimis, G; Raina, T, 2019) |
| " Similarly, in patients with stable coronary artery disease, two-thirds of whom had a history of myocardial infarction, dual antithrombotic therapy with very-low-dose rivaroxaban and aspirin also resulted in improved ischaemic outcomes." | 5.01 | Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease? ( Geisler, T; Kristensen, SD; Storey, RF; Sumaya, W, 2019) |
| "Aspirin decreases the risk of recurrent thrombotic events in patients with coronary artery disease or peripheral artery disease but the risk of recurrent events remains high." | 5.01 | How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland? ( Eikelboom, JW; Guzik, TJ; Kruger, PC, 2019) |
| "Although aspirin (ASA) is the mainstay of treatment for the prevention of recurrent ischemic stroke, the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial showed ASA monotherapy to be inferior to clopidogrel in preventing recurrent adverse cardiovascular outcomes in patients with high cardiac risks." | 5.01 | Aspirin Versus Clopidogrel Monotherapy for the Treatment of Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis. ( Ding, J; Xu, GM; Yuan, J, 2019) |
| "The literature indicates that patients with coronary artery disease (CAD), including those with an acute coronary syndrome, may safely undergo low-dose aspirin challenge and/or desensitization." | 4.95 | Aspirin challenge and desensitization: how, when and why. ( Caruso, C; Cortellini, G; Romano, A, 2017) |
| "Aspirin has been the mainstay for secondary prevention of coronary artery disease to decrease early recurrence and severity of recurrent cardiovascular events." | 4.95 | Usefulness of PA32540 in Protecting the Gastric Layer While Providing Secondary Prevention for Coronary Artery Disease. ( Haseeb, S; Kagolanu, D; Lam, P; Munnangi, S; Sayedy, N; Shah, S; Stephenson, K; Viswanathan, P, 2017) |
| " Whether aspirin ameliorates this risk in patients with established coronary artery disease undergoing cardiac or noncardiac surgery is unknown." | 4.95 | Clinical outcomes associated with per-operative discontinuation of aspirin in patients with coronary artery disease: A systematic review and meta-analysis. ( Cooper, CJ; Husnain, M; Kanjwal, Y; Khan, AR; Khan, MS; Khuder, SA; Luni, FK; Riaz, H; Riaz, IB; Riaz, T; Taleb, M, 2017) |
| " The question addressed was whether continuation of administration of preoperative aspirin until the day of coronary artery bypass grafting (CABG) could minimize postoperative mortality, prevalence of postoperative myocardial infarction (MI) with or without influence on postoperative bleeding, packed red blood cell (PRBC) transfusion and reoperation for bleeding." | 4.95 | What is the impact of preoperative aspirin administration on patients undergoing coronary artery bypass grafting? ( Aboul-Hassan, SS; Cichon, R; Marczak, J; Stankowski, T, 2017) |
| "Aspirin is indicated for primary and secondary prevention of cardiovascular diseases (CVD) by major guidelines." | 4.95 | Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. ( Bliden, K; Chaudhary, R; Gurbel, PA; Sharma, T; Tantry, U, 2017) |
| " While aspirin remains the cornerstone for secondary prevention of CAD, DAPT significantly reduces recurrent ischemic adverse events at the expense of an increased risk of major bleeding complications." | 4.93 | [Dual antiplatelet therapy for treatment and secondary prevention of coronary artery disease: indications, modalities and duration]. ( Degrauwe, S; Iglesias, JF, 2016) |
| " Meta-analyses revealed that aspirin in combination with FDD was significantly more effective at alleviating angina pectoris and improving electrocardiogram (ECG) results relative to aspirin therapy alone, reflected by the summary effects for the clinical markedly effective (OR = 2." | 4.93 | Clinical Therapeutic Effects of Aspirin in Combination with Fufang Danshen Diwan, a Traditional Chinese Medicine Formula, on Coronary Heart Disease: A Systematic Review and Meta-Analysis. ( He, J; Huang, J; Kong, X; Tang, X; Ye, F, 2016) |
| "The use of aspirin in coronary artery disease and address the unmet need of aspirin therapy in patients with history of hypersensitivity reactions to aspirin (acetylsalicylic acid; ASA) or other nonsteroidal inflammatory drugs (NSAIDs)." | 4.91 | Aspirin desensitization for cardiovascular disease. ( Woessner, KM, 2015) |
| " Patients with indications for antithrombotic therapy often will have coexisting vascular disease, such as coronary artery disease, requiring concomitant antiplatelet therapy with aspirin alone or more commonly with a dual antiplatelet regimen, aspirin and clopidogrel, or prasugrel or ticagrelor." | 4.90 | Combining antiplatelet and antithrombotic therapy (triple therapy): what are the risks and benefits? ( Alpert, JS; Asencio, LA; Huang, JJ, 2014) |
| "Pharmacogenomics has been implicated in the response variability of antiplatelet drugs in coronary artery disease (CAD), particularly for aspirin and clopidogrel." | 4.90 | Pharmacogenomics of oral antiplatelet drugs. ( de Boer, A; Deneer, VH; Klungel, OH; Yasmina, A, 2014) |
| " In patients on triple antithrombotic therapy with vitamin K antagonists, aspirin, and clopidogrel, a single clinical trial indicates that withdrawal of aspirin may reduce bleeding risk without increasing the risk of coronary thrombosis." | 4.90 | Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease. ( Thompson, PL; Verheugt, FW, 2014) |
| " The latter roles provide the fundamental basis for the most widely implemented pharmacologic management of coronary artery disease--dual antiplatelet therapy with aspirin to inhibit platelet thromboxane A2 generation, and a P2Y12 receptor inhibitor to prevent adenosine diphosphate (ADP)-induced platelet activation." | 4.89 | Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account. ( Gesheff, MG; Gurbel, PA; Mahla, E; Tantry, US, 2013) |
| "Dual antiplatelet therapy of clopidogrel added aspirin is an established treatment strategy to prevent recurrent ischemic event occurrence in coronary artery disease patients." | 4.89 | Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring. ( Gurbel, PA; Tantry, US, 2013) |
| "Aspirin is still the mainstay of antiplatelet therapy in the secondary prevention of coronary artery disease." | 4.89 | Aspirin and aspirin resistance in coronary artery disease. ( Apostolakis, S; Kasmeridis, C; Lip, GY, 2013) |
| "Aspirin is integral in the primary and secondary prevention of coronary artery disease and acute coronary syndrome." | 4.88 | Aspirin resistance: current status and role of tailored therapy. ( Cannon, CP; Grinstein, J, 2012) |
| "For many years clopidogrel was the 'gold standard' ADP receptor antagonist in patients with coronary artery disease in combination with acetylsalicylic acid, i." | 4.88 | Clopidogrel in coronary artery disease: update 2012. ( Huber, K, 2012) |
| " Zofenopril proved to be very effective in patients with coronary artery disease and myocardial infarction, thanks to its unique effective mechanism of action for improving blood pressure control, left ventricular function and myocardial ischemia burden, as well as angiotensin-converting enzyme inhibition." | 4.88 | Long-term clinical experience with zofenopril. ( Bacchelli, S; Borghi, C; Degli Esposti, D, 2012) |
| " In this paper, we summarize and place in clinical context the new trial findings regarding anticoagulation (dabigatran), antiplatelet therapy (ticagrelor, clopidogrel, prasugrel and aspirin), percutaneous coronary management (thrombectomy, multivessel/left main disease and biodegradable polymers), medical therapy for coronary disease (ivabradine and rosuvastatin) and management of heart failure (beta-blocker strategy, atrial fibrillation and resynchronization therapy)." | 4.86 | Recent advances in cardiology. ( Menown, IA; Shand, JA, 2010) |
| "Standard double antiplatelet therapy (aspirin plus clopidogrel) used in patients with coronary artery disease during acute coronary syndromes (ACS) and/or in conjunction with percutaneous coronary interventions (PCI) has some limitations." | 4.86 | [Antiplatelet therapy in coronary heart disease. Some problems and achivements]. ( Gratsianskiĭ, NA, 2010) |
| " Although monotherapy with either aspirin or clopidogrel has been validated in secondary prevention, for high-risk patients such as those with acute coronary syndromes or requiring percutaneous coronary intervention, dual antiplatelet therapy appears to be most beneficial." | 4.85 | Role of antiplatelet therapy across the spectrum of patients with coronary artery disease. ( Bhatt, DL, 2009) |
| "The present review focuses on the roles of thromboxane A2 (TxA2) in arterial thrombosis, atherogenesis, vascular stent-related ischemic events and renal proteinuria." | 4.85 | Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. ( Alberts, P; Bounameaux, H; Fontana, P; Mann, J; Sakariassen, KS; Sorensen, AS, 2009) |
| "Current guidelines support dual antiplatelet therapy with aspirin and clopidogrel (Plavix) in a number of clinical scenarios, ie, in ST-segment-elevation myocardial infarction (MI), non-ST-elevation MI, and percutaneous coronary intervention." | 4.85 | Dual antiplatelet therapy in coronary artery disease: a case-based approach. ( Menon, V; Raymond, C, 2009) |
| " aspirin) is pivotal in patients with or at risk of coronary artery disease." | 4.84 | The hazards of discontinuing acetylsalicylic acid therapy in those at risk of coronary artery disease. ( Biondi-Zoccai, GG; Lotrionte, M, 2008) |
| "The purpose of this article was to determine the incidence of in-stent thrombosis (IST) after coronary stent implantation in patients with cocaine abuse." | 4.84 | Increased incidence of in-stent thrombosis related to cocaine use: case series and review of literature. ( Arora, R; Bahekar, A; Handa, K; Khosla, S; Khraisat, A; Singh, S; Trivedi, A, 2007) |
| "Secondary prevention of coronary events in coronary artery disease (CAD) patients with aspirin is generally accepted because of ease of administration, predictable safety, and proven efficacy." | 4.83 | Long-term anticoagulant therapy in patients with coronary artery disease. ( Husted, SE; Kher, A; Ziegler, BK, 2006) |
| "The role of aspirin in patients with coronary artery disease (CAD) is well established, yet patients happen to discontinue aspirin according to physician's advice or unsupervised." | 4.83 | A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. ( Abbate, A; Agostoni, P; Biondi-Zoccai, GG; Burzotta, F; Fusaro, M; Lotrionte, M; Sangiorgi, G; Sheiban, I; Testa, L, 2006) |
| "Using the key terms acute coronary syndrome, atherothrombosis, ischemic stroke, myocardial infarction, MI, peripheral arterial disease, TIA, transient ischemic attack, unstable angina,aspirin,ticlopidine,dipyridamole, and clopidogrel, we searched the MEDLINE database as well as the trial register of the Cochrane Groups to identify studies published from 1960 to August 2004." | 4.82 | Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. ( Anand, SS; Tran, H, 2004) |
| "To provide a diagnostic strategy for evaluating and treating patients with aspirin sensitivity, with additional consideration for issues specific to patients with coronary artery disease (CAD)." | 4.82 | Aspirin sensitivity: implications for patients with coronary artery disease. ( Gollapudi, RR; Simon, RA; Stevenson, DD; Teirstein, PS, 2004) |
| " On the contrary, the initial treatment with clopidogrel in addition to aspirin and anticoagulation led to a 20% relative risk reduction for an endpoint of death, myocardial infarction and stroke in the CURE trial." | 4.81 | [Modern therapy in acute coronary syndrome]. ( Blankenberg, S; Espinola-Klein, C; Meyer, J; Rupprecht, HJ, 2002) |
| "Recently, studies have attempted to explore the interaction between ACE inhibitors and aspirin (acetylsalicylic acid) when both drugs are used concomitantly to reduce mortality in patients with coronary artery disease." | 4.81 | Interaction between aspirin and ACE Inhibitors: resolving discrepancies using a meta-analysis. ( Caamaño, F; Etminan, M; Rochon, PA; Takkouche, B, 2002) |
| "On the basis of this methodology, enoxaparin would appear to be more effective than placebo when added to aspirin in acute coronary syndromes." | 4.81 | Enoxaparin in acute coronary syndromes: evidence for superiority over placebo or untreated control. ( Cruickshank, MK; Massel, D, 2002) |
| " Aspirin in doses of approximately 300 mg/day may be recommended for the primary prevention of myocardial infarction (MI), but only in those patients with a moderate to high risk of cardiovascular disease." | 4.78 | Risk factors, interventions and therapeutic agents in the prevention of atherosclerosis-related ischaemic diseases. ( Verstraete, M, 1991) |
| " We aim to compare rates of postoperative bleeding, stroke and major adverse events (stroke, death or MI) among patients on Aspirin alone (ASAA) versus DAPT (Clopidogrel and Aspirin)." | 4.31 | Dual Antiplatelet Therapy Is Associated with Increased Risk of Bleeding and Decreased Risk of Stroke Following Carotid Endarterectomy. ( Dakour, H; Elsayed, N; Malas, MB; Marmor, R; Patel, RJ; Ramachandran, M, 2023) |
| "The innovative pharmacological combination of low-dose rivaroxaban plus aspirin provides clinicians with an ideal opportunity to intensify the medical treatment of patients with coronary artery disease (CAD) and comorbid peripheral artery disease (PAD)." | 4.31 | Cost-effectiveness analysis of screening for peripheral artery disease in patients with coronary artery disease in China: A Markov model. ( Qiu, Y; Wang, Y; Xing, Y; Yang, L; Yuan, Z, 2023) |
| "Dual pathway inhibition (DPI) with low-dose rivaroxaban and aspirin in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD) reduces the occurrence of cardiovascular (CV) events; however, the underlying mechanisms explaining these latter CV benefits are not clearly understood." | 4.31 | Dual Pathway Inhibition with Rivaroxaban and Aspirin Reduces Inflammatory Biomarkers in Atherosclerosis. ( Attena, E; Cotticelli, C; D'Alterio, G; D'Onofrio, A; Fabiani, D; Golino, P; Leonardi, S; Maione, B; Nigro, G; Rago, A; Russo, V; Sarpa, S, 2023) |
| "Within 12 months, ticagrelor 90 mg monotherapy was the only treatment associated with lower mortality, without bleeding risk trade-off compared with aspirin and clopidogrel." | 4.31 | Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneou ( Aboyans, V; Angiolillo, D; Atar, D; Capodanno, D; Fox, KAA; Halvorsen, S; James, S; Jüni, P; Kunadian, V; Landi, A; Leonardi, S; Mehran, R; Montalescot, G; Navarese, EP; Niebauer, J; Oliva, A; Piccolo, R; Price, S; Storey, RF; Valgimigli, M; Völler, H; Vranckx, P; Windecker, S, 2023) |
| "Many patients with coronary artery disease (CAD) have reduced the effect of aspirin, which may partly be explained by immature platelets." | 4.31 | Immature platelets and cardiovascular events in patients with stable coronary artery disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Pedersen, OB, 2023) |
| " A total of 477 patients receiving double antiaggregation therapy with aspirin and clopidogrel, after suffering a first event, were followed for 1 year to record relapse, as a surrogate end point to measure their therapeutic response, as defined by presenting with an acute coronary event (unstable angina, ST-segment-elevation myocardial infarction, or non-ST-segment-elevation myocardial infarction), stent thrombosis/restenosis, or cardiac mortality." | 4.12 | Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome. ( Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A, 2022) |
| "Low-dose aspirin (LDA) is the backbone for secondary prevention of coronary artery disease, although limited by gastric toxicity." | 4.12 | Prediction of Low-Dose Aspirin-Induced Gastric Toxicity Using Nuclear Magnetic Resonance Spectroscopy-Based Pharmacometabolomics in Rats. ( Abd Aziz, F; Ch'ng, ES; Ibrahim, B; Khalil, NA; Mohammed, M; Sha'aban, A; Teh, CH; Zainal, H, 2022) |
| "We aimed to investigate the effectiveness and safety of ticagrelor in comparison with clopidogrel on a background of aspirin for elderly Chinese patients with coronary artery disease 12 months after percutaneous coronary intervention." | 4.12 | Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study. ( Chen, Y; Gao, H; Han, P; Li, C; Lian, K; Liang, Y; Liu, Y; Tan, Z; Tao, F; Wang, Q; Wang, Z; Xu, S; Yang, L; Zhang, A; Zhang, Y; Zhao, S; Zhu, B, 2022) |
| " Univariate analysis showed that a family history of CHD, history of type 2 diabetes, hypertension, smoking, and drinking, discontinuation of aspirin, use of conventional dose statins, calcified lesions, ≥ 3 implanted stents, stent length ≥ 30 mm, stent diameter < 3 mm, and tandem stent increased the risk of restenosis." | 4.12 | Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease: A retrospective observational study. ( Bian, YJ; Liu, Y; Xue, YT; Zhang, J; Zhang, Q; Zhao, K, 2022) |
| " The COMPASS trial has shown that in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD), low-dose rivaroxaban (2." | 4.12 | [ANMCO Position paper: Evidence and practical indications for the use of low-dose rivaroxaban in stable coronary artery disease and peripheral artery disease]. ( Altamura, V; Bianco, M; Caldarola, P; Ceravolo, R; Cipriani, M; Colivicchi, F; De Luca, L; Di Fusco, SA; Francese, GM; Gabrielli, D; Gulizia, MM; Lucà, F; Nardi, F; Navazio, A; Oliva, F; Riccio, C; Rizzello, V; Scicchitano, P; Valente, S, 2022) |
| "Background The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial decreased major adverse cardiovascular events with very low-dose rivaroxaban and aspirin in patients with coronary artery disease and peripheral artery disease." | 4.12 | Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study. ( Abdel-Qadir, H; Chu, A; Farkouh, ME; Ferreira-Legere, LE; Goodman, SG; Ko, DT; Porter, J; Sheth, MS; Tam, DY; Udell, JA; Yu, B, 2022) |
| "Patients with diabetes and no obstructive coronary artery disease (CAD) as assessed by coronary angiography (CAG) are frequently treated with aspirin and statins." | 4.12 | Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Registry. ( Bøtker, HE; Heide-Jørgensen, U; Maeng, M; Olesen, KKW; Sørensen, HT; Thim, T; Thomsen, RW, 2022) |
| "Ticagrelor plus aspirin could reduce the risks of major adverse cardiac events in diabetic patients with stable coronary artery disease (SCD), and yet it also increases bleeding risk." | 4.02 | Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease. ( Shi, L; Wu, B, 2021) |
| "This study aimed to investigate the cost-effectiveness of low-dose rivaroxaban plus aspirin versus aspirin alone for patients with stable cardiovascular diseases in the Taiwan setting." | 4.02 | Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases. ( Chang, WT; Chen, ZC; Chou, CC; Lee, MC; Liao, CT; Strong, C; Toh, HS; Wu, WS; Yu, T, 2021) |
| "Dual antiplatelet therapy with aspirin and clopidogrel is commonly used for coronary artery disease (CAD) patients undergoing percutaneous coronary intervention to prevent stent thrombosis and ischemic events." | 4.02 | Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease. ( Chen, XP; Du, YX; Li, MP; Ma, QL; Peng, LM; Song, PY; Zhu, KX, 2021) |
| "To examine the association between CAC, bleeding, and ASCVD and explore the net estimated effect of aspirin at different CAC thresholds." | 4.02 | Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease. ( Ajufo, E; Ayers, CR; de Lemos, JA; Joshi, PH; Khera, A; Rohatgi, A; Vigen, R, 2021) |
| "To determine whether pre-hospitalization use of aspirin is associated with all-cause mortality in coronavirus disease 2019 (COVID-19) patients with coronary artery disease (CAD)." | 4.02 | Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease. ( Chen, C; Chen, P; Li, H; Wang, DW; Wang, F; Yuan, S, 2021) |
| " Case presentation A 66-year-old Japanese male patient received regorafenib for metastatic colorectal carcinoma and apixaban for deep vein thrombosis." | 4.02 | Early stent thrombosis confirmed in a cancer patient receiving regorafenib, despite triple antithrombotic therapy: a case report. ( Matoba, S; Ookura, T; Shoji, K; Yanishi, K; Zen, K, 2021) |
| "Clopidogrel is widely used for antiplatelet therapy in patients with coronary artery disease (CAD), but clopidogrel resistance (CR) is relatively common in these patients." | 4.02 | The expression profile of platelet-derived miRNA in coronary artery disease patients with clopidogrel resistance. ( Chen, R; Chen, X; Cheng, J; Hu, H; Hu, Y; Lin, S; Xu, X, 2021) |
| "5 mg twice daily) plus aspirin (100 mg once daily) with aspirin alone in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) and related subgroups." | 4.02 | Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy. ( Cortesi, PA; Di Laura, D; Ferrara, P; Maggioni, AP; Mantovani, LG, 2021) |
| " We conducted a network meta-analysis to compare ticagrelor with other receptor antagonists (P2Y12) inhibitors and aspirin in monotherapy or combination in the treatment of patients with high risk for cardiovascular or cerebrovascular disease, defined as coronary artery disease, acute coronary syndrome, stroke or transient ischemic attack, or peripheral artery disease." | 4.02 | Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events. ( Bálint, A; El Alaoui El Abdallaoui, O; Komócsi, A; Kupó, P; Tornyos, D, 2021) |
| "Aspirin is indispensable in secondary prevention of ischemic events in patients with coronary artery disease (CAD)." | 3.96 | Enhanced Platelet Reactivity under Aspirin Medication and Major Adverse Cardiac and Cerebrovascular Events in Patients with Coronary Artery Disease. ( Ayhan, A; Dannenberg, L; Helten, C; Hohlfeld, T; Kelm, M; Knoop, B; Konsek, D; Levkau, B; Metzen, D; Mourikis, P; Naguib, D; Petzold, T; Pöhl, M; Polzin, A; Trojovsky, K; Veulemans, V; Zako, S; Zeus, T, 2020) |
| "Patients treated with ticagrelor and aspirin usually suffer from bleeding events, especially mild bleeding which is one of the main factors reducing patients' adherence to ticagrelor." | 3.96 | Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischemic risk compared with 75-100 mg aspirin daily in coronary artery disease patients: insights from the TIFU (Ticagrelor in Fuwai Hospital) study. ( Chen, R; Chen, Y; Li, J; Liu, C; Sheng, Z; Song, L; Tan, Y; Yan, H; Zhao, H; Zhou, J; Zhou, P, 2020) |
| " Despite long-term antiplatelet therapy with aspirin, recurrent cardiovascular events remain common in patients with coronary artery disease (CAD)." | 3.96 | Imbalance between Fibrin Clot Formation and Fibrinolysis Predicts Cardiovascular Events in Patients with Stable Coronary Artery Disease. ( Ajjan, RA; Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S, 2020) |
| "In patients undergoing either MAG or SAG in the TiCAB trial, ticagrelor monotherapy compared with aspirin did not affect the rate of cardiovascular death, non-fatal MI, stroke or repeat revascularization, or the rate of bleeding, at 1 year after CABG." | 3.96 | Ticagrelor monotherapy versus aspirin in patients undergoing multiple arterial or single arterial coronary artery bypass grafting: insights from the TiCAB trial. ( Böning, A; Kastrati, A; Laufer, G; Misfeld, M; Nowak, B; Sandner, SE; Schunkert, H; Stritzke, J; Tebbe, U; von Scheidt, M; Wiedemann, D, 2020) |
| "To evaluate whether initial treatment with low-dose compared with high-dose aspirin in children with KD is associated with an increase in fever recrudescence." | 3.96 | Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin. ( Belarski, E; Carroll, AE; John, CC; Manaloor, J; Ofner, S; Platt, B; Wood, JB, 2020) |
| "The RE-DUAL PCI trial reported that dabigatran dual therapy (110/150 mg twice daily, plus clopidogrel or ticagrelor) reduced bleeding events versus warfarin triple therapy (warfarin plus aspirin and clopidogrel or ticagrelor) in patients with atrial fibrillation who underwent percutaneous coronary intervention, with noninferiority in composite thromboembolic events." | 3.96 | Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percut ( Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Kimura, T; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2020) |
| "Recent American College of Cardiology/American Heart Association Primary Prevention Guidelines recommended considering low-dose aspirin therapy only among adults 40 to 70 years of age who are at higher atherosclerotic cardiovascular disease (ASCVD) risk but not at high risk of bleeding." | 3.96 | Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis). ( Al Rifai, M; Blaha, MJ; Blumenthal, RS; Budoff, M; Cainzos-Achirica, M; Dardari, Z; Duprez, DA; Dzaye, O; Greenland, P; Hong, J; McEvoy, JW; Miedema, MD; Mortensen, MB; Nasir, K; Yeboah, J, 2020) |
| "This study aimed to determine the effect of preoperative aspirin administration on early and long-term clinical outcomes in patients suffering from diabetes mellitus (DM) undergoing coronary artery bypass grafting (CABG)." | 3.96 | Impact of Preoperative Aspirin on Long-Term Outcomes in Diabetic Patients Following Coronary Artery Bypass Grafting: a Propensity Score Matched Study. ( Aboul-Hassan, SS; Cichon, R; Lipowski, A; Marczak, J; Moskal, L; Nawotka, M; Peksa, M; Sá, MPBO; Stanislawski, R; Stankowski, T, 2020) |
| " Among current therapies, low-dose aspirin has been shown to reduce cardiovascular thrombosis." | 3.96 | A Pathophysiologic Primary Prevention Review of Aspirin Administration to Prevent Cardiovascular Thrombosis. ( Burchiel, S; Eaton, RP; Schade, DS, 2020) |
| "To identify whether lymphocyte hydrogen sulfide production is a potential biomarker for predicting coronary artery lesions (CAL) in children with Kawasaki disease (KD)." | 3.96 | Lymphocyte Hydrogen Sulfide Production Predicts Coronary Artery Lesions in Children with Kawasaki Disease: A Preliminary, Single-Center Study. ( Jiao, F; Lin, J; Ma, L; Wang, W; Zhao, H, 2020) |
| "A total of 41 Japanese coronary artery disease patients under HD who received aspirin and clopidogrel were enrolled." | 3.91 | High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis. ( Ariyoshi, N; Fujii, K; Fujimoto, Y; Kitahara, H; Kobayashi, Y; Kohno, Y; Nishi, T; Ohno, Y, 2019) |
| "To evaluate the effect of prestroke aspirin (PA) use on initial stroke severity, early neurologic deterioration (END), stroke recurrence, hemorrhagic transformation (HT), and functional outcome in patients with ischemic stroke (IS)." | 3.91 | Prestroke Aspirin Use is Associated with Clinical Outcomes in Ischemic Stroke Patients with Atherothrombosis, Small Artery Disease, and Cardioembolic Stroke. ( Han, Z; Lin, J; Luo, H; Yi, X; Zhou, J; Zhou, Q, 2019) |
| "Our study evaluated patients with ACS or stable coronary artery disease undergoing PCI and treated with mono-antiplatelet therapy with P2Y12 inhibitors due to aspirin intolerance shows a 25% incidence of POCE at one year." | 3.91 | Management of aspirin intolerance in patients undergoing percutaneous coronary intervention. The role of mono-antiplatelet therapy: a retrospective, multicenter, study. ( Bianco, M; Biscaglia, S; Campo, G; Cerrato, E; Corleto, A; Destefanis, P; Giolitto, S; Gravinese, C; Lo Savio, L; Luciano, A; Nuñez-Gil, I; Pozzi, R; Quadri, G; Tizzani, E; Varbella, F, 2019) |
| "In the COMPASS trial, combined aspirin and rivaroxaban treatment reduced ischaemic events in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD)." | 3.91 | External applicability of the COMPASS trial: the Western Denmark Heart Registry. ( Eikelboom, JW; Kristensen, SD; Maeng, M; Olesen, KKW; Thim, T; Würtz, M, 2019) |
| "In this prospective cohort study, 2439 Chinese patients with acute coronary syndrome or stable coronary artery disease undergoing coronary stent implantation and receiving clopidogrel and aspirin were consecutively recruited." | 3.91 | Impact of Platelet Endothelial Aggregation Receptor-1 Genotypes on Platelet Reactivity and Early Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention and Treated With Aspirin and Clopidogrel. ( Chan, NC; Chen, J; Fan, Y; Hu, X; Kong, D; Li, C; Li, J; Wang, F; Xu, K; Xu, L; Yang, L; Yang, M; Ye, S; Ying, L; Zhang, J; Zhang, S; Zhang, X; Zhu, H; Zhu, T, 2019) |
| "Patients with coronary artery disease (CAD) on DAPT maintenance dose (including aspirin 100 mg OD, plus clopidogrel 75 mg OD, or prasugrel 10 mg OD, or ticagrelor 90 mg BID) were prospectively enrolled before cessation of the P2Y12-inhibitor therapy." | 3.91 | Course of platelet miRNAs after cessation of P2Y12 antagonists. ( Andric, T; Haller, PM; Huber, K; Jäger, B; Kahl, BS; Piackova, E; Stojkovic, S; Vargas, KG; Wojta, J, 2019) |
| "The aims of the present study were to describe the proportion of patients eligible for the COMPASS trial within the Reduction of Atherothrombosis for Continued Health (REACH) registry, the reasons for ineligibility, and to put in perspective the characteristics and outcomes of trial-eligible patients from the REACH registry compared with those of patients enrolled in the reference aspirin arm of the COMPASS trial." | 3.88 | External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. ( Aboyans, V; Abtan, J; Anand, S; Bhatt, DL; Bosch, J; Branch, KR; Connolly, SJ; Darmon, A; Ducrocq, G; Dyal, L; Eagle, KA; Eikelboom, JW; Elbez, Y; Fox, KAA; Keltai, K; Probstfield, J; Sorbets, E; Steg, PG; Yusuf, S, 2018) |
| "BackgroundHigh-dose aspirin (HDA) is used with intravenous immunoglobulin (IVIg) in Kawasaki disease (KD)." | 3.88 | Duration of high-dose aspirin therapy does not affect long-term coronary artery outcomes in Kawasaki disease. ( Binstadt, BA; Braunlin, EA; Migally, K; Zhang, L, 2018) |
| "Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the cornerstone of the pharmacologic management of patients with acute coronary syndrome (ACS) and/or receiving coronary stents." | 3.88 | [ANMCO/ANCE/ARCA/GICR-IACPR intersociety consensus document: long-term antiplatelet therapy in patients with coronary artery disease]. ( Abrignani, MG; Ambrosetti, M; Aspromonte, N; Barile, G; Caporale, R; Casolo, G; Chiuini, E; Colivicchi, F; De Luca, L; Di Lenarda, A; Faggiano, P; Gabrielli, D; Geraci, G; Gulizia, MM; La Manna, AG; Maggioni, AP; Marchese, A; Massari, FM; Mureddu, GF; Musumeci, G; Nardi, F; Panno, AV; Pedretti, RFE; Piredda, M; Pusineri, E; Riccio, C; Rossini, R; Scotto Di Uccio, F; Urbinati, S; Varbella, F; Zito, GB, 2018) |
| "The authors investigated the risk of bleeding, ischemic stroke, MI, and all-cause mortality associated with direct oral anticoagulants (DOACs) compared with vitamin K antagonists (VKAs) in combination with aspirin, clopidogrel, or both in patients with AF following MI and/or PCI." | 3.88 | Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease. ( Berger, JS; Gislason, GH; Lamberts, M; Lock Hansen, M; Nissen Bonde, A; Olesen, JB; Pallisgaard, JL; Sindet-Pedersen, C; Staerk, L; Torp-Pedersen, C, 2018) |
| " The aim of the current study was to evaluate changes in aspirin and statin use in patients suspected for coronary artery disease after CAC scoring and normal single photon emission computed tomography (SPECT) MPI." | 3.85 | Changes in cardiovascular medication after coronary artery calcium scanning and normal single photon emission computed tomography myocardial perfusion imaging in symptomatic patients. ( Engbers, EM; Jager, PL; Knollema, S; Mouden, M; Ottervanger, JP; Timmer, JR, 2017) |
| "Seventy patients with stable coronary artery disease, supplemented with aspirin, participated in this pilot study." | 3.85 | MMP-2, MMP-9, and TIMP-4 and Response to Aspirin in Diabetic and Nondiabetic Patients with Stable Coronary Artery Disease: A Pilot Study. ( Bil-Lula, I; Gąsior, M; Kaczmarski, J; Kuliczkowski, W; Mysiak, A; Negrusz-Kawecka, M; Radomski, M; Urbaniak, J, 2017) |
| "This study is the largest to investigate platelet aggregation in stable coronary artery disease patients receiving aspirin as single antithrombotic therapy." | 3.85 | Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S; Würtz, M, 2017) |
| "Despite a preponderance of risk factors for CAV among patients receiving aspirin (male sex, ischemic heart disease as the etiology of heart failure, and smoking), aspirin therapy was associated with a lower rate of moderate or severe CAV at 5 years." | 3.85 | Early aspirin use and the development of cardiac allograft vasculopathy. ( Bergmark, BA; Gabardi, S; Givertz, MM; Kim, M; Mehra, MR; Page, DS; Smallwood, JA; Stewart, GC; Woodcome, EL; Zelniker, TA, 2017) |
| "Elderly, hospitalized coronary artery disease patients on regular aspirin treatment were enrolled from January 2014 to September 2016." | 3.85 | Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease. ( Chen, XH; Feng, XR; Fu, SW; He, XQ; Liang, WY; Liu, ML; Liu, WW; McCaffrey, TA; Zhang, JW, 2017) |
| "The initial EROSION study (Effective Anti-Thrombotic Therapy Without Stenting: Intravascular Optical Coherence Tomography-Based Management in Plaque Erosion) demonstrated that patients with acute coronary syndrome caused by plaque erosion might be stabilized with aspirin and ticagrelor without stenting for ≤1 month." | 3.85 | EROSION Study (Effective Anti-Thrombotic Therapy Without Stenting: Intravascular Optical Coherence Tomography-Based Management in Plaque Erosion): A 1-Year Follow-Up Report. ( Bryniarski, K; Hou, J; Hu, S; Jang, IK; Jia, H; Lee, H; Li, L; Liu, H; Ma, L; Sugiyama, T; Wang, C; Xing, L; Xu, M; Yamamoto, E; Yu, B; Zhang, S; Zhu, Y, 2017) |
| "The combined use of aspirin and oral anticoagulant therapy in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) has been questioned due to an increased risk of major bleeding with little to no benefit in preventing ischemic events." | 3.85 | Combined aspirin and anticoagulant therapy in patients with atrial fibrillation. ( Eckman, MH; So, CH, 2017) |
| " The objective was to examine the relation between all-cause mortality and the concentrations of urinary 11-dehydro thromboxane B2 (11dhTxB2) and 8-IsoPGF2α in patients with stable coronary artery disease (CAD)." | 3.85 | Residual thromboxane activity and oxidative stress: influence on mortality in patients with stable coronary artery disease. ( Bennett-Firmin, J; Bottiglieri, T; Lopez, LR; McCullough, PA; Peterson, M; Sathyamoorthy, M; Schiffmann, R; Schussler, JM; Swift, C; Tecson, KM; Vasudevan, A; Velasco, CE, 2017) |
| "There are limited data on aspirin (ASA) desensitization for patients with coronary artery disease." | 3.85 | Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease). ( Angiolillo, DJ; Anzuini, A; Bianco, M; Bossi, I; Capodanno, D; Colombo, P; Dossena, C; Iorio, A; Leonardi, S; Lettieri, C; Musumeci, G; Pozzi, R; Rigattieri, S; Rossini, R; Senni, M, 2017) |
| "In this hypothesis generating pilot analysis, dipyrone medication in aspirin treated coronary artery disease patients is associated with an increased cumulative incidence of death, MI or stroke as well as all-cause mortality and ischemic events." | 3.85 | Analgesic medication with dipyrone in patients with coronary artery disease: Relation to MACCE. ( Achilles, A; Dannenberg, L; Hohlfeld, T; Kelm, M; Levkau, B; Mohring, A; Piayda, K; Polzin, A; Zeus, T, 2017) |
| " Individuals who underwent coronary stenting and completed 12 months of thienopyridine plus aspirin therapy without ischemic or bleeding events remained on an aspirin regimen and were randomized to continued thienopyridine therapy vs placebo for 18 additional months." | 3.85 | Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. ( Apruzzese, PK; Cannon, CP; Cohen, DJ; Cutlip, DE; D'Agostino, RB; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017) |
| "Aspirin is the cornerstone of antiplatelet therapy in patients with coronary artery disease (CAD)." | 3.83 | Prevalence of aspirin resistance in Asian-Indian patients with stable coronary artery disease. ( Arun, SS; Chadha, DS; Jayaprasad, V; Karthikeyan, G; Sumana, B, 2016) |
| " As hyperuricemia activates platelet turnover, aspirin resistance may be specifically induced by increased serum uric acid (SUA) levels." | 3.83 | Does high serum uric acid level cause aspirin resistance? ( Alihanoglu, YI; Bilgin, M; Ergin, A; Esin, F; Evrengul, H; Kaftan, HA; Kilic, ID; Ozkan, E; Ozkan, H; Yildiz, BS, 2016) |
| " Our results suggest that this strategy is not beneficial as compared to aspirin alone in terms of ischaemic or bleeding events." | 3.83 | Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study). ( Bauters, C; Caudmont, S; Ketelers, R; Lamblin, N; Lemaire, N; Lemesle, G; Meurice, T; Philias, A; Schurtz, G; Tricot, O, 2016) |
| "Using the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (n = 10,135), we analyzed outcomes in patients with coronary artery disease (n = 1827) according to treatment with triple antithrombotic therapy (defined as concurrent therapy with an oral anticoagulant, a thienopyridine, and aspirin) or dual antithrombotic therapy (comprising either an oral anticoagulant and one antiplatelet agent [OAC plus AA] or 2 antiplatelet drugs and no anticoagulant [DAP])." | 3.83 | Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. ( Ansell, J; Chang, P; Fonarow, GC; Gersh, BJ; Go, AS; Hylek, EM; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Rao, M; Simon, DN; Singer, DE; Thomas, L, 2016) |
| "Aspirin use for primary prevention in patients at high risk with diabetes mellitus (DM) is often recommended under the assumption that most patients with DM have coronary artery disease (CAD)." | 3.83 | Value of Coronary Computed Tomography Angiography in Tailoring Aspirin Therapy for Primary Prevention of Atherosclerotic Events in Patients at High Risk With Diabetes Mellitus. ( Bax, JJ; de Graaf, MA; Delgado, V; Dimitriu-Leen, AC; Jukema, JW; Kharagjitsingh, AV; Knuuti, J; Kroft, LJ; Scholte, AJ; van den Hoogen, IJ; van Rosendael, AR; Wolterbeek, R, 2016) |
| "No aspirin resistance was detected among patients with stable coronary artery disease." | 3.83 | The lack of aspirin resistance in patients with coronary artery disease. ( Balogh, L; Bereczky, Z; Édes, I; Haramura, G; Homoródi, N; Katona, É; Kiss, RG; Kovács, EG; Leé, S; Muszbek, L; Péterfy, H; Shemirani, AH; Szőke, G, 2016) |
| "Within this retrospective observational spontaneous clinical study 44 patients (31 males and 13 females) all presenting stable coronary artery disease were evaluated; 25 subjects were treated with only acetylsalicylic acid and/or clopidogrel in association with statins (standard therapeutic protocol) while for the other 18 subjects the standard therapeutic protocol was integrated with Arnica comp." | 3.83 | Effects of Arnica comp.-Heel® on reducing cardiovascular events in patients with stable coronary disease. ( Bianchi, M; Di Nardo, V; Fioranelli, M; Roccia, MG, 2016) |
| "In patients receiving dual antiplatelet therapy for coronary artery disease, higher PTH levels are associated with an increased ADP-mediated platelet reactivity and suboptimal response to clopidogrel, especially for values above 96." | 3.83 | Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor. ( Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M, 2016) |
| " Vorapaxar, a novel platelet thrombin receptor (PAR-1/4) blocker, is currently approved for post-myocardial infarction and peripheral artery disease indications on top of clopidogrel or/and aspirin." | 3.83 | Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trial. ( Bekbossynova, M; Cattaneo, M; Golukhova, E; Kim, MH; Marciniak, TA; Pya, Y; Serebruany, VL, 2016) |
| "New antithrombotic therapies have significantly improved the outcomes of patients with acute coronary syndrome (ACS), where the introduction of ticagrelor has provided the greatest mortality benefits." | 3.83 | Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study. ( Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M, 2016) |
| " Among 614 participants with a preoperative diagnosis of coronary artery disease (CAD), in-hospital aspirin use was significantly higher in the contemporary period (66% vs 30." | 3.83 | Perioperative antiplatelet therapy and cardiovascular outcomes in patients undergoing joint and spine surgery. ( Berger, JS; Errico, T; Iorio, R; Nukala, S; Oberweis, BS; Radford, MJ; Rosenberg, A; Smilowitz, NR; Stuchin, S, 2016) |
| " However, higher on-treatment platelet reactivity was associated with lower plasma miR-223 in patients with coronary artery disease (CAD) on dual antiplatelet therapy (DAPT) including clopidogrel and aspirin." | 3.81 | Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report. ( Chyrchel, B; Chyrchel, M; Kołton-Wróż, M; Kruszelnicka, O; Mielecki, W; Surdacki, A; Totoń-Żurańska, J; Wołkow, P, 2015) |
| "By using data from the Get With The Guidelines-Coronary Artery Disease registry, we compared adherence to 6 performance measures (aspirin within 24 hours, discharge on aspirin, discharge on beta-blockers, patients with low ejection fraction discharged on angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, smoking cessation counseling, and use of lipid-lowering medications) in eligible patients with coronary artery disease who underwent coronary artery bypass graft surgery, percutaneous coronary intervention, or no intervention between 2003 and 2008." | 3.81 | Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease. ( Bhatt, DL; Cannon, CP; Deedwania, P; Fonarow, GC; Grau-Sepulveda, M; Hernandez, AF; Kumbhani, DJ; Laskey, WK; Peacock, WF; Peterson, ED; Schwamm, LH, 2015) |
| "Aspirin is recommended in stable coronary artery disease based on myocardial infarction and stroke studies." | 3.81 | Impact of aspirin according to type of stable coronary artery disease: insights from a large international cohort. ( Bavry, AA; Cooper-DeHoff, RM; Gong, Y; Handberg, EM; Pepine, CJ, 2015) |
| "We sought to examine the risk of mortality associated with nonobstructive coronary artery disease (CAD) and to determine the impact of baseline statin and aspirin use on mortality." | 3.81 | Prognostic and therapeutic implications of statin and aspirin therapy in individuals with nonobstructive coronary artery disease: results from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter registry) re ( Achenbach, S; Al-Mallah, M; Berman, DS; Budoff, MJ; Cademartiri, F; Callister, TQ; Chang, HJ; Chen, L; Cheng, VY; Chinnaiyan, K; Chow, BJ; Cury, R; Delago, A; Dunning, A; Feuchtner, G; Hadamitzky, M; Hausleiter, J; Karlsberg, RP; Kaufmann, PA; Kim, YJ; LaBounty, T; Leipsic, J; Lin, F; Maffei, E; McPherson, R; Min, JK; Raff, GL; Shaw, LJ; Small, G; Villines, TC; Yam, Y, 2015) |
| "Preoperatively continued aspirin use was not associated with increased risk of intra- and post-operative blood loss, blood transfusion requirements and composite outcome of in-hospital death, stroke and reoperation for bleeding in off-pump CABG." | 3.81 | Effect of preoperatively continued aspirin use on early and mid-term outcomes in off-pump coronary bypass surgery: a propensity score-matched study of 1418 patients. ( Pan, S; Song, Y; Sun, H; Wu, H; Xiao, F; Xu, J, 2015) |
| "Aspirin is a cornerstone in management of coronary artery disease (CAD)." | 3.81 | Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S; Würtz, M, 2015) |
| "Presence of non-obstructive coronary artery disease (CAD) is associated with increased prescription of cardiovascular preventive medications including aspirin." | 3.81 | Association between Aspirin Therapy and Clinical Outcomes in Patients with Non-Obstructive Coronary Artery Disease: A Cohort Study. ( Hwang, IC; Jeon, JY; Kim, HK; Kim, HM; Kim, Y; Kim, YJ; Lee, SP; Sohn, DW; Sung, J; Yoon, YE, 2015) |
| " The aim of our study was to compare between two established methods of aspirin response, urinary 11-dehydrothromboxane B2 (11dhTXB2) and platelet Light Transmission Aggregometry (LTA) assays in elderly Chinese patients with coronary artery disease (CAD), and to investigate the clinical significance of both methods in predicting cardiovascular events." | 3.81 | Comparison between urinary 11-dehydrothromboxane B2 detection and platelet Light Transmission Aggregometry (LTA) assays for evaluating aspirin response in elderly patients with coronary artery disease. ( Chen, X; Feng, X; Fu, SW; Liu, M; Liu, T; McCaffrey, TA; Zhang, J, 2015) |
| " As stents are prone to thrombosis, which can potentially be devastating, patients are treated with dual antiplatelet therapy with aspirin plus a thienopyridine for at least 6-12 months after stent placement." | 3.81 | Assessing the optimal strategy for dual antiplatelet therapy. ( Chang, L; Yeh, RW, 2015) |
| "Dual antiplatelet therapy with clopidogrel and aspirin is the current standard of care in the management of patients with coronary artery disease (CAD) and acute coronary syndrome (ACS)." | 3.81 | Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease. ( Arya, V; Bhargava, M; Mahajan, P; Mohanty, A; Saraf, A; Sawhney, JP, 2015) |
| "To elucidate the correlation between urinary 11-dehydro-thromboxane B2 (11dhTxB2) and clinical efficacy of aspirin treatment in patients with type 2 diabete and coronary artery disease (CAD)." | 3.81 | [Correlation between the level of the urinary 11-dehydrothromboxane B2 and the clinical efficacy of aspirin in patients with type 2 diabetes and coronary artery disease]. ( Bai, ZS; Chen, XH; Feng, XR; Liu, ML; Liu, TF; Zhang, JW, 2015) |
| " We included 48 patients with type II diabetes and stable coronary artery disease treated with aspirin 75 mg daily and 50 healthy individuals not taking any medications." | 3.80 | Rapid evaluation of platelet function using the Multiplate® Analyzer. ( Christensen, KH; Grove, EL; Hvas, AM; Kristensen, SD; Rubak, P; Würtz, M, 2014) |
| " Clopidrogel and aspirin are antiplatelet agents widely used in the treatment of peripheral vascular, cerebrovascular, and coronary artery disease." | 3.80 | Spontaneous chest wall hematoma with dual antiplatelet therapy. ( Bevan, P; Bunton, R; Menon, A, 2014) |
| " However, in patients with atrial fibrillation (AF), there is a concern that combining warfarin with dual antiplatelet therapy may increase the risk of bleeding." | 3.80 | Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents. ( Araki, T; Enomoto, Y; Hara, H; Hori, M; Iijima, R; Itaya, H; Ito, N; Nagashima, Y; Nakamura, M; Shiba, M; Sugi, K; Tokue, M; Utsunomiya, M; Yamazaki, K, 2014) |
| "We studied the association of thrombin generation potential with platelet protease activated receptor (PAR)-1 regulation and platelet activation in 52 stable coronary artery disease patients on continuous therapy with aspirin and clopidogrel (n = 42) or prasugrel (n = 10)." | 3.80 | Association of thrombin generation potential with platelet PAR-1 regulation and P-selectin expression in patients on dual antiplatelet therapy. ( Ay, C; Badr Eslam, R; Eichelberger, B; Gremmel, T; Lang, IM; Panzer, S; Posch, F, 2014) |
| "We recruited 50 volunteers from the Oglala Sioux Tribe with coronary artery disease taking aspirin and clopidogrel." | 3.80 | Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans. ( Best, LG; Dobesh, PP; Oestreich, JH, 2014) |
| "Aspirin and statin therapy are mainstay treatments in patients with coronary artery disease (CAD)." | 3.80 | Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin. ( Bliden, KP; Ens, G; Franzese, CJ; Gesheff, MG; Gurbel, PA; Guyer, K; Singh, M; Singla, A; Stapleton, D; Tabrizchi, A; Tantry, US; Toth, PP, 2014) |
| "Increased incidence of coronary artery disease has led to the increased use of dual antiplatelet therapy composed of aspirin and clopidogrel." | 3.80 | [Clinical impact of dual antiplatelet therapy on peptic ulcer disease]. ( Ahn, DG; Kim, BJ; Kim, JG; Kim, JW, 2014) |
| "Patients (DM, n = 30; non-DM, n = 30) with stable coronary artery disease taking aspirin 81 mg/day and P2Y12 antagonist naive were enrolled." | 3.80 | Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. ( Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Franchi, F; Guzman, LA; Jakubowski, JA; Moser, BA; Rollini, F; Sugidachi, A; Tello-Montoliu, A; Ueno, M, 2014) |
| "The effects of dual antiplatelet therapy with aspirin and clopidogrel on the progression of native coronary artery disease after coronary artery bypass grafting are unknown." | 3.80 | Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial. ( Al-Atassi, T; Kulik, A; Le May, M; Ruel, M; Une, D; Voisine, P, 2014) |
| "Patients on aspirin therapy for 1 week or longer with known or suspected coronary artery disease undergoing nonurgent cardiac catheterization (n=1172), of whom 924 were on aspirin and clopidogrel therapy, were studied." | 3.80 | Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients. ( Bliden, KP; Franzese, C; Gurbel, PA; Jeong, YH; Kang, K; Lev, EI; Pandya, S; Tantry, US, 2014) |
| "We included 985 Danish patients with stable coronary artery disease treated with aspirin 75 mg/day mono antiplatelet therapy." | 3.80 | Genetic determinants of on-aspirin platelet reactivity: focus on the influence of PEAR1. ( Grove, EL; Hvas, AM; Kristensen, SD; Nissen, PH; Würtz, M, 2014) |
| "A total of 2141 patients with coronary artery disease treated exclusively with Cypher sirolimus-eluting stents (SES) or Endeavor zotarolimus-eluting stents (ZES) were considered for retrospective analysis." | 3.79 | Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents. ( Chen, F; Gao, Y; He, J; Luo, Y; Lv, S; Ren, X; Wu, C; Yu, X; Zhang, X; Zhang, Y, 2013) |
| " We examined whether plasma L5 levels are elevated in patients with ST-segment elevation myocardial infarction (STEMI) and whether aspirin provides epigenetic protection of human coronary artery ECs (HCAECs) exposed to L5." | 3.79 | Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: a novel cytoprotective role of aspirin in acute myocardial infarction. ( Chang, FH; Chang, PY; Chang, SF; Chen, CH; Chen, YJ; Huang, WH; Lee, YT; Lu, J; Lu, SC; Yang, TC, 2013) |
| " Limited data are available exploring the age dependency of ex vivo aspirin response in young and old patients with stable coronary artery disease." | 3.79 | Relation of aspirin response to age in patients with stable coronary artery disease. ( Bental, T; Kornowski, R; Lev, EI; Solodky, A; Vaduganathan, M; Vaturi, M, 2013) |
| "The aim of the study was to determine the association of coronary computed tomographic angiography (CTA)-identified coronary artery disease (CAD) with post-test aspirin, statin, and antihypertensive medication use and changes in cholesterol and blood pressure (BP)." | 3.79 | Changes in preventive medical therapies and CV risk factors after CT angiography. ( Cheezum, MK; Hulten, EA; Kircher, J; Smith, RM; Surry, L; Taylor, AJ; Villines, TC; York, M, 2013) |
| "The aim of this study was to evaluate the association of PON1 genetic variants with the susceptibility to coronary artery disease (CAD) and with the clinical endpoints in aspirin and clopidogrel (dual antiplatelet therapy)-treated Han Chinese patients with CAD after percutaneous coronary intervention (PCI)." | 3.79 | Association of PON1 genotype and haplotype with susceptibility to coronary artery disease and clinical outcomes in dual antiplatelet-treated Han Chinese patients. ( Chen, JY; Kang, YH; Lai, WH; Lao, HY; Li, XX; Wu, H; Yu, XY; Zhong, SL, 2013) |
| " To assess the efficacy and safety of aspirin desensitisation in Chinese patients with coronary artery disease." | 3.79 | Aspirin desensitisation for Chinese patients with coronary artery disease. ( Chan, HL; Chan, KK; Chau, CH; Cheung, CY; Cheung, GS; Choi, MC; Lee, JK; Li, SK; Tsui, KL; Wu, KL, 2013) |
| "Patients with established coronary artery disease (CAD) are likely to receive a combination of aspirin, a statin, and blood pressure (BP)-lowering agents." | 3.79 | The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease. ( Bots, ML; Grobbee, DE; Lafeber, M; Nathoe, H; Spiering, W; van der Graaf, Y; Visseren, FL, 2013) |
| "We included 177 stable coronary artery disease patients on aspirin monotherapy." | 3.79 | Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure. ( Ajjan, R; Grove, EL; Hess, K; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S, 2013) |
| "This study sought to assess the usefulness of clopidogrel-pathway genotyping and on-treatment platelet reactivity (OTR) testing in predicting major adverse cardiac events (MACE) in stable coronary artery disease (CAD) patients receiving drug-eluting stents (DES) under dual antiplatelet (clopidogrel plus aspirin) therapy." | 3.79 | Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. ( Briguori, C; Condorelli, G; De Micco, F; Focaccio, A; Latronico, MV; Pagnotta, P; Papa, L; Roncarati, R; Visconti, G; Viviani Anselmi, C, 2013) |
| "Variability in the response to aspirin (sometimes known as aspirin resistance) in modulating platelet activity is a potentially important clinical issue in coronary artery disease (CAD), but may be also be important in other areas of pathophysiology." | 3.79 | Vascular and platelet responses to aspirin in patients with coronary artery disease. ( Blann, AD; Kuzniatsova, N; Lip, GY, 2013) |
| "Aspirin (ASA) reduces adverse events in coronary artery disease (CAD) patients by inhibiting platelets." | 3.79 | Prevalence of high platelet reactivity in aspirin-treated patients referred for coronary angiography. ( Croce, K; Gottschall, C; Manfroi, C; Manica, A; Marchini, JF; Rodrigues, LH; Sarmento-Leite, R, 2013) |
| "To characterize the clinical presentation of a cohort of patients with coronary artery disease (CAD) and aspirin reactions." | 3.79 | Characterization of aspirin allergies in patients with coronary artery disease. ( Feng, CH; Stevenson, DD; White, AA, 2013) |
| "A 73-year-old woman was admitted to our hospital with anterior acute myocardial infarction due to subacute thrombosis after coronary stenting with a zotarolimus-eluting stent (ZES), which is a newly developed drug-eluting stent that has been widely used since May 2009 in Japan." | 3.78 | A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent. ( Arima, M; Matsuda, A; Nitta, M; Shimizu, M; Yoshida, K, 2012) |
| "The widespread use of aspirin-driven vascular prevention strategies does not impede the occurrence of first and recurrent ischemic strokes in numerous subjects." | 3.78 | Ischemic stroke in patients receiving aspirin. ( Ameriso, S; Ameriso, SF; Povedano, GP; Pujol Lereis, VA, 2012) |
| "We included 417 patients with coronary artery disease on aspirin mono-therapy and 21 aspirin-naïve healthy individuals." | 3.78 | Platelet aggregation is dependent on platelet count in patients with coronary artery disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Würtz, M, 2012) |
| "These were post hoc analyses of datasets from the Aspirin Myocardial Infarction Study, a 1:1 randomized, double-blind clinical trial, conducted from 1975 to 1979, that examined mortality rates following daily aspirin administration over three years in individuals with documented MI." | 3.78 | Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction. ( Dabbous, O; Hariri, A; Krishnan, E; Lingala, B; Pandya, BJ, 2012) |
| "Increased residual platelet reactivity remains a burden for coronary artery disease (CAD) patients who received a coronary stent and do not respond sufficiently to treatment with acetylsalicylic acid and clopidogrel." | 3.78 | Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study. ( Ahrens, I; Bode, C; Brandt, C; Duerschmied, D; Mauler, M; Moser, M; Weidner, S, 2012) |
| " We present a case of postoperative simultaneous left anterior descending and right coronary stent thrombosis that followed cessation of long-term aspirin therapy in a patient with stable coronary artery disease." | 3.78 | Simultaneous left anterior descending and right coronary stent thrombosis after aspirin withdrawal. ( Abdelmalak, HD; Camporesi, EM; Karlnoski, R; Mangar, D; Omar, HR, 2012) |
| "Platelet reactivity was assessed by the light transmission aggregometry and TxB(2) assay in 423 patients with coronary artery disease (CAD) on aspirin." | 3.78 | P2RY1 and P2RY12 polymorphisms and on-aspirin platelet reactivity in patients with coronary artery disease. ( Aung, PP; Barnard, J; Bhatt, DL; Gaussem, P; Kottke-Marchant, K; Murugesan, G; Silverstein, RL; Timur, AA; Wang, QK; Zhang, L, 2012) |
| " The majority of patients had stable coronary artery disease (73%) and received sirolimus-eluting stents (93%), and approximately 90% of thienopyridine was ticlopidine." | 3.78 | Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2. ( Abe, M; Araki, M; Byrne, RA; Ehara, N; Eizawa, H; Fujiwara, H; Furukawa, Y; Inada, T; Iwabuchi, M; Kaburagi, S; Kadota, K; Kastrati, A; Kimura, T; Kita, T; Mitsudo, K; Mitsuoka, H; Mizoguchi, T; Morimoto, T; Nakagawa, Y; Nakano, A; Natsuaki, M; Nobuyoshi, M; Nohara, R; Shiomi, H; Shizuta, S; Suwa, S; Tada, T; Takizawa, A; Taniguchi, R; Tazaki, J, 2012) |
| "Aspirin is the most commonly used antiplatelet agent in patients with coronary artery disease (CAD)." | 3.78 | Aspirin sensitivity and coronary artery disease: implications for the practicing cardiologist. ( Das, P; Lieberman, P; Pattanaik, D, 2012) |
| "This study aimed to characterize the in vitro effect of EV-077, a compound that antagonises the binding of prostanoids and isoprostanes to the thromboxane receptor (TP) and inhibits the thromboxane synthase (TS), on platelet aggregation of patients with type-2 diabetes and coronary artery disease (CAD) on chronic aspirin treatment." | 3.78 | EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin. ( Alberts, P; Armesto, AR; Cattaneo, M; Daray, FM; Errasti, AE; Femia, EA; Meyer, JP; Nowak, W; Podda, GM; Pugliano, M; Razzari, C; Rothlin, RP; Sakariassen, KS; Sorensen, AS, 2012) |
| " An objective causality assessment suggested that the liver hematoma was possibly related to the combination of clopidogrel and aspirin." | 3.78 | Dual antiplatelet agent-induced spontaneous liver hematoma. ( Darwish, OS; Iqbal, E, 2012) |
| "To investigate the impact of platelet turnover on the antiplatelet effect of aspirin in patients with stable coronary artery disease (CAD) and to identify determinants of platelet turnover." | 3.77 | Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Mortensen, SB, 2011) |
| " We determined the association of CYP2C19 loss-of-function (*2) and gain-of-function (*17) allele status with platelet reactivity in 118 stented patients on DAPT ≥2 weeks and in 143 patients with stable coronary artery disease on aspirin therapy alone." | 3.77 | The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. ( Bliden, KP; Gurbel, PA; Pakyz, RE; Ryan, K; Shuldiner, AR; Tantry, US, 2011) |
| "192 Caucasian patients with stable coronary artery disease treated with daily aspirin were recruited and followed for 3 years." | 3.77 | Genetic determinants of response to aspirin: appraisal of 4 candidate genes. ( Diodati, JG; Lordkipanidzé, M; Palisaitis, DA; Pharand, C; Schampaert, E; Turgeon, J, 2011) |
| "An increasing number of patients suffering from cardiovascular disease, especially coronary artery disease (CAD), are treated with aspirin and/or clopidogrel for the prevention of major adverse events." | 3.77 | Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on ( Cattaneo, M; Chassot, PG; Eichinger, S; Hofmann, N; Huber, K; Korte, W; Rickli, H; Spannagl, M; Verheugt, F; von Heymann, C; Ziegler, B, 2011) |
| "This study demonstrates that high on treatment platelet reactivity with aspirin and/or clopidogrel is common amongst patients who develop stent thrombosis." | 3.77 | High on treatment platelet reactivity and stent thrombosis. ( French, JK; Juergens, CP; Parikh, D; Rajendran, S; Shugman, I, 2011) |
| "We hypothesized that single-nucleotide polymorphisms (SNPs) associated with heightened in vitro platelet function during aspirin exposure (which we define as "laboratory aspirin resistance") would be associated with greater risk for death, myocardial infarction (MI) or stroke among patients with coronary artery disease regularly using aspirin." | 3.77 | Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use. ( Horton, J; Newby, LK; Shah, SH; Shaw, LK; Voora, D, 2011) |
| "Pre-hospitalization medication such as aspirin and nitrates has been shown to affect the mode of presentation in acute coronary syndrome (ACS)." | 3.77 | Differences in the mode of presentation for acute coronary syndrome by pre-hospitalization medication, in relation to coronary risk factors, East-Osaka acute coronary syndrome (EACS) registry. ( Hoshida, S; Iwasaka, J; Iwasaka, T; Kijima, Y; Lim, YJ; Yuasa, F, 2011) |
| "We enrolled 202 consecutive patients with stable coronary artery disease (CAD) undergoing PCI and treated with clopidogrel." | 3.77 | Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention. ( Abe, T; Deguchi, M; Hokimoto, S; Horio, E; Iwashita, S; Kaikita, K; Miyazaki, Y; Nakagawa, K; Nakamura, S; Ogawa, H; Ono, T; Sato, K; Sugiyama, S; Sumida, H; Tayama, S; Tsujita, K; Yamabe, H; Yamamoto, K, 2011) |
| "Increased baseline platelet reactivity as well as diabetes mellitus and acute coronary syndrome are associated with low aspirin response in the aged patients." | 3.77 | [Aspirin response and related factors in aged patients]. ( Fan, Y; Feng, XR; Liu, F; Liu, ML; Liu, QZ; Tian, QP, 2011) |
| "Two hundred consecutive subjects suffering from stable coronary artery disease and under daily aspirin therapy were enrolled in our study." | 3.76 | Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin. ( Diodati, JG; Lordkipanidzé, M; Palisaitis, DA; Pharand, C; Schampaert, E; Turgeon, J, 2010) |
| "The aim of this study was to assess the association between "aspirin non responsiveness" in patients with coronary artery diseases (CAD) and the risk of major adverse cardiovascular events (MACE)." | 3.76 | Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease. ( Abderazek, F; Addad, F; Ben-Farhat, M; Chakroun, T; Dridi, Z; Elalamy, I; Gamra, H; Hamdi, S; Hassine, M; Samama, MM, 2010) |
| "To evaluate the effect of proton pump inhibitors (PPIs) on the platelet response to aspirin in patients with coronary artery disease (CAD)." | 3.76 | The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Würtz, M, 2010) |
| "Platelet hyperreactivity in MEA might be a better risk predictor for stent thrombosis than the assessment of the specific clopidogrel effect with the VASP phosphorylation assay." | 3.76 | Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. ( Christ, G; Delle-Karth, G; Huber, K; Jilma, B; Lang, IM; Siller-Matula, JM, 2010) |
| "We sought to assess the impact of renal function on platelet reactivity in patients with diabetes mellitus (DM) and coronary artery disease on aspirin and clopidogrel therapy." | 3.76 | Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. ( Alfonso, F; Angiolillo, DJ; Bass, TA; Bernardo, E; Capodanno, D; Fernandez-Ortiz, A; Ferreiro, JL; Jimenez-Quevedo, P; Macaya, C; Sabaté, M; Ueno, M; Vivas, D, 2010) |
| "The inability of aspirin (ASA) to adequately suppress platelet aggregation is associated with future risk of coronary artery disease (CAD)." | 3.76 | A combined genome-wide linkage and association approach to find susceptibility loci for platelet function phenotypes in European American and African American families with coronary artery disease. ( Becker, DM; Becker, LC; Faraday, N; Hererra-Galeano, JE; Kim, Y; Mantese, VJ; Mathias, RA; Ruczinski, I; Sung, H; Wilson, AF; Yanek, LR, 2010) |
| " We tested the hypothesis that the endocannabinoid, 2-arachidonyl glycerol (2-AG), induces platelet aggregation by a COX-mediated mechanism rather than through CB(1) receptor activation, in blood obtained from healthy volunteers and patients with coronary artery disease receiving low dose aspirin." | 3.76 | 2-arachidonyl glycerol activates platelets via conversion to arachidonic acid and not by direct activation of cannabinoid receptors. ( Barrett, F; Keown, OP; Leslie, SJ; Macrury, SM; Megson, IL; Neilson, I; Wainwright, CL; Winterburn, TJ, 2010) |
| "This study sought to evaluate the platelet response to aspirin and the immature platelet fraction in patients with previous stent thrombosis (ST)." | 3.76 | Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. ( Grove, EL; Hvas, AM; Jensen, LO; Kaltoft, AK; Kristensen, SD; Tilsted, HH; Wulff, LN; Würtz, M, 2010) |
| "To report a case of metastatic leiomyosarcoma, in which a patient developed chest pain accompanied by acute left bundle-branch block (LBBB) after gemcitabine infusion." | 3.75 | Gemcitabine-induced acute coronary syndrome: a case report. ( Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Ozdemir, M; Ozturk, B; Sahin, G; Tacoy, G; Topal, S; Yaman, E; Yildiz, R, 2009) |
| "7% male) at risk for coronary artery disease (CAD) before and after low dose aspirin." | 3.75 | Leukocyte count is associated with increased platelet reactivity and diminished response to aspirin in healthy individuals with a family history of coronary artery disease. ( Becker, DM; Becker, LC; Faraday, N; Herrera-Galeano, JE; Kral, B; Moy, TF; Qayyum, R; Vaidya, D; Yanek, LR, 2009) |
| "Aspirin reduces cardiovascular events in patients with coronary artery disease (CAD), but studies report a highly variable response to aspirin, often referred to as 'aspirin low-responsiveness'." | 3.75 | Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. ( Daví, G; Grove, EL; Hedegaard, SS; Hvas, AM; Kristensen, SD; Refsgaard, J; Rocca, B, 2009) |
| "One hundred and sixty-one coronary artery disease patients taking aspirin alone and 91 patients taking a combination of aspirin and clopidogrel were enrolled." | 3.75 | Evaluation of the platelet count drop method for assessment of platelet function in comparison with "gold standard" light transmission aggregometry. ( Diodati, JG; Lordkipanidzé, M; Palisaitis, DA; Pharand, C; Schampaert, E, 2009) |
| "Aspirin chemoprophylaxis for coronary artery disease (CAD) is recommended for persons with the metabolic syndrome." | 3.75 | Native platelet aggregation and response to aspirin in persons with the metabolic syndrome and its components. ( Becker, DM; Becker, LC; Faraday, N; Moy, TF; Vaidya, D; Yanek, LR, 2009) |
| "This study sought to investigate the incidence of stent thrombosis (ST) in patients treated with drug-eluting stents (DES) and clearly defined short-term dual antiplatelet therapy (DAT) for three or six months for sirolimus-eluting stents (SES) or paclitaxel-eluting stents (PES), respectively." | 3.75 | Incidence of stent thrombosis in patients with drug eluting stents and short-term dual antiplatelet therapy. ( Hartenthaler, B; Hofmann, R; Hönig, S; Kammler, J; Kerschner, K; Kypta, A; Lambert, T; Leisch, F; Steinwender, C, 2009) |
| "In this prospective study of 700 aspirin-treated patients presenting for angiographic evaluation of coronary artery disease, residual platelet COX-1 function measured by serum thromboxane B(2) and COX-1-independent platelet function measured by PFA-100 collagen-ADP CT, but not indirect COX-1-dependent assays (arachidonic acid-stimulated platelet markers, shortened PFA-100 collagen-epinephrine CT), correlate with subsequent major adverse cardiovascular events." | 3.75 | Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. ( Barnard, MR; Christie, DJ; Fox, ML; Frelinger, AL; Furman, MI; Li, Y; Linden, MD; Michelson, AD, 2009) |
| "Clopidogrel as a sole anti-platelet treatment after coronary stenting resulted in a relatively high percentage of subacute stent thrombosis." | 3.75 | Coronary artery stenting in patients treated by clopidogrel without aspirin. ( Amit, G; Leibowitz, D; Rott, D; Weiss, AT; Zahger, D, 2009) |
| "Despite the availability of various prevention guidelines on coronary artery disease, secondary prevention practice utilizing aspirin, beta-blockers, angiotensin converting enzyme inhibitors and statins still can be sub-optimal." | 3.74 | Five-year follow-up of drug utilization for secondary prevention in coronary artery disease. ( Apikoglu Rabus, S; Izzettin, FV; Karakaya, O; Kargin, R; Sancar, M; Yakut, C, 2008) |
| "Aspirin is currently known to give inadequate protection against coronary artery disease in diabetes compared to person without it." | 3.74 | A study of aspirin resistance in type 2 diabetes. ( Chaudhuri, U; Chowdhury, S; Lahiri, P; Mukhopadhyay, P; Pandit, K; Singla, MK, 2008) |
| " A patient suffering from coronary artery disease and taking metoprolol and aspirin was stung by wasps and developed cutaneous allergic signs including rash, urticaria and orbital oedema." | 3.74 | Hymenoptera sting-induced Kounis syndrome: effects of aspirin and beta-blocker administration. ( Ioannidis, TI; Karpeta, MZ; Kounis, GN; Kounis, NG; Mazarakis, A; Notaras, SP; Rallis, DG; Tsintoni, AC, 2007) |
| "Secondary post hoc analysis of an existing dataset consisting of 711 patients after coronary stenting (n = 601) and ischemic stroke (n = 110) treated previously with aspirin for at least 1 month, and then with aspirin + clopidogrel for at least 7 days was performed." | 3.74 | Combination antiplatelet therapy with aspirin and clopidogrel: the role of antecedent and concomitant doses of aspirin. An analysis of 711 patients. ( Atar, D; Malinin, AI; Serebruany, VL, 2007) |
| " We examined 66 healthy control individuals, 144 aspirin users with stable coronary artery disease (CAD), and 245 CAD patients treated with aspirin and clopidogrel." | 3.74 | Determination of aspirin responsiveness by use of whole blood platelet aggregometry. ( Giannitsis, E; Hohlfeld, T; Ivandic, BT; Katus, HA; Schlick, P; Staritz, P, 2007) |
| " Poisson regression models were used to assess whether CAM use was independently associated with lower rates of aspirin, beta-blocker, and statin use in 596 patients with established coronary artery disease (CAD)." | 3.74 | Self-reported use of complementary and alternative medicine in patients with previous acute coronary syndrome. ( Banerjee, S; Buchanan, DM; Decker, C; Huddleston, J; Jones, A; Kosiborod, M; Spertus, JA; Stoner, C, 2007) |
| "To determine whether patients with documented myocardial infarction (MI) while on aspirin therapy (cases) were more likely to be aspirin resistant than were patients with coronary artery disease (CAD) who had no history of MI (controls) and to assess clinical predictors of aspirin resistance in patients with stable CAD." | 3.74 | Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. ( Colby, E; Dorsch, MP; Dunn, SP; Lee, JS; Lynch, DR; Montague, D; Rodgers, JE; Schwartz, T; Smyth, SS, 2007) |
| "Silent myocardial ischemia (SMI) is a relatively common complication in patients with coronary artery disease (CAD) under aspirin therapy presenting with upper gastrointestinal hemorrhage (UGIH)." | 3.74 | A risk score to predict silent myocardial ischemia in patients with coronary artery disease under aspirin therapy presenting with upper gastrointestinal hemorrhage. ( Chen, CC; Chong, CF; Kuo, CD; Wang, TL, 2007) |
| "Recent studies have suggested that low-dose aspirin has preserved benefit with less bleeding compared with standard-dose aspirin when given with or without clopidogrel in patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACSs)." | 3.74 | Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative. ( Cannon, CP; Gibler, WB; Milford-Beland, S; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Tickoo, S, 2007) |
| "We sought to compare the results obtained from six major platelet function tests in the assessment of the prevalence of aspirin resistance in patients with stable coronary artery disease." | 3.74 | A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. ( Diodati, JG; Lordkipanidzé, M; Palisaitis, DA; Pharand, C; Schampaert, E; Turgeon, J, 2007) |
| "We sought to determine the clinical significance of aspirin resistance measured by a point-of-care assay in stable patients with coronary artery disease (CAD)." | 3.74 | Aspirin resistance and adverse clinical events in patients with coronary artery disease. ( Chen, WH; Cheng, X; Kwok, JY; Lau, CP; Lee, PY; Ng, W; Tse, HF, 2007) |
| "Hyperhomocysteinemia confers an increased risk of coronary artery disease, stroke, and deep vein thrombosis, and is a strong predictor of mortality among patients with ischemic heart disease." | 3.74 | Homocysteine (Hcy) follow-up study. ( Blum, A; Blum, N; Eizenberg, MM; Hijazi, I, 2007) |
| "Platelet function analyses, which included measures of platelet aggregation and activation, were performed in 173 T2DM patients with coronary artery disease on chronic treatment with aspirin and clopidogrel." | 3.74 | Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. ( Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bass, TA; Bernardo, E; Costa, MA; Escaned, J; Fernandez-Ortiz, A; Guzman, LA; Hernández-Antolin, R; Jimenez-Quevedo, P; Macaya, C; Moreno, R; Palazuelos, J; Sabaté, M, 2007) |
| " Therefore, we investigated the effects of these polymorphisms on platelet aggregation in aspirin-treated patients with coronary artery disease (CAD)." | 3.74 | P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease. ( Bierend, A; Böger, RH; Maas, R; Rau, T; Schwedhelm, E, 2008) |
| "In patients with RI undergoing PCI, adding abciximab to clopidogrel plus aspirin increases the risk of bleeding without benefit in reducing the risk of ischemic complications within the first 30 days." | 3.74 | Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function. ( Kastrati, A; Mann, JF; Mehilli, J; Ndrepepa, G; Pinkau, T; Schömig, A; Schulz, S, 2008) |
| "In our study, endothelial dysfunction was found in all the patients with stable coronary artery disease, without any association of its presence and severity with aspirin resistance." | 3.74 | [The relationship between aspirin resistance and endothelial dysfunction in patients with stable coronary artery disease]. ( Buğra, Z; Elitok, A; Nişanci, Y; Oflaz, H; Onür, I; Pamukçu, B, 2008) |
| "Between September 1999 and April 2002, a total of 1,236 patients hospitalized for acute coronary syndrome (ACS) were questioned in order to determine whether aspirin intake had been interrupted." | 3.73 | Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. ( Benhamou, M; Cerboni, P; Ferrari, E; Marcel, B, 2005) |
| "To study the discontinuation of aspirin therapy as a risk factor for ischemic stroke (IS)." | 3.73 | Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. ( Bezerra, DC; Bogousslavsky, J; Maulaz, AB; Michel, P, 2005) |
| "We sought to determine patterns of aspirin use and the relationship between aspirin prescription and outcomes in patients with coronary artery disease (CAD) and heart failure (HF)." | 3.73 | Aspirin use in older patients with heart failure and coronary artery disease: national prescription patterns and relationship with outcomes. ( Foody, JM; Havranek, EP; Krumholz, HM; Masoudi, FA; Rathore, SS; Wolfe, P, 2005) |
| "Utilization rates of aspirin, beta blockers, angiotensin-converting enzyme inhibitors, and statins singly and as part of a multidrug regimen before hospitalization were measured in 109,540 patients with a history of coronary artery disease presenting with acute myocardial infarction to 1,283 hospitals participating in the National Registry of Myocardial Infarction-4." | 3.73 | Use of combination evidence-based medical therapy prior to acute myocardial infarction (from the National Registry of Myocardial Infarction-4). ( Frederick, PD; Goldberg, RJ; Gore, JM; Spencer, FA; Tiefenbrunn, AJ, 2005) |
| "A total of 991 patients with coronary artery disease (CAD) on low-dose aspirin were prospectively followed-up for two years for the occurrence and clinical features of first hospitalized episode of UGIB." | 3.73 | Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease. ( Chen, WH; Cheng, X; Lai, KC; Lam, KF; Lau, CP; Lee, PY; Li, SW; Ng, M; Ng, W; Tse, HF; Wong, WM, 2006) |
| "Thrombotic events still occur in aspirin-treated patients with coronary artery disease." | 3.73 | Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. ( Barnard, MR; Fox, ML; Frelinger, AL; Furman, MI; Li, Y; Linden, MD; Michelson, AD, 2006) |
| "To evaluate recent trends, we examined longitudinal national data on the outpatient use of warfarin in atrial fibrillation (AF), beta-blockers and aspirin in coronary artery disease (CAD), and angiotensin-converting enzyme inhibitors (ACEIs) in congestive heart failure (CHF)." | 3.72 | The underutilization of cardiac medications of proven benefit, 1990 to 2002. ( Radley, DC; Stafford, RS, 2003) |
| "We report the incidence of aspirin nonresponsiveness in a prospective, multicenter registry (n=422 patients) to be 23% using the Ultegra Rapid Platelet Function Assay-ASA, and determined a history of coronary artery disease to be associated with twice the odds of being an aspirin nonresponder (odds ratio 2." | 3.72 | Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. ( Aucoin-Barry, D; Block, EH; Block, PC; Gray, W; Ladenheim, M; Manuelian, D; Monbouquette, R; Reisman, M; Simon, DI; Wang, JC, 2003) |
| "The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes." | 3.72 | Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004) |
| "Acetylsalicylic acid, or aspirin, is widely used in secondary prevention of coronary artery diseases, but the inhibition of platelet aggregation is not uniform in all individuals." | 3.71 | Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. ( Allal, J; Brizard, A; Christiaens, L; Coisne, D; Duplantier, C; Herpin, D; Macchi, L; Mauco, G, 2002) |
| "As platelet hyperactivity is important in atherosclerosis and smoking, we hypothesized higher levels of soluble platelet membrane glycoprotein V (gpV) in 95 patients with peripheral artery disease (PAD) and 92 with coronary artery disease (CAD) compared to 99 healthy controls, and examined the effects of aspirin and of smoking two cigarettes on soluble gpV and platelet function." | 3.71 | Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis--the influence of aspirin and cigarette smoking. ( Blann, AD; Cazenave, JP; Galajda, P; Gurney, D; Lanza, F; Lip, GY; Moog, S, 2001) |
| "Despite substantial evidence that antiplatelet therapy saves lives and reduces adverse events in patients with coronary artery disease (CAD), use of the most widely available and lowest cost antiplatelet agent, aspirin, continues to be disappointingly low." | 3.71 | Underuse of aspirin in a referral population with documented coronary artery disease. ( Califf, RM; Chen, A; DeLong, ER; Hammill, BG; Kramer, JM; LaPointe, NA; McCants, CB; Muhlbaier, LH; Ostbye, T, 2002) |
| "We report the prevalence of use of aspirin, beta blockers, angiotensin-converting enzyme (ACE) inhibitors or angiotensin II type 1 receptor blockers, statins, and calcium channel blockers in older persons with coronary artery disease (CAD) in an academic nursing home." | 3.71 | Underutilization of aspirin, beta blockers, angiotensin-converting enzyme inhibitors, and lipid-lowering drugs and overutilization of calcium channel blockers in older persons with coronary artery disease in an academic nursing home. ( Aronow, WS; Ghosh, S; Ziesmer, V, 2002) |
| "The current standard of care for patients with non-ST-segment elevation acute coronary syndromes (ACS) includes antithrombotic therapy with aspirin and heparin." | 3.71 | Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. ( Antman, EM; Ball, SP; Becker, RC; Gibson, M; Murphy, SA; Rush, JE; Sanderink, G; Spencer, FA, 2002) |
| " The secondary endpoint is a composite of major adverse cardiovascular and cerebrovascular events (MACCE), including all-cause death, cardiac death, nonfatal myocardial infarction, stent thrombosis, ischemia-driven target vessel revascularization, and stroke." | 3.30 | Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority ra ( Gong, Y; Li, J; Wang, X; Wang, Y; Zhou, T, 2023) |
| "This study aimed to investigate the pharmacodynamic effects of indobufen and low-dose aspirin in patients with coronary atherosclerosis." | 3.01 | Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosis. ( Abdus, S; Bai, J; Eikelboom, JW; Gong, X; Gu, Q; Li, C; Lu, Y; Mei, L; Shi, L; Tan, C; Ullah, I; Wang, G; Yang, M; Ye, Z, 2021) |
| "Aspirin was discontinued on the day of the index procedure but given prior to the procedure; prasugrel was administered in the catheterization laboratory immediately after the successful procedure, and aspirin-free prasugrel became the therapy regimen from that moment." | 2.94 | Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD: The ASET Pilot Study. ( Campos, CM; Cavalcante, R; de Almeida Sampaio, FB; De Martino, F; Falcão, BAA; Guimarães, PO; Hara, H; Kawashima, H; Kogame, N; Leite, RS; Lemos, PA; Meireles, GC; Modolo, R; Morais, GR; Moulin, B; Ono, M; Onuma, Y; Ribeiro, EE; Serruys, PW; Tinoco, J; Wang, R, 2020) |
| "We examined new cancers diagnosed in relation to gastrointestinal or genitourinary bleeding among patients enrolled in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) and determined the hazard of new cancer diagnosis after bleeding at these sites." | 2.90 | Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. ( Aboyans, V; Alings, M; Anand, SS; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Connolly, SJ; Cook-Bruns, N; Eikelboom, JW; Felix, C; Fox, KAA; Hart, RG; Maggioni, AP; Moayyedi, P; O'Donnell, M; Rydén, L; Shestakovska, O; Verhamme, P; Widimsky, P; Yusuf, S; Zhu, J, 2019) |
| " evening) dosing on the anti-aggregative effect of platelets in patients with CAD and arterial hypertension (AH)." | 2.90 | The effect of acetylsalicylic acid dosed at bedtime on the anti-aggregation effect in patients with coronary heart disease and arterial hypertension: A randomized, controlled trial. ( Krasińska, B; Krasiński, M; Krasiński, Z; Miciak-Lawicka, E; Paluszkiewicz, L; Rzymski, P; Tykarski, A, 2019) |
| " The primary outcome measured was the composite of major adverse cardiac events (MACE), including cardiac death, myocardial infarction (MI), or ischaemia-driven target lesion revascularisation at the 12-month follow-up." | 2.87 | Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy. ( Cho, DK; Choi, S; Hong, BK; Hong, MK; Jang, Y; Jeon, DW; Kang, TS; Kang, WC; Kim, BK; Kim, BO; Kim, JS; Kim, S; Kim, YH; Kwon, HM; Lee, BK; Lee, OH; Min, PK; Shin, DH; Woo, SI; Yoon, YW, 2018) |
| " Outcomes included composite major adverse cardiovascular events, noncardiovascular death, gastrointestinal or renal events, and components of the composite." | 2.87 | Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen. ( Abdallah, MS; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Reed, GW; Shao, M; Solomon, DH; Wisniewski, L; Wolski, K; Yeomans, N, 2018) |
| "Dabigatran is a direct acting (anti-II) oral anticoagulant which does not interfere with CYP and has favourable safety and efficacy profiles compared with VKAs." | 2.82 | Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study. ( Ajjan, RA; Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Franchi, F; Guzman, LA; King, R; Phoenix, F; Rollini, F; Tello-Montoliu, A; Zenni, MM, 2016) |
| "Aspirin was started within 12 h, and study medication within 72 h after CABG." | 2.82 | Ticagrelor and aspirin for the prevention of cardiovascular events after coronary artery bypass graft surgery. ( Bernstein, V; Cairns, J; Mancini, GB; Mayo, J; Saw, J; Skarsgard, P; Starovoytov, A; Wong, GC; Ye, J, 2016) |
| "Biodegradable-polymer drug-eluting stents (BP-DES) were developed to be as effective as second-generation durable-polymer drug-eluting stents (DP-DES) and as safe >1 year as bare-metal stents (BMS)." | 2.80 | Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome tria ( Alber, H; Buser, P; Conen, D; Eberli, F; Galatius, S; Gilgen, N; Hoffmann, A; Jeger, R; Kaiser, C; Kurz, DJ; Moccetti, T; Müller, C; Naber, C; Pedrazzini, G; Pfisterer, M; Rickenbacher, P; Rickli, H; Skov Jensen, J; Steiner, M; Vogt, DR; Von Felten, S; Vuillomenet, A; Wadt Hansen, K; Wanitschek, M; Weilenmann, D, 2015) |
| "CAD patients with type 2 diabetes had higher platelet aggregation (all p-values <0." | 2.80 | The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin. ( Gregersen, S; Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S, 2015) |
| " We sought to evaluate platelet reactivity during loading and maintenance dosing of ticagrelor versus clopidogrel, and the pharmacokinetic profile of ticagrelor and its metabolite AR-C124910XX, in black patients with stable CAD taking low-dose aspirin (acetylsalicylic acid)." | 2.80 | Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study. ( Angiolillo, DJ; Caplan, RJ; Carlson, GF; Ferdinand, KC; Maya, J; Teng, R; Waksman, R, 2015) |
| " However, the effects of EV-077 on pharmacodynamic (PD) profiles in patients with DM and coronary artery disease (CAD) while on antiplatelet therapy is poorly explored and represented the aim of this in vitro pilot investigation." | 2.79 | Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation. ( Angiolillo, DJ; Bender, N; Darlington, A; Desai, B; Franchi, F; Muñiz-Lozano, A; Patel, R; Rollini, F; Sakariassen, KS; Tello-Montoliu, A; Wilson, RE, 2014) |
| " At the end of the dosing interval on day 28, mean final-extent IPA was 10." | 2.79 | Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. ( Emanuelsson, H; Hiasa, Y; Teng, R, 2014) |
| " Following this randomized pilot study, it may be justified to perform a large-scale randomized study comparing 50- and 75-mg dosing of clopidogrel in Japanese patients undergoing coronary stent implantation." | 2.79 | Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial. ( Fujimoto, Y; Iwata, Y; Kadohira, T; Kitahara, H; Kobayashi, Y; Morino, T; Ohkubo, K; Sugimoto, K, 2014) |
| "Aspirin was used in 94." | 2.78 | Current medical management of stable coronary artery disease before and after elective percutaneous coronary intervention. ( Ardati, AK; Aronow, HD; Chetcuti, S; Grossman, PM; Gurm, HS; Moscucci, M; Pitt, B; Share, D; Smith, DE, 2013) |
| "Aspirin was prescribed indefinitely, and a thienopyridine for at least six months." | 2.78 | Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial. ( Claessen, BE; Dangas, GD; Mehran, R; Stone, GW; Xu, K, 2013) |
| "Ozone treatment significantly (P<0." | 2.77 | Effects of ozone therapy on haemostatic and oxidative stress index in coronary artery disease. ( Delgado-Roche, L; Díaz-Batista, A; Martínez-Sánchez, G; Pérez-Davison, G; Re, L, 2012) |
| " The aim of this study was to perform serial pharmacodynamic assessments of prasugrel with high-dose clopidogrel in patients with DM." | 2.76 | A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. ( Angiolillo, DJ; Badimon, JJ; Baker, BA; Effron, MB; Frelinger, AL; Jakubowski, JA; Michelson, AD; Ojeh, CK; Saucedo, JF; Zhu, B, 2011) |
| " (2) Clopidogrel may be under dosed in obese patients." | 2.75 | Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. ( Bode, C; Diehl, P; Halscheid, C; Helbing, T; Moser, M; Olivier, C, 2010) |
| "Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition compared with non-diabetics following P2Y(12) receptor blockade." | 2.73 | A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. ( Angiolillo, DJ; Aslam, M; Bass, TA; Box, LC; Capranzano, P; Charlton, RK; Desai, B; Goto, S; Guzman, LA; Shoemaker, SB; Suzuki, Y; Zenni, MM, 2008) |
| "Aspirin treatment affects the reproducibility of both PFA-100 and OPA." | 2.73 | Monitoring aspirin therapy with the Platelet Function Analyzer-100. ( Grove, EL; Hvas, AM; Kristensen, SD; Mortensen, J; Nielsen, HL; Pedersen, SB; Poulsen, TS; Refsgaard, J; Thygesen, SS, 2008) |
| " Decision to increase clopidogrel dosage may vary on the basis of the assay used, thus highlighting the need for unambiguous guidelines with respect to assay selection, as platelet function assays are not interchangeable." | 2.73 | Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. ( Diodati, JG; Lordkipanidzé, M; Nguyen, TA; Palisaitis, DA; Pharand, C; Schampaert, E, 2008) |
| " Additional controlled studies are warranted to confirm this observation and determine whether long-term use of low-dose colchicine can improve clinical outcomes in patients with advanced vascular disease." | 2.73 | Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. ( Nidorf, M; Thompson, PL, 2007) |
| "Aspirin has the potential to influence C-reactive protein (CRP) levels, an inflammatory marker, by its anti-inflammatory activity." | 2.73 | C-reactive protein levels increase after exercise testing in patients with increased platelet reactivity. ( Aydinalp, A; Bal, U; Demir, O; Ertan, C; Gulmez, O; Konas, D; Muderrisoglu, H; Ozin, B; Yildirir, A, 2007) |
| "Aspirin has been widely prescribed over the last several decades as part of primary CAD prevention strategy." | 2.72 | Aspirin for Primary Prevention of Coronary Artery Disease. ( Aronow, WS; Bandyopadhyay, D; Deedwania, P; Ghosh, RK; Gupta, M; Jain, V; Kapadia, S; Lavie, CJ; Qamar, A; Ujjawal, A, 2021) |
| "Aspirin has been the mainstay of both secondary and primary prevention of cardiovascular disease for half a century." | 2.72 | Aspirin in Primary Prevention: What Changed? A Critical Appraisal of Current Evidence. ( Dasa, O; Pearson, TA; Pepine, CJ, 2021) |
| "Sarpogrelate treatment reduces restenosis after coronary stenting, which suggests that serotonin released from activated platelets may play an important role in stent restenosis." | 2.71 | Sarpogrelate treatment reduces restenosis after coronary stenting. ( Fujita, M; Ho, M; Ishii, K; Miki, O; Miwa, K; Miyamoto, A; Mizuno, K; Tsukahara, R, 2003) |
| "Probucol is a lipid-lowering drug that has an antioxidant effect." | 2.70 | Effect of antioxidant probucol for preventing stent restenosis. ( Cha, KS; Han, JY; Kim, HJ; Kim, JS; Kim, MH, 2002) |
| "5 mg/kg intravenous (IV), and eptifibatide using the ESPIRIT dosing (180 g/kg bolus IV, immediately followed by a 2 g/kg/minute continuous IV infusion, and then a second 180 g/kg bolus IV ten minutes after the first bolus)." | 2.70 | Use of clopidogrel loading, enoxaparin, and double-bolus eptifibatide in the setting of early percutaneous coronary intervention for acute coronary syndromes. ( Bertolet, BD; Gupta, A; Miller, L, 2002) |
| "Ticlopidine therapy was discontinued in 1." | 2.68 | Combined antiplatelet therapy with ticlopidine and aspirin. A simplified approach to intracoronary stent management. ( Bauters, C; Bedossa, M; Bertrand, ME; Bonnet, JL; Danchin, N; Grollier, G; Lablanche, JM; Leclercq, C; McFadden, EP; Vahanian, A; Van Belle, E, 1996) |
| " Targeted screening for subclinical coronary atherosclerosis with coronary artery calcium scores is prudent to guide appropriately dosed aspirin use to mitigate the increasing frequency of sports-related sudden cardiac death due to plaque rupture." | 2.61 | Aspirin to Prevent Sudden Cardiac Death in Athletes with High Coronary Artery Calcium Scores. ( Noakes, TD; Siegel, AJ, 2019) |
| "Major bleeding was significantly higher with DAPT (OR 1." | 2.58 | Dual versus single antiplatelet therapy after coronary artery bypass graft surgery: An updated meta-analysis. ( Blumenthal, RS; Cardoso, R; Gluckman, TJ; Knijnik, L; McEvoy, JW; Metkus, TS; Rivera, M; Whelton, SP, 2018) |
| " Discharge from hospital with aspirin was the primary end point, whereas rates of adverse reactions being a secondary outcome." | 2.53 | Efficacy and Safety of Available Protocols for Aspirin Hypersensitivity for Patients Undergoing Percutaneous Coronary Intervention: A Survey and Systematic Review. ( Bernardi, A; Bianco, M; Carini, G; Cerrato, E; D'Ascenzo, F; DiNicolantonio, JJ; Gaita, F; Montefusco, A; Moretti, C; Omedè, P; Pozzi, R; Varbella, F; Zoccai, GB, 2016) |
| "Aspirin therapy has been proven to decrease mortality and major adverse cardiovascular events in patients with CAD." | 2.53 | The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. ( Hernandez, AF; Johnston, A; Jones, WS, 2016) |
| "Guidelines from the American Heart Association/American College of Cardiology recommend a higher dosage of aspirin daily following Percutaneous Coronary Intervention (PCI), whereas guidelines from the European Society of Cardiology recommend a lower dosage." | 2.53 | Adverse clinical outcomes associated with a low dose and a high dose of aspirin following percutaneous coronary intervention: a systematic review and meta-analysis. ( Bundhun, PK; Huang, WQ; Janoo, G; Teeluck, AR, 2016) |
| "Treatment with aspirin and new P2Y12 receptor blockers has further reduced the rate of cardiovascular death, myocardial infarction or stroke after ACS compared with aspirin and clopidogrel." | 2.52 | Dual antiplatelet therapy for coronary artery disease. ( Lee, CW, 2015) |
| " However, NSAIDs are associated with a number of adverse effects, especially in patients with cardiovascular disease (CVD)." | 2.52 | Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease. ( Cicci, JD; Danelich, IM; Lose, JM; Reed, BN; Tefft, BJ; Wright, SS, 2015) |
| " Endpoints included major adverse cardiac effects (MACEs), target lesion revascularization (TLR), target vessel revascularization (TVR), death, stent thrombosis, bleeding and adverse drug reactions during a 9-12 months period, as well as platelet activities." | 2.52 | Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. ( Bundhun, PK; Chen, MH; Qin, T, 2015) |
| "It is essential to define/quantify the postoperative blood loss that precludes administration of early aspirin." | 2.50 | Who might benefit from early aspirin after coronary artery surgery? ( Bilkhu, R; Gukop, P; Gutman, N; Karapanagiotidis, GT, 2014) |
| " In recent years, a growing body of evidence regarding potential risks from chronic use of NSAIDs has emerged." | 2.50 | Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes. ( Capodanno, D; Capranzano, P; Gargiulo, G; Longo, G; Tamburino, C, 2014) |
| " There is also no significant difference in major adverse cardiac and cerebrovascular events between the 2 therapies, except the smaller occurrence rate of target-lesion revascularization in the triple-therapy group (OR: 0." | 2.48 | The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis. ( He, J; He, Y; Liu, G; Ma, C; Tang, P; Wang, P; Yang, J; Zhou, R; Zhou, S, 2012) |
| " Therefore, several new antiplatelet treatment strategies have been developed in order to optimize platelet inhibition: a) modification of dosing of commonly used agents; b) use of new agents; and c) addition of a third antiplatelet drug (triple therapy)." | 2.48 | Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease. ( Angiolillo, DJ; Ferreiro, JL, 2012) |
| " Ongoing studies are challenging the current one-size-fits-all dosing strategy, but the preceding evaluation of platelet function assays has not been adequate." | 2.48 | Antiplatelet effect of aspirin in patients with coronary artery disease. ( Grove, EL, 2012) |
| " This article provides an overview on antiplatelet drug response variability, an update on definitions, including the role of pharmacodynamic testing, underlying mechanisms - with emphasis on recent understandings on pharmacogenetics and drug-drug interactions - and current and future perspectives on individualized antiplatelet therapy." | 2.47 | Antiplatelet drug therapy: role of pharmacodynamic and genetic testing. ( Angiolillo, DJ; Tello-Montoliu, A; Ueno, M, 2011) |
| " If both Clopidogrel and PPI need to be prescribed, a split dosage regimen of PPI in the morning and clopidogrel in the evening can be recommended." | 2.46 | [Dilemma between gastroprotection and cardiovascular prevention]. ( Kandulski, A; Malfertheiner, P; Venerito, M, 2010) |
| "Coronary artery disease is highly prevalent and is the major cause of morbidity and mortality in diabetic patients." | 2.45 | Prevention and management of coronary artery disease in patients with diabetes mellitus. ( Majid, A, 2009) |
| "Future advances in the treatment of coronary artery disease will likely occur as we further refine the role of these established antiplatelet drugs and develop agents that bind to novel targets in the thrombotic cascade." | 2.42 | The expanding role of antiplatelet agents in coronary artery disease. A current review of aspirin, glycoprotein IIb/IIIa inhibitors, and the thienopyridines. ( Bhatt, DL; Hostetter, JC, 2003) |
| "Aspirin has been studied and used most extensively." | 2.42 | Role of antiplatelet drugs in the prevention of cardiovascular events. ( Tendera, M; Wojakowski, W, 2003) |
| " Clinicians should ensure that patients at high risk of atherothrombosis (>3% risk over 5 years) are compliant with aspirin therapy and are taking the correct dosage (75-150 mg/day)." | 2.42 | Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice. ( Eikelboom, JW; Hankey, GJ, 2004) |
| " A daily dosage of 75 to 150 mg is sufficient to reduce the rate of future cardiac events." | 2.42 | [Risk management of coronary artery disease--pharmacological therapy]. ( Hofmann, T, 2004) |
| "The myriad deleterious effects of hyperlipidemia that promote a prothrombotic and antifibrinolytic vascular milieu serve to elucidate the importance of lipid reduction as an additional secondary prevention measure." | 2.38 | Atherothrombotic insights into secondary prevention after acute myocardial infarction. ( Loscalzo, J; Rabbani, LE, 1993) |
| "Minor bleedings were observed in 19 (17." | 1.91 | [Comparison of Various Regimens of Antithrombotic Therapy in Patients With Valvular Heart Disease and Coronary Artery Disease After Surgical and Interventional Interventions]. ( Berdibekov, BS; Bulaeva, NI; Golukhova, EZ; Kubova, MC; Ruzina, EV, 2023) |
| " This study intends to carry out an evaluation of whether combining rivaroxaben with aspirin will be effective and safe in treating patients experiencing chronic CAD." | 1.72 | Evaluation of efficacy and safety of rivaroxaban combined with aspirin in patients with chronic coronary artery disease: A protocol for systematic review and meta-analysis. ( Li, X; Wang, H; Wu, H; Wu, X; Xie, G, 2022) |
| "The best treatment for coronary artery disease (CAD) in patients with type 2 diabetes (DM2) and chronic kidney disease is unknown." | 1.62 | Effect of diabetic kidney disease on therapeutic strategies for coronary artery disease: ten year follow-up. ( Batista, DV; Filho, JPPL; Filho, RK; Garcia, RMR; Garzillo, CL; Hueb, W; Junior, CVS; Lima, EG; Martins, EB; Ramires, JAF; Rezende, PC, 2021) |
| "Compared with ASA, DAPT showed a non-significant impact on long-term survival and demonstrated to be a safe option." | 1.56 | Early dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass surgery: survival and safety outcomes. ( Amorim, MJ; Barros, AS; Cerqueira, RJ; Ferreira, AF; Leite-Moreira, AF; Lourenço, AP; Moreira, R; Pinho, P; Rocha-Gomes, JN; Saraiva, FA, 2020) |
| "Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the only option for complete revascularization in some patients with diffuse coronary artery disease." | 1.56 | Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study. ( Feng, W; Song, Y; Tiemuerniyazi, X; Xu, F; Yan, H, 2020) |
| "Aspirin plays a well-established role in this setting, and for a long time, clopidogrel use has been restricted to patients allergic to aspirin." | 1.51 | Dual platelet antiaggregation therapy after myocardial revascularization surgery. ( Batista, DV; Feitosa, MPM; Lima, EG; Linhares Filho, JPP; Lobo Filho, HG; Serrano Júnior, CV; Soffiatti, CD, 2019) |
| "Aspirin resistance was defined by a normal platelet function testing result for those who had continued taking aspirin until the day before the platelet function testing." | 1.51 | Aspirin Resistance Incidence and Associations Between Aspirin Effect and Outcomes in Cardiac Surgery. ( Ho, KM; Nicola, H, 2019) |
| "Five patients (5." | 1.51 | [The Pathways to Increase the Efficacy of Drug Therapy in Patients with Ischemic Heart Disease after Coronary Artery Bypass Grafting]. ( Barbarash, OL; Hryachkova, ON; Kashtalap, VV; Shibanova, IA; Zykov, MV, 2019) |
| "Stable coronary artery disease is associated with a heightened procoagulant platelet response." | 1.48 | Novel assay demonstrates that coronary artery disease patients have heightened procoagulant platelet response. ( Campbell, H; Chen, VM; Connor, D; Hogg, PJ; Kritharides, L; Lau, E; Lau, JK; Liang, HP; Muller, D; Pasalic, L; Pennings, GJ; Wing-Lun, E, 2018) |
| "Although depressive disorders have been associated with increased risk of worse outcomes with cardiovascular diseases (CVDs), its relation with access to and quality of cardiovascular care is not well studied." | 1.48 | Impact of Depressive Disorder on Access and Quality of Care in Veterans With Prevalent Cardiovascular Disease. ( Butler, J; Lacey, M; Parikh, PB; Shroyer, AL; Srivastava, P, 2018) |
| "Aspirin use was updated at each clinic visit and considered as a time-varying covariate." | 1.46 | Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events. ( Bavry, AA; Bhatt, DL; Elbez, Y; Elgendy, IY; Mahmoud, AN; Sorbets, E; Steg, PG, 2017) |
| "It is a marker of atherosclerotic plaque burden and the strongest independent predictor of future myocardial infarction and mortality." | 1.46 | Cardiac Society of Australia and New Zealand position statement executive summary: coronary artery calcium scoring. ( Chan, J; Chow, CK; Hamilton-Craig, CR; Jelinek, VM; Liew, GY; Younger, JF, 2017) |
| "Bleeding was the primary outcome." | 1.46 | Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions. ( Agarwal, S; Barakat, AF; Chaudhury, P; Ellis, SG; Faza, NN; Kapadia, SR; Mentias, A; Murat Tuzcu, E; Parashar, A; Wayangankar, S, 2017) |
| " This is coherent with the emergence of an uninhibited subpopulation of reticulated platelets during treatment with aspirin plus thienopyridine, explained by the short pharmacokinetic half-lives of these drugs." | 1.46 | Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies. ( Armstrong, PC; Chan, MV; Ferreira, PM; Hayman, MA; Hoefer, T; Knowles, RB; Tucker, AT; Warner, TD, 2017) |
| "The total thrombus-formation analysis system (T-TAS) was developed for quantitative analysis of platelet thrombus formation by the use of microchips with thrombogenic surfaces (collagen, platelet chip [PL-chip]; collagen plus tissue factor, atherome chip [AR-chip])." | 1.43 | Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy. ( Arima, Y; Hokimoto, S; Ishii, M; Ito, M; Kaikita, K; Kojima, S; Nakagawa, K; Ogawa, H; Oimatsu, Y; Sakamoto, K; Sueta, D; Tsujita, K, 2016) |
| "Aspirin is a key player in the management and prevention of stroke and myocardial infarction in patients with atherothrombosis." | 1.43 | A study into the genetic basis of aspirin resistance in Pakistani patients with coronary artery disease. ( Akhtar, N; Junaid, A; Mohyuddin, A; Mukarram, O, 2016) |
| "Aspirin (53." | 1.43 | Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience. ( Fahed, E; Ghauche, J; Maarrawi, J; Menassa-Moussa, L; Moussa, R; Nohra, G; Okais, N; Rahme, R; Rizk, T; Samaha, E, 2016) |
| " We investigated if the effect of aspirin declined during the 24-hour dosing interval in patients with coronary artery disease and type 2 diabetes, and whether this correlated with increased platelet turnover." | 1.42 | Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes. ( Christensen, KH; Grove, EL; Hvas, AM; Kristensen, SD; Würtz, M, 2015) |
| "Aspirin is the key treatment in the secondary prevention of atherothrombosis." | 1.42 | Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy. ( Amsallem, M; Bal dit Sollier, C; Dillinger, JG; Drouet, L; Henry, P; Manzo-Silberman, S; Sideris, G; Voicu, S, 2015) |
| "Aspirin response was assessed by 0." | 1.42 | [Association between CMTM5 gene rs723840 single nucleotide polymorphism and high on asprin platelet reactivity]. ( Bai, ZS; Chen, XH; Feng, XR; Liu, ML; Liu, TF; Zhang, JW, 2015) |
| "Consecutive patients with atherosclerotic plaque detected by coronary CT angiography were enrolled in our study from September 2013 to December 2014, grouped as <50% stenosis and ≥ 50% stenosis." | 1.42 | [Influence of coronary CT angiography findings on prevention strategies of coronary artery disease]. ( Dai, R; Gao, Y; Hou, Z; Jiang, S; Li, Z; Liu, K; Lü, B; Ren, X; Wang, Z; Yin, W, 2015) |
| "Aspirin resistance was detected in 22 (16." | 1.40 | Hypertension as a risk factor for aspirin and clopidogrel resistance in patients with stable coronary artery disease. ( Akturk, IF; Caglar, FN; Caglar, IM; Erturk, M; Surgit, O; Tuncer, N; Uzun, F; Yalcın, AA, 2014) |
| "Patients with ESRD are at higher risk for coronary artery disease (CAD) and also their post-interventional outcome is worse compared to patients with normal renal function." | 1.40 | Haemodialysis impairs clopidogrel but not aspirin responsiveness in patients with end-stage renal disease. Results of a pilot study. ( Bocksch, W; Fateh-Moghadam, S; Gawaz, M; Geisler, T; Htun, P; Kan, T; Mueller, E; Pohle, C; Schindler, R, 2014) |
| "Bleeding was assessed using the Bleeding Academic Research Consortium criteria." | 1.40 | Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes. ( Byrne, RA; Kastrati, A; Laugwitz, KL; Ndrepepa, G; Neumann, FJ; Pache, J; Pöhler, A; Richardt, G; Schulz, S, 2014) |
| "Eicosapentaenoic acid (EPA) has been widely accepted to have antiatherosclerotic effects." | 1.40 | Effects of eicosapentaenoic acid on platelet function in patients taking long-term aspirin following coronary stent implantation. ( Hosogoe, N; Ishikawa, S; Isshiki, T; Takada, K; Yokoyama, N, 2014) |
| "Aspirin PR was 3-33% and clopidogrel PR was 10-35% in visit-1." | 1.40 | Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy. ( Barnard, J; Bhatt, DL; Kottke-Marchant, K; Murugesan, G; Timur, AA; Zhang, L, 2014) |
| "Coronary artery disease is associated with high morbidity and mortality." | 1.40 | Demographic and clinical characteristics of patients with stable coronary artery disease: results from the CLARIFY registry in Spain. ( Ferrari, R; García-Moll, X; Greenlaw, N; Zamorano, JL, 2014) |
| "Fibrinogen levels were elevated in T2DM (p< 0." | 1.40 | The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease. ( Ajjan, RA; Grant, PJ; Grove, EL; Hvas, AM; Kristensen, SD; Kurdee, Z; Larsen, SB; Neergaard-Petersen, S; Phoenix, F, 2014) |
| "Inflammation has been proposed to modify platelet function." | 1.39 | Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB, 2013) |
| " Hydrolytic effectiveness varies widely primarily from non-genetic variation of BChE activity that affects aspirin bioavailability in blood and the ability of aspirin to inhibit platelet aggregation." | 1.39 | Aspirin hydrolysis in plasma is a variable function of butyrylcholinesterase and platelet-activating factor acetylhydrolase 1b2 (PAFAH1b2). ( Allayee, H; Hartiala, J; Hazen, SL; Marathe, GK; McIntyre, TM; Tang, WH; Zhou, G, 2013) |
| "Non-aspirin NSAID use was not associated with either AVC or CAC in either cohort." | 1.39 | Associations between aspirin and other non-steroidal anti-inflammatory drugs and aortic valve or coronary artery calcification: the Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study. ( Budoff, M; Delaney, JA; Dragano, N; Elmariah, S; Erbel, R; Jöckel, KH; Kälsch, H; Kronmal, RA; Lehmann, N; Mahabadi, AA; Moebus, S; Möhlenkamp, S; Nasir, K; O'Brien, KD; Psaty, BM; Winterstein, AG, 2013) |
| "Different aspirin dosing regimens have been suggested to impact outcomes when used in combination with adenosine diphosphate (ADP) P2Y12 receptor antagonists." | 1.39 | Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Results of an in vitro pilot investigation. ( Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Franchi, F; Guzman, LA; Muñiz-Lozano, A; Patel, R; Rollini, F; Tello-Montoliu, A; Thano, E; Wilson, RE, 2013) |
| "Aspirin is an essential component of peri-PCI pharmacotherapy." | 1.39 | The clinical outcomes of percutaneous coronary intervention performed without pre-procedural aspirin. ( Aronow, HD; Gurm, HS; Kenaan, M; Seth, M; Share, D; Wohns, D, 2013) |
| "Diabetes mellitus is an independent predictor of adverse clinical events after drug-eluting stent implantation." | 1.39 | Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study. ( Chen, X; Han, Y; Jiang, T; Jing, Q; Li, Y; Liu, H; Ma, Y; Wang, G; Wang, S; Wang, X; Yan, G; Yang, L; Zhang, L; Zhu, G, 2013) |
| "Bleeding has emerged as a predictor of early and late mortality after percutaneous coronary interventions." | 1.38 | Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. ( Angiolillo, DJ; Capodanno, D; Gavazzi, A; Guagliumi, G; Lettieri, C; Musumeci, G; Romano, M; Rosiello, R; Rossini, R; Valsecchi, O, 2012) |
| "Aspirin has been shown to decrease postoperative CABG mortality and ischemic events." | 1.38 | Effect of timing of chronic preoperative aspirin discontinuation on morbidity and mortality in patients having combined coronary artery bypass grafting and valve surgery. ( Blackstone, E; Cho, L; Jacob, M; Smedira, N; Williams, S, 2012) |
| "Aspirin resistance was detected in 27 patients (16." | 1.38 | [The frequency of aspirin resistance by a modified thrombelastography method and its relationship with clinical and laboratory parameters in patients with stable coronary artery disease]. ( Caylı, M; Demirtaş, M; Kanadaşı, M; Karaarslan, O; Koç, M; Sahin, DY; Uysal, OK, 2012) |
| " If cigarette smoking is associated with a dose-response effect on pharmacodynamic measures in clopidogrel-treated patients is unknown." | 1.38 | Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012) |
| "Omeprazole, a PPI, has been reported to weaken the antiplatelet effects of clopidogrel." | 1.38 | Effects of PPIs and an H2 blocker on the antiplatelet function of clopidogrel in Japanese patients under dual antiplatelet therapy. ( Horiuchi, H; Ikeda, T; Imai, M; Jinnai, T; Kato, Y; Kimura, T; Makiyama, T; Shirakawa, R; Tada, T; Tazaki, J; Yamane, K, 2012) |
| "Aspirin resistance has been described in some patient populations such as those with an acute coronary syndrome, ischemic stroke, percutaneous coronary intervention with drug-eluting stent, stent re-stenosis, and diabetes mellitus (DM)." | 1.38 | Effect of hypoglycemic drugs on aspirin resistance in patients with diabetes mellitus. ( Ariturk, Z; Cil, H; Elbey, MA; Gündüz, E; Islamoglu, Y; Kaya, H; Soydinc, S; Tekbas, E; Yavuz, C, 2012) |
| " Response to aspirin was reassessed 1 month after hospital discharge and non-responders received a directly observed intake of aspirin to exclude any biological non-response due to bioavailability problems." | 1.37 | Non-adherence to aspirin in patients undergoing coronary stenting: negative impact of comorbid conditions and implications for clinical management. ( Bonnet, JL; Carrieri, P; Cohen, W; Cuisset, T; Fourcade, L; Fugon, L; Gaborit, B; Molines, L; Quilici, J; Roux, P, 2011) |
| "Sarpogrelate was administered to 22 of 33 patients with SEA in addition to aspirin therapy, and platelet aggregation, plasma serotonin concentration, and plasma plasminogen activator inhibitor (PAI) activity were measured before and 1 week after administration." | 1.37 | Effects of additional treatment of sarpogrelate to aspirin therapy on platelet aggregation and plasma plasminogen activator inhibitor activity in patients with stable effort angina. ( Kajiwara, I; Miyamoto, S; Ogawa, H; Soejima, H, 2011) |
| " A dose-response relation between the number of G alleles at rs12041331 and expression of PEAR1 protein in human platelets was confirmed by Western blotting and ELISA." | 1.37 | Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression. ( Becker, DM; Becker, LC; Bray, PF; Chen, MH; Faraday, N; Friedman, AD; Gylfason, A; Herrera-Galeano, JE; Johnson, AD; Mathias, R; O'Donnell, CJ; Qayyum, R; Ruczinski, I; Suktitipat, B; Thorsteinsdottir, U; Tofler, GH; Yanek, LR; Yang, XP, 2011) |
| " The OR adjusted for sex, Gunma score (the predictive score for IVIG unresponsiveness), and dosage of initial IVIG (1 or 2 g/kg) was 0." | 1.37 | Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: a retrospective study. ( Asano, Y; Hatai, Y; Ishibashi, N; Ishiwata, T; Kanai, T; Kawamura, Y; Kobayashi, T; Nakatani, K; Nishiyama, M; Nonoyama, S; Sato, H; Takeshita, S; Takizawa, M; Tsujimoto, H, 2011) |
| "Hypertension is a common risk factor for peripheral arterial disease (PAD)." | 1.36 | Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. ( Anderson, RD; Bavry, AA; Cooper-Dehoff, RM; Denardo, SJ; Gong, Y; Handberg, EM; Pepine, CJ, 2010) |
| " Five patients out of 32 developed CAA, with no statistical significance when analyzed for IVIG dosage or IVIG-resistance." | 1.36 | Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome. ( Angelone, DF; Compagnone, A; De Nisco, A; De Rosa, G; Delogu, AB; Leo, A; Onesimo, R; Rigante, D; Rizzo, D; Valentini, P, 2010) |
| " Primary end point was the combined incidence of major adverse coronary events and major bleedings." | 1.36 | Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel. ( Di Sciascio, G; Irini, D; Pasceri, V; Patti, G; Pelliccia, F; Pristipino, C; Roncella, A; Speciale, G; Varveri, A, 2010) |
| "Nuisance bleeding is common in patients on prolonged DAPT post-DES implantation and can impact compliance." | 1.36 | Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. ( Ben-Dor, I; Collins, SD; Delhaye, C; Gaglia, MA; Gonzalez, MA; Kaneshige, K; Kent, KM; Li, Y; Maluenda, G; Pichard, AD; Satler, LF; Scheinowitz, M; Suddath, WO; Syed, AI; Torguson, R; Wakabayashi, K; Waksman, R; Xue, Z, 2010) |
| "Diabetic patients with CAD had significantly higher levels of both platelet aggregation and activation compared to non-diabetic patients with CAD despite treatment with the same dosage of aspirin." | 1.36 | Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Mortensen, SB, 2010) |
| "We hypothesized that patients with coronary atherosclerosis have increased plasma levels of cathepsin S (CATS) and cathepsin B (CATB) mRNA, the genes that are involved in atherosclerotic plaque development and destabilization." | 1.36 | Increased plasma levels of CATS mRNA but not CATB mRNA in patients with coronary atherosclerosis. ( Cerne, A; Cerne, D; Kranjec, I; Marc, J; Stern, I; Zorman, D, 2010) |
| "Hypertension was untreated in 125 patients (33." | 1.35 | Secondary prevention of coronary artery disease in urban Indian primary care. ( Gupta, R, 2009) |
| "Combined carotid stenting and cardiac surgery, performed in the same operating room under only heparin and aspirin, seems a safe and effective strategy for the treatment of patients with concomitant carotid and cardiac disease." | 1.35 | Safety and effectiveness of combining carotid artery stenting with cardiac surgery: preliminary results of a single-center experience. ( Capuano, F; Faraglia, V; Palombo, G; Rizzo, L; Sinatra, R; Stella, N; Taurino, M, 2009) |
| "Aspirin resistance is an emerging clinical entity." | 1.35 | Report: frequency of aspirin resistance in patients with coronory artery disease in Pakistan. ( Ahmed, W; Akhtar, N; Junaid, A; Khalid, A; Rahman, H; Shah, MA, 2009) |
| "Aspirin resistance was defined as an ARU (aspirin reaction units) > or =550, and clopidogrel resistance was defined as platelet inhibition <20%." | 1.35 | Prevalence and risk factors for aspirin and clopidogrel resistance in patients with coronary artery disease or ischemic cerebrovascular disease. ( Han, K; Jeon, HK; Kim, H; Lee, HK, 2009) |
| "Aspirin resistance was defined as a closure time (CT) <186 s with Col/Epi cartridges, despite regular aspirin therapy." | 1.35 | Relationship between the serum sCD40L level and aspirin-resistant platelet aggregation in patients with stable coronary artery disease. ( Midilli, K; Nisanci, Y; Oflaz, H; Onur, I; Pamukcu, B; Yilmaz, E; Yilmaz, G, 2008) |
| " One hundred sixty-one patients on 100 mg of aspirin co-medication underwent elective coronary stenting and were given an initial dosage of 600 mg clopidogrel, followed by 75 mg clopidogrel daily." | 1.35 | How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. ( Engelhardt, A; Lask, S; Mügge, A; Neubauer, H, 2008) |
| "Aspirin resistance was defined when epinephrine closure time <174 s." | 1.34 | Prevalence and biologic profile of aspirin resistance in patients with angiographically proven coronary artery disease. ( de Lafuente, JP; Iriarte, JA; Lafita, M; Molinero, E; Monica, S; Narvaez, I; Saez, Y; Sagastagoitia, JD; Vacas, M, 2007) |
| "Aspirin has reduced the risk of cardiovascular events by 25%." | 1.34 | [Pathogenesis and prevention tactics of aspirin resistance]. ( Zhang, JP; Zhang, RG, 2007) |
| "328 patients with type 2 diabetes mellitus (mean age, 58." | 1.34 | Management outcomes of patients with type 2 diabetes: targeting the 10-year absolute risk of coronary heart disease. ( Phillipov, G; Phillips, PJ; Yong, TY, 2007) |
| "Aspirin non-response was defined as: 1) slope steeper than 12%/min in AA-aggregations, and 2) by closure time shorter than 170 s in PFA-100." | 1.33 | Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. ( Backman, JT; Kankuri, E; Karhunen, PJ; Lassila, R; Lepäntalo, A; Mikkelsson, J; Reséndiz, JC; Viiri, L, 2006) |
| "Aspirin resistance was defined according to published criteria for these 3 assays of platelet function." | 1.33 | Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. ( Becker, DM; Becker, LC; Bray, PF; Faraday, N; Herrera-Galeano, JE; Moy, TF; Segal, JB; Yanek, LR, 2006) |
| "Aspirin treatment with 300 mg o." | 1.33 | Aspirin reduces anticardiolipin antibodies in patients with coronary artery disease. ( Andreotti, F; Ikonomidis, I; Kremastinos, DT; Lekakis, J; Loizou, S; Nihoyannopoulos, P; Revela, I; Vamvakou, G, 2006) |
| "Aspirin treatment reduced the development of atherosclerosis by approximately 47%." | 1.32 | Suppression of oxidative stress as a mechanism of reduction of hypercholesterolemic atherosclerosis by aspirin. ( Lee, P; Prasad, K, 2003) |
| "Systemic vasculitis has been reported in some cases." | 1.32 | [Myocardial infarction after influenza vaccination]. ( Bonz, A; Langenfeld, H; Ritter, O; Strotmann, J, 2003) |
| "Patients with complex coronary stenoses had a significantly (P<0." | 1.32 | Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris. ( Christiansen, M; Cole, D; Cosin-Sales, J; Holt, DW; Kaminski, P; Kaski, JC; Overgaard, MT; Oxvig, C, 2004) |
| "Most patients with PAD die of either heart attacks or strokes and they die of the former conditions far earlier than controls." | 1.32 | [Antiplatelet therapy in patients with peripheral arterial disease (PAD)]. ( Diehm, C; Huber, R; Lawall, H, 2004) |
| "Acute myocardial infarctions were registered in group 1 in 25% (11." | 1.29 | [Emergency intracoronary stent implantation: complications and experiences with 124 patients]. ( Arens, R; Heuer, H; Krakau, I; Müller, T; Rissel, U; Schulze-Waltrup, N; Willgeroth, W, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (0.25) | 18.7374 |
| 1990's | 20 (1.66) | 18.2507 |
| 2000's | 368 (30.62) | 29.6817 |
| 2010's | 660 (54.91) | 24.3611 |
| 2020's | 151 (12.56) | 2.80 |
| Authors | Studies |
|---|---|
| Vranckx, P | 7 |
| Valgimigli, M | 19 |
| Odutayo, A | 1 |
| Serruys, PW | 7 |
| Hamm, C | 5 |
| Steg, PG | 32 |
| Heg, D | 4 |
| Mc Fadden, EP | 1 |
| Onuma, Y | 6 |
| Benit, E | 3 |
| Janssens, L | 3 |
| Diletti, R | 2 |
| Ferrario, M | 3 |
| Huber, K | 12 |
| Räber, L | 2 |
| Windecker, S | 15 |
| Jüni, P | 5 |
| Viscusi, MM | 2 |
| Mangiacapra, F | 4 |
| Bressi, E | 2 |
| Sticchi, A | 1 |
| Colaiori, I | 2 |
| Capuano, M | 2 |
| Ricottini, E | 2 |
| Cavallari, I | 2 |
| Spoto, S | 2 |
| Di Sciascio, G | 3 |
| Ussia, GP | 2 |
| Grigioni, F | 1 |
| Yashima, F | 1 |
| Inohara, T | 1 |
| Nishida, H | 1 |
| Shimoji, K | 1 |
| Ueno, K | 1 |
| Noma, S | 1 |
| Yamaji, K | 1 |
| Ishii, H | 1 |
| Tanaka, N | 2 |
| Kohsaka, S | 1 |
| Amano, T | 1 |
| Ikari, Y | 1 |
| Pracoń, R | 1 |
| Demkow, M | 1 |
| Anthopolos, R | 1 |
| Mazurek, T | 1 |
| Drożdż, J | 1 |
| Witkowski, A | 2 |
| Gajos, G | 4 |
| Pruszczyk, P | 1 |
| Roik, M | 1 |
| Łoboz-Grudzień, K | 1 |
| Lesiak, M | 2 |
| Reczuch, K | 1 |
| Kalarus, Z | 1 |
| Kryczka, K | 1 |
| Henzel, J | 1 |
| Kaczmarska-Dyrda, E | 1 |
| Maksym, J | 1 |
| Jonik, S | 1 |
| Krekora, J | 1 |
| Celińska-Spodar, M | 1 |
| Jaroch, J | 1 |
| Łanocha, M | 1 |
| Szulik, M | 1 |
| Szwed, H | 1 |
| Rużyłło, W | 2 |
| Kusumoto, GO | 1 |
| Higashi, M | 1 |
| Shigematsu, K | 1 |
| Yamaura, K | 1 |
| Coleman, CI | 1 |
| Kharat, AA | 1 |
| Bookhart, B | 1 |
| Baker, WL | 1 |
| Han, Y | 5 |
| Kodesh, A | 1 |
| Lev, E | 5 |
| Leshem-Lev, D | 1 |
| Solodky, A | 5 |
| Kornowski, R | 7 |
| Perl, L | 3 |
| Santana-Mateos, M | 1 |
| Medina-Gil, JM | 1 |
| Saavedra-Santana, P | 1 |
| Martínez-Quintana, E | 1 |
| Rodríguez-González, F | 1 |
| Tugores, A | 1 |
| Wang, H | 4 |
| Li, X | 3 |
| Wu, X | 1 |
| Wu, H | 4 |
| Xie, G | 1 |
| Barry, HC | 1 |
| Yin, C | 1 |
| Wang, Y | 4 |
| Mo, C | 1 |
| Yue, Z | 1 |
| Sun, Y | 2 |
| Hu, D | 3 |
| Ullah, W | 1 |
| Zahid, S | 1 |
| Sandhyavenu, H | 1 |
| Faisaluddin, M | 1 |
| Khalil, F | 1 |
| Pasha, AK | 1 |
| Alraies, MC | 1 |
| Cuisset, T | 6 |
| Rao, SV | 1 |
| Sabouret, P | 3 |
| Savage, MP | 2 |
| Fischman, DL | 1 |
| Sha'aban, A | 1 |
| Zainal, H | 1 |
| Khalil, NA | 1 |
| Abd Aziz, F | 1 |
| Ch'ng, ES | 1 |
| Teh, CH | 1 |
| Mohammed, M | 1 |
| Ibrahim, B | 1 |
| Lee, YJ | 1 |
| Cho, JY | 2 |
| Yun, KH | 3 |
| Lee, SJ | 2 |
| Hong, SJ | 3 |
| Ahn, CM | 3 |
| Kim, BK | 6 |
| Ko, YG | 4 |
| Choi, D | 4 |
| Hong, MK | 9 |
| Jang, Y | 7 |
| Kim, JS | 7 |
| Bhatt, DL | 47 |
| James, SK | 1 |
| Darlington, O | 1 |
| Hoskin, L | 1 |
| Simon, T | 6 |
| Fox, KM | 1 |
| Leiter, LA | 6 |
| Mehta, SR | 6 |
| Harrington, RA | 7 |
| Himmelmann, A | 6 |
| Ridderstråle, W | 4 |
| Andersson, M | 3 |
| Bueno, H | 3 |
| De Luca, L | 5 |
| Tank, A | 1 |
| Mellström, C | 2 |
| McEwan, P | 1 |
| Fox, KAA | 11 |
| Aboyans, V | 6 |
| Debus, ES | 1 |
| Zeymer, U | 4 |
| Cowie, MR | 2 |
| Patel, M | 1 |
| Welsh, RC | 3 |
| Bosch, J | 11 |
| Gay, A | 1 |
| Vogtländer, K | 1 |
| Anand, SS | 10 |
| Hori, M | 3 |
| Zhu, J | 5 |
| Liang, Y | 4 |
| Connolly, SJ | 12 |
| Maggioni, A | 2 |
| Yusuf, S | 14 |
| Eikelboom, JW | 19 |
| Suzuki, T | 2 |
| Kawai, S | 1 |
| Morihana, E | 1 |
| Kawabe, S | 1 |
| Iwata, N | 1 |
| Saito, K | 1 |
| Yoshikawa, T | 1 |
| Yasuda, K | 1 |
| Liu, Z | 1 |
| Yang, Z | 1 |
| Ge, Y | 1 |
| Wang, L | 5 |
| Jiang, H | 1 |
| Sapountzi, E | 1 |
| Fidani, L | 1 |
| Giannopoulos, A | 1 |
| Galli-Tsinopoulou, A | 1 |
| Goto, S | 6 |
| Patel, RJ | 1 |
| Marmor, R | 1 |
| Dakour, H | 1 |
| Elsayed, N | 1 |
| Ramachandran, M | 1 |
| Malas, MB | 1 |
| Sohn, M | 1 |
| Chun, EJ | 3 |
| Lim, S | 3 |
| Xu, S | 1 |
| Chen, Y | 5 |
| Gao, H | 1 |
| Tan, Z | 1 |
| Wang, Q | 3 |
| Liu, Y | 8 |
| Zhu, B | 2 |
| Tao, F | 1 |
| Zhao, S | 1 |
| Yang, L | 5 |
| Zhang, Y | 4 |
| Wang, Z | 3 |
| Han, P | 1 |
| Zhang, A | 1 |
| Li, C | 8 |
| Lian, K | 1 |
| Galli, M | 1 |
| Rollini, F | 10 |
| Been, L | 2 |
| Zenni, MM | 4 |
| Angiolillo, DJ | 31 |
| Franchi, F | 7 |
| Adik-Pathak, L | 1 |
| Shirodkar, S | 1 |
| Gupta, A | 3 |
| Seecheran, NA | 1 |
| Sukha, D | 1 |
| Grimaldos, K | 1 |
| Grimaldos, G | 1 |
| Richard, S | 1 |
| Ishmael, A | 1 |
| Gomes, C | 1 |
| Kampradi, L | 1 |
| Seecheran, R | 1 |
| Seecheran, V | 1 |
| Peram, L | 1 |
| Dookeeram, D | 1 |
| Giddings, S | 1 |
| Sandy, S | 1 |
| Ramlackhansingh, A | 1 |
| Raza, S | 1 |
| Umaharan, P | 1 |
| Tello-Montoliu, A | 12 |
| Schneider, D | 1 |
| Luu, JM | 1 |
| Wei, J | 1 |
| Shufelt, CL | 1 |
| Asif, A | 1 |
| Tjoe, B | 1 |
| Theriot, P | 1 |
| Bairey Merz, CN | 1 |
| Xing, Y | 1 |
| Qiu, Y | 1 |
| Yuan, Z | 1 |
| Abtan, J | 5 |
| Elbez, Y | 4 |
| Ducrocq, G | 4 |
| Smith, SC | 2 |
| Ohman, EM | 4 |
| Eagle, KA | 4 |
| Fox, K | 5 |
| Petrov, I | 2 |
| Sinnaeve, PR | 1 |
| Pais, P | 1 |
| Wilson, P | 1 |
| Zhang, J | 9 |
| Zhang, Q | 5 |
| Zhao, K | 3 |
| Bian, YJ | 3 |
| Xue, YT | 3 |
| Di Fusco, SA | 2 |
| Rizzello, V | 2 |
| Scicchitano, P | 2 |
| Lucà, F | 2 |
| Altamura, V | 2 |
| Bianco, M | 5 |
| Valente, S | 2 |
| Riccio, C | 3 |
| Caldarola, P | 2 |
| Cipriani, M | 2 |
| Francese, GM | 2 |
| Navazio, A | 2 |
| Nardi, F | 3 |
| Ceravolo, R | 2 |
| Gulizia, MM | 4 |
| Gabrielli, D | 4 |
| Oliva, F | 2 |
| Colivicchi, F | 4 |
| Sheth, MS | 2 |
| Yu, B | 3 |
| Chu, A | 2 |
| Porter, J | 2 |
| Tam, DY | 2 |
| Ferreira-Legere, LE | 2 |
| Goodman, SG | 6 |
| Farkouh, ME | 3 |
| Ko, DT | 2 |
| Abdel-Qadir, H | 2 |
| Udell, JA | 3 |
| Caldeira, D | 2 |
| Marques Antunes, M | 2 |
| Alves, M | 2 |
| Pinto, FJ | 2 |
| Russo, V | 1 |
| Fabiani, D | 1 |
| Leonardi, S | 8 |
| Attena, E | 1 |
| D'Alterio, G | 1 |
| Cotticelli, C | 1 |
| Rago, A | 1 |
| Sarpa, S | 1 |
| Maione, B | 1 |
| D'Onofrio, A | 1 |
| Golino, P | 1 |
| Nigro, G | 1 |
| Ruiz-Nodar, JM | 1 |
| Branch, KRH | 3 |
| Probstfield, JL | 2 |
| Maggioni, AP | 9 |
| Muehlhofer, E | 4 |
| Avezum, A | 5 |
| Widimsky, P | 6 |
| Yi, Q | 2 |
| Shestakovska, O | 9 |
| Kaul, U | 2 |
| Arambam, P | 1 |
| Sinha, SK | 1 |
| Abhaichand, R | 1 |
| Parida, AK | 1 |
| Banker, D | 1 |
| Mody, R | 1 |
| Khan, A | 1 |
| Sharma, R | 2 |
| Moorthy, N | 1 |
| Chandra, S | 1 |
| Koduganti, SC | 1 |
| Garg, R | 1 |
| Sarma, PR | 1 |
| Agrawal, DK | 1 |
| Reddy, KMK | 1 |
| Bangalore, S | 1 |
| Landi, A | 2 |
| Caglioni, S | 1 |
| Navarese, EP | 3 |
| Oliva, A | 1 |
| Piccolo, R | 6 |
| Angiolillo, D | 1 |
| Atar, D | 3 |
| Capodanno, D | 12 |
| Halvorsen, S | 3 |
| James, S | 5 |
| Kunadian, V | 3 |
| Mehran, R | 19 |
| Montalescot, G | 6 |
| Niebauer, J | 1 |
| Price, S | 1 |
| Storey, RF | 9 |
| Völler, H | 1 |
| Chow, JK | 1 |
| Bagai, A | 1 |
| Tan, MK | 2 |
| Har, BJ | 1 |
| Yip, AMC | 1 |
| Paniagua, M | 1 |
| Elbarouni, B | 1 |
| Bainey, KR | 1 |
| Paradis, JM | 1 |
| Maranda, R | 1 |
| Cantor, WJ | 1 |
| Eisenberg, MJ | 3 |
| Dery, JP | 1 |
| Madan, M | 1 |
| Cieza, T | 1 |
| Matteau, A | 1 |
| Roth, S | 1 |
| Lavi, S | 1 |
| Glanz, A | 1 |
| Gao, D | 1 |
| Tahiliani, R | 1 |
| Kim, HH | 1 |
| Robinson, SD | 1 |
| Daneault, B | 1 |
| Chong, AY | 1 |
| Le May, MR | 2 |
| Ahooja, V | 1 |
| Gregoire, JC | 1 |
| Nadeau, PL | 1 |
| Laksman, Z | 1 |
| Heilbron, B | 1 |
| Yung, D | 1 |
| Minhas, K | 1 |
| Bourgeois, R | 1 |
| Overgaard, CB | 1 |
| Bonakdar, H | 1 |
| Logsetty, G | 1 |
| Lavoie, AJ | 1 |
| De LaRochelliere, R | 2 |
| Mansour, S | 1 |
| Spindler, C | 1 |
| Yan, AT | 2 |
| Zhou, T | 1 |
| Gong, Y | 3 |
| Li, J | 7 |
| Wang, X | 8 |
| Chandiramani, R | 1 |
| Spirito, A | 1 |
| Johnson, JW | 2 |
| Mehta, A | 1 |
| Vogel, B | 5 |
| Faillace, RT | 1 |
| Gragnano, F | 2 |
| Calabrò, P | 3 |
| Spaccarotella, C | 1 |
| Simonetti, F | 1 |
| Esposito, G | 2 |
| Pedersen, OB | 1 |
| Larsen, SB | 13 |
| Kristensen, SD | 33 |
| Hvas, AM | 28 |
| Grove, EL | 28 |
| Kumbhani, DJ | 3 |
| de Lemos, JA | 3 |
| Cao, D | 1 |
| Pirondini, L | 1 |
| Franzone, A | 5 |
| Kim, HS | 14 |
| von Scheidt, M | 4 |
| Pettersen, AR | 1 |
| Zhao, Q | 2 |
| Woodward, M | 1 |
| Chiarito, M | 1 |
| McFadden, EP | 3 |
| Park, KW | 4 |
| Kastrati, A | 13 |
| Seljeflot, I | 3 |
| Zhu, Y | 3 |
| Kang, J | 2 |
| Schunkert, H | 7 |
| Arnesen, H | 3 |
| Pocock, S | 5 |
| Ruzina, EV | 1 |
| Berdibekov, BS | 1 |
| Bulaeva, NI | 2 |
| Kubova, MC | 1 |
| Golukhova, EZ | 2 |
| Chen, Z | 3 |
| Cai, Y | 2 |
| He, Y | 2 |
| Kovacevic, M | 1 |
| Pompei, G | 1 |
| Cleland, JGF | 2 |
| Pellicori, P | 1 |
| Liang, EH | 1 |
| Kim, CY | 1 |
| Sheikh, J | 1 |
| Samant, SA | 1 |
| Shrestha, A | 1 |
| Wilson, J | 1 |
| Stys, A | 1 |
| Garcia, E | 1 |
| Rivas Rios, J | 1 |
| Rivas, A | 1 |
| Agarwal, M | 1 |
| Kureti, M | 1 |
| Nagaraju, D | 1 |
| Wali, M | 1 |
| Briceno, M | 1 |
| Moon, JY | 2 |
| Kairouz, V | 1 |
| Yaranov, D | 1 |
| Suryadevara, S | 1 |
| Soffer, D | 1 |
| Bass, TA | 14 |
| Gorog, DA | 2 |
| Witberg, G | 1 |
| Zusman, O | 1 |
| Bental, T | 2 |
| Plakht, I | 1 |
| Gabbay, H | 1 |
| Gerber, Y | 1 |
| Held, C | 2 |
| Leonsson-Zachrisson, M | 1 |
| Opolski, G | 4 |
| Zateyshchikov, D | 1 |
| Ge, J | 2 |
| Nicolau, JC | 3 |
| Corbalán, R | 1 |
| Cornel, JH | 1 |
| Alings, M | 3 |
| Berkowitz, SD | 7 |
| Cook-Bruns, N | 1 |
| Felix, C | 3 |
| Hart, RG | 4 |
| Moayyedi, P | 1 |
| O'Donnell, M | 5 |
| Rydén, L | 1 |
| Verhamme, P | 2 |
| Wang, J | 3 |
| Liu, J | 2 |
| Zhou, Y | 1 |
| Wang, F | 3 |
| Xu, K | 5 |
| Kong, D | 2 |
| Bai, J | 2 |
| Chen, J | 3 |
| Gong, X | 4 |
| Meng, H | 1 |
| Bosch, JJ | 1 |
| Dagenais, GR | 3 |
| Leong, DP | 1 |
| Cairns, JA | 1 |
| Tasto, C | 1 |
| Cook Bruns, N | 2 |
| Diaz, R | 1 |
| Shimamatsu, J | 1 |
| Sasaki, KI | 1 |
| Katsuki, Y | 1 |
| Kawasaki, T | 1 |
| Murasato, Y | 1 |
| Ajisaka, H | 1 |
| Yokoi, H | 5 |
| Tashiro, H | 1 |
| Harada, A | 1 |
| Hirakawa, Y | 1 |
| Ishizaki, Y | 1 |
| Ishimatsu, T | 1 |
| Kagiyama, K | 1 |
| Fukumoto, Y | 1 |
| Kakuma, T | 1 |
| Ueno, T | 2 |
| Hwang, IC | 2 |
| Lee, H | 2 |
| Yoon, YE | 3 |
| Choi, IS | 2 |
| Kim, HL | 1 |
| Chang, HJ | 3 |
| Lee, JY | 4 |
| Choi, JA | 1 |
| Kim, HJ | 3 |
| Cho, GY | 1 |
| Park, JB | 1 |
| Lee, SP | 2 |
| Kim, HK | 2 |
| Kim, YJ | 3 |
| Sohn, DW | 2 |
| Saito, Y | 2 |
| Kobayashi, Y | 4 |
| Aboul-Hassan, SS | 3 |
| Stankowski, T | 3 |
| Marczak, J | 3 |
| Peksa, M | 2 |
| Nawotka, M | 2 |
| Stanislawski, R | 2 |
| Cichon, R | 3 |
| Vanassche, T | 1 |
| Fox, KA | 2 |
| Hu, S | 5 |
| Belcaro, G | 1 |
| Cesarone, MR | 1 |
| Feragalli, B | 1 |
| Cotellese, R | 1 |
| Dugall, M | 1 |
| Scipione, C | 1 |
| Scipione, V | 1 |
| Maione, C | 1 |
| Dannenberg, L | 3 |
| Metzen, D | 1 |
| Zako, S | 2 |
| Pöhl, M | 1 |
| Mourikis, P | 2 |
| Helten, C | 2 |
| Trojovsky, K | 1 |
| Naguib, D | 2 |
| Konsek, D | 1 |
| Knoop, B | 1 |
| Ayhan, A | 1 |
| Hohlfeld, T | 7 |
| Petzold, T | 2 |
| Levkau, B | 3 |
| Veulemans, V | 1 |
| Zeus, T | 6 |
| Kelm, M | 7 |
| Polzin, A | 6 |
| Sheng, Z | 1 |
| Tan, Y | 1 |
| Liu, C | 1 |
| Zhou, P | 1 |
| Zhou, J | 2 |
| Chen, R | 2 |
| Song, L | 1 |
| Zhao, H | 2 |
| Yan, H | 2 |
| Stefanescu Schmidt, AC | 1 |
| Yeh, RW | 9 |
| Kereiakes, DJ | 11 |
| Tanguay, JF | 1 |
| Hsieh, WH | 3 |
| Massaro, JM | 5 |
| Mauri, L | 12 |
| Cutlip, DE | 5 |
| Hesterberg, K | 1 |
| Rawal, A | 1 |
| Khan, S | 1 |
| Rashid, A | 1 |
| Jones, D | 1 |
| Siddiqui, T | 1 |
| Khader, TA | 1 |
| Nayyar, M | 1 |
| Shah, R | 2 |
| Chichareon, P | 2 |
| Modolo, R | 2 |
| Kerkmeijer, L | 1 |
| Tomaniak, M | 1 |
| Kogame, N | 2 |
| Takahashi, K | 1 |
| Chang, CC | 2 |
| Komiyama, H | 1 |
| Moccetti, T | 2 |
| Talwar, S | 1 |
| Colombo, A | 7 |
| Maillard, L | 3 |
| Barlis, P | 1 |
| Wykrzykowska, J | 1 |
| Piek, JJ | 2 |
| Garg, S | 2 |
| Lopes, RD | 6 |
| Wojdyla, DM | 2 |
| Vora, AN | 1 |
| Thomas, L | 2 |
| Vinereanu, D | 2 |
| Granger, CB | 6 |
| Aronson, R | 1 |
| Thiele, H | 1 |
| Alexander, JH | 5 |
| Peterson, ED | 10 |
| De Caterina, R | 1 |
| Bode, C | 3 |
| Gersh, B | 1 |
| Rubin, GA | 1 |
| Kirtane, AJ | 11 |
| Chen, S | 2 |
| Redfors, B | 3 |
| Weisz, G | 10 |
| Baber, U | 12 |
| Stuckey, TD | 8 |
| Witzenbichler, B | 13 |
| Rinaldi, MJ | 8 |
| Neumann, FJ | 11 |
| Metzger, DC | 7 |
| Henry, TD | 11 |
| Cox, DA | 7 |
| Duffy, PL | 7 |
| Brodie, BR | 7 |
| Mazzaferri, EL | 7 |
| Ali, ZA | 1 |
| Ben-Yehuda, O | 5 |
| Stone, GW | 15 |
| Barbato, E | 4 |
| Neergaard-Petersen, S | 9 |
| Ajjan, RA | 3 |
| Sandner, SE | 2 |
| Wiedemann, D | 2 |
| Misfeld, M | 2 |
| Böning, A | 2 |
| Tebbe, U | 1 |
| Nowak, B | 1 |
| Stritzke, J | 1 |
| Laufer, G | 3 |
| Cho, S | 1 |
| Kang, TS | 2 |
| Shin, DH | 4 |
| Song, YB | 3 |
| Hahn, JY | 3 |
| Choi, SH | 3 |
| Gwon, HC | 3 |
| Paven, E | 1 |
| Dillinger, JG | 4 |
| Bal Dit Sollier, C | 4 |
| Vidal-Trecan, T | 1 |
| Berge, N | 1 |
| Dautry, R | 1 |
| Gautier, JF | 1 |
| Drouet, L | 4 |
| Riveline, JP | 1 |
| Henry, P | 4 |
| Shiyovich, A | 2 |
| Sasson, L | 2 |
| Ten Berg, JM | 12 |
| de Veer, A | 2 |
| Oldgren, J | 7 |
| Zateyshchikov, DA | 1 |
| Jansky, P | 1 |
| Seung, KB | 7 |
| Hohnloser, SH | 7 |
| Lip, GYH | 7 |
| Nordaby, M | 7 |
| Kleine, E | 3 |
| Cannon, CP | 17 |
| Maeng, M | 7 |
| Miede, C | 5 |
| Kimura, T | 9 |
| Lamy, A | 1 |
| Levy, P | 1 |
| Mealing, S | 1 |
| Millier, A | 1 |
| Mernagh, P | 1 |
| Cristeau, O | 1 |
| Bowrin, K | 1 |
| Briere, JB | 1 |
| Alexopoulos, D | 3 |
| Mpahara, A | 1 |
| Kassimis, G | 2 |
| Platt, B | 1 |
| Belarski, E | 1 |
| Manaloor, J | 1 |
| Ofner, S | 1 |
| Carroll, AE | 1 |
| John, CC | 1 |
| Wood, JB | 1 |
| García-Ropero, Á | 1 |
| Vargas-Delgado, AP | 1 |
| Santos-Gallego, CG | 1 |
| Badimon, JJ | 4 |
| Wokhlu, A | 1 |
| Wymer, D | 1 |
| Taasan, V | 1 |
| Winchester, DE | 1 |
| Raco, DL | 1 |
| Lopau, K | 1 |
| Wanner, C | 1 |
| Martí, D | 1 |
| Carballeira, D | 1 |
| Morales, MJ | 1 |
| Concepción, R | 1 |
| Del Castillo, H | 1 |
| Marschall, A | 1 |
| Delgado-Calva, FA | 1 |
| Dejuán-Bitriá, C | 1 |
| Pérez-Guzmán, J | 1 |
| López-Soberón, E | 1 |
| Palazuelos, J | 2 |
| Álvarez-Antón, S | 1 |
| Tantry, U | 2 |
| Cummings, C | 1 |
| Mackrell, P | 1 |
| Gonze, M | 1 |
| Ulloa, K | 1 |
| Bafford, R | 1 |
| Rout, A | 1 |
| Sukhi, A | 1 |
| Gurbel, P | 2 |
| Ditali, V | 1 |
| Carrozzi, C | 1 |
| Ujjawal, A | 1 |
| Gupta, M | 1 |
| Ghosh, RK | 1 |
| Jain, V | 1 |
| Bandyopadhyay, D | 1 |
| Qamar, A | 1 |
| Aronow, WS | 2 |
| Deedwania, P | 2 |
| Kapadia, S | 1 |
| Lavie, CJ | 1 |
| Cainzos-Achirica, M | 1 |
| Miedema, MD | 1 |
| McEvoy, JW | 4 |
| Al Rifai, M | 1 |
| Greenland, P | 2 |
| Dardari, Z | 1 |
| Budoff, M | 4 |
| Blumenthal, RS | 8 |
| Yeboah, J | 1 |
| Duprez, DA | 1 |
| Mortensen, MB | 1 |
| Dzaye, O | 1 |
| Hong, J | 1 |
| Nasir, K | 7 |
| Blaha, MJ | 4 |
| Berry, NC | 1 |
| Gajanana, D | 1 |
| Rogers, T | 1 |
| Weintraub, WS | 2 |
| Kolm, P | 1 |
| Iantorno, M | 1 |
| Khalid, N | 1 |
| Shlofmitz, E | 1 |
| Khan, JM | 1 |
| Musallam, A | 1 |
| Ben-Dor, I | 3 |
| Satler, LF | 3 |
| Zhang, C | 1 |
| Torguson, R | 2 |
| Waksman, R | 5 |
| Varol, S | 1 |
| Şahin, İ | 1 |
| Kum, G | 1 |
| Katkat, F | 1 |
| Okuyan, E | 1 |
| Liu, L | 2 |
| Guzik, TJ | 4 |
| Keller, L | 1 |
| Zhang, M | 1 |
| Xue, Q | 1 |
| Hu, J | 1 |
| Liu, H | 4 |
| Wang, R | 2 |
| Dai, C | 1 |
| Fu, J | 2 |
| Qian, J | 1 |
| Fischman, D | 2 |
| Costa, F | 4 |
| Rocha-Gomes, JN | 1 |
| Saraiva, FA | 1 |
| Cerqueira, RJ | 1 |
| Moreira, R | 1 |
| Ferreira, AF | 1 |
| Barros, AS | 1 |
| Amorim, MJ | 1 |
| Pinho, P | 1 |
| Lourenço, AP | 1 |
| Leite-Moreira, AF | 1 |
| González-Juanatey, JR | 1 |
| Almendro-Delia, M | 1 |
| Cosín-Sales, J | 2 |
| Bellmunt-Montoya, S | 1 |
| Gómez-Doblas, JJ | 1 |
| Riambau, V | 1 |
| García-Moll, X | 2 |
| García-Alegría, J | 1 |
| Hernández, JL | 1 |
| Lozano, FS | 1 |
| Suarez Fernández, C | 1 |
| Formigli, D | 1 |
| Meessen, J | 1 |
| Uguccioni, M | 1 |
| Cosentino, N | 2 |
| Paolillo, C | 1 |
| Di Lenarda, A | 2 |
| Scherillo, M | 1 |
| Tiemuerniyazi, X | 1 |
| Song, Y | 4 |
| Xu, F | 2 |
| Feng, W | 2 |
| Gryaznov, AA | 1 |
| Saeyeldin, A | 1 |
| Abdelbaky, M | 1 |
| Zafar, MA | 1 |
| Tanweer, M | 1 |
| Papanikolaou, D | 1 |
| Imran, M | 1 |
| Li, Y | 10 |
| Ziganshin, BA | 1 |
| Elefteriades, JA | 1 |
| Vogt, JC | 1 |
| Manning, PG | 1 |
| Sheikh, O | 1 |
| Aronow, HD | 4 |
| Chilton, RJ | 1 |
| Cigarroa, JE | 2 |
| Wu, B | 1 |
| Shi, L | 3 |
| Eikelboom, R | 1 |
| Muller Moran, HR | 1 |
| Lodewyks, C | 1 |
| Yan, W | 1 |
| Zelentsov, I | 1 |
| Arora, RC | 1 |
| Calderone, D | 1 |
| Bao, D | 1 |
| Liao, Z | 1 |
| Han, X | 1 |
| Li, Z | 3 |
| Liu, WH | 1 |
| Shi, J | 2 |
| Zhong, Y | 1 |
| Liu, SJ | 1 |
| Liu, SM | 1 |
| Darmon, A | 2 |
| Mas, JL | 1 |
| Cacoub, P | 1 |
| Billaut-Laden, I | 1 |
| DeMaria, AN | 1 |
| Bentur, O | 1 |
| Carlson, M | 1 |
| Seng Yue, C | 1 |
| Martin, LH | 1 |
| Midkiff, J | 1 |
| Mueller, M | 1 |
| Meek, T | 1 |
| Garza, D | 1 |
| Gibson, CM | 4 |
| Coller, BS | 1 |
| Lee, MC | 1 |
| Liao, CT | 1 |
| Toh, HS | 1 |
| Chou, CC | 1 |
| Chang, WT | 1 |
| Chen, ZC | 1 |
| Wu, WS | 1 |
| Yu, T | 1 |
| Strong, C | 1 |
| Abdus, S | 2 |
| Tan, C | 2 |
| Gu, Q | 2 |
| Yang, M | 3 |
| Wang, G | 4 |
| Asad, ZUA | 1 |
| Zhang, ZZ | 1 |
| Zhang, SZ | 1 |
| Zhou, HM | 1 |
| Fan, YQ | 1 |
| Liu, MH | 1 |
| Zhong, XB | 1 |
| Yang, DY | 1 |
| Guo, Y | 2 |
| Zhuang, XD | 1 |
| Liao, XX | 1 |
| Guimarães, PO | 1 |
| De Martino, F | 1 |
| Tinoco, J | 1 |
| Ribeiro, EE | 1 |
| Kawashima, H | 1 |
| Ono, M | 1 |
| Hara, H | 2 |
| Cavalcante, R | 1 |
| Moulin, B | 1 |
| Falcão, BAA | 1 |
| Leite, RS | 1 |
| de Almeida Sampaio, FB | 1 |
| Morais, GR | 1 |
| Meireles, GC | 1 |
| Campos, CM | 1 |
| Lemos, PA | 2 |
| Roccasalva, F | 1 |
| Ferrante, G | 1 |
| Moran, TB | 1 |
| Plana, JC | 1 |
| Zhu, KX | 1 |
| Song, PY | 1 |
| Li, MP | 1 |
| Du, YX | 1 |
| Ma, QL | 1 |
| Peng, LM | 1 |
| Chen, XP | 1 |
| Ajufo, E | 1 |
| Ayers, CR | 1 |
| Vigen, R | 1 |
| Joshi, PH | 1 |
| Rohatgi, A | 1 |
| Khera, A | 1 |
| Leiva, O | 1 |
| Nickenig, G | 3 |
| Gabor Kiss, R | 1 |
| Ongen, Z | 1 |
| Navarro Estrada, J | 1 |
| Oude Ophuis, T | 1 |
| Chiang, MH | 1 |
| Liu, HE | 1 |
| Wang, JL | 1 |
| Dasa, O | 1 |
| Pepine, CJ | 3 |
| Pearson, TA | 1 |
| Taha, A | 1 |
| Nielsen, SJ | 1 |
| Bergfeldt, L | 1 |
| Ahlsson, A | 1 |
| Friberg, L | 1 |
| Björck, S | 1 |
| Franzén, S | 1 |
| Jeppsson, A | 1 |
| Wang, HY | 1 |
| Cai, ZX | 1 |
| Yin, D | 1 |
| Yang, YJ | 1 |
| Song, WH | 1 |
| Dou, KF | 1 |
| Moskal, L | 1 |
| Lipowski, A | 1 |
| Sá, MPBO | 1 |
| Yuan, S | 2 |
| Chen, P | 1 |
| Li, H | 3 |
| Chen, C | 1 |
| Wang, DW | 1 |
| Lee, SY | 3 |
| Cho, BR | 1 |
| Jang, WJ | 1 |
| Oh, JH | 3 |
| Chun, WJ | 1 |
| Park, YH | 1 |
| Im, ES | 1 |
| Jeong, JO | 1 |
| Oh, SK | 2 |
| Cho, DK | 4 |
| Koh, YY | 1 |
| Bae, JW | 2 |
| Choi, JW | 1 |
| Lee, WS | 2 |
| Yoon, HJ | 1 |
| Lee, SU | 3 |
| Cho, JH | 4 |
| Choi, WG | 2 |
| Rha, SW | 4 |
| Lee, JM | 2 |
| Park, TK | 1 |
| Yang, JH | 3 |
| Choi, JH | 2 |
| Lee, SH | 4 |
| Schade, DS | 1 |
| Burchiel, S | 1 |
| Eaton, RP | 1 |
| Shoji, K | 1 |
| Zen, K | 3 |
| Ookura, T | 1 |
| Yanishi, K | 1 |
| Matoba, S | 1 |
| Sikharulidze, I | 1 |
| Chelidze, K | 1 |
| Mamatsashvili, I | 1 |
| Wittbrodt, E | 1 |
| Bhalla, N | 1 |
| Sundell, KA | 1 |
| Hunt, P | 1 |
| Wong, ND | 2 |
| Kuster, M | 1 |
| Feng, C | 1 |
| Chen, F | 3 |
| Li, L | 5 |
| Li, Q | 2 |
| Xia, S | 1 |
| Akao, M | 1 |
| Yasuda, S | 2 |
| Kaikita, K | 9 |
| Ako, J | 3 |
| Matoba, T | 1 |
| Nakamura, M | 4 |
| Miyauchi, K | 1 |
| Hagiwara, N | 1 |
| Kimura, K | 3 |
| Hirayama, A | 3 |
| Matsui, K | 5 |
| Ogawa, H | 9 |
| Lin, S | 2 |
| Xu, X | 1 |
| Hu, H | 1 |
| Cheng, J | 1 |
| Hu, Y | 1 |
| Chen, X | 4 |
| Ferrara, P | 1 |
| Cortesi, PA | 1 |
| Di Laura, D | 1 |
| Mantovani, LG | 1 |
| Cattalini, M | 1 |
| Della Paolera, S | 1 |
| Zunica, F | 1 |
| Bracaglia, C | 1 |
| Giangreco, M | 1 |
| Verdoni, L | 1 |
| Meini, A | 1 |
| Sottile, R | 1 |
| Caorsi, R | 1 |
| Zuccotti, G | 1 |
| Fabi, M | 1 |
| Montin, D | 1 |
| Meneghel, A | 1 |
| Consolaro, A | 1 |
| Dellepiane, RM | 1 |
| Maggio, MC | 1 |
| La Torre, F | 1 |
| Marchesi, A | 1 |
| Simonini, G | 1 |
| Villani, A | 1 |
| Cimaz, R | 1 |
| Ravelli, A | 1 |
| Taddio, A | 1 |
| Kim, BS | 3 |
| Chan, N | 1 |
| Hsu, G | 1 |
| Makaryus, AN | 4 |
| Chopra, M | 1 |
| Cohen, SL | 1 |
| Makaryus, JN | 2 |
| Milojevic, M | 1 |
| Zimpfer, D | 1 |
| Zellmer, S | 1 |
| Peterson, BE | 1 |
| Gabriel Steg, P | 2 |
| Haji Aghajani, M | 1 |
| Moradi, O | 1 |
| Amini, H | 1 |
| Azhdari Tehrani, H | 1 |
| Pourheidar, E | 1 |
| Rabiei, MM | 1 |
| Sistanizad, M | 1 |
| Asleh, R | 1 |
| Briasoulis, A | 2 |
| Smith, B | 1 |
| Lopez, C | 1 |
| Alnsasra, H | 1 |
| Pereira, NL | 1 |
| Edwards, BS | 1 |
| Clavell, AL | 1 |
| Stulak, JM | 1 |
| Locker, C | 1 |
| Kremers, WK | 1 |
| Daly, RC | 1 |
| Lerman, A | 2 |
| Kushwaha, SS | 1 |
| McGuire, DK | 4 |
| Teoh, H | 2 |
| Lev, EI | 6 |
| Kiss, RG | 5 |
| Dalby, AJ | 2 |
| Prats, J | 1 |
| Lee, JJ | 1 |
| Amerena, J | 1 |
| Kosiborod, MN | 1 |
| Olesen, KKW | 3 |
| Heide-Jørgensen, U | 1 |
| Thim, T | 3 |
| Thomsen, RW | 1 |
| Bøtker, HE | 3 |
| Sørensen, HT | 2 |
| Cohen, DJ | 7 |
| Sartori, S | 4 |
| Sharma, SK | 4 |
| Farhan, S | 6 |
| Goel, R | 1 |
| Zhang, Z | 1 |
| Briguori, C | 3 |
| Collier, T | 1 |
| Dangas, G | 4 |
| Dudek, D | 1 |
| Escaned, J | 5 |
| Gil, R | 1 |
| Han, YL | 3 |
| Krucoff, MW | 4 |
| Moliterno, D | 2 |
| Sardella, G | 2 |
| Qu, J | 1 |
| Zhang, H | 3 |
| Rao, C | 2 |
| Zhao, Y | 2 |
| Sun, H | 2 |
| Liu, S | 1 |
| Wang, S | 3 |
| Zheng, Z | 4 |
| Koo, BK | 2 |
| Rhee, TM | 1 |
| Yang, HM | 2 |
| Won, KB | 1 |
| Lee, NH | 6 |
| Hur, SH | 4 |
| Yoon, J | 1 |
| Park, TH | 2 |
| Lim, SW | 2 |
| Cho, YH | 5 |
| Jeon, DW | 3 |
| Kim, SH | 3 |
| Han, JK | 1 |
| Shin, ES | 3 |
| Dizon, K | 1 |
| Ng, PCK | 1 |
| Battistella, M | 1 |
| Bálint, A | 1 |
| Tornyos, D | 1 |
| El Alaoui El Abdallaoui, O | 1 |
| Kupó, P | 1 |
| Komócsi, A | 1 |
| Sharma, M | 2 |
| Ye, Z | 1 |
| Mei, L | 1 |
| Ullah, I | 1 |
| Lu, Y | 1 |
| Batista, DV | 2 |
| Hueb, W | 2 |
| Lima, EG | 3 |
| Rezende, PC | 2 |
| Garzillo, CL | 2 |
| Garcia, RMR | 1 |
| Filho, JPPL | 1 |
| Martins, EB | 1 |
| Junior, CVS | 1 |
| Ramires, JAF | 1 |
| Filho, RK | 1 |
| Faggioni, M | 2 |
| Giustino, G | 5 |
| Ariti, C | 3 |
| Gibson, M | 2 |
| Giacoppo, D | 1 |
| Aquino, M | 3 |
| Chandrasekhar, J | 3 |
| Moliterno, DJ | 3 |
| Chieffo, A | 4 |
| Kini, AS | 4 |
| Hsu, CH | 1 |
| Yu, SM | 1 |
| Lau, SC | 1 |
| Chen, YL | 1 |
| Pei, D | 1 |
| Liu, IC | 1 |
| Cavalca, V | 1 |
| Rocca, B | 2 |
| Veglia, F | 1 |
| Petrucci, G | 1 |
| Porro, B | 1 |
| Myasoedova, V | 1 |
| De Cristofaro, R | 1 |
| Turnu, L | 1 |
| Bonomi, A | 1 |
| Songia, P | 1 |
| Cavallotti, L | 1 |
| Zanobini, M | 1 |
| Camera, M | 1 |
| Alamanni, F | 1 |
| Parolari, A | 1 |
| Patrono, C | 1 |
| Tremoli, E | 1 |
| Benedetto, U | 2 |
| Altman, DG | 1 |
| Gerry, S | 1 |
| Gray, A | 1 |
| Lees, B | 1 |
| Flather, M | 4 |
| Taggart, DP | 1 |
| Pitts, R | 1 |
| Daugherty, SL | 1 |
| Tang, F | 2 |
| Jones, P | 1 |
| Ho, PM | 2 |
| Tsai, TT | 2 |
| Spertus, J | 1 |
| Maddox, TM | 3 |
| Verdoia, M | 11 |
| Daffara, V | 1 |
| Pergolini, P | 8 |
| Rolla, R | 8 |
| Marino, P | 8 |
| Bellomo, G | 8 |
| Carriero, A | 2 |
| De Luca, G | 13 |
| Oimatsu, Y | 2 |
| Ishii, M | 3 |
| Mitsuse, T | 1 |
| Ito, M | 3 |
| Arima, Y | 4 |
| Sueta, D | 3 |
| Takahashi, A | 1 |
| Iwashita, S | 5 |
| Yamamoto, E | 3 |
| Kojima, S | 3 |
| Hokimoto, S | 7 |
| Tsujita, K | 5 |
| Engbers, EM | 1 |
| Timmer, JR | 1 |
| Mouden, M | 1 |
| Knollema, S | 1 |
| Jager, PL | 1 |
| Ottervanger, JP | 1 |
| Zhang, JW | 4 |
| Liu, TF | 3 |
| Chen, XH | 4 |
| Liang, WY | 2 |
| Feng, XR | 5 |
| Fu, SW | 3 |
| McCaffrey, TA | 3 |
| Liu, ML | 5 |
| Secemsky, EA | 2 |
| Apruzzese, PK | 2 |
| Pareek, M | 2 |
| Bavry, AA | 4 |
| Elgendy, IY | 1 |
| Mahmoud, AN | 1 |
| Sorbets, E | 2 |
| Choi, HI | 1 |
| Ahn, JM | 5 |
| Kang, SH | 2 |
| Lee, PH | 2 |
| Kang, SJ | 6 |
| Lee, SW | 10 |
| Kim, YH | 10 |
| Lee, CW | 9 |
| Park, SW | 8 |
| Park, DW | 8 |
| Park, SJ | 8 |
| Kern, A | 1 |
| Gil, RJ | 1 |
| Bojko, K | 1 |
| Sienkiewicz, E | 1 |
| Januszko-Giergielewicz, B | 1 |
| Górny, J | 1 |
| Bil, J | 1 |
| Li, M | 1 |
| Yu, X | 2 |
| He, J | 4 |
| Gao, Y | 3 |
| Zhang, X | 4 |
| Wu, C | 2 |
| Luo, Y | 2 |
| Ren, X | 3 |
| Cortellini, G | 1 |
| Caruso, C | 1 |
| Romano, A | 1 |
| Chang, KW | 1 |
| Arbit, B | 1 |
| Hsu, JC | 1 |
| Madsen, M | 2 |
| Egholm, G | 1 |
| Jensen, LO | 3 |
| Raungaard, B | 1 |
| Gargiulo, G | 4 |
| Santucci, A | 3 |
| Ariotti, S | 3 |
| Baldo, A | 3 |
| Tumscitz, C | 2 |
| Moschovitis, A | 3 |
| Xia, H | 1 |
| Feng, K | 1 |
| Iijima, R | 3 |
| Shinke, T | 3 |
| Okada, H | 2 |
| Ito, Y | 2 |
| Ando, K | 2 |
| Anzai, H | 2 |
| Tanaka, H | 2 |
| Ueda, Y | 3 |
| Takiuchi, S | 2 |
| Nishida, Y | 2 |
| Ohira, H | 2 |
| Kawaguchi, K | 2 |
| Kadotani, M | 3 |
| Niinuma, H | 2 |
| Omiya, K | 2 |
| Morita, T | 2 |
| Yasaka, Y | 3 |
| Inoue, K | 2 |
| Ishiwata, S | 2 |
| Ochiai, M | 3 |
| Hamasaki, T | 2 |
| Didier, R | 1 |
| Morice, MC | 3 |
| Barragan, P | 2 |
| Noryani, AAL | 2 |
| Noor, HA | 2 |
| Majwal, T | 2 |
| Hovasse, T | 2 |
| Castellant, P | 2 |
| Schneeberger, M | 2 |
| Bressolette, E | 2 |
| Wojcik, J | 2 |
| Delarche, N | 2 |
| Blanchard, D | 2 |
| Jouve, B | 2 |
| Ormezzano, O | 2 |
| Paganelli, F | 3 |
| Levy, G | 2 |
| Sainsous, J | 2 |
| Carrie, D | 4 |
| Furber, A | 2 |
| Berlan, J | 1 |
| Darremont, O | 2 |
| Le Breton, H | 2 |
| Lyuycx-Bore, A | 2 |
| Gommeaux, A | 2 |
| Cassat, C | 2 |
| Kermarrec, A | 2 |
| Cazaux, P | 2 |
| Druelles, P | 2 |
| Dauphin, R | 2 |
| Armengaud, J | 2 |
| Dupouy, P | 2 |
| Champagnac, D | 2 |
| Ohlmann, P | 3 |
| Ben Amer, H | 1 |
| Ungi, I | 3 |
| Gilard, M | 4 |
| Lee, KY | 1 |
| Hwang, BH | 1 |
| Kim, TH | 2 |
| Kim, CJ | 1 |
| Kim, JJ | 3 |
| Choo, EH | 1 |
| Choi, IJ | 1 |
| Choi, Y | 1 |
| Park, HW | 1 |
| Koh, YS | 2 |
| Kim, PJ | 2 |
| Kim, MJ | 1 |
| Jeon, DS | 3 |
| Jung, JI | 1 |
| Chang, K | 2 |
| Amano, H | 1 |
| Saito, D | 1 |
| Yabe, T | 1 |
| Okubo, R | 1 |
| Toda, M | 1 |
| Ikeda, T | 2 |
| Im, E | 1 |
| Suh, Y | 1 |
| Her, AY | 1 |
| Lee, K | 5 |
| Kang, WC | 4 |
| Yoo, SY | 1 |
| Cheong, SS | 3 |
| Hage, A | 1 |
| Voisine, P | 3 |
| Erthal, F | 1 |
| Larose, É | 3 |
| Glineur, D | 1 |
| Chow, B | 1 |
| Tremblay, H | 1 |
| Fortier, J | 1 |
| Ko, G | 1 |
| Une, D | 2 |
| Farkouh, M | 1 |
| Mesana, TG | 2 |
| LeMay, M | 1 |
| Kulik, A | 4 |
| Ruel, M | 4 |
| Lin, SH | 1 |
| Furer, A | 1 |
| Maehara, A | 4 |
| Généreux, P | 4 |
| Ayele, GM | 1 |
| Mintz, GS | 1 |
| Kuliczkowski, W | 6 |
| Radomski, M | 1 |
| Gąsior, M | 1 |
| Urbaniak, J | 1 |
| Kaczmarski, J | 3 |
| Mysiak, A | 1 |
| Negrusz-Kawecka, M | 1 |
| Bil-Lula, I | 1 |
| Schoos, M | 1 |
| Bhasin, A | 1 |
| Sorrentino, S | 2 |
| Kini, A | 2 |
| Kruckoff, M | 1 |
| Iakovou, I | 2 |
| Cohen, D | 1 |
| Stuckey, T | 2 |
| Würtz, M | 13 |
| Kim, M | 1 |
| Bergmark, BA | 1 |
| Zelniker, TA | 1 |
| Mehra, MR | 2 |
| Stewart, GC | 1 |
| Page, DS | 1 |
| Woodcome, EL | 1 |
| Smallwood, JA | 1 |
| Gabardi, S | 1 |
| Givertz, MM | 1 |
| Kagolanu, D | 1 |
| Sayedy, N | 1 |
| Haseeb, S | 1 |
| Shah, S | 1 |
| Lam, P | 1 |
| Munnangi, S | 1 |
| Viswanathan, P | 1 |
| Stephenson, K | 1 |
| Liu, WW | 1 |
| He, XQ | 1 |
| Jawaid, H | 1 |
| Hussain, A | 1 |
| Imtiaz, F | 1 |
| Hamilton-Craig, CR | 1 |
| Chow, CK | 2 |
| Younger, JF | 1 |
| Jelinek, VM | 1 |
| Chan, J | 1 |
| Liew, GY | 1 |
| Casella, G | 1 |
| Resciniti, E | 1 |
| Gallo, P | 1 |
| Ho, LGY | 1 |
| Curtis, N | 1 |
| Barbieri, L | 9 |
| Schaffer, A | 8 |
| Suryapranata, H | 9 |
| Lee, BK | 5 |
| Lee, OH | 1 |
| Min, PK | 2 |
| Yoon, YW | 1 |
| Hong, BK | 2 |
| Kim, BO | 1 |
| Woo, SI | 1 |
| Choi, S | 1 |
| Kim, S | 3 |
| Kwon, HM | 2 |
| Baos, S | 1 |
| Underwood, W | 1 |
| Culliford, L | 1 |
| Reeves, BC | 1 |
| Rogers, CA | 1 |
| Bowles, R | 1 |
| Johnson, T | 1 |
| Baumbach, A | 1 |
| Mumford, A | 1 |
| Dagenais, G | 1 |
| Dyal, L | 2 |
| Lanas, F | 1 |
| Metsarinne, K | 1 |
| Dans, AL | 1 |
| Ha, JW | 2 |
| Parkhomenko, AN | 1 |
| Avezum, AA | 1 |
| Lonn, E | 1 |
| Lisheng, L | 1 |
| Torp-Pedersen, C | 3 |
| Keltai, K | 3 |
| Yusoff, K | 1 |
| Varigos, JD | 1 |
| Xu, Z | 1 |
| Zhu, T | 2 |
| Zocca, P | 1 |
| van der Heijden, LC | 1 |
| Kok, MM | 1 |
| Löwik, MM | 1 |
| Hartmann, M | 1 |
| Stoel, MG | 1 |
| Louwerenburg, JW | 1 |
| de Man, FHAF | 1 |
| Linssen, GCM | 1 |
| Knottnerus, IL | 1 |
| Doggen, CJM | 1 |
| van Houwelingen, KG | 1 |
| von Birgelen, C | 1 |
| Patel, P | 2 |
| Nigam, N | 1 |
| Sengupta, N | 1 |
| Sharifi, M | 1 |
| Kamali, A | 1 |
| Ghandi, Y | 1 |
| Anand, S | 1 |
| Branch, KR | 2 |
| Probstfield, J | 1 |
| Lim, GB | 1 |
| Frisch, A | 1 |
| Heidle, KJ | 1 |
| Frisch, SO | 1 |
| Ata, A | 1 |
| Kramer, B | 1 |
| Colleran, C | 1 |
| Carlson, JN | 1 |
| Xing, L | 1 |
| Sugiyama, T | 1 |
| Jia, H | 1 |
| Ma, L | 5 |
| Wang, C | 1 |
| Xu, M | 1 |
| Bryniarski, K | 2 |
| Hou, J | 1 |
| Zhang, S | 4 |
| Jang, IK | 2 |
| Lee, CH | 1 |
| Park, GM | 2 |
| Choi, YJ | 2 |
| Nam, CW | 2 |
| Shin, WY | 2 |
| Seo, JB | 1 |
| Choi, SW | 5 |
| Lee, JH | 4 |
| Her, SH | 1 |
| Ju, J | 1 |
| Lu, F | 1 |
| Gao, R | 3 |
| Xu, H | 1 |
| Kopin, D | 2 |
| Jones, WS | 3 |
| Sherwood, MW | 1 |
| Wallentin, L | 8 |
| Lewis, BS | 1 |
| Verheugt, FWA | 2 |
| Bahit, MC | 1 |
| Parkhomenko, A | 1 |
| Kuroda, K | 1 |
| Otake, H | 2 |
| Kinutani, H | 1 |
| Urasawa, K | 1 |
| Kataoka, T | 1 |
| Yoshiyama, M | 1 |
| Fujii, K | 2 |
| Inoue, T | 1 |
| Kawata, M | 1 |
| Grenier, J | 1 |
| Langer, A | 1 |
| Goldin, L | 1 |
| Connelly, KA | 1 |
| Cheng, AYY | 1 |
| Fitchett, D | 1 |
| Fonarow, GC | 6 |
| Frank Peacock, W | 1 |
| Laskey, WK | 2 |
| Grau-Sepulveda, MV | 1 |
| Smith, EE | 1 |
| Hernandez, AF | 4 |
| Abreu, AM | 1 |
| Boronat, V | 1 |
| Kouchoukos, NT | 1 |
| Migally, K | 1 |
| Braunlin, EA | 1 |
| Zhang, L | 7 |
| Binstadt, BA | 1 |
| Pasalic, L | 1 |
| Wing-Lun, E | 1 |
| Lau, JK | 1 |
| Campbell, H | 1 |
| Pennings, GJ | 2 |
| Lau, E | 1 |
| Connor, D | 1 |
| Liang, HP | 1 |
| Muller, D | 1 |
| Kritharides, L | 2 |
| Hogg, PJ | 1 |
| Chen, VM | 1 |
| Srivastava, P | 1 |
| Butler, J | 1 |
| Shroyer, AL | 1 |
| Lacey, M | 1 |
| Parikh, PB | 1 |
| Patel, SS | 1 |
| Guzman, LA | 7 |
| Lin, FP | 1 |
| Pence, T | 1 |
| Reichman, T | 1 |
| John, B | 1 |
| Celi, FS | 1 |
| Liptrap, E | 1 |
| Bhati, C | 1 |
| Siddiqui, MS | 1 |
| Mahla, E | 2 |
| Metzler, H | 1 |
| Bornemann-Cimenti, H | 1 |
| Prueller, F | 1 |
| Raggam, RB | 1 |
| Pregartner, G | 1 |
| Berghold, A | 1 |
| Baumann, A | 1 |
| Goeroeg, C | 1 |
| Gurbel, PA | 25 |
| Pereira, P | 1 |
| Kapoor, A | 1 |
| Sinha, A | 2 |
| Agarwal, SK | 1 |
| Pande, S | 1 |
| Khanna, R | 1 |
| Srivastava, N | 1 |
| Kumar, S | 1 |
| Garg, N | 2 |
| Tewari, S | 1 |
| Goel, P | 1 |
| Reed, GW | 1 |
| Abdallah, MS | 1 |
| Shao, M | 2 |
| Wolski, K | 1 |
| Wisniewski, L | 1 |
| Yeomans, N | 1 |
| Lüscher, TF | 2 |
| Borer, JS | 1 |
| Graham, DY | 1 |
| Husni, ME | 1 |
| Solomon, DH | 2 |
| Libby, P | 1 |
| Menon, V | 2 |
| Lincoff, AM | 1 |
| Nissen, SE | 2 |
| Hartinger, J | 1 |
| Novotny, R | 1 |
| Bilkova, J | 1 |
| Kvasnicka, T | 1 |
| Mitas, P | 1 |
| Sima, M | 1 |
| Hlubocky, J | 1 |
| Kvasnicka, J | 1 |
| Slanar, O | 1 |
| Lindner, J | 1 |
| Gibler, WB | 2 |
| VanWagner, LB | 1 |
| Grigoryan, MV | 1 |
| Ryabinina, MN | 1 |
| Horsman, C | 1 |
| Frederick, T | 1 |
| Abrignani, MG | 1 |
| Ambrosetti, M | 1 |
| Aspromonte, N | 1 |
| Barile, G | 1 |
| Caporale, R | 1 |
| Casolo, G | 1 |
| Chiuini, E | 1 |
| Faggiano, P | 1 |
| Geraci, G | 1 |
| La Manna, AG | 1 |
| Marchese, A | 1 |
| Massari, FM | 1 |
| Mureddu, GF | 1 |
| Musumeci, G | 3 |
| Panno, AV | 1 |
| Pedretti, RFE | 1 |
| Piredda, M | 1 |
| Pusineri, E | 1 |
| Rossini, R | 3 |
| Scotto Di Uccio, F | 1 |
| Urbinati, S | 1 |
| Varbella, F | 3 |
| Zito, GB | 1 |
| Raina, T | 1 |
| Kalantzi, KI | 1 |
| Ntalas, IV | 1 |
| Chantzichristos, VG | 1 |
| Tsoumani, ME | 1 |
| Adamopoulos, D | 1 |
| Asimakopoulos, C | 1 |
| Bourdakis, A | 1 |
| Darmanis, P | 1 |
| Dimitriadou, A | 1 |
| Gkiokas, S | 1 |
| Ipeirotis, K | 1 |
| Kitikidou, K | 1 |
| Klonaris, I | 1 |
| Kostaki, A | 1 |
| Logothetis, D | 1 |
| Mainas, K | 1 |
| Mais, T | 1 |
| Maragiannis, A | 1 |
| Martiadou, K | 1 |
| Mavronasos, K | 1 |
| Michelongonas, I | 1 |
| Mitropoulos, D | 1 |
| Papadimitriou, G | 1 |
| Papadopoulos, A | 1 |
| Papaioakeim, M | 1 |
| Sofillas, K | 1 |
| Stabola, S | 1 |
| Stefanakis, E | 1 |
| Stergiou, D | 1 |
| Thoma, M | 1 |
| Zenetos, A | 1 |
| Zisekas, S | 1 |
| Goudevenos, JA | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Tang, QJ | 1 |
| Lei, HP | 1 |
| Chen, JY | 3 |
| Deng, CY | 1 |
| Sheng, WS | 1 |
| Fu, YH | 1 |
| Li, XH | 1 |
| Lin, YB | 1 |
| Zhong, SL | 2 |
| Brunner, S | 1 |
| Rizas, K | 1 |
| Hamm, W | 1 |
| Mehr, M | 1 |
| Lackermair, K | 1 |
| Dangas, GD | 4 |
| McAndrew, T | 2 |
| Nascimento Silva, JS | 1 |
| de Barros, IML | 1 |
| Cantarelli, FL | 1 |
| Alves, RC | 1 |
| Falcão, FJA | 1 |
| Silva, JMDS | 1 |
| de Oliveira, FRA | 1 |
| Pedrosa, RP | 1 |
| Weingärtner, O | 1 |
| Schulze, PC | 1 |
| Möbius-Winkler, S | 1 |
| Wustrow, I | 1 |
| Sarafoff, N | 3 |
| Haller, B | 1 |
| Rössner, L | 1 |
| Sibbing, D | 6 |
| Schüpke, S | 1 |
| Ibrahim, T | 2 |
| Anetsberger, A | 1 |
| Laugwitz, KL | 4 |
| Bernlochner, I | 2 |
| Gnanenthiran, SR | 1 |
| Yiannikas, J | 1 |
| Lowe, HC | 2 |
| Brieger, D | 3 |
| Limaye, S | 1 |
| Ohno, Y | 1 |
| Kitahara, H | 2 |
| Kohno, Y | 1 |
| Ariyoshi, N | 1 |
| Nishi, T | 1 |
| Fujimoto, Y | 2 |
| Cardoso, R | 1 |
| Knijnik, L | 1 |
| Whelton, SP | 1 |
| Rivera, M | 1 |
| Gluckman, TJ | 1 |
| Metkus, TS | 1 |
| Fortuni, F | 1 |
| Ferlini, M | 2 |
| Angelini, F | 1 |
| Crimi, G | 1 |
| Somaschini, A | 1 |
| Cornara, S | 1 |
| Potenza, A | 1 |
| De Servi, S | 1 |
| Oltrona Visconti, L | 1 |
| De Ferrari, GM | 1 |
| van Es, GA | 1 |
| van Meijeren, C | 1 |
| Möllmann, H | 1 |
| Zurakowski, A | 2 |
| Dominici, M | 2 |
| Van Geuns, RJ | 2 |
| Slagboom, T | 3 |
| Zhuo, X | 1 |
| Zhuo, B | 1 |
| Ouyang, S | 1 |
| Niu, P | 1 |
| Xiao, M | 1 |
| Bloom, JL | 1 |
| Darst, JR | 1 |
| Prok, L | 1 |
| Soep, JB | 1 |
| Dauerman, HL | 1 |
| Price, MJ | 3 |
| Christen, T | 1 |
| Allocco, DJ | 1 |
| Meredith, IT | 1 |
| Chen, H | 1 |
| Power, D | 1 |
| Achilles, A | 2 |
| M'Pembele, R | 1 |
| Podsvyadek, Y | 1 |
| Grandoch, M | 1 |
| Al-Sofiani, ME | 1 |
| Yanek, LR | 7 |
| Faraday, N | 7 |
| Kral, BG | 1 |
| Mathias, R | 2 |
| Becker, LC | 7 |
| Becker, DM | 7 |
| Vaidya, D | 5 |
| Kalyani, RR | 1 |
| Sindet-Pedersen, C | 1 |
| Lamberts, M | 2 |
| Staerk, L | 1 |
| Nissen Bonde, A | 1 |
| Berger, JS | 2 |
| Pallisgaard, JL | 1 |
| Lock Hansen, M | 1 |
| Gislason, GH | 2 |
| Olesen, JB | 2 |
| Siegel, AJ | 1 |
| Noakes, TD | 1 |
| Brener, SJ | 2 |
| Myles, PS | 3 |
| Smith, JA | 3 |
| Kasza, J | 2 |
| Silbert, B | 3 |
| Jayarajah, M | 3 |
| Painter, T | 3 |
| Cooper, DJ | 3 |
| Marasco, S | 3 |
| McNeil, J | 3 |
| Bussières, JS | 3 |
| McGuinness, S | 3 |
| Chan, MTV | 2 |
| Wallace, S | 3 |
| Forbes, A | 3 |
| Lin, J | 2 |
| Han, Z | 1 |
| Yi, X | 1 |
| Luo, H | 1 |
| Zhou, Q | 1 |
| Waldmann, E | 1 |
| Ooi, EMM | 1 |
| Chan, DC | 1 |
| Barrett, HPR | 1 |
| Watts, GF | 1 |
| Parhofer, KG | 1 |
| Byrne, K | 2 |
| Landoni, G | 2 |
| Chopra, AM | 1 |
| Ferraris, VA | 1 |
| Krasińska, B | 1 |
| Paluszkiewicz, L | 1 |
| Miciak-Lawicka, E | 1 |
| Krasiński, M | 1 |
| Rzymski, P | 1 |
| Tykarski, A | 1 |
| Krasiński, Z | 1 |
| Spinthakis, N | 1 |
| Farag, M | 1 |
| Gue, YX | 1 |
| Srinivasan, M | 1 |
| Wellsted, DM | 1 |
| Pagidipati, NJ | 1 |
| Coles, A | 2 |
| Hemal, K | 1 |
| Lee, KL | 2 |
| Dolor, RJ | 2 |
| Pellikka, PA | 2 |
| Mark, DB | 3 |
| Patel, MR | 2 |
| Litwin, SE | 1 |
| Daubert, MA | 1 |
| Shah, SH | 2 |
| Hoffmann, U | 4 |
| Douglas, PS | 3 |
| Jastrzebska, M | 1 |
| Marcinowska, Z | 1 |
| Oledzki, S | 1 |
| Chelstowski, K | 1 |
| Siennicka, A | 1 |
| Klysz, M | 1 |
| Clark, JS | 1 |
| Dargham, BB | 1 |
| Baskar, A | 1 |
| Tejani, I | 1 |
| Cui, Z | 1 |
| Chauhan, S | 1 |
| Sum-Ping, J | 1 |
| Weideman, RA | 1 |
| Banerjee, S | 2 |
| Lemesle, G | 6 |
| Khan, SA | 1 |
| Khan, B | 1 |
| Latham, SB | 1 |
| Toba, T | 1 |
| Sugizaki, Y | 1 |
| Takeshige, R | 1 |
| Onishi, H | 1 |
| Nagasawa, A | 1 |
| Tsukiyama, Y | 1 |
| Yanaka, K | 1 |
| Nagano, Y | 1 |
| Yamamoto, H | 1 |
| Kawamori, H | 1 |
| Matsuura, A | 1 |
| Ishihara, T | 1 |
| Matsumoto, D | 1 |
| Igarashi, N | 1 |
| Hayashi, T | 1 |
| Fujii, T | 1 |
| Shite, J | 1 |
| Okada, M | 1 |
| Sakakibara, T | 1 |
| Hirata, KI | 1 |
| Sang, W | 1 |
| Wei, M | 1 |
| Ng, KKH | 1 |
| Catanese, L | 1 |
| Varigos, J | 1 |
| Tonkin, A | 1 |
| Bruns, NC | 1 |
| Coppens, M | 1 |
| Weitz, JI | 2 |
| Eikelboom, JWA | 1 |
| Kessler, T | 2 |
| Wolf, B | 1 |
| Eriksson, N | 1 |
| Kofink, D | 1 |
| Mahmoodi, BK | 1 |
| Rai, H | 1 |
| Tragante, V | 1 |
| Åkerblom, A | 1 |
| Becker, RC | 6 |
| Bopp, R | 1 |
| Katus, HA | 3 |
| Mayer, K | 1 |
| Munz, M | 1 |
| Nordio, F | 1 |
| O'Donoghue, ML | 1 |
| Sager, HB | 1 |
| Solakov, L | 1 |
| Wobst, J | 1 |
| Asselbergs, FW | 2 |
| Byrne, RA | 4 |
| Erdmann, J | 1 |
| Koenig, W | 2 |
| Chen, YC | 1 |
| Lin, FY | 2 |
| Lin, YW | 1 |
| Cheng, SM | 1 |
| Lin, RH | 1 |
| Chuang, CL | 1 |
| Sheu, JS | 1 |
| Chen, SM | 1 |
| Tsai, CS | 1 |
| Huang, H | 1 |
| Xi, Y | 1 |
| Bai, Y | 1 |
| Ma, C | 2 |
| Brueckmann, M | 1 |
| Barylski, M | 1 |
| Filipiak, KJ | 3 |
| Gierlotka, M | 2 |
| Legutko, J | 1 |
| Stępińska, J | 1 |
| Wojakowski, W | 3 |
| Sumaya, W | 1 |
| Geisler, T | 9 |
| Christiansen, MK | 1 |
| Nyegaard, M | 1 |
| Jensen, HK | 1 |
| McFadden, E | 2 |
| Serruys, P | 1 |
| Liebetrau, C | 1 |
| Buszman, P | 1 |
| Bolognese, L | 2 |
| Aminian, A | 1 |
| Vrolix, M | 2 |
| Naber, C | 2 |
| Prokopczuk, J | 1 |
| Steg, G | 1 |
| Nardin, M | 6 |
| Negro, F | 1 |
| Gravinese, C | 1 |
| Cerrato, E | 2 |
| Nuñez-Gil, I | 1 |
| Destefanis, P | 1 |
| Luciano, A | 1 |
| Biscaglia, S | 1 |
| Quadri, G | 1 |
| Tizzani, E | 1 |
| Corleto, A | 1 |
| Giolitto, S | 1 |
| Lo Savio, L | 1 |
| Campo, G | 3 |
| Pozzi, R | 3 |
| Feitosa, MPM | 1 |
| Soffiatti, CD | 1 |
| Linhares Filho, JPP | 1 |
| Lobo Filho, HG | 1 |
| Serrano Júnior, CV | 1 |
| Luo, WH | 1 |
| Huang, JW | 1 |
| Zhang, PD | 1 |
| Greenberg, B | 1 |
| Neaton, JD | 1 |
| Anker, SD | 1 |
| Byra, WM | 1 |
| Deng, H | 1 |
| Fu, M | 1 |
| La Police, DA | 1 |
| Lam, CSP | 1 |
| Nessel, CC | 1 |
| Spiro, TE | 1 |
| van Veldhuisen, DJ | 1 |
| Vanden Boom, CM | 1 |
| Zannad, F | 1 |
| Ye, S | 1 |
| Xu, L | 1 |
| Zhu, H | 1 |
| Fan, Y | 2 |
| Ying, L | 1 |
| Hu, X | 1 |
| Chan, NC | 1 |
| Tantry, US | 17 |
| Ten Cate, H | 1 |
| Friede, KA | 1 |
| Voora, D | 2 |
| Metsarinne, KP | 1 |
| Nishikawa, M | 1 |
| Takeda, Y | 1 |
| Isomura, N | 1 |
| Tanigawa, T | 1 |
| Nanasato, M | 1 |
| Tsukahara, K | 2 |
| Takayama, T | 2 |
| Kato, M | 1 |
| Nishikawa, H | 2 |
| Nishimura, Y | 1 |
| Isshiki, T | 3 |
| Calogiuri, G | 1 |
| Nettis, E | 1 |
| Mandurino-Mirizzi, A | 1 |
| Di Leo, E | 1 |
| Macchia, L | 1 |
| Foti, C | 1 |
| Vacca, A | 1 |
| Kounis, NG | 2 |
| Harskamp, RE | 1 |
| Kruger, PC | 1 |
| Yuan, J | 1 |
| Xu, GM | 1 |
| Ding, J | 1 |
| Cheng, RK | 1 |
| Klein, A | 1 |
| Barnes, GD | 1 |
| Jäger, B | 2 |
| Stojkovic, S | 2 |
| Haller, PM | 2 |
| Piackova, E | 2 |
| Kahl, BS | 1 |
| Andric, T | 2 |
| Vargas, KG | 1 |
| Wojta, J | 3 |
| Hall, KT | 1 |
| Buring, JE | 2 |
| Passow, D | 1 |
| Sesso, HD | 1 |
| Zee, RYL | 1 |
| Ridker, PM | 2 |
| Chasman, DI | 1 |
| Nicola, H | 1 |
| Ho, KM | 1 |
| Barbarash, OL | 2 |
| Kashtalap, VV | 1 |
| Zykov, MV | 1 |
| Hryachkova, ON | 1 |
| Shibanova, IA | 1 |
| Gremmel, T | 3 |
| Sulzgruber, P | 1 |
| Niessner, A | 1 |
| Baigent, C | 1 |
| Holmes, MV | 1 |
| Jiao, F | 1 |
| Wang, W | 1 |
| Tscharre, M | 1 |
| Bruno, V | 1 |
| Rohla, M | 1 |
| Egger, F | 1 |
| Weiss, TW | 1 |
| Hübl, W | 1 |
| Willheim, M | 1 |
| Geppert, A | 1 |
| Freynhofer, MK | 1 |
| Hosokawa, K | 1 |
| Dahlen, JR | 1 |
| Fu, S | 1 |
| Ping, P | 1 |
| Ye, P | 1 |
| Luo, L | 1 |
| Mastoris, I | 1 |
| Wisgrill, L | 1 |
| Spittler, A | 1 |
| Lv, S | 1 |
| Sellke, FW | 1 |
| Akturk, IF | 1 |
| Caglar, FN | 1 |
| Erturk, M | 3 |
| Tuncer, N | 1 |
| Yalcın, AA | 1 |
| Surgit, O | 1 |
| Uzun, F | 1 |
| Caglar, IM | 1 |
| Bitton, A | 1 |
| Choudhry, NK | 1 |
| Matlin, OS | 1 |
| Swanton, K | 1 |
| Shrank, WH | 1 |
| Zhou, G | 1 |
| Marathe, GK | 1 |
| Hartiala, J | 1 |
| Hazen, SL | 1 |
| Allayee, H | 1 |
| Tang, WH | 1 |
| McIntyre, TM | 1 |
| Chang, PY | 1 |
| Chen, YJ | 1 |
| Chang, FH | 1 |
| Lu, J | 2 |
| Huang, WH | 1 |
| Yang, TC | 1 |
| Lee, YT | 1 |
| Chang, SF | 1 |
| Lu, SC | 1 |
| Chen, CH | 1 |
| Fujikawa, T | 2 |
| Noda, T | 1 |
| Tada, S | 1 |
| Tanaka, A | 2 |
| Kaufmann, J | 1 |
| Wellnhofer, E | 1 |
| Kappert, K | 1 |
| Urban, D | 1 |
| Meyborg, H | 1 |
| Hauptmann, T | 1 |
| Müller, A | 1 |
| Meixner, M | 1 |
| Graf, K | 1 |
| Fleck, E | 1 |
| Stawowy, P | 1 |
| Meves, SH | 1 |
| Hummel, T | 1 |
| Endres, HG | 2 |
| Mayböck, N | 1 |
| Kaiser, AF | 2 |
| Schröder, KD | 1 |
| Rüdiger, K | 1 |
| Overbeck, U | 1 |
| Mumme, A | 1 |
| Mügge, A | 5 |
| Neubauer, H | 4 |
| Postula, M | 1 |
| Janicki, PK | 1 |
| Rosiak, M | 2 |
| Przybylkowski, A | 1 |
| Kaplon-Cieslicka, A | 1 |
| Grygorowicz, T | 1 |
| Trzepla, E | 1 |
| Czlonkowski, A | 1 |
| Vaturi, M | 1 |
| Vaduganathan, M | 3 |
| Jeong, YH | 5 |
| Kubica, J | 1 |
| Cheezum, MK | 1 |
| Hulten, EA | 1 |
| Smith, RM | 1 |
| Taylor, AJ | 1 |
| Kircher, J | 1 |
| Surry, L | 1 |
| York, M | 1 |
| Villines, TC | 2 |
| Karathanos, A | 1 |
| Bliden, KP | 14 |
| Logan, DK | 1 |
| Lasseter, KC | 1 |
| White, A | 1 |
| Nolin, TD | 1 |
| Maa, JF | 1 |
| Bailey, WL | 1 |
| Jakubowski, JA | 7 |
| Ojeh, CK | 2 |
| Baker, BA | 3 |
| Rubak, P | 2 |
| Hardlei, TF | 1 |
| Kang, YH | 1 |
| Lao, HY | 1 |
| Lai, WH | 1 |
| Li, XX | 1 |
| Yu, XY | 1 |
| Franken, CC | 1 |
| Krüger, JC | 2 |
| Overbeck, K | 1 |
| Ardati, AK | 1 |
| Pitt, B | 1 |
| Smith, DE | 1 |
| Share, D | 2 |
| Moscucci, M | 1 |
| Chetcuti, S | 1 |
| Grossman, PM | 1 |
| Gurm, HS | 2 |
| Lee, JK | 1 |
| Tsui, KL | 1 |
| Cheung, CY | 1 |
| Chau, CH | 1 |
| Chan, HL | 1 |
| Wu, KL | 1 |
| Cheung, GS | 1 |
| Choi, MC | 1 |
| Chan, KK | 1 |
| Li, SK | 1 |
| Karolczak, K | 2 |
| Kamysz, W | 1 |
| Karafova, A | 1 |
| Drzewoski, J | 2 |
| Watala, C | 4 |
| Rouine-Rapp, K | 1 |
| McDermott, MW | 1 |
| Tsantes, AE | 1 |
| Ikonomidis, I | 3 |
| Papadakis, I | 1 |
| Bonovas, S | 1 |
| Gialeraki, A | 1 |
| Kottaridi, C | 1 |
| Kyriakou, E | 1 |
| Kokori, S | 1 |
| Douramani, P | 1 |
| Kopterides, P | 1 |
| Karakitsos, P | 1 |
| Lekakis, J | 2 |
| Kapsimali, V | 1 |
| Luchessi, AD | 1 |
| Silbiger, VN | 1 |
| Hirata, RD | 1 |
| Lima-Neto, LG | 1 |
| Cavichioli, D | 1 |
| Iñiguez, A | 1 |
| Bravo, M | 1 |
| Bastos, G | 1 |
| Sousa, AG | 3 |
| Brión, M | 1 |
| Carracedo, A | 1 |
| Hirata, MH | 1 |
| McCormack, T | 1 |
| Panchal, HB | 1 |
| Shah, T | 1 |
| Albalbissi, K | 1 |
| Molnar, J | 1 |
| Coffey, B | 1 |
| Khosla, S | 2 |
| Ramu, V | 1 |
| Delaney, JA | 1 |
| Lehmann, N | 1 |
| Jöckel, KH | 1 |
| Elmariah, S | 1 |
| Psaty, BM | 2 |
| Mahabadi, AA | 1 |
| Kronmal, RA | 3 |
| O'Brien, KD | 1 |
| Möhlenkamp, S | 1 |
| Moebus, S | 1 |
| Dragano, N | 1 |
| Winterstein, AG | 1 |
| Erbel, R | 2 |
| Kälsch, H | 1 |
| Thano, E | 1 |
| Patel, R | 3 |
| Wilson, RE | 2 |
| Muñiz-Lozano, A | 2 |
| Darlington, A | 6 |
| Desai, B | 9 |
| Lafeber, M | 1 |
| Spiering, W | 1 |
| van der Graaf, Y | 2 |
| Nathoe, H | 1 |
| Bots, ML | 1 |
| Grobbee, DE | 1 |
| Visseren, FL | 1 |
| Fujisue, K | 2 |
| Sugiyama, S | 3 |
| Ono, T | 3 |
| Matsuzawa, Y | 2 |
| Akiyama, E | 2 |
| Sugamura, K | 2 |
| Matsubara, J | 2 |
| Kurokawa, H | 2 |
| Sumida, H | 3 |
| Oniki, K | 3 |
| Nakagawa, K | 5 |
| Darvish-Kazem, S | 1 |
| Gandhi, M | 1 |
| Marcucci, M | 1 |
| Douketis, JD | 1 |
| Bender, N | 1 |
| Sakariassen, KS | 3 |
| Schrör, K | 6 |
| Pietruszynski, R | 1 |
| Kasznicki, J | 1 |
| Suh, SY | 1 |
| Oh, PC | 2 |
| Choi, H | 1 |
| Moon, CI | 1 |
| Han, SH | 1 |
| Ahn, T | 2 |
| Shin, EK | 1 |
| Ajjan, R | 1 |
| Hess, K | 1 |
| DeFilippis, AP | 2 |
| Oloyede, OS | 1 |
| Andrikopoulou, E | 1 |
| Saenger, AK | 1 |
| Palachuvattil, JM | 1 |
| Fasoro, YA | 1 |
| Guallar, E | 1 |
| Kickler, TS | 2 |
| Jaffe, AS | 1 |
| Gerstenblith, G | 1 |
| Schulman, SP | 2 |
| Rade, JJ | 1 |
| Mandel, L | 1 |
| Weiss, SA | 1 |
| Bayers, S | 1 |
| Shulman, ST | 2 |
| Paller, AS | 1 |
| Park, JJ | 1 |
| Kang, HJ | 1 |
| Park, BE | 1 |
| Cha, KS | 4 |
| Rhew, JY | 2 |
| Jeon, HK | 2 |
| Jeong, MH | 5 |
| Hwang, KK | 2 |
| Yoon, JH | 4 |
| Moon, KW | 1 |
| Chae, IH | 3 |
| Kenaan, M | 1 |
| Seth, M | 1 |
| Wohns, D | 1 |
| Han, S | 3 |
| Park, YK | 1 |
| Jang, JY | 1 |
| Kwon, CH | 1 |
| Cho, YR | 1 |
| Kim, WJ | 1 |
| Lee, SG | 3 |
| Seong, IW | 5 |
| Lim, DS | 3 |
| Choi, YS | 2 |
| Yang, JY | 2 |
| Kim, KS | 3 |
| Chae, JK | 2 |
| Suh, IW | 2 |
| Park, HS | 2 |
| Nah, DY | 2 |
| Jang, JS | 2 |
| Acharji, S | 1 |
| Lakshmanadoss, U | 1 |
| Rudzinski, W | 1 |
| Stapleton, DD | 1 |
| Kaluski, E | 1 |
| Sato, D | 1 |
| Koga, S | 1 |
| Yasunaga, T | 1 |
| Nakata, T | 1 |
| Takeno, M | 1 |
| Koide, Y | 1 |
| Ikeda, S | 1 |
| Ashizawa, N | 1 |
| Maemura, K | 1 |
| Gesheff, MG | 2 |
| Ueno, M | 8 |
| Ferreiro, JL | 8 |
| Rassaf, T | 2 |
| Böhm, A | 1 |
| Lüth, A | 1 |
| Kleuser, B | 1 |
| Kroemer, HK | 1 |
| Rauch, BH | 1 |
| Feres, F | 8 |
| Costa, RA | 3 |
| Abizaid, A | 8 |
| Leon, MB | 2 |
| Marin-Neto, JA | 3 |
| Botelho, RV | 2 |
| King, SB | 3 |
| Negoita, M | 1 |
| Liu, M | 2 |
| de Paula, JE | 2 |
| Mangione, JA | 3 |
| Meireles, GX | 1 |
| Castello, HJ | 1 |
| Nicolela, EL | 1 |
| Perin, MA | 2 |
| Devito, FS | 2 |
| Labrunie, A | 1 |
| Salvadori, D | 2 |
| Gusmão, M | 1 |
| Staico, R | 4 |
| Costa, JR | 4 |
| de Castro, JP | 1 |
| Abizaid, AS | 1 |
| Christensen, KH | 2 |
| Cully, M | 1 |
| Viviani Anselmi, C | 1 |
| Roncarati, R | 1 |
| Papa, L | 1 |
| Visconti, G | 1 |
| Focaccio, A | 1 |
| De Micco, F | 1 |
| Latronico, MV | 1 |
| Pagnotta, P | 1 |
| Condorelli, G | 1 |
| Bevan, P | 1 |
| Menon, A | 1 |
| Bunton, R | 1 |
| Petricević, M | 7 |
| Biocina, B | 7 |
| Konosić, S | 2 |
| Burcar, I | 1 |
| Sirić, F | 1 |
| Mihaljević, MZ | 1 |
| Ivancan, V | 2 |
| Svetina, L | 3 |
| Gasparović, H | 6 |
| Oprea, AD | 1 |
| Popescu, WM | 1 |
| Htun, P | 4 |
| Kan, T | 1 |
| Mueller, E | 1 |
| Pohle, C | 1 |
| Schindler, R | 1 |
| Gawaz, M | 8 |
| Bocksch, W | 1 |
| Fateh-Moghadam, S | 4 |
| Enomoto, Y | 1 |
| Tokue, M | 1 |
| Ito, N | 1 |
| Nagashima, Y | 1 |
| Araki, T | 1 |
| Yamazaki, K | 1 |
| Utsunomiya, M | 1 |
| Itaya, H | 1 |
| Shiba, M | 1 |
| Sugi, K | 1 |
| Pelliccia, F | 2 |
| Rosano, G | 1 |
| Marazzi, G | 1 |
| Vitale, C | 1 |
| Spoletini, I | 1 |
| Franzoni, F | 1 |
| Speziale, G | 1 |
| Polacco, M | 1 |
| Greco, C | 1 |
| Gaudio, C | 1 |
| Dominiak, M | 1 |
| Wcisło, T | 1 |
| Krzemińska-Pakuła, M | 1 |
| Bednarkiewicz, Z | 1 |
| Figiel, Ł | 1 |
| Kasprzak, JD | 1 |
| Xhelili, E | 1 |
| Steiner, S | 1 |
| Koppensteiner, R | 1 |
| Kopp, CW | 1 |
| Panzer, S | 4 |
| Li, W | 1 |
| Heiselman, DE | 1 |
| Badr Eslam, R | 2 |
| Posch, F | 1 |
| Lang, IM | 3 |
| Eichelberger, B | 1 |
| Ay, C | 1 |
| Lip, GY | 9 |
| Lassen, JF | 2 |
| Mikkelsen, AP | 1 |
| Sørensen, R | 1 |
| Køber, L | 1 |
| Hansen, ML | 1 |
| Chadha, DS | 1 |
| Sumana, B | 1 |
| Karthikeyan, G | 1 |
| Jayaprasad, V | 1 |
| Arun, SS | 1 |
| Kreutz, RP | 2 |
| Bitar, A | 1 |
| Owens, J | 1 |
| Desta, Z | 1 |
| Breall, JA | 3 |
| von der Lohe, E | 1 |
| Vatta, M | 1 |
| Nystrom, P | 1 |
| Jin, Y | 1 |
| Flockhart, DA | 1 |
| Ercan, S | 1 |
| Davutoglu, V | 1 |
| Ozer, O | 3 |
| López-Farré, AJ | 1 |
| Modrego, J | 1 |
| Azcona, L | 1 |
| Guerra, R | 1 |
| Segura, A | 1 |
| Rodríguez, P | 1 |
| Zamorano-León, JJ | 1 |
| Lahera, V | 1 |
| Macaya, C | 6 |
| Oestreich, JH | 1 |
| Best, LG | 1 |
| Dobesh, PP | 1 |
| Asencio, LA | 1 |
| Huang, JJ | 1 |
| Alpert, JS | 1 |
| Wisman, PP | 1 |
| Roest, M | 1 |
| de Groot, PG | 1 |
| Moll, FL | 1 |
| de Borst, GJ | 1 |
| Yasmina, A | 1 |
| de Boer, A | 1 |
| Klungel, OH | 1 |
| Deneer, VH | 1 |
| Fiedler, KA | 1 |
| Schulz, S | 4 |
| Mehilli, J | 3 |
| Xu, YF | 1 |
| Yu, F | 1 |
| Mao, F | 1 |
| Ye, XW | 1 |
| Ruan, XZ | 1 |
| Kopjar, T | 4 |
| Djuric, Z | 1 |
| Vardi, M | 1 |
| Debidda, M | 1 |
| Song, PS | 1 |
| Ndrepepa, G | 2 |
| Richardt, G | 1 |
| Pöhler, A | 1 |
| Pache, J | 1 |
| Greene, SJ | 1 |
| Alkhawam, L | 1 |
| Chitose, T | 1 |
| Mizobe, M | 1 |
| Akasaka, T | 2 |
| Morita, K | 1 |
| Miyazaki, H | 1 |
| Singla, A | 1 |
| Toth, PP | 1 |
| Tabrizchi, A | 1 |
| Ens, G | 1 |
| Guyer, K | 1 |
| Singh, M | 3 |
| Franzese, CJ | 1 |
| Stapleton, D | 1 |
| Takada, K | 1 |
| Ishikawa, S | 1 |
| Yokoyama, N | 1 |
| Hosogoe, N | 1 |
| Timur, AA | 2 |
| Murugesan, G | 2 |
| Barnard, J | 2 |
| Kottke-Marchant, K | 2 |
| Kozuma, K | 1 |
| Gukop, P | 1 |
| Gutman, N | 1 |
| Bilkhu, R | 1 |
| Karapanagiotidis, GT | 1 |
| Herová, M | 1 |
| Schmid, M | 1 |
| Gemperle, C | 1 |
| Loretz, C | 1 |
| Hersberger, M | 1 |
| Youn, YN | 1 |
| Yi, G | 1 |
| Lee, S | 2 |
| Joo, HC | 1 |
| Yoo, KJ | 1 |
| Hulten, E | 1 |
| Bittencourt, MS | 1 |
| Singh, A | 1 |
| O'Leary, D | 1 |
| Christman, MP | 1 |
| Osmani, W | 1 |
| Abbara, S | 1 |
| Steigner, ML | 1 |
| Truong, QA | 1 |
| Rybicki, FF | 1 |
| Klein, J | 1 |
| Hainer, J | 1 |
| Brady, TJ | 1 |
| Ghoshhajra, BB | 1 |
| Hachamovitch, R | 1 |
| Di Carli, MF | 1 |
| Blankstein, R | 1 |
| Hiasa, Y | 2 |
| Teng, R | 4 |
| Emanuelsson, H | 1 |
| Legrand, V | 1 |
| Chenu, P | 1 |
| Martinez, C | 1 |
| Dens, J | 1 |
| Gach, O | 1 |
| Boland, J | 1 |
| Claeys, MJ | 1 |
| Magne, J | 1 |
| Wijns, W | 4 |
| Zamorano, JL | 1 |
| Ferrari, R | 3 |
| Greenlaw, N | 2 |
| Collet, JP | 4 |
| Hulot, JS | 2 |
| Anzaha, G | 1 |
| Kerneis, M | 2 |
| Silvain, J | 2 |
| Cayla, G | 2 |
| O'Connor, SA | 2 |
| Barthélémy, O | 2 |
| Beygui, F | 2 |
| Galier, S | 1 |
| Brugier, D | 1 |
| Stanek, EJ | 1 |
| Charland, SL | 1 |
| Gallois, V | 1 |
| Rangé, G | 1 |
| Van Belle, E | 2 |
| Elhadad, S | 1 |
| Schiele, F | 1 |
| Lhoest, N | 1 |
| Rousseau, H | 1 |
| Aubry, P | 1 |
| Monségu, J | 1 |
| Saint-Etienne, C | 1 |
| Vicaut, E | 1 |
| Velagapudi, P | 1 |
| Turagam, MK | 1 |
| Agrawal, H | 1 |
| Mittal, M | 1 |
| Kocheril, AG | 1 |
| Aggarwal, K | 1 |
| Floyd, CN | 1 |
| Goodman, T | 1 |
| Becker, S | 1 |
| Chen, N | 1 |
| Mustafa, A | 1 |
| Schofield, E | 1 |
| Campbell, J | 1 |
| Ward, M | 1 |
| Sharma, P | 2 |
| Ferro, A | 1 |
| Ahn, DG | 1 |
| Kim, BJ | 1 |
| Kim, JW | 1 |
| Kim, JG | 1 |
| Gutiérrez Barrios, A | 1 |
| Luna, AA | 1 |
| del Rio-Lechuga, A | 1 |
| Otero, JO | 1 |
| Mazuecos, JB | 1 |
| Phoenix, F | 2 |
| Kurdee, Z | 1 |
| Grant, PJ | 1 |
| Moser, BA | 1 |
| Sugidachi, A | 2 |
| Al-Atassi, T | 1 |
| Le May, M | 1 |
| Longo, G | 1 |
| Capranzano, P | 6 |
| Tamburino, C | 2 |
| Thompson, PL | 2 |
| Verheugt, FW | 7 |
| Lamblin, N | 3 |
| Meurice, T | 2 |
| Tricot, O | 2 |
| Lallemant, R | 1 |
| Nugue, O | 1 |
| Delomez, M | 1 |
| Equine, O | 1 |
| Tondeux, S | 1 |
| Bauters, C | 6 |
| Kim, N | 1 |
| Pandya, S | 1 |
| Kang, K | 1 |
| Franzese, C | 1 |
| Chyrchel, B | 1 |
| Totoń-Żurańska, J | 1 |
| Kruszelnicka, O | 1 |
| Chyrchel, M | 1 |
| Mielecki, W | 1 |
| Kołton-Wróż, M | 1 |
| Wołkow, P | 2 |
| Surdacki, A | 1 |
| Nissen, PH | 1 |
| Gitt, AK | 1 |
| Zahn, R | 1 |
| Christ, G | 2 |
| Siller-Matula, JM | 3 |
| Francesconi, M | 1 |
| Dechant, C | 1 |
| Grohs, K | 1 |
| Podczeck-Schweighofer, A | 1 |
| Higaki, T | 1 |
| Kurisu, S | 1 |
| Watanabe, N | 1 |
| Ikenaga, H | 1 |
| Shimonaga, T | 1 |
| Iwasaki, T | 2 |
| Mitsuba, N | 1 |
| Ishibashi, K | 1 |
| Dohi, Y | 1 |
| Fukuda, Y | 1 |
| Kihara, Y | 1 |
| Kaiser, C | 1 |
| Galatius, S | 1 |
| Jeger, R | 1 |
| Gilgen, N | 1 |
| Skov Jensen, J | 1 |
| Alber, H | 1 |
| Wanitschek, M | 1 |
| Eberli, F | 1 |
| Kurz, DJ | 1 |
| Pedrazzini, G | 1 |
| Rickli, H | 2 |
| Weilenmann, D | 1 |
| Vuillomenet, A | 2 |
| Steiner, M | 1 |
| Von Felten, S | 1 |
| Vogt, DR | 1 |
| Wadt Hansen, K | 1 |
| Rickenbacher, P | 1 |
| Conen, D | 1 |
| Müller, C | 1 |
| Buser, P | 1 |
| Hoffmann, A | 1 |
| Pfisterer, M | 1 |
| Peacock, WF | 1 |
| Grau-Sepulveda, M | 1 |
| Schwamm, LH | 1 |
| Handberg, EM | 2 |
| Cooper-DeHoff, RM | 2 |
| Berland, J | 1 |
| Endresen, K | 1 |
| Benamer, H | 1 |
| Boschat, J | 2 |
| Sardar, P | 1 |
| Nairooz, R | 2 |
| Pekler, G | 1 |
| Hamilos, M | 1 |
| Saloustros, I | 1 |
| Skalidis, E | 1 |
| Igoumenidis, N | 1 |
| Kambouris, M | 1 |
| Chlouverakis, G | 1 |
| Vougia, D | 1 |
| Loggakis, I | 1 |
| Vardas, PE | 1 |
| Kochiadakis, G | 1 |
| Chow, BJ | 1 |
| Small, G | 1 |
| Yam, Y | 1 |
| Chen, L | 1 |
| McPherson, R | 1 |
| Achenbach, S | 1 |
| Al-Mallah, M | 1 |
| Berman, DS | 2 |
| Budoff, MJ | 4 |
| Cademartiri, F | 1 |
| Callister, TQ | 1 |
| Cheng, VY | 1 |
| Chinnaiyan, K | 1 |
| Cury, R | 1 |
| Delago, A | 1 |
| Dunning, A | 1 |
| Feuchtner, G | 1 |
| Hadamitzky, M | 2 |
| Hausleiter, J | 1 |
| Karlsberg, RP | 1 |
| Kaufmann, PA | 1 |
| Leipsic, J | 1 |
| LaBounty, T | 1 |
| Lin, F | 1 |
| Maffei, E | 1 |
| Raff, GL | 1 |
| Shaw, LJ | 3 |
| Min, JK | 3 |
| Manchuelle, A | 1 |
| Delhaye, C | 3 |
| Schurtz, G | 3 |
| Sudre, A | 2 |
| Hurt, C | 1 |
| Bonello, L | 2 |
| Puymirat, E | 1 |
| Young, R | 1 |
| Carrubba, CJ | 1 |
| McClelland, RL | 2 |
| Xiao, F | 1 |
| Pan, S | 1 |
| Xu, J | 1 |
| Sinigaglia, F | 1 |
| Moscarella, E | 1 |
| Ando, G | 1 |
| Oreto, G | 1 |
| Zijlstra, F | 1 |
| Patialiakas, A | 1 |
| Thury, A | 1 |
| Colangelo, S | 2 |
| Tebaldi, M | 1 |
| Tondi, S | 1 |
| Roffi, M | 1 |
| Menozzi, A | 1 |
| de Cesare, N | 2 |
| Garbo, R | 1 |
| Meliga, E | 2 |
| Testa, L | 2 |
| Gabriel, HM | 1 |
| Airoldi, F | 1 |
| Liistro, F | 1 |
| Dellavalle, A | 1 |
| Modrau, IS | 1 |
| Amsallem, M | 1 |
| Manzo-Silberman, S | 1 |
| Sideris, G | 3 |
| Voicu, S | 2 |
| Kang, DO | 1 |
| Yu, CW | 1 |
| Kim, HD | 1 |
| Joo, HJ | 1 |
| Choi, RK | 1 |
| Park, JS | 1 |
| Lee, HJ | 1 |
| Park, JH | 4 |
| Richter, S | 1 |
| Merx, MW | 1 |
| Yazkan, R | 1 |
| Ceviker, K | 1 |
| Camas, HE | 1 |
| Ovbiagele, B | 1 |
| Ignjatovic, V | 1 |
| Pavlovic, S | 1 |
| Miloradovic, V | 1 |
| Andjelkovic, N | 1 |
| Davidovic, G | 1 |
| Djurdjevic, P | 1 |
| Stolic, R | 1 |
| Iric-Cupic, V | 1 |
| Simic, I | 1 |
| Ignjatovic, VD | 1 |
| Petrovic, N | 1 |
| Smiljanic, Z | 1 |
| Zdravkovic, V | 1 |
| Simovic, S | 1 |
| Jovanovic, D | 1 |
| Nesic, J | 1 |
| Taylor, J | 1 |
| Andreotti, F | 3 |
| Schulze, V | 1 |
| Kołodziejczak, M | 1 |
| Buffon, A | 1 |
| Brouwer, M | 1 |
| Kowalewski, M | 1 |
| Parati, G | 1 |
| Danelich, IM | 1 |
| Wright, SS | 1 |
| Lose, JM | 1 |
| Tefft, BJ | 1 |
| Cicci, JD | 1 |
| Reed, BN | 1 |
| Sambola, A | 1 |
| García-Dorado, D | 3 |
| Szychta, W | 1 |
| Majstrak, F | 1 |
| Rijo, Y | 1 |
| Canabal, J | 1 |
| Fiandor, A | 1 |
| Bobolea, I | 1 |
| Quirce, S | 1 |
| Cabañas, R | 1 |
| Gao, F | 3 |
| Shen, H | 2 |
| Wang, ZJ | 2 |
| Yang, SW | 2 |
| Liu, XL | 2 |
| Zhou, YJ | 2 |
| Jeon, JY | 1 |
| Kim, Y | 2 |
| Kim, HM | 1 |
| Sung, J | 1 |
| Eisen, A | 1 |
| Liu, T | 2 |
| Feng, X | 1 |
| Chan, PH | 1 |
| Li, WH | 1 |
| Hai, JJ | 1 |
| Tse, HF | 4 |
| Siu, CW | 1 |
| Woessner, KM | 1 |
| Gregersen, S | 1 |
| Maya, J | 1 |
| Carlson, GF | 2 |
| Caplan, RJ | 1 |
| Ferdinand, KC | 1 |
| Milicic, D | 1 |
| Chang, L | 1 |
| Gielen, CL | 1 |
| Bruggemans, EF | 1 |
| Stijnen, T | 1 |
| Eikenboom, J | 1 |
| Tavilla, G | 1 |
| Brand, A | 1 |
| Klautz, RJ | 1 |
| Arya, V | 1 |
| Mahajan, P | 1 |
| Saraf, A | 1 |
| Mohanty, A | 1 |
| Sawhney, JP | 1 |
| Bhargava, M | 1 |
| Nührenberg, TG | 1 |
| Stratz, C | 1 |
| Leggewie, S | 1 |
| Hochholzer, W | 1 |
| Valina, CM | 1 |
| Gick, M | 1 |
| Trenk, D | 2 |
| Siasos, G | 1 |
| Zaromitidou, M | 1 |
| Oikonomou, E | 1 |
| Mourouzis, K | 1 |
| Tsalamandris, S | 1 |
| Kioufis, S | 1 |
| Kokkou, E | 1 |
| Vavuranakis, M | 1 |
| Zografos, T | 1 |
| Antonopoulos, A | 1 |
| Dimitropoulos, S | 1 |
| Stefanadis, C | 1 |
| Papavassiliou, AG | 1 |
| Tousoulis, D | 1 |
| Calcagno, S | 1 |
| Lucisano, L | 1 |
| Mancone, M | 1 |
| Cavallo, E | 1 |
| Pennacchi, M | 1 |
| Stio, RE | 1 |
| Izumi, D | 1 |
| Miyahara, M | 1 |
| Fujimoto, N | 1 |
| Fukuoka, S | 1 |
| Sakai, M | 1 |
| Dohi, K | 1 |
| Sliwka, J | 1 |
| Zysko, D | 1 |
| Zembala, M | 2 |
| Steter, D | 1 |
| Kim, MH | 5 |
| Serebruany, V | 3 |
| Galper, BZ | 1 |
| Wang, YC | 1 |
| Einstein, AJ | 1 |
| Vergallo, R | 1 |
| Aguirre, AD | 1 |
| Abtahian, F | 1 |
| Minami, Y | 1 |
| Soeda, T | 1 |
| Chatzizisis, YS | 1 |
| Croce, K | 2 |
| Erglis, A | 1 |
| Mintale, I | 1 |
| Latkovskis, G | 1 |
| Balode, I | 1 |
| Jegere, S | 1 |
| Bajare, I | 1 |
| Rozenbergs, A | 1 |
| Kim, DW | 1 |
| Kim, DS | 1 |
| Kwan, J | 1 |
| Choi, CU | 1 |
| Yang, YM | 1 |
| Bae, JH | 2 |
| Jung, KT | 1 |
| Pyun, WB | 1 |
| Cha, TJ | 1 |
| Chun, KJ | 3 |
| Kim, YD | 1 |
| Kim, DI | 1 |
| Kim, TI | 1 |
| Bundhun, PK | 2 |
| Qin, T | 1 |
| Chen, MH | 2 |
| Okeke, NL | 1 |
| Chin, T | 1 |
| Clement, M | 1 |
| Chow, SC | 1 |
| Hicks, CB | 1 |
| Palla, M | 1 |
| Kim, YS | 1 |
| Lee, SR | 1 |
| Baek, C | 1 |
| Park, HJ | 1 |
| Kim, HY | 1 |
| Chung, WS | 1 |
| Kok, MG | 1 |
| Mandolini, C | 1 |
| Moerland, PD | 1 |
| de Ronde, MW | 1 |
| Sondermeijer, BM | 2 |
| Halliani, A | 1 |
| Nieuwland, R | 1 |
| Cipollone, F | 1 |
| Creemers, EE | 2 |
| Meijers, JC | 1 |
| Pinto-Sietsma, SJ | 2 |
| Golanski, R | 1 |
| Bijak, M | 1 |
| Boryczka, K | 1 |
| Golanski, J | 3 |
| Patel, RM | 1 |
| Naue, VM | 1 |
| Camargo, G | 1 |
| Sabioni, LR | 1 |
| Lima, Rde S | 1 |
| Derenne, ME | 1 |
| Lorenzo, AR | 1 |
| Freire, MD | 1 |
| Azevedo Filho, CF | 1 |
| Resende, ES | 1 |
| Gottlieb, I | 1 |
| Dunne, E | 1 |
| Egan, K | 1 |
| McFadden, S | 1 |
| Foley, D | 1 |
| Kenny, D | 2 |
| Klasic, A | 1 |
| Lakusic, N | 1 |
| Gaspar, L | 1 |
| Kruzliak, P | 1 |
| Yang, Y | 2 |
| Ding, R | 1 |
| Sáez, ME | 2 |
| González-Pérez, A | 2 |
| Johansson, S | 2 |
| García Rodríguez, LA | 2 |
| Cho, JR | 1 |
| King, R | 1 |
| Bhatti, M | 1 |
| DeGroat, C | 1 |
| Yildiz, BS | 1 |
| Ozkan, E | 1 |
| Esin, F | 1 |
| Alihanoglu, YI | 1 |
| Ozkan, H | 1 |
| Bilgin, M | 1 |
| Kilic, ID | 1 |
| Ergin, A | 1 |
| Kaftan, HA | 1 |
| Evrengul, H | 1 |
| Bai, ZS | 2 |
| Lü, B | 2 |
| Liu, K | 1 |
| Hou, Z | 1 |
| Yin, W | 1 |
| Jiang, S | 1 |
| Dai, R | 1 |
| Nenna, A | 1 |
| Spadaccio, C | 1 |
| Prestipino, F | 1 |
| Lusini, M | 1 |
| Sutherland, FW | 1 |
| Beattie, GW | 1 |
| Petitti, T | 1 |
| Nappi, F | 1 |
| Chello, M | 1 |
| Bernardi, A | 1 |
| D'Ascenzo, F | 1 |
| Omedè, P | 1 |
| Montefusco, A | 1 |
| DiNicolantonio, JJ | 1 |
| Zoccai, GB | 1 |
| Carini, G | 1 |
| Moretti, C | 1 |
| Gaita, F | 1 |
| Liu, F | 2 |
| Zhao, L | 1 |
| Wu, L | 1 |
| Liang, X | 1 |
| Chu, C | 1 |
| He, L | 1 |
| Huang, G | 1 |
| Sakamoto, K | 2 |
| Hermiller, JB | 2 |
| Lemaire, N | 1 |
| Caudmont, S | 1 |
| Philias, A | 1 |
| Ketelers, R | 1 |
| Rao, M | 1 |
| Simon, DN | 1 |
| Ansell, J | 1 |
| Gersh, BJ | 2 |
| Go, AS | 1 |
| Hylek, EM | 1 |
| Kowey, P | 1 |
| Piccini, JP | 2 |
| Singer, DE | 1 |
| Chang, P | 1 |
| Mahaffey, KW | 2 |
| Dimitriu-Leen, AC | 1 |
| Scholte, AJ | 1 |
| van Rosendael, AR | 1 |
| van den Hoogen, IJ | 1 |
| Kharagjitsingh, AV | 1 |
| Wolterbeek, R | 1 |
| Knuuti, J | 1 |
| Kroft, LJ | 1 |
| Delgado, V | 1 |
| Jukema, JW | 1 |
| de Graaf, MA | 1 |
| Bax, JJ | 1 |
| Sakr, HI | 1 |
| Alamri, HS | 1 |
| Almoghairi, AM | 1 |
| Alkhudair, AA | 1 |
| AlMasood, AS | 1 |
| Saw, J | 3 |
| Wong, GC | 2 |
| Mayo, J | 1 |
| Bernstein, V | 1 |
| Mancini, GB | 2 |
| Ye, J | 1 |
| Skarsgard, P | 1 |
| Starovoytov, A | 2 |
| Cairns, J | 1 |
| Lau, YC | 1 |
| Xiong, Q | 1 |
| Ranjit, P | 1 |
| Blann, AD | 5 |
| Homoródi, N | 1 |
| Kovács, EG | 1 |
| Katona, É | 1 |
| Shemirani, AH | 1 |
| Haramura, G | 1 |
| Balogh, L | 1 |
| Bereczky, Z | 1 |
| Szőke, G | 1 |
| Péterfy, H | 1 |
| Édes, I | 1 |
| Muszbek, L | 1 |
| Fioranelli, M | 1 |
| Bianchi, M | 1 |
| Roccia, MG | 1 |
| Di Nardo, V | 1 |
| Zhang, D | 1 |
| Liu, D | 1 |
| Cai, W | 1 |
| Yan, C | 1 |
| Bittl, JA | 2 |
| Bradley, SM | 1 |
| Wijeysundera, DN | 1 |
| Lim, WH | 1 |
| Yoon, CH | 1 |
| Choi, DJ | 1 |
| Park, WJ | 2 |
| Doh, JH | 1 |
| Kim, MA | 1 |
| Ahn, YK | 2 |
| Hyon, MS | 2 |
| Kim, YK | 1 |
| Lee, HC | 1 |
| Seol, SH | 1 |
| Han, KR | 1 |
| Kim, SW | 1 |
| Levine, GN | 1 |
| Bates, ER | 1 |
| Brindis, RG | 2 |
| Fihn, SD | 1 |
| Fleisher, LA | 1 |
| Lange, RA | 1 |
| Mack, MJ | 1 |
| Mukherjee, D | 1 |
| Newby, LK | 3 |
| O'Gara, PT | 1 |
| Sabatine, MS | 2 |
| Smith, PK | 1 |
| Guo, J | 1 |
| Ogawa, K | 1 |
| Kujiraoka, T | 1 |
| Ishihara, M | 1 |
| Kunimoto, S | 1 |
| Kanai, T | 2 |
| Hattori, H | 1 |
| Serebruany, VL | 5 |
| Golukhova, E | 1 |
| Pya, Y | 1 |
| Bekbossynova, M | 1 |
| Cattaneo, M | 3 |
| Marciniak, TA | 1 |
| Metzger, C | 1 |
| Francese, DP | 1 |
| Ozan, O | 1 |
| Wang, SH | 1 |
| Hou, FL | 1 |
| Tian, YJ | 1 |
| Liu, YH | 1 |
| Zheng, SL | 1 |
| Curl, K | 1 |
| LeBude, B | 1 |
| Ruggiero, N | 1 |
| Rose, A | 1 |
| Patel, S | 1 |
| Ogilby, D | 1 |
| Walinsky, P | 1 |
| Jasti, B | 1 |
| Savage, M | 1 |
| Shah, RR | 1 |
| Pillai, A | 1 |
| Omar, A | 1 |
| Zhao, J | 1 |
| Arora, V | 1 |
| Kapoor, D | 1 |
| Poommipanit, P | 1 |
| Mooney, JF | 1 |
| Hillis, GS | 1 |
| Lee, VW | 1 |
| Halliwell, R | 1 |
| Vicaretti, M | 1 |
| Moncrieff, C | 1 |
| Scott, SA | 1 |
| Peter, I | 1 |
| Linderman, M | 1 |
| Sload, J | 1 |
| Qiao, W | 1 |
| Desnick, RJ | 1 |
| Fuster, V | 2 |
| Hajjar, RJ | 1 |
| Mimoso, J | 1 |
| Faza, NN | 1 |
| Mentias, A | 1 |
| Parashar, A | 1 |
| Chaudhury, P | 1 |
| Barakat, AF | 1 |
| Agarwal, S | 1 |
| Wayangankar, S | 1 |
| Ellis, SG | 1 |
| Murat Tuzcu, E | 1 |
| Kapadia, SR | 1 |
| Soeiro, Ade M | 1 |
| Mansur, Ade P | 1 |
| Schaan, BD | 1 |
| Caramelli, B | 1 |
| Rochitte, CE | 1 |
| Serrano, CV | 2 |
| Calderaro, D | 1 |
| Gualandro, DM | 1 |
| Marcondes-Braga, FG | 1 |
| Lima, FG | 1 |
| Oliveira, FM | 1 |
| Azevedo, FR | 1 |
| Chauhan, H | 1 |
| Salles, JE | 1 |
| Soares, J | 1 |
| Cardoso, JN | 1 |
| Pellanda, LC | 1 |
| Sacilotto, L | 1 |
| Baracioli, L | 1 |
| Bortolotto, LA | 1 |
| César, LA | 1 |
| Ochiai, ME | 1 |
| Minami, MH | 1 |
| Pinheiro, MB | 1 |
| Moretti, MA | 1 |
| Oliveira, MT | 1 |
| Admoni, SN | 1 |
| Lottenberg, SA | 1 |
| Rocha, VZ | 1 |
| Mathias, W | 1 |
| Ong, P | 1 |
| Sechtem, U | 1 |
| Zhang, ZF | 1 |
| Sha, WH | 1 |
| Tan, GY | 1 |
| Wang, QY | 1 |
| Vega Hernández, B | 2 |
| Bangueses Quintana, R | 2 |
| Samaniego Lampón, B | 2 |
| Lozano Martínez-Luengas, Í | 2 |
| Gala Ortiz, G | 1 |
| Segovia Martínez de Salinas, E | 1 |
| Kinnaird, T | 1 |
| Butt, M | 2 |
| Abdul, F | 1 |
| Yazji, K | 1 |
| Hailan, A | 1 |
| Gallagher, S | 1 |
| Ossei-Gerning, N | 1 |
| Chase, A | 1 |
| Choudhury, A | 1 |
| Smith, D | 1 |
| Anderson, R | 1 |
| Parvataneni, R | 1 |
| Sato, K | 2 |
| Yamanaga, K | 1 |
| Miyazaki, T | 1 |
| Tabata, N | 1 |
| Yamamuro, M | 1 |
| Soejima, H | 2 |
| Mukarram, O | 1 |
| Akhtar, N | 2 |
| Junaid, A | 2 |
| Mohyuddin, A | 1 |
| Johnston, A | 1 |
| Degrauwe, S | 1 |
| Iglesias, JF | 1 |
| Karmali, KN | 1 |
| Lloyd-Jones, DM | 1 |
| Berendsen, MA | 1 |
| Goff, DC | 2 |
| Sanghavi, DM | 1 |
| Brown, NC | 1 |
| Korenovska, L | 1 |
| Huffman, MD | 1 |
| Du, J | 1 |
| Jiang, L | 2 |
| Camaro, C | 1 |
| Damen, SA | 1 |
| Brouwer, MA | 1 |
| Kedhi, E | 1 |
| Rognoni, A | 1 |
| van T Hof, AW | 1 |
| Ligtenberg, E | 1 |
| de Boer, MJ | 1 |
| Fahed, E | 1 |
| Ghauche, J | 1 |
| Rahme, R | 1 |
| Okais, N | 1 |
| Samaha, E | 1 |
| Nohra, G | 1 |
| Rizk, T | 1 |
| Maarrawi, J | 1 |
| Menassa-Moussa, L | 1 |
| Moussa, R | 1 |
| Syska, K | 1 |
| Chiżynski, K | 1 |
| Kassasir, H | 1 |
| Watała, C | 1 |
| Sakowicz, A | 1 |
| Magnani, G | 2 |
| Marino, M | 2 |
| Morales Martínez de Tejada, Á | 1 |
| Abaurrea-Ortiz, MD | 1 |
| Resor, CD | 1 |
| Nathan, A | 1 |
| Bonaca, MP | 1 |
| Cohen, M | 3 |
| Goodrich, E | 1 |
| Ophuis, TO | 1 |
| Ruda, M | 1 |
| Špinar, J | 1 |
| Jensen, E | 1 |
| Held, P | 1 |
| Morrow, DA | 2 |
| Braunwald, E | 1 |
| Janoo, G | 1 |
| Teeluck, AR | 1 |
| Huang, WQ | 1 |
| Ghantous, AE | 1 |
| Ferneini, EM | 1 |
| de Waha, A | 1 |
| Sandner, S | 1 |
| Boening, A | 1 |
| Koch-Buettner, K | 1 |
| Hammel, D | 1 |
| Hambrecht, R | 1 |
| Danner, BC | 1 |
| Schöndube, FA | 1 |
| Goerlach, G | 1 |
| Fischlein, T | 1 |
| Schmoeckel, M | 1 |
| Oberhoffer, M | 1 |
| Schulz, R | 1 |
| Walther, T | 1 |
| Ziegelhöffer, T | 1 |
| Knosalla, C | 1 |
| Schönrath, F | 1 |
| Beyersdorf, F | 1 |
| Siepe, M | 1 |
| Attmann, T | 1 |
| Mohr, FW | 1 |
| Sievers, HH | 1 |
| Joost, A | 1 |
| Putman, LM | 1 |
| Radke, PW | 1 |
| Lange, R | 1 |
| Cremer, J | 1 |
| Palmerini, T | 4 |
| Luni, FK | 1 |
| Riaz, H | 1 |
| Khan, AR | 1 |
| Riaz, T | 1 |
| Husnain, M | 1 |
| Riaz, IB | 1 |
| Khan, MS | 1 |
| Taleb, M | 1 |
| Kanjwal, Y | 1 |
| Cooper, CJ | 1 |
| Khuder, SA | 1 |
| So, CH | 1 |
| Eckman, MH | 1 |
| Ladapo, JA | 1 |
| Huang, M | 1 |
| Pelberg, RA | 1 |
| Sigurdsson, G | 1 |
| Severance, HW | 1 |
| Huang, J | 2 |
| Tang, X | 1 |
| Ye, F | 2 |
| Kong, X | 1 |
| Chan, MT | 1 |
| Russo, M | 1 |
| Nardi, P | 1 |
| Saitto, G | 1 |
| Bovio, E | 1 |
| Pellegrino, A | 1 |
| Scafuri, A | 1 |
| Ruvolo, G | 1 |
| McCullough, PA | 2 |
| Vasudevan, A | 2 |
| Lopez, LR | 2 |
| Swift, C | 2 |
| Peterson, M | 2 |
| Bennett-Firmin, J | 2 |
| Schiffmann, R | 2 |
| Bottiglieri, T | 2 |
| Smilowitz, NR | 1 |
| Oberweis, BS | 1 |
| Nukala, S | 1 |
| Rosenberg, A | 1 |
| Stuchin, S | 1 |
| Iorio, R | 1 |
| Errico, T | 1 |
| Radford, MJ | 1 |
| Zhang, JJ | 1 |
| Gao, XF | 1 |
| Ge, Z | 1 |
| Tian, NL | 1 |
| Liu, ZZ | 1 |
| Chen, SL | 1 |
| Grodzinsky, A | 1 |
| Arnold, SV | 1 |
| Wang, TY | 1 |
| Gosch, K | 1 |
| Jones, PG | 1 |
| Spertus, JA | 2 |
| Chhatriwalla, AK | 1 |
| Lind, M | 1 |
| Graham, G | 1 |
| Kosiborod, M | 2 |
| Sharma, T | 1 |
| Bliden, K | 1 |
| Chaudhary, R | 1 |
| Tecson, KM | 1 |
| Sathyamoorthy, M | 1 |
| Schussler, JM | 1 |
| Velasco, CE | 1 |
| Yanagawa, Y | 1 |
| Omori, K | 1 |
| Takeuchi, I | 1 |
| Jitsuiki, K | 1 |
| Yoshizawa, T | 1 |
| Ishikawa, K | 1 |
| Kando, Y | 1 |
| Fukata, M | 1 |
| Ohsaka, H | 1 |
| Lee, DH | 1 |
| Hur, JH | 1 |
| Min, SH | 1 |
| Lee, JE | 1 |
| Oh, TJ | 1 |
| Kim, KM | 1 |
| Jang, HC | 1 |
| Han, SJ | 1 |
| Kang, DK | 1 |
| Marchini, JF | 2 |
| Pinto, MR | 1 |
| Novaes, GC | 1 |
| Badran, AV | 1 |
| Pavão, RB | 1 |
| Figueiredo, GL | 1 |
| Lago, IM | 1 |
| Lima-Filho, MO | 1 |
| Lemos, DC | 1 |
| Tonani, M | 1 |
| Antloga, CM | 1 |
| Oliveira, L | 1 |
| Lorenzi, JC | 1 |
| Goldhammer, JE | 1 |
| Herman, CR | 1 |
| Sun, JZ | 1 |
| Della Riva, D | 1 |
| Bacchi Reggiani, L | 1 |
| Sangiorgi, D | 1 |
| Biondi-Zoccai, G | 1 |
| Angelini, GD | 1 |
| Pufulete, M | 1 |
| White, J | 1 |
| Yildirim, A | 2 |
| Lübbers, HT | 1 |
| Saydam, F | 1 |
| Değirmenci, İ | 1 |
| Birdane, A | 1 |
| Özdemir, M | 2 |
| Ulus, T | 1 |
| Özbayer, C | 1 |
| Çolak, E | 1 |
| Ata, N | 1 |
| Güneş, HV | 1 |
| Strisciuglio, T | 1 |
| Di Gioia, G | 1 |
| De Biase, C | 1 |
| Delrue, L | 1 |
| Pellicano, M | 1 |
| Bartunek, J | 1 |
| Vanderheyden, M | 1 |
| Izzo, R | 1 |
| Trimarco, B | 1 |
| Chen, YT | 1 |
| Chen, HT | 1 |
| Hsu, CY | 1 |
| Chao, PW | 1 |
| Kuo, SC | 1 |
| Ou, SM | 1 |
| Shih, CJ | 1 |
| Yu, J | 1 |
| Ooi, SY | 1 |
| Iorio, A | 1 |
| Lettieri, C | 2 |
| Bossi, I | 1 |
| Colombo, P | 1 |
| Rigattieri, S | 1 |
| Dossena, C | 1 |
| Anzuini, A | 2 |
| Senni, M | 1 |
| Elbadawi, A | 1 |
| Saad, M | 1 |
| Zuliani Mauro, MF | 1 |
| Costa, R | 3 |
| Piva E Mattos, LA | 1 |
| Siqueira, D | 3 |
| Sousa, A | 1 |
| Chen, DC | 1 |
| Singh, GD | 1 |
| Armstrong, EJ | 1 |
| Waldo, SW | 1 |
| Laird, JR | 1 |
| Amsterdam, EA | 1 |
| Mohring, A | 1 |
| Piayda, K | 1 |
| Barstow, C | 1 |
| McDivitt, JD | 1 |
| Requena, G | 1 |
| Maguire, A | 1 |
| Blankenberg, S | 2 |
| Grieve, R | 1 |
| Pocock, SJ | 1 |
| Vega, AM | 1 |
| Armstrong, PC | 1 |
| Hoefer, T | 1 |
| Knowles, RB | 1 |
| Tucker, AT | 1 |
| Hayman, MA | 1 |
| Ferreira, PM | 1 |
| Chan, MV | 1 |
| Warner, TD | 1 |
| Gupta, R | 3 |
| Ozan, MO | 1 |
| Pershukov, IV | 1 |
| Ostaschenko, SL | 1 |
| Kuznetsova, TN | 1 |
| Scherbo, SN | 1 |
| Karben, ZA | 1 |
| Sokryukina, EV | 1 |
| Omarov, AA | 1 |
| Ramazanov, DM | 1 |
| Bosak, NV | 1 |
| Shulzhenko, LV | 1 |
| Kalmatov, RK | 1 |
| Batyraliev, TA | 1 |
| Sidorenko, BA | 1 |
| van Klaveren, D | 1 |
| Pilgrim, T | 1 |
| Zanchin, T | 1 |
| Steyerberg, EW | 1 |
| D'Agostino, RB | 1 |
| Herrera-Galeano, JE | 4 |
| Wilson, AF | 2 |
| Bray, P | 1 |
| Apikoglu Rabus, S | 1 |
| Izzettin, FV | 1 |
| Sancar, M | 1 |
| Karakaya, O | 1 |
| Kargin, R | 1 |
| Yakut, C | 1 |
| Aslam, M | 1 |
| Charlton, RK | 3 |
| Suzuki, Y | 1 |
| Box, LC | 1 |
| Shoemaker, SB | 1 |
| Meade, TW | 2 |
| Berger, PB | 2 |
| Ezekowitz, M | 2 |
| O'Connor, CM | 3 |
| Vorchheimer, DA | 3 |
| Guyatt, GH | 2 |
| Addad, F | 6 |
| Chakroune, T | 1 |
| Asma, A | 1 |
| Abderazek, F | 4 |
| Zohra, D | 1 |
| Ghrissi, I | 1 |
| Hassine, M | 6 |
| Gamra, H | 6 |
| Elalamy, I | 7 |
| Pokov, I | 1 |
| Chesebro, J | 1 |
| Badimon, J | 1 |
| Banasiak, W | 1 |
| Wilkins, A | 1 |
| Pociupany, R | 1 |
| Ponikowski, P | 1 |
| Vigoda, MM | 1 |
| Rodríguez, LI | 1 |
| Wu, E | 1 |
| Perry, K | 1 |
| Duncan, R | 1 |
| Birnbach, DJ | 1 |
| Lubarsky, DA | 1 |
| Veeraputhiran, M | 1 |
| Sundermeyer, M | 1 |
| Mortensen, J | 4 |
| Poulsen, TS | 1 |
| Refsgaard, J | 2 |
| Nielsen, HL | 3 |
| Pedersen, SB | 4 |
| Thygesen, SS | 2 |
| Lotrionte, M | 2 |
| Biondi-Zoccai, GG | 2 |
| Duzenli, MA | 1 |
| Ozdemir, K | 1 |
| Aygul, N | 1 |
| Soylu, A | 1 |
| Tokac, M | 1 |
| Rao, GH | 1 |
| Gori, AM | 1 |
| Marcucci, R | 1 |
| Migliorini, A | 1 |
| Valenti, R | 1 |
| Moschi, G | 1 |
| Paniccia, R | 1 |
| Buonamici, P | 1 |
| Gensini, GF | 2 |
| Vergara, R | 1 |
| Abbate, R | 1 |
| Antoniucci, D | 1 |
| Guthikonda, S | 1 |
| Alviar, CL | 1 |
| Arikan, M | 1 |
| Tellez, A | 1 |
| DeLao, T | 1 |
| Granada, JF | 1 |
| Dong, JF | 1 |
| Kleiman, NS | 4 |
| Durmaz, T | 1 |
| Keles, T | 1 |
| Ozdemir, O | 1 |
| Bayram, NA | 1 |
| Akcay, M | 1 |
| Yeter, E | 1 |
| Bozkurt, E | 1 |
| Schwartz, KA | 1 |
| Schwartz, DE | 1 |
| Barber, K | 1 |
| Reeves, M | 1 |
| De Franco, AC | 1 |
| Peace, AJ | 1 |
| Tedesco, AF | 1 |
| Foley, DP | 1 |
| Dicker, P | 1 |
| Berndt, MC | 1 |
| Lordkipanidzé, M | 9 |
| Pharand, C | 8 |
| Nguyen, TA | 1 |
| Schampaert, E | 7 |
| Palisaitis, DA | 7 |
| Diodati, JG | 8 |
| Terashima, M | 1 |
| Kinoshita, Y | 1 |
| Kimura, M | 1 |
| Nasu, K | 1 |
| Ehara, M | 1 |
| Tsuchikane, E | 1 |
| Matsubara, T | 1 |
| Asakura, Y | 1 |
| Katoh, O | 1 |
| Shaw, JA | 1 |
| Bobik, A | 1 |
| Murphy, A | 1 |
| Kanellakis, P | 1 |
| Blombery, P | 1 |
| Mukhamedova, N | 1 |
| Woollard, K | 1 |
| Lyon, S | 1 |
| Sviridov, D | 1 |
| Dart, AM | 1 |
| Schäfer, A | 1 |
| Weinberger, S | 1 |
| Flierl, U | 1 |
| Eigenthaler, M | 1 |
| Störk, S | 1 |
| Walter, U | 1 |
| Ertl, G | 1 |
| Bauersachs, J | 1 |
| Braun, OO | 2 |
| Johnell, M | 1 |
| Varenhorst, C | 2 |
| Brandt, JT | 2 |
| Winters, KJ | 4 |
| Erlinge, D | 2 |
| Siegbahn, A | 3 |
| Ivandic, BT | 2 |
| Kurz, K | 1 |
| Keck, F | 1 |
| Staritz, P | 2 |
| Lehrke, S | 1 |
| Giannitsis, E | 2 |
| Tourmousoglou, CE | 1 |
| Rokkas, CK | 1 |
| Ferguson, AD | 1 |
| Dokainish, H | 1 |
| Lakkis, N | 1 |
| Natarajan, A | 1 |
| Marshall, SM | 1 |
| Worthley, SG | 2 |
| Zaman, AG | 2 |
| Xiang, YZ | 1 |
| Béres, BJ | 1 |
| Tóth-Zsámboki, E | 1 |
| Vargová, K | 1 |
| László, A | 1 |
| Masszi, T | 1 |
| Kerecsen, G | 1 |
| Préda, I | 1 |
| Mende, A | 1 |
| Obata, JE | 1 |
| Sano, K | 1 |
| Hirano, M | 1 |
| Kitta, Y | 1 |
| Kodama, Y | 1 |
| Nakamura, T | 2 |
| Kawabata, K | 1 |
| Saitoh, Y | 1 |
| Fujioka, D | 1 |
| Kobayashi, T | 4 |
| Satoh, K | 1 |
| Ozaki, Y | 1 |
| Yano, T | 1 |
| Kugiyama, K | 1 |
| Canbay, A | 1 |
| Ozcan, O | 1 |
| Kim, KE | 1 |
| Woo, KS | 2 |
| Goh, RY | 2 |
| Quan, ML | 1 |
| Han, JY | 3 |
| Jian, Z | 1 |
| Huang, L | 1 |
| Guo, H | 1 |
| Qian, D | 1 |
| Fu, W | 1 |
| Li, A | 1 |
| Ernest, CS | 1 |
| Small, DS | 1 |
| Rohatagi, S | 1 |
| Salazar, DE | 1 |
| Wrishko, RE | 1 |
| Chodosh, A | 1 |
| Korr, KS | 1 |
| Burtt, D | 1 |
| Ozturk, B | 1 |
| Tacoy, G | 1 |
| Coskun, U | 1 |
| Yaman, E | 1 |
| Sahin, G | 1 |
| Buyukberber, S | 1 |
| Yildiz, R | 1 |
| Kaya, AO | 1 |
| Topal, S | 1 |
| Benekli, M | 1 |
| Haberl, K | 1 |
| Prillinger, K | 1 |
| Lang, I | 1 |
| Jilma, B | 2 |
| Palombo, G | 1 |
| Stella, N | 1 |
| Faraglia, V | 1 |
| Rizzo, L | 1 |
| Capuano, F | 1 |
| Sinatra, R | 1 |
| Taurino, M | 1 |
| Steinhubl, SR | 5 |
| Brennan, DM | 1 |
| Topol, EJ | 1 |
| Kral, B | 1 |
| Qayyum, R | 2 |
| Moy, TF | 3 |
| Hedegaard, SS | 2 |
| Daví, G | 1 |
| Turgeon, J | 3 |
| Motovska, Z | 1 |
| Petr, R | 1 |
| Bilkova, D | 1 |
| Marinov, I | 1 |
| Simek, S | 1 |
| Kala, P | 1 |
| Majid, A | 1 |
| Jennings, LK | 1 |
| Dean, J | 1 |
| Yujie, Z | 1 |
| Yingxin, Z | 1 |
| Yuyang, L | 1 |
| Yonghe, G | 1 |
| Wanjun, C | 1 |
| Zheng, C | 1 |
| Escárcega, RO | 1 |
| Garcia-Carrasco, M | 1 |
| Jara, LJ | 1 |
| Cervera, R | 1 |
| Khalid, A | 1 |
| Ahmed, W | 1 |
| Shah, MA | 1 |
| Rahman, H | 1 |
| Pastor-Pérez, FJ | 1 |
| Rivera, J | 1 |
| Lozano, ML | 1 |
| Marín, F | 1 |
| Mirabella, F | 1 |
| Francaviglia, B | 1 |
| Di Salvo, ME | 1 |
| Galassi, AR | 2 |
| Ionescu, CN | 1 |
| Chrissoheris, M | 1 |
| Caraccciolo, EA | 1 |
| Morath, T | 2 |
| Stegherr, J | 2 |
| Braun, S | 2 |
| Vogt, W | 1 |
| Schömig, A | 4 |
| von Beckerath, N | 3 |
| Spinler, SA | 1 |
| Dai, X | 1 |
| Jauhar, R | 1 |
| Singla, MK | 1 |
| Lahiri, P | 1 |
| Mukhopadhyay, P | 1 |
| Pandit, K | 1 |
| Chaudhuri, U | 1 |
| Chowdhury, S | 1 |
| Steinwender, C | 1 |
| Hartenthaler, B | 1 |
| Lambert, T | 1 |
| Kypta, A | 1 |
| Kammler, J | 1 |
| Hönig, S | 1 |
| Hofmann, R | 1 |
| Kerschner, K | 1 |
| Leisch, F | 1 |
| Chakroun, T | 5 |
| Ben-Farhat, M | 3 |
| Hamdi, S | 3 |
| Dridi, Z | 4 |
| Samama, MM | 2 |
| Conti, AA | 1 |
| Siddique, A | 1 |
| Shantsila, E | 2 |
| Guerra, M | 1 |
| Mota, JC | 1 |
| Veloso, M | 1 |
| Gama, V | 1 |
| Vouga, L | 1 |
| Santagostino, M | 1 |
| Secco, GG | 1 |
| Cassetti, E | 1 |
| Giuliani, L | 1 |
| Franchi, E | 1 |
| Coppo, L | 1 |
| Iorio, S | 1 |
| Venegoni, L | 1 |
| Rondano, E | 1 |
| Dell'Era, G | 1 |
| Rizzo, C | 1 |
| Monaco, F | 1 |
| Tuleta, I | 1 |
| Bauriedel, G | 2 |
| Hasenbank, I | 1 |
| Andrié, R | 1 |
| Pabst, S | 1 |
| Skowasch, D | 2 |
| Tanajura, LF | 2 |
| Mattos, LA | 1 |
| Bonan, R | 2 |
| Sousa, JE | 2 |
| Aleil, B | 1 |
| Jacquemin, L | 1 |
| De Poli, F | 1 |
| Zaehringer, M | 1 |
| Cazenave, JP | 2 |
| Dickele, MC | 1 |
| Monassier, JP | 1 |
| Gachet, C | 1 |
| Densem, C | 1 |
| Walsh, S | 1 |
| Jokhi, P | 1 |
| Fox, R | 1 |
| Wong, G | 1 |
| Buller, C | 1 |
| Ricci, D | 1 |
| Fung, A | 1 |
| Frere, C | 1 |
| Quilici, J | 2 |
| Morange, PE | 1 |
| Mouret, JP | 1 |
| Bali, L | 1 |
| Moro, PJ | 1 |
| Lambert, M | 1 |
| Alessi, MC | 1 |
| Bonnet, JL | 3 |
| Margolis, JR | 1 |
| Jing, Q | 2 |
| Xu, B | 2 |
| Shang, X | 1 |
| Jiang, T | 2 |
| Qiu, J | 1 |
| Maldonado, G | 1 |
| Awata, M | 1 |
| Nanto, S | 1 |
| Uematsu, M | 1 |
| Morozumi, T | 1 |
| Watanabe, T | 1 |
| Onishi, T | 1 |
| Iida, O | 1 |
| Sera, F | 1 |
| Minamiguchi, H | 1 |
| Kotani, J | 1 |
| Nagata, S | 1 |
| Zanati, SG | 1 |
| Mouraria, GG | 1 |
| Matsubara, LS | 1 |
| Giannini, M | 1 |
| Matsubara, BB | 1 |
| Mrdovic, I | 1 |
| Savic, L | 1 |
| Perunicic, J | 1 |
| Asanin, M | 1 |
| Lasica, R | 1 |
| Marinkovic, J | 1 |
| Vasiljevic, Z | 1 |
| Ostojic, M | 1 |
| Kumar, A | 1 |
| Kao, J | 1 |
| Furgieri, A | 1 |
| Sabatè, M | 7 |
| Hamon, M | 1 |
| Repetto, A | 1 |
| Brugaletta, S | 1 |
| Parrinello, G | 1 |
| Percoco, G | 1 |
| Sial, JA | 1 |
| Ferman, MT | 1 |
| Saghir, T | 1 |
| Rasool, SI | 1 |
| Sen, N | 2 |
| Ozlü, MF | 1 |
| Başar, N | 1 |
| Ozcan, F | 1 |
| Güngör, O | 1 |
| Turak, O | 1 |
| Malçok, O | 1 |
| Cağli, K | 1 |
| Maden, O | 2 |
| Erbay, AR | 2 |
| Demir, AD | 2 |
| Kogushi, M | 1 |
| Dastros-Pitei, D | 1 |
| Undas, A | 5 |
| Stepień, E | 1 |
| Branicka, A | 1 |
| Zmudka, K | 3 |
| Tracz, W | 1 |
| Sanioglu, S | 1 |
| Tetik, S | 1 |
| Sokullu, O | 1 |
| Deniz, H | 1 |
| Aydemir, N | 1 |
| Yilmaz, M | 1 |
| Arslan, IY | 1 |
| Bilgen, F | 1 |
| Kim, H | 1 |
| Lee, HK | 1 |
| Han, K | 1 |
| Walsh, SN | 1 |
| Kerchner, K | 1 |
| Sangüeza, OP | 1 |
| Yilmazer, MM | 1 |
| Mese, T | 1 |
| Demirpençe, S | 1 |
| Tavli, V | 1 |
| Devrim, I | 1 |
| Guven, B | 1 |
| Oner, T | 1 |
| Orgun, LT | 1 |
| Vitrinel, A | 1 |
| Alberts, P | 2 |
| Fontana, P | 1 |
| Mann, J | 1 |
| Bounameaux, H | 1 |
| Sorensen, AS | 2 |
| Ghenim, R | 1 |
| Roncalli, J | 1 |
| Tidjane, AM | 1 |
| Bongard, V | 1 |
| Ziani, A | 1 |
| Boudou, N | 1 |
| Dumonteil, N | 1 |
| Marcheix, B | 1 |
| Léobon, B | 1 |
| Bagur, R | 2 |
| Bertrand, OF | 2 |
| Rodés-Cabau, J | 2 |
| Rinfret, S | 2 |
| Nguyen, CM | 1 |
| Noel, B | 1 |
| Larochellière, RD | 1 |
| Poirier, P | 1 |
| Costerousse, O | 2 |
| Roy, L | 2 |
| LaBounty, TM | 1 |
| Devereux, RB | 1 |
| Weinsaft, JW | 1 |
| Gransar, H | 1 |
| Rozanski, A | 1 |
| Hayes, SW | 1 |
| Friedman, JD | 1 |
| Miranda, R | 1 |
| Zürn, C | 1 |
| Simonenko, R | 1 |
| Rapin, M | 1 |
| Kraibooj, H | 1 |
| Kilias, A | 1 |
| Bigalke, B | 6 |
| Stellos, K | 5 |
| Schwab, M | 1 |
| May, AE | 4 |
| Herdeg, C | 2 |
| Antonino, MJ | 3 |
| Stephens, G | 1 |
| Gretler, DD | 1 |
| Jurek, MM | 1 |
| Pakyz, RE | 2 |
| Shuldiner, AR | 2 |
| Conley, PB | 1 |
| Benhamou, Y | 1 |
| Lévesque, H | 1 |
| Proulx, G | 1 |
| Gleeton, O | 1 |
| Dewilde, W | 2 |
| Berg, JT | 1 |
| Philipp, S | 1 |
| Böse, D | 1 |
| Marso, SP | 1 |
| Schwartz, RS | 1 |
| König, A | 1 |
| Garcia-Garcia, HM | 2 |
| Stakos, D | 1 |
| Henkelmann, N | 1 |
| Raymond, C | 1 |
| Butler, K | 2 |
| Gesheff, T | 2 |
| Wei, C | 3 |
| Patil, SB | 1 |
| Karunakaran, A | 1 |
| Parris, C | 1 |
| Purdy, D | 1 |
| Wilson, V | 1 |
| Ledley, GS | 1 |
| Diehl, P | 1 |
| Olivier, C | 1 |
| Halscheid, C | 1 |
| Helbing, T | 1 |
| Moser, M | 2 |
| Delle-Karth, G | 1 |
| Gilchrist, IC | 3 |
| Frelinger, AL | 5 |
| Linden, MD | 4 |
| Barnard, MR | 4 |
| Fox, ML | 4 |
| Christie, DJ | 1 |
| Furman, MI | 4 |
| Michelson, AD | 6 |
| Anderson, RD | 1 |
| Denardo, SJ | 1 |
| Sharma, RK | 1 |
| Reddy, HK | 1 |
| Singh, VN | 1 |
| Voelker, DJ | 1 |
| Bhatt, G | 1 |
| Menown, IA | 1 |
| Shand, JA | 1 |
| Lewis, WR | 1 |
| Ellrodt, AG | 1 |
| Peterson, E | 1 |
| LaBresh, KA | 1 |
| Pan, W | 1 |
| Arruda-Olson, AM | 1 |
| Reeder, GS | 2 |
| Bell, MR | 1 |
| Weston, SA | 1 |
| Roger, VL | 1 |
| Rigante, D | 1 |
| Valentini, P | 1 |
| Rizzo, D | 1 |
| Leo, A | 1 |
| De Rosa, G | 1 |
| Onesimo, R | 1 |
| De Nisco, A | 1 |
| Angelone, DF | 1 |
| Compagnone, A | 1 |
| Delogu, AB | 1 |
| Ramanath, VS | 1 |
| Armstrong, DF | 1 |
| Grzybowski, M | 1 |
| Rahnama-Mohagdam, S | 1 |
| Tamhane, UU | 1 |
| Gordon, K | 1 |
| Froehlich, JB | 1 |
| Jackson, EA | 1 |
| Hatoum, IJ | 1 |
| Nelson, JJ | 1 |
| Cook, NR | 1 |
| Hu, FB | 1 |
| Rimm, EB | 1 |
| Harel, N | 1 |
| Mager, A | 1 |
| Brosh, D | 1 |
| Assali, A | 1 |
| Roller, M | 1 |
| Battler, A | 2 |
| Akhter, M | 1 |
| Kothari, S | 1 |
| Nie, R | 1 |
| Luo, N | 1 |
| Abderrazek, F | 2 |
| Gerotziafas, G | 2 |
| Pasceri, V | 1 |
| Patti, G | 1 |
| Pristipino, C | 1 |
| Irini, D | 1 |
| Varveri, A | 1 |
| Roncella, A | 1 |
| Speciale, G | 1 |
| Rhee, KE | 1 |
| Califf, RM | 3 |
| Boden, WE | 1 |
| Hirsch, AT | 1 |
| Alberts, MJ | 1 |
| Cable, G | 1 |
| Breet, N | 1 |
| Ten Berg, J | 1 |
| Kuroiwa, Y | 1 |
| Oyanagi, R | 1 |
| Fuse, S | 2 |
| Mori, T | 1 |
| Kamada, A | 1 |
| Tsutsumi, H | 1 |
| Morino, Y | 1 |
| Hayashi, Y | 1 |
| Muramatsu, T | 1 |
| Noguchi, Y | 1 |
| Kato, K | 1 |
| Shibata, Y | 1 |
| Doi, O | 1 |
| Yamashita, T | 1 |
| Morimoto, T | 2 |
| Abe, M | 2 |
| Hinohara, T | 1 |
| Mitsudo, K | 2 |
| Morita, S | 1 |
| Ebina, T | 1 |
| Kosuge, M | 1 |
| Hibi, K | 1 |
| Okuda, J | 1 |
| Iwahashi, N | 1 |
| Maejima, N | 1 |
| Nakachi, T | 1 |
| Ohtsuka, F | 1 |
| Hashiba, K | 1 |
| Tahara, Y | 1 |
| Sugano, T | 1 |
| Umemura, S | 1 |
| Gao, P | 1 |
| Xiong, H | 1 |
| Hu, SS | 1 |
| Nie, B | 1 |
| Yan, ZX | 1 |
| Jia, de A | 1 |
| Yu, M | 1 |
| Bernardo, E | 5 |
| Vivas, D | 1 |
| Jimenez-Quevedo, P | 3 |
| Alfonso, F | 7 |
| Fernandez-Ortiz, A | 6 |
| Cleland, JG | 1 |
| Johnsen, HL | 1 |
| Behan, MW | 1 |
| Chew, DP | 2 |
| Aylward, PE | 1 |
| Rostoff, P | 2 |
| Piwowarska, W | 3 |
| Engelhardt, A | 2 |
| Lask, S | 2 |
| Börgel, J | 1 |
| Wong, YW | 1 |
| Prakash, R | 1 |
| Scheinowitz, M | 1 |
| Wakabayashi, K | 1 |
| Maluenda, G | 1 |
| Syed, AI | 1 |
| Collins, SD | 1 |
| Gonzalez, MA | 2 |
| Gaglia, MA | 1 |
| Xue, Z | 1 |
| Kaneshige, K | 1 |
| Suddath, WO | 2 |
| Kent, KM | 2 |
| Pichard, AD | 3 |
| Eshtehardi, P | 2 |
| Cook, S | 1 |
| Billinger, M | 1 |
| Togni, M | 2 |
| Garachemani, A | 1 |
| Meier, B | 2 |
| Hess, OM | 2 |
| Wenaweser, P | 2 |
| Gabbasov, Z | 1 |
| Ivanova, O | 1 |
| Kogan-Yasny, V | 1 |
| Vasilieva, E | 1 |
| Mortensen, SB | 2 |
| Mezilis, N | 1 |
| Dardas, P | 1 |
| Ninios, V | 1 |
| Tsikaderis, D | 1 |
| Mueller, K | 1 |
| Aichele, S | 2 |
| Ninci, E | 1 |
| Mathias, RA | 1 |
| Sung, H | 1 |
| Mantese, VJ | 1 |
| Hererra-Galeano, JE | 1 |
| Ruczinski, I | 2 |
| Jim, MH | 1 |
| Yung, AS | 1 |
| Tang, GK | 1 |
| Fan, KY | 1 |
| Chow, WH | 1 |
| Desai, SP | 1 |
| Januzzi, JL | 1 |
| Pande, AN | 1 |
| Pomerantsev, EV | 1 |
| Resnic, FS | 1 |
| Fossel, A | 1 |
| Chibnik, LB | 1 |
| Kojuri, J | 1 |
| Mahmoody, Y | 1 |
| Zangbar Sabegh, B | 1 |
| Jannati, M | 1 |
| Mahboodi, A | 1 |
| Khalili, A | 1 |
| Keown, OP | 1 |
| Winterburn, TJ | 1 |
| Wainwright, CL | 1 |
| Macrury, SM | 1 |
| Neilson, I | 1 |
| Barrett, F | 1 |
| Leslie, SJ | 1 |
| Megson, IL | 1 |
| Dvir, D | 1 |
| Gratsianskiĭ, NA | 2 |
| Abrecht, L | 1 |
| Zwahlen, M | 1 |
| Schmidlin, K | 1 |
| Haeberli, A | 1 |
| Arméro, S | 1 |
| Camoin Jau, L | 1 |
| Omar Aït Mokhtar, O | 1 |
| Mancini, J | 1 |
| Burignat-Bonello, C | 1 |
| Tahirou, I | 1 |
| Arques, S | 1 |
| Dignat-George, F | 1 |
| Violi, F | 1 |
| Pignatelli, P | 1 |
| Basili, S | 1 |
| Wulff, LN | 2 |
| Kaltoft, AK | 1 |
| Tilsted, HH | 2 |
| Chouchene, S | 1 |
| Gerotziafas, GT | 2 |
| Hatmi, M | 2 |
| Müller, K | 2 |
| Herkommer, M | 1 |
| da Rosa, EM | 1 |
| Tormen, WC | 1 |
| Lopes, EF | 1 |
| Siriswangvat, S | 1 |
| Sansanayudh, N | 1 |
| Nathisuwan, S | 1 |
| Panomvana, D | 1 |
| Yong, AS | 1 |
| Chang, M | 1 |
| Hamzah, A | 1 |
| Chung, T | 1 |
| Qi, M | 1 |
| Behnia, M | 1 |
| Krilis, SA | 1 |
| Ng, MK | 1 |
| Stern, I | 1 |
| Marc, J | 1 |
| Kranjec, I | 1 |
| Zorman, D | 1 |
| Cerne, A | 1 |
| Cerne, D | 1 |
| Kim, BR | 1 |
| Kim, JE | 1 |
| Yu, LH | 1 |
| Roe, M | 1 |
| Dai, D | 2 |
| Rumsfeld, JS | 1 |
| Cryer, BL | 1 |
| Contant, CF | 1 |
| Lanas, A | 1 |
| Schnitzer, TJ | 1 |
| Shook, TL | 1 |
| Lapuerta, P | 1 |
| Goldsmith, MA | 1 |
| Laine, L | 1 |
| Scirica, BM | 1 |
| Murphy, SA | 4 |
| Venerito, M | 1 |
| Kandulski, A | 1 |
| Malfertheiner, P | 1 |
| Gao, G | 1 |
| Pi, Y | 1 |
| Armstrong, M | 1 |
| Hudzik, B | 1 |
| Szkodzinski, J | 1 |
| Danikiewicz, A | 1 |
| Wilczek, K | 1 |
| Romanowski, W | 1 |
| Lekston, A | 1 |
| Polonski, L | 1 |
| Zubelewicz-Szkodzinska, B | 1 |
| Vanesson, L | 1 |
| Koussa, M | 1 |
| Fayad, G | 1 |
| Lablanche, JM | 2 |
| Modine, T | 1 |
| Tardif, JC | 1 |
| Delarochelliere, R | 1 |
| Naidoo, S | 1 |
| Wells, GA | 1 |
| Vermillet, A | 1 |
| Boval, B | 1 |
| Guyetand, C | 1 |
| Petroni, T | 1 |
| Sanchez, DR | 1 |
| Diez Roux, AV | 1 |
| Michos, ED | 1 |
| Schreiner, PJ | 1 |
| Burke, GL | 1 |
| Watson, K | 1 |
| Williams, JB | 1 |
| Delong, ER | 3 |
| Dokholyan, RS | 1 |
| Ou, FS | 1 |
| Ferguson, TB | 1 |
| Awidi, A | 1 |
| Saleh, A | 1 |
| Dweik, M | 1 |
| Kailani, B | 1 |
| Abu-Fara, M | 1 |
| Nabulsi, R | 1 |
| Bener, A | 1 |
| Masumura, Y | 1 |
| Matsuo, K | 1 |
| Akazawa, Y | 1 |
| Nishio, M | 1 |
| Hirata, A | 1 |
| Kashiwase, K | 1 |
| Nemoto, T | 1 |
| Kashiyama, T | 1 |
| Wada, M | 1 |
| Muller, JE | 1 |
| Kodama, K | 1 |
| Caixeta, A | 1 |
| Lansky, AJ | 1 |
| Ruygrok, P | 1 |
| Gordon, P | 1 |
| Yaqub, M | 1 |
| Miquel-Hebert, K | 2 |
| Veldhof, S | 2 |
| Sood, P | 1 |
| Su, X | 1 |
| Jonnavithula, L | 1 |
| Sudhir, K | 2 |
| Saucedo, JF | 1 |
| Effron, MB | 1 |
| Bischofs, C | 1 |
| Banya, W | 1 |
| Cay, S | 1 |
| Cagirci, G | 1 |
| Aydogdu, S | 1 |
| Balbay, Y | 1 |
| Patel, A | 1 |
| Dharmashankar, K | 4 |
| Kodali, M | 3 |
| Tomasello, SD | 3 |
| Seecheran, N | 2 |
| White, HD | 2 |
| Ryan, K | 1 |
| Yun, SC | 3 |
| Bang, DW | 1 |
| Park, HK | 1 |
| Park, CB | 1 |
| Kim, MK | 1 |
| Park, KH | 1 |
| Korte, W | 1 |
| Chassot, PG | 1 |
| Eichinger, S | 1 |
| von Heymann, C | 1 |
| Hofmann, N | 1 |
| Spannagl, M | 1 |
| Ziegler, B | 1 |
| Verheugt, F | 1 |
| Arima, M | 1 |
| Matsuda, A | 1 |
| Nitta, M | 1 |
| Yoshida, K | 1 |
| Shimizu, M | 1 |
| Szczeklik, A | 5 |
| Yang, EH | 1 |
| Perez, E | 1 |
| Zhiroff, KA | 1 |
| Burstein, S | 1 |
| DiChiara, J | 2 |
| Xanthopoulou, I | 1 |
| Karantalis, V | 1 |
| Mitropoulou, G | 1 |
| Damelou, A | 1 |
| Davlouros, P | 1 |
| Bulut, D | 1 |
| Becker, V | 1 |
| Feuring, M | 1 |
| Wehling, M | 1 |
| Ruf, A | 1 |
| Burkhardt, H | 1 |
| Schultz, A | 1 |
| Amoah, V | 1 |
| Smallwood, A | 1 |
| Worrall, AP | 1 |
| Lovatt, T | 1 |
| Armesilla, AL | 1 |
| Nevill, AM | 1 |
| Cotton, JM | 1 |
| Egred, M | 1 |
| Rajendran, S | 1 |
| Parikh, D | 1 |
| Shugman, I | 1 |
| French, JK | 1 |
| Juergens, CP | 1 |
| Choi, EK | 1 |
| Cho, IS | 1 |
| Choi, SI | 1 |
| Rivera, JJ | 2 |
| Zalewski, J | 2 |
| Nessler, J | 2 |
| Fugon, L | 1 |
| Cohen, W | 1 |
| Roux, P | 1 |
| Gaborit, B | 1 |
| Molines, L | 1 |
| Fourcade, L | 1 |
| Carrieri, P | 1 |
| Folks, B | 1 |
| Leblanc, WG | 1 |
| Staton, EW | 1 |
| Pace, WD | 1 |
| Pujol Lereis, VA | 1 |
| Ameriso, S | 1 |
| Povedano, GP | 1 |
| Ameriso, SF | 1 |
| Niccoli, G | 1 |
| Minelli, S | 1 |
| Crea, F | 1 |
| Bailey, AL | 1 |
| Campbell, CL | 1 |
| Kajiwara, I | 1 |
| Miyamoto, S | 1 |
| Cassese, S | 1 |
| Villari, B | 1 |
| Berti, S | 1 |
| Bellone, P | 1 |
| Alfieri, A | 1 |
| Montinaro, A | 1 |
| Quaranta, G | 1 |
| Marraccini, P | 1 |
| Piscione, F | 1 |
| Wang, ZX | 1 |
| Men, JL | 1 |
| Ren, J | 1 |
| Wei, MX | 1 |
| Gesheff, M | 1 |
| Horton, J | 1 |
| Shaw, LK | 2 |
| Harjai, KJ | 1 |
| Shenoy, C | 1 |
| Orshaw, P | 1 |
| Usmani, S | 1 |
| Boura, J | 1 |
| Mehta, RH | 1 |
| Yang, XP | 1 |
| Suktitipat, B | 1 |
| Johnson, AD | 1 |
| Tofler, GH | 1 |
| Friedman, AD | 1 |
| Gylfason, A | 1 |
| Thorsteinsdottir, U | 1 |
| Bray, PF | 3 |
| O'Donnell, CJ | 1 |
| Bisdas, T | 1 |
| Haverich, A | 1 |
| Teebken, OE | 1 |
| Höchtl, T | 1 |
| Tentzeris, I | 1 |
| Bailey, SR | 1 |
| Kaltenbach, L | 1 |
| Messenger, J | 1 |
| Santos, MT | 1 |
| Moscardo, A | 1 |
| Vallés, J | 1 |
| Hoshida, S | 1 |
| Yuasa, F | 1 |
| Lim, YJ | 1 |
| Kijima, Y | 1 |
| Iwasaka, J | 1 |
| Iwasaka, T | 1 |
| Yamamoto, K | 1 |
| Miyazaki, Y | 1 |
| Horio, E | 1 |
| Abe, T | 1 |
| Deguchi, M | 1 |
| Tayama, S | 1 |
| Yamabe, H | 1 |
| Nakamura, S | 1 |
| Cummings, CC | 1 |
| Dubois, BV | 1 |
| Herzog, WR | 1 |
| Kafian, S | 1 |
| Mobarrez, F | 1 |
| Kalani, M | 1 |
| Wallén, H | 1 |
| Samad, BA | 1 |
| Zakhem, B | 1 |
| Labarthe, B | 1 |
| Babin, J | 1 |
| Bryckaert, M | 1 |
| Théroux, P | 1 |
| Bonnefoy, A | 1 |
| Bonaventura, K | 1 |
| Sonntag, S | 1 |
| Kleber, FX | 1 |
| Weng, KP | 1 |
| Ou, SF | 1 |
| Lin, CC | 1 |
| Hsieh, KS | 1 |
| Ishiwata, T | 1 |
| Sato, H | 1 |
| Takizawa, M | 1 |
| Kawamura, Y | 1 |
| Tsujimoto, H | 1 |
| Nakatani, K | 1 |
| Ishibashi, N | 1 |
| Nishiyama, M | 1 |
| Hatai, Y | 1 |
| Asano, Y | 1 |
| Takeshita, S | 1 |
| Nonoyama, S | 1 |
| Russo, MW | 1 |
| Pierson, J | 1 |
| Narang, T | 1 |
| Montegudo, A | 1 |
| Eskind, L | 1 |
| Gulati, S | 1 |
| Romano, M | 1 |
| Rosiello, R | 1 |
| Guagliumi, G | 2 |
| Valsecchi, O | 1 |
| Gavazzi, A | 1 |
| Neudorf, U | 1 |
| Ikeda, Y | 1 |
| Jacob, M | 1 |
| Smedira, N | 1 |
| Blackstone, E | 1 |
| Williams, S | 1 |
| Cho, L | 1 |
| Kunac, N | 1 |
| Silverman, MG | 1 |
| Raggi, P | 1 |
| Berman, D | 1 |
| Callister, T | 1 |
| Rumberger, JA | 1 |
| Rana, JS | 1 |
| Krishnan, E | 1 |
| Pandya, BJ | 1 |
| Lingala, B | 1 |
| Hariri, A | 1 |
| Dabbous, O | 1 |
| Zarifis, J | 1 |
| Bandi, A | 1 |
| Mossialos, L | 1 |
| Galea, V | 1 |
| Tsinopoulos, G | 1 |
| Chaari, M | 1 |
| Baccouche, H | 1 |
| Sassi, M | 1 |
| Tian, QP | 1 |
| Liu, QZ | 1 |
| Sivapalaratnam, S | 1 |
| Basart, H | 1 |
| Watkins, NA | 1 |
| Maiwald, S | 1 |
| Rendon, A | 1 |
| Krishnan, U | 1 |
| Hovingh, K | 1 |
| Ouwehand, WH | 1 |
| Kastelein, JJ | 1 |
| Goodall, AH | 1 |
| Trip, MD | 1 |
| Duerschmied, D | 1 |
| Ahrens, I | 1 |
| Mauler, M | 1 |
| Brandt, C | 1 |
| Weidner, S | 1 |
| Omar, HR | 1 |
| Mangar, D | 1 |
| Karlnoski, R | 1 |
| Abdelmalak, HD | 1 |
| Camporesi, EM | 1 |
| Sahin, DY | 1 |
| Koç, M | 1 |
| Caylı, M | 1 |
| Uysal, OK | 1 |
| Karaarslan, O | 1 |
| Kanadaşı, M | 1 |
| Demirtaş, M | 1 |
| Saji, T | 1 |
| Otani, T | 1 |
| Takeuchi, K | 1 |
| Arakawa, H | 1 |
| Kato, T | 1 |
| Hara, T | 1 |
| Hamaoka, K | 1 |
| Ogawa, S | 1 |
| Miura, M | 1 |
| Nomura, Y | 1 |
| Ichida, F | 1 |
| Seki, M | 1 |
| Fukazawa, R | 1 |
| Ogawa, C | 1 |
| Furuno, K | 1 |
| Tokunaga, H | 1 |
| Takatsuki, S | 1 |
| Hara, S | 1 |
| Morikawa, A | 1 |
| Paikin, JS | 1 |
| Franchini, M | 1 |
| Coppola, A | 1 |
| Kiviniemi, T | 1 |
| Karjalainen, P | 1 |
| Pietilä, M | 1 |
| Ylitalo, A | 1 |
| Niemelä, M | 1 |
| Vikman, S | 1 |
| Puurunen, M | 1 |
| Biancari, F | 1 |
| Airaksinen, KE | 1 |
| Yamane, K | 1 |
| Kato, Y | 1 |
| Tazaki, J | 2 |
| Tada, T | 2 |
| Makiyama, T | 1 |
| Imai, M | 1 |
| Jinnai, T | 1 |
| Shirakawa, R | 1 |
| Horiuchi, H | 1 |
| Park, Y | 1 |
| Ahn, JH | 1 |
| Kwon, TJ | 1 |
| Park, JR | 1 |
| Hwang, SJ | 1 |
| Gho, EH | 1 |
| Kwak, CH | 1 |
| Hwang, JY | 1 |
| Calvert, SB | 1 |
| Kramer, JM | 3 |
| Anstrom, KJ | 1 |
| Kaltenbach, LA | 1 |
| Stafford, JA | 1 |
| Allen LaPointe, NM | 2 |
| Ringwala, SM | 1 |
| Dibattiste, PM | 1 |
| Schneider, DJ | 1 |
| Deja, MA | 1 |
| Kargul, T | 1 |
| Domaradzki, W | 1 |
| Stącel, T | 1 |
| Mazur, W | 1 |
| Gocoł, R | 1 |
| Gaszewska-Żurek, E | 1 |
| Żurek, P | 1 |
| Pytel, A | 1 |
| Woś, S | 1 |
| Aung, PP | 1 |
| Wang, QK | 1 |
| Gaussem, P | 1 |
| Silverstein, RL | 1 |
| Schwartz, J | 1 |
| Allison, MA | 1 |
| Rifkin, DE | 1 |
| Wright, CM | 1 |
| Wang, P | 1 |
| Zhou, S | 1 |
| Zhou, R | 1 |
| Liu, G | 1 |
| Tang, P | 1 |
| Yang, J | 1 |
| Kettunen, R | 1 |
| Lepojärvi, M | 1 |
| Laine, M | 1 |
| Natsuaki, M | 1 |
| Furukawa, Y | 1 |
| Nakagawa, Y | 1 |
| Kadota, K | 1 |
| Iwabuchi, M | 1 |
| Shizuta, S | 1 |
| Shiomi, H | 1 |
| Ehara, N | 1 |
| Mizoguchi, T | 1 |
| Mitsuoka, H | 1 |
| Inada, T | 1 |
| Araki, M | 1 |
| Kaburagi, S | 1 |
| Taniguchi, R | 1 |
| Eizawa, H | 1 |
| Nakano, A | 1 |
| Suwa, S | 1 |
| Takizawa, A | 1 |
| Nohara, R | 1 |
| Fujiwara, H | 1 |
| Nobuyoshi, M | 1 |
| Kita, T | 1 |
| Rai, M | 1 |
| Seip, RL | 1 |
| McKay, RG | 1 |
| Hirst, J | 1 |
| Thompson, PD | 1 |
| Ruaño, G | 1 |
| Kovacic, JC | 1 |
| Lee, P | 2 |
| Karajgikar, R | 1 |
| Narechania, B | 1 |
| Suleman, J | 1 |
| Moreno, PR | 1 |
| Grinstein, J | 1 |
| Ariturk, Z | 1 |
| Islamoglu, Y | 1 |
| Gündüz, E | 1 |
| Yavuz, C | 1 |
| Cil, H | 1 |
| Tekbas, E | 1 |
| Soydinc, S | 1 |
| Kaya, H | 1 |
| Elbey, MA | 1 |
| Pettersen, AÅ | 1 |
| Opstad, TB | 1 |
| Bratseth, V | 1 |
| Martínez-Sánchez, G | 1 |
| Delgado-Roche, L | 1 |
| Díaz-Batista, A | 1 |
| Pérez-Davison, G | 1 |
| Re, L | 1 |
| Johnston, M | 1 |
| Hirsh, J | 1 |
| Pare, G | 1 |
| Mehta, S | 1 |
| Teo, KK | 1 |
| Sloane, D | 1 |
| Kuzniatsova, N | 3 |
| Velu, S | 1 |
| Strojek, K | 1 |
| Kurzelewski, M | 1 |
| Ostrowski, M | 1 |
| Rabczenko, D | 1 |
| Liang, M | 1 |
| Liew, TV | 1 |
| Puri, A | 1 |
| Hyde, L | 1 |
| Devlin, G | 1 |
| Altarev, SS | 1 |
| Jiang, J | 1 |
| Xiang, MX | 1 |
| Dong, L | 1 |
| Liu, XB | 1 |
| Hu, XY | 1 |
| Feng, Y | 1 |
| Wang, JA | 1 |
| Pattanaik, D | 1 |
| Lieberman, P | 1 |
| Das, P | 1 |
| Nagata, Y | 1 |
| Inomata, J | 1 |
| Kinoshita, M | 1 |
| Kurokawa, K | 1 |
| Aburadani, I | 1 |
| Maruyama, M | 1 |
| Usuda, K | 1 |
| Bajolle, F | 1 |
| Laux, D | 1 |
| El Mallah, W | 1 |
| Klein, AJ | 1 |
| Brilakis, ES | 1 |
| Yan, G | 1 |
| Ma, Y | 1 |
| Zhu, G | 1 |
| Lv, H | 1 |
| Ji, H | 1 |
| Femia, EA | 1 |
| Daray, FM | 1 |
| Podda, GM | 1 |
| Razzari, C | 1 |
| Pugliano, M | 1 |
| Errasti, AE | 1 |
| Armesto, AR | 1 |
| Nowak, W | 1 |
| Meyer, JP | 1 |
| Rothlin, RP | 1 |
| Lønnebakken, MT | 1 |
| Gerdts, E | 1 |
| Pedersen, OM | 1 |
| Ferreira-González, I | 1 |
| Marsal, JR | 1 |
| Ribera, A | 1 |
| Permanyer-Miralda, G | 1 |
| García-Del Blanco, B | 1 |
| Martí, G | 1 |
| Cascant, P | 1 |
| Masotti-Centol, M | 1 |
| Carrillo, X | 1 |
| Mauri, J | 1 |
| Batalla, N | 1 |
| Larrousse, E | 1 |
| Martín, E | 1 |
| Serra, A | 2 |
| Rumoroso, JR | 1 |
| Ruiz-Salmerón, R | 1 |
| de la Torre, JM | 1 |
| Cequier, A | 1 |
| Gómez-Hospital, JA | 1 |
| Martín-Yuste, V | 1 |
| Pesaro, AE | 1 |
| Katz, M | 1 |
| Campos, AH | 1 |
| Marti, LC | 1 |
| Martins, HS | 1 |
| Sunahara, RS | 1 |
| Maranhão, RC | 1 |
| Sharma, KK | 1 |
| Guptha, S | 1 |
| Borghi, C | 1 |
| Bacchelli, S | 1 |
| Degli Esposti, D | 1 |
| Drissa, A | 1 |
| Manzo Silberman, S | 1 |
| Logeart, D | 1 |
| Hess, CN | 1 |
| Broderick, S | 1 |
| Alexander, KP | 2 |
| Darwish, OS | 1 |
| Iqbal, E | 1 |
| Farooq, V | 1 |
| Dorange, C | 1 |
| Rapoza, R | 1 |
| Chevalier, B | 1 |
| Kozan, Ö | 1 |
| Yang, LX | 1 |
| Liu, HL | 1 |
| Qu, P | 1 |
| Li, WM | 1 |
| Jiang, TM | 1 |
| Li, SM | 1 |
| Jing, QM | 1 |
| Zhang, QY | 1 |
| Gao, RL | 1 |
| Tomaszuk-Kazberuk, A | 1 |
| Kozuch, M | 1 |
| Malyszko, J | 1 |
| Bachorzewska-Gajewska, H | 1 |
| Dobrzycki, S | 1 |
| Musial, WJ | 1 |
| Gusmão, MO | 1 |
| Castello, H | 1 |
| Nicolela, E | 1 |
| Mulukutla, SR | 1 |
| Marroquin, OC | 1 |
| Vlachos, HA | 1 |
| Selzer, F | 1 |
| Toma, C | 1 |
| Kip, KE | 1 |
| Abbott, JD | 1 |
| Holper, E | 1 |
| Lee, JS | 2 |
| Khandhar, S | 1 |
| Kutcher, M | 1 |
| Kelsey, S | 1 |
| Smith, C | 1 |
| Faxon, D | 1 |
| Williams, DO | 1 |
| Ohkubo, K | 1 |
| Iwata, Y | 1 |
| Kadohira, T | 1 |
| Sugimoto, K | 1 |
| Morino, T | 1 |
| Belardi, JA | 1 |
| Albertal, M | 1 |
| Lin, Y | 1 |
| Huang, Y | 1 |
| Lu, Z | 1 |
| Luo, C | 1 |
| shi, Y | 1 |
| Zeng, Q | 1 |
| Cao, Y | 1 |
| Ji, Q | 1 |
| Kasmeridis, C | 1 |
| Apostolakis, S | 1 |
| Manica, A | 1 |
| Sarmento-Leite, R | 1 |
| Manfroi, C | 1 |
| Rodrigues, LH | 1 |
| Gottschall, C | 1 |
| Kaider, A | 1 |
| Huang, KW | 1 |
| Luo, JC | 1 |
| Leu, HB | 1 |
| Huang, CC | 1 |
| Hou, MC | 1 |
| Chen, TS | 1 |
| Lu, CL | 1 |
| Lin, HC | 1 |
| Lee, FY | 1 |
| Chang, FY | 1 |
| Claessen, BE | 1 |
| Feng, CH | 1 |
| White, AA | 1 |
| Stevenson, DD | 2 |
| Christiansen, EH | 1 |
| Thayssen, P | 1 |
| Krusell, LR | 1 |
| Hansen, KN | 1 |
| Kaltoft, A | 1 |
| Terkelsen, CJ | 1 |
| Villadsen, AB | 1 |
| Ravkilde, J | 1 |
| Aarøe, J | 1 |
| Thuesen, L | 2 |
| Smits, PC | 1 |
| Hofma, S | 1 |
| Vázquez, N | 1 |
| Valdés, M | 1 |
| Voudris, V | 1 |
| Goy, JJ | 1 |
| Nouche, RT | 1 |
| den Heijer, P | 1 |
| van der Ent, M | 1 |
| Bolla, VH | 1 |
| Berg, R | 1 |
| Chirkov, YY | 1 |
| Holmes, AS | 1 |
| Willoughby, SR | 1 |
| Stewart, S | 1 |
| Horowitz, JD | 1 |
| Strandberg, T | 1 |
| Vanhanen, H | 1 |
| Wittes, J | 1 |
| Saulsbury, FT | 1 |
| Macchi, L | 4 |
| Christiaens, L | 4 |
| Brabant, S | 1 |
| Sorel, N | 1 |
| Allal, J | 3 |
| Mauco, G | 2 |
| Brizard, A | 2 |
| Kübler, W | 2 |
| Ferrini, R | 1 |
| Clark, B | 1 |
| Ashby, DT | 1 |
| Conditt, G | 1 |
| Hirose, M | 1 |
| Underwood, P | 1 |
| Beck, P | 1 |
| Traynor, K | 1 |
| Di Micco, B | 1 |
| Colonna, G | 1 |
| Di Micco, P | 1 |
| Di Micco, G | 1 |
| Russo, BM | 1 |
| Macalello, MA | 1 |
| Ragone, R | 1 |
| Stafford, RS | 1 |
| Radley, DC | 1 |
| Yeh, ET | 1 |
| Palusinski, RP | 1 |
| Andersen, K | 1 |
| Hurlen, M | 1 |
| Herpin, D | 1 |
| Coisne, D | 1 |
| Duplantier, C | 1 |
| Malinin, AI | 3 |
| Callahan, KP | 2 |
| McKenzie, ME | 1 |
| Klinkhardt, U | 1 |
| Bauersachs, R | 1 |
| Adams, J | 1 |
| Graff, J | 1 |
| Lindhoff-Last, E | 1 |
| Harder, S | 1 |
| Rossatto, ER | 1 |
| da Silva, LB | 1 |
| Pereira, GS | 1 |
| Bonan, CD | 1 |
| Battastini, AM | 1 |
| Ribeiro, JP | 1 |
| Sarkis, JJ | 1 |
| Mueller, C | 1 |
| Roskamm, H | 1 |
| Hunziker, P | 1 |
| Marsch, S | 1 |
| Perruchoud, A | 1 |
| Buettner, HJ | 1 |
| Prasad, K | 1 |
| Fujita, M | 1 |
| Mizuno, K | 1 |
| Ho, M | 1 |
| Tsukahara, R | 1 |
| Miyamoto, A | 1 |
| Miki, O | 1 |
| Ishii, K | 1 |
| Miwa, K | 1 |
| Belhassen, L | 1 |
| Pelle, G | 1 |
| Dubois-Rande, JL | 1 |
| Adnot, S | 1 |
| Hoey, J | 1 |
| Ali Raza, J | 1 |
| Movahed, A | 1 |
| Wang, FW | 1 |
| Osman, A | 1 |
| Otero, J | 1 |
| Stouffer, GA | 1 |
| Waxman, S | 1 |
| Afzal, A | 1 |
| Uretsky, BF | 1 |
| Sharma, AK | 1 |
| Ajani, AE | 1 |
| GebreEyesus, A | 1 |
| Varghese, J | 1 |
| Pinnow, E | 1 |
| Lindsay, J | 1 |
| Ziegler, BK | 2 |
| Rasmussen, LH | 1 |
| Hildebrandt, PR | 1 |
| Nielsen, HK | 1 |
| Husted, SE | 2 |
| Mohri, M | 1 |
| Hiatt, BL | 1 |
| Schieffer, B | 1 |
| Drexler, H | 1 |
| Azar, RR | 1 |
| Klayme, S | 1 |
| Germanos, M | 1 |
| Kassab, R | 1 |
| Tawm, S | 1 |
| Aboujaoudé, S | 1 |
| Naman, R | 1 |
| Voskoboĭ, VI | 1 |
| Rebrov, AP | 1 |
| Hodgson, JM | 1 |
| SoRelle, R | 1 |
| Averkov, OV | 1 |
| Shalaev, SV | 1 |
| ALEXANDER, WD | 1 |
| MACDOUGALL, AI | 1 |
| OLIVER, MF | 1 |
| BOYD, GS | 1 |
| Boccara, F | 1 |
| Cohen, A | 1 |
| Hostetter, JC | 1 |
| Remes, V | 1 |
| Helenius, I | 1 |
| Musiał, J | 1 |
| Sanak, M | 4 |
| Dropiński, J | 4 |
| Tuleja, E | 1 |
| Wegrzyn, W | 4 |
| Tendera, M | 1 |
| Ritter, O | 1 |
| Bonz, A | 1 |
| Strotmann, J | 1 |
| Langenfeld, H | 1 |
| Lombardi, A | 1 |
| Vandelli, R | 1 |
| Cerè, E | 1 |
| Di Pasquale, G | 1 |
| Ortolani, P | 1 |
| Marzocchi, A | 2 |
| Gaiba, W | 1 |
| Neri, S | 1 |
| Marrozzini, C | 1 |
| Aquilina, M | 1 |
| Branzi, A | 1 |
| Title, LM | 1 |
| Giddens, K | 1 |
| McInerney, MM | 1 |
| McQueen, MJ | 1 |
| Nassar, BA | 1 |
| Wang, JC | 1 |
| Aucoin-Barry, D | 1 |
| Manuelian, D | 1 |
| Monbouquette, R | 1 |
| Reisman, M | 1 |
| Gray, W | 1 |
| Block, PC | 1 |
| Block, EH | 1 |
| Ladenheim, M | 1 |
| Simon, DI | 2 |
| Holman, WL | 1 |
| Sansom, M | 1 |
| Kiefe, CI | 1 |
| Hubbard, SG | 1 |
| Delong, JF | 1 |
| Allman, RM | 1 |
| Hankey, GJ | 1 |
| Frishman, WH | 1 |
| McLeod, AL | 1 |
| Brooks, L | 1 |
| Taylor, V | 1 |
| Currie, PF | 1 |
| Dewhurst, NG | 1 |
| Wascher, TC | 1 |
| Nihoyannopoulos, P | 2 |
| Gohlke, H | 1 |
| Schirmer, A | 1 |
| Theobald, KH | 1 |
| Christiansen, M | 1 |
| Kaminski, P | 1 |
| Oxvig, C | 1 |
| Overgaard, MT | 1 |
| Cole, D | 1 |
| Holt, DW | 1 |
| Kaski, JC | 1 |
| Chen, WH | 4 |
| Lee, PY | 3 |
| Ng, W | 3 |
| Lau, CP | 3 |
| Li, JJ | 1 |
| Fang, CH | 1 |
| Arjomand, H | 1 |
| Ezekowitz, MD | 1 |
| Santa-Cruz, RA | 1 |
| Kandzari, DE | 1 |
| Matetzky, S | 1 |
| Shenkman, B | 1 |
| Guetta, V | 1 |
| Shechter, M | 1 |
| Beinart, R | 1 |
| Bienart, R | 1 |
| Goldenberg, I | 1 |
| Novikov, I | 1 |
| Pres, H | 1 |
| Savion, N | 1 |
| Varon, D | 1 |
| Hod, H | 1 |
| Hackam, DG | 1 |
| Ramanuja, S | 1 |
| Kalaria, VG | 1 |
| Hofmann, T | 1 |
| Fangio, P | 1 |
| De Jonghe, B | 1 |
| Lachérade, JC | 1 |
| Terville, JP | 1 |
| Outin, H | 1 |
| Diehm, C | 1 |
| Lawall, H | 1 |
| Huber, R | 1 |
| Ezekowitz, J | 1 |
| McAlister, FA | 1 |
| Humphries, KH | 1 |
| Norris, CM | 1 |
| Tonelli, M | 1 |
| Ghali, WA | 1 |
| Knudtson, ML | 1 |
| Rioufol, G | 1 |
| Finet, G | 1 |
| Ginon, I | 1 |
| André-Fouët, X | 1 |
| Nobles-James, C | 1 |
| James, EA | 1 |
| Sowers, JR | 1 |
| Tran, H | 1 |
| Maree, AO | 1 |
| Fitzgerald, DJ | 1 |
| Kubler, PA | 1 |
| Pillans, PI | 1 |
| Marrinan, MC | 1 |
| Frogley, M | 1 |
| Gollapudi, RR | 2 |
| Teirstein, PS | 2 |
| Simon, RA | 1 |
| Okrainec, K | 1 |
| Platt, R | 1 |
| Pilote, L | 1 |
| Ferrari, E | 1 |
| Benhamou, M | 1 |
| Cerboni, P | 1 |
| Marcel, B | 1 |
| McCabe, CH | 1 |
| Mackman, N | 1 |
| Wong, HC | 1 |
| Antman, EM | 2 |
| Silberman, S | 1 |
| Neukirch-Stoop, C | 1 |
| Bernstein, RA | 1 |
| Albers, GW | 1 |
| Rittersma, SZ | 1 |
| van der Wal, AC | 1 |
| Koch, KT | 1 |
| Henriques, JP | 1 |
| Mulder, KJ | 1 |
| Ploegmakers, JP | 1 |
| Meesterman, M | 1 |
| de Winter, RJ | 1 |
| Gerrah, R | 1 |
| Ehrlich, S | 1 |
| Tshori, S | 1 |
| Sahar, G | 1 |
| Helton, TJ | 1 |
| Savonitto, S | 1 |
| Ambrosini, V | 1 |
| Tolaro, S | 1 |
| Petronio, AS | 1 |
| Bongo, AS | 1 |
| Gaglione, A | 1 |
| Arad, Y | 1 |
| Spadaro, LA | 1 |
| Roth, M | 1 |
| Newstein, D | 1 |
| Guerci, AD | 1 |
| Hobikoglu, GF | 2 |
| Norgaz, T | 2 |
| Aksu, H | 2 |
| Nurkalem, Z | 1 |
| Narin, A | 2 |
| Maulaz, AB | 1 |
| Bezerra, DC | 1 |
| Michel, P | 1 |
| Bogousslavsky, J | 1 |
| Derghazarian, S | 1 |
| Masoudi, FA | 1 |
| Wolfe, P | 1 |
| Havranek, EP | 1 |
| Rathore, SS | 1 |
| Foody, JM | 1 |
| Krumholz, HM | 1 |
| Spencer, FA | 2 |
| Frederick, PD | 1 |
| Goldberg, RJ | 1 |
| Gore, JM | 1 |
| Tiefenbrunn, AJ | 1 |
| Blann, A | 1 |
| Abaci, A | 1 |
| Caliskan, M | 1 |
| Bayram, F | 1 |
| Yilmaz, Y | 1 |
| Cetin, M | 1 |
| Unal, A | 1 |
| Cetin, S | 1 |
| Kulkarni, SP | 1 |
| Lytle, B | 1 |
| Heiss, G | 1 |
| Burgstahler, C | 1 |
| Reimann, A | 1 |
| Beck, T | 1 |
| Kuettner, A | 1 |
| Heuschmid, M | 1 |
| Kopp, AF | 1 |
| Schroeder, S | 1 |
| Robinson, CR | 1 |
| Martin, JL | 1 |
| Canham, RM | 1 |
| Abdullah, SM | 1 |
| Hillis, LD | 1 |
| Keeley, EC | 1 |
| Kher, A | 1 |
| Sotiriou, SN | 1 |
| Orlova, VV | 1 |
| Al-Fakhri, N | 1 |
| Ihanus, E | 1 |
| Economopoulou, M | 1 |
| Isermann, B | 1 |
| Bdeir, K | 1 |
| Nawroth, PP | 1 |
| Preissner, KT | 1 |
| Gahmberg, CG | 1 |
| Koschinsky, ML | 1 |
| Chavakis, T | 1 |
| Musial, J | 2 |
| Jakiela, B | 2 |
| Cooke, GE | 1 |
| Liu-Stratton, Y | 1 |
| Ferketich, AK | 1 |
| Moeschberger, ML | 1 |
| Frid, DJ | 1 |
| Magorien, RD | 1 |
| Binkley, PF | 1 |
| Goldschmidt-Clermont, PJ | 1 |
| Henrikson, CA | 1 |
| Howell, EE | 1 |
| Bush, DE | 2 |
| Chandra-Strobos, N | 1 |
| Vasil'eva, EIu | 1 |
| Kas'ianova, OV | 1 |
| Shpektor, AV | 1 |
| Lepäntalo, A | 1 |
| Mikkelsson, J | 1 |
| Reséndiz, JC | 1 |
| Viiri, L | 1 |
| Backman, JT | 1 |
| Kankuri, E | 1 |
| Karhunen, PJ | 1 |
| Lassila, R | 1 |
| Ramírez, C | 3 |
| Hernández, R | 3 |
| Moreno, R | 4 |
| Bañuelos, C | 4 |
| Costa, MA | 4 |
| Vallurupalli, NG | 1 |
| Goldhaber, SZ | 2 |
| Klutmann, M | 1 |
| Tillmanns, C | 1 |
| Gulba, DC | 1 |
| Viktor, A | 1 |
| Schneider-Schmitt, M | 1 |
| Lüderitz, B | 1 |
| Ujiie, Y | 1 |
| Hirosaka, A | 1 |
| Mitsugi, M | 1 |
| Ohwada, T | 1 |
| Igarashi, M | 1 |
| Kijima, M | 1 |
| Komatsu, N | 1 |
| Hisa, S | 1 |
| Abe, Y | 1 |
| Tsuda, T | 1 |
| Yaoita, H | 1 |
| Maehara, K | 1 |
| Maruyama, Y | 1 |
| Shimamoto, K | 1 |
| Kawana, M | 1 |
| Jernberg, T | 1 |
| Payne, CD | 1 |
| Darstein, C | 1 |
| Naganuma, H | 1 |
| Markuszewski, L | 1 |
| Rysz, J | 1 |
| Spychalska, M | 1 |
| Funabashi, N | 1 |
| Asano, M | 1 |
| Komuro, I | 1 |
| Cavallari, U | 2 |
| Trabetti, E | 2 |
| Pignatti, PF | 2 |
| Nizankowski, R | 1 |
| Heitzer, T | 1 |
| Rudolph, V | 1 |
| Schwedhelm, E | 2 |
| Karstens, M | 1 |
| Sydow, K | 1 |
| Ortak, M | 1 |
| Tschentscher, P | 1 |
| Meinertz, T | 1 |
| Böger, R | 1 |
| Baldus, S | 1 |
| Williams, MS | 1 |
| Ng'alla, LS | 1 |
| Kranzhofer, R | 1 |
| Ruef, J | 1 |
| Wong, WM | 1 |
| Lai, KC | 1 |
| Li, SW | 1 |
| Ng, M | 1 |
| Lam, KF | 1 |
| Cheng, X | 2 |
| Mixon, T | 1 |
| Fitzsimmons, P | 1 |
| Olivier, AC | 1 |
| Hollman, JL | 1 |
| Freedman, JE | 2 |
| Granitskiĭ, NA | 1 |
| Nicholls, SJ | 1 |
| Tuzcu, EM | 1 |
| Sipahi, I | 1 |
| Schoenhagen, P | 1 |
| Késmárky, G | 1 |
| Fehér, G | 1 |
| Koltai, K | 1 |
| Horváth, B | 1 |
| Tóth, K | 1 |
| von Beckerath, O | 1 |
| Segal, JB | 1 |
| Lau, WC | 1 |
| McLaughlin, TJ | 1 |
| Pamukcu, B | 5 |
| Oflaz, H | 5 |
| Oncul, A | 3 |
| Umman, B | 3 |
| Mercanoglu, F | 2 |
| Ozcan, M | 2 |
| Meric, M | 3 |
| Nisanci, Y | 5 |
| Lorusso, R | 1 |
| De Cicco, G | 1 |
| Beghi, C | 1 |
| Gherli, T | 1 |
| Poli, E | 1 |
| Corradi, D | 1 |
| Maestri, R | 1 |
| Bonadonna, S | 1 |
| Mancini, T | 1 |
| Giustina, A | 1 |
| Descarries, LM | 1 |
| Leduc, L | 1 |
| Khairy, P | 1 |
| Mercier, LA | 1 |
| Agostoni, P | 1 |
| Abbate, A | 1 |
| Fusaro, M | 1 |
| Burzotta, F | 1 |
| Sheiban, I | 1 |
| Sangiorgi, G | 1 |
| Rembold, CM | 1 |
| Vamvakou, G | 1 |
| Loizou, S | 1 |
| Revela, I | 1 |
| Kremastinos, DT | 1 |
| Ioannidis, TI | 1 |
| Mazarakis, A | 1 |
| Notaras, SP | 1 |
| Karpeta, MZ | 1 |
| Tsintoni, AC | 1 |
| Kounis, GN | 1 |
| Rallis, DG | 1 |
| Onur, I | 4 |
| Newburger, JW | 1 |
| Sleeper, LA | 1 |
| McCrindle, BW | 1 |
| Minich, LL | 1 |
| Gersony, W | 1 |
| Vetter, VL | 1 |
| Atz, AM | 1 |
| Li, JS | 1 |
| Takahashi, M | 1 |
| Baker, AL | 1 |
| Colan, SD | 1 |
| Mitchell, PD | 1 |
| Klein, GL | 1 |
| Sundel, RP | 1 |
| Narvaez, I | 1 |
| Sagastagoitia, JD | 1 |
| Vacas, M | 1 |
| Saez, Y | 1 |
| Lafita, M | 1 |
| Monica, S | 1 |
| de Lafuente, JP | 1 |
| Molinero, E | 1 |
| Iriarte, JA | 1 |
| Schlick, P | 1 |
| Buchanan, MR | 1 |
| Destegul, E | 1 |
| Akyuz, U | 1 |
| Unal Dai, S | 1 |
| Nidorf, M | 1 |
| Przyklenk, K | 1 |
| Eshaghian, S | 1 |
| Kaul, S | 1 |
| Amin, S | 1 |
| Shah, PK | 1 |
| Diamond, GA | 1 |
| Decker, C | 1 |
| Huddleston, J | 1 |
| Buchanan, DM | 1 |
| Stoner, C | 1 |
| Jones, A | 1 |
| Dorsch, MP | 1 |
| Lynch, DR | 1 |
| Dunn, SP | 1 |
| Rodgers, JE | 1 |
| Schwartz, T | 1 |
| Colby, E | 1 |
| Montague, D | 1 |
| Smyth, SS | 1 |
| Karlsson, G | 1 |
| Rehman, J | 1 |
| Kalaria, V | 1 |
| Zhang, RG | 1 |
| Zhang, JP | 1 |
| Chen, CC | 1 |
| Chong, CF | 1 |
| Kuo, CD | 1 |
| Wang, TL | 1 |
| Tickoo, S | 1 |
| Roe, MT | 1 |
| Milford-Beland, S | 1 |
| Pollack, CV | 1 |
| Buch, AN | 1 |
| Singh, S | 2 |
| Roy, P | 1 |
| Javaid, A | 1 |
| Smith, KA | 1 |
| George, CE | 1 |
| Ben-Hamda, K | 1 |
| Kapp, M | 1 |
| Göhring-Frischholz, K | 1 |
| Daub, K | 1 |
| Dösch, C | 1 |
| Langer, H | 1 |
| Gulmez, O | 2 |
| Yildirir, A | 2 |
| Kaynar, G | 1 |
| Konas, D | 2 |
| Aydinalp, A | 2 |
| Ertan, C | 2 |
| Ozin, B | 2 |
| Muderrisoglu, H | 2 |
| Yong, TY | 1 |
| Phillipov, G | 1 |
| Phillips, PJ | 1 |
| Koylan, N | 1 |
| Bugra, Z | 2 |
| Thatipelli, MR | 1 |
| McBane, RD | 1 |
| Rooke, TW | 1 |
| Rosales, GA | 1 |
| Hodge, D | 1 |
| Herges, RM | 1 |
| Wysokinski, WE | 1 |
| Biernat, M | 1 |
| Dziedzina, S | 1 |
| Plutecka, H | 1 |
| Kwok, JY | 1 |
| Granmyr, J | 1 |
| Ball, P | 1 |
| Curran, S | 1 |
| Bal, U | 1 |
| Demir, O | 1 |
| Blum, A | 1 |
| Hijazi, I | 1 |
| Eizenberg, MM | 1 |
| Blum, N | 1 |
| Chaganti, SK | 1 |
| Gesheff, TB | 1 |
| Kreutz, Y | 1 |
| Wenger, NK | 1 |
| Elikowski, W | 1 |
| Hanszke, E | 1 |
| Biczysko, W | 1 |
| Rzeźniczak, J | 1 |
| Kruk-Zagajewska, A | 1 |
| Zawilska, K | 1 |
| Valencia, R | 1 |
| Sawhney, N | 1 |
| Lee, SS | 1 |
| Wong, GB | 1 |
| Banares, M | 1 |
| Schatz, RA | 1 |
| Ko, JK | 2 |
| Kim, JH | 3 |
| Hernández-Antolin, R | 1 |
| Schmaier, AH | 1 |
| Grube, E | 1 |
| Dawkins, KD | 2 |
| Banning, AP | 1 |
| Hauptman, K | 1 |
| Marco, J | 1 |
| Popma, JJ | 1 |
| Buellesfeld, L | 1 |
| Koglin, J | 1 |
| Russell, ME | 1 |
| Gebel, JM | 1 |
| Mann, KG | 1 |
| Bierend, A | 1 |
| Rau, T | 1 |
| Maas, R | 1 |
| Böger, RH | 1 |
| Jindeel, A | 1 |
| Censarek, P | 1 |
| Steger, G | 1 |
| Paolini, C | 1 |
| Grosser, T | 1 |
| Zimmermann, N | 1 |
| Fleckenstein, D | 1 |
| Weber, AA | 1 |
| Perneby, C | 1 |
| Wallén, NH | 1 |
| Hofman-Bang, C | 1 |
| Tornvall, P | 1 |
| Ivert, T | 1 |
| Li, N | 1 |
| Hjemdahl, P | 1 |
| Lu, YL | 1 |
| Chen, YD | 1 |
| Lü, SZ | 2 |
| Walker, CW | 1 |
| Dawley, CA | 1 |
| Fletcher, SF | 1 |
| Ahn, Y | 1 |
| Jeong, JW | 1 |
| Kim, KH | 2 |
| Ahn, TH | 1 |
| Park, CG | 1 |
| Kim, KY | 1 |
| Midilli, K | 1 |
| Yilmaz, G | 1 |
| Yilmaz, E | 1 |
| Arora, R | 1 |
| Khraisat, A | 1 |
| Handa, K | 1 |
| Bahekar, A | 1 |
| Trivedi, A | 1 |
| Rott, D | 1 |
| Leibowitz, D | 1 |
| Amit, G | 1 |
| Zahger, D | 1 |
| Weiss, AT | 1 |
| Johnson, SG | 1 |
| Rogers, K | 1 |
| Delate, T | 1 |
| Witt, DM | 1 |
| Gengo, FM | 1 |
| Rainka, M | 1 |
| Robson, M | 1 |
| Gengo, MF | 1 |
| Forrest, A | 1 |
| Hourihane, M | 1 |
| Bates, V | 1 |
| Turley, AJ | 1 |
| Roberts, AP | 1 |
| Morley, R | 1 |
| Thornley, AR | 1 |
| Owens, WA | 1 |
| de Belder, MA | 1 |
| Podolecka, E | 1 |
| Ciszewski, A | 1 |
| Kepka, C | 1 |
| Mazurkiewicz, Ł | 1 |
| Hobbs, L | 1 |
| Lyle, B | 1 |
| van Werkum, JW | 1 |
| Topcu, Y | 1 |
| Postma, S | 1 |
| Kelder, JC | 2 |
| Hackeng, CM | 1 |
| Mitsutake, R | 1 |
| Shirai, K | 1 |
| Saito, N | 1 |
| Miura, S | 1 |
| Saku, K | 1 |
| Liu, XH | 1 |
| DU, X | 1 |
| Kang, JP | 1 |
| Lü, Q | 1 |
| Ma, CS | 1 |
| Ragot, S | 1 |
| Mergy, J | 1 |
| Vincent, C | 1 |
| Brewster, JB | 1 |
| Kedar, V | 1 |
| Sundaram, CP | 1 |
| Andrade, J | 1 |
| Al Ali, A | 1 |
| Skliut, M | 1 |
| Jamieson, DG | 1 |
| Blair, P | 1 |
| Enriquez, JR | 1 |
| Pratap, P | 1 |
| Zbilut, JP | 1 |
| Calvin, JE | 1 |
| Volgman, AS | 1 |
| Pinkau, T | 1 |
| Mann, JF | 1 |
| Badimon, L | 1 |
| Vilahur, G | 1 |
| Ghosh, K | 1 |
| Shetty, S | 1 |
| Mota, L | 1 |
| Elitok, A | 1 |
| Chan, MY | 1 |
| Cohen, MG | 1 |
| Dyke, CK | 1 |
| Myles, SK | 1 |
| Aberle, LG | 1 |
| Lin, M | 1 |
| Walder, J | 1 |
| Chronos, N | 1 |
| Melloni, C | 1 |
| Tonkens, RM | 1 |
| Rusconi, CP | 1 |
| Grainger, DJ | 1 |
| Kemp, PR | 1 |
| Metcalfe, JC | 1 |
| Liu, AC | 1 |
| Lawn, RM | 1 |
| Williams, NR | 1 |
| Grace, AA | 1 |
| Schofield, PM | 1 |
| Chauhan, A | 1 |
| Takatsu, F | 1 |
| Nishiyama, A | 1 |
| Shiga, Y | 1 |
| Watarai, M | 1 |
| Shimizu, S | 1 |
| Fitch, LL | 1 |
| Buchwald, H | 1 |
| Matts, JP | 1 |
| Campos, CT | 1 |
| Long, JM | 1 |
| Rabbani, LE | 1 |
| Loscalzo, J | 1 |
| Rissel, U | 1 |
| Müller, T | 1 |
| Schulze-Waltrup, N | 1 |
| Krakau, I | 1 |
| Arens, R | 1 |
| Willgeroth, W | 1 |
| Heuer, H | 1 |
| Barrabés, JA | 1 |
| Oliveras, J | 1 |
| Ruiz-Meana, M | 1 |
| Solares, J | 1 |
| Burillo, AG | 1 |
| Lidón, RM | 1 |
| Antolín, M | 1 |
| Castell, J | 1 |
| Soler-Soler, J | 1 |
| Grollier, G | 1 |
| Danchin, N | 1 |
| Bedossa, M | 1 |
| Leclercq, C | 1 |
| Vahanian, A | 1 |
| Bertrand, ME | 1 |
| Gurfinkel, E | 1 |
| Lee, JR | 1 |
| Kim, EK | 1 |
| Seo, JW | 1 |
| Chesebro, JH | 2 |
| Calver, AL | 1 |
| Blows, LJ | 1 |
| Harmer, S | 1 |
| Gray, HH | 1 |
| Morgan, JH | 1 |
| Simpson, IA | 1 |
| Helft, G | 1 |
| Osende, JI | 1 |
| Rodriguez, OJ | 1 |
| Muhlestin, JB | 1 |
| Chazov, EI | 1 |
| Park, JC | 2 |
| Kang, KT | 1 |
| Kim, NH | 1 |
| Bae, Y | 1 |
| Cho, JG | 1 |
| Kang, JC | 1 |
| Tiffany, BR | 1 |
| Barrali, R | 1 |
| Yu, H | 1 |
| Rifai, N | 1 |
| Voisard, R | 1 |
| Fischer, R | 1 |
| Osswald, M | 1 |
| Voglic, S | 1 |
| Baur, R | 1 |
| Susa, M | 1 |
| Hombach, V | 1 |
| Gawlinski, A | 1 |
| Moughrabi, S | 1 |
| Tillisch, JH | 1 |
| Hutten, BA | 1 |
| Plokker, HW | 1 |
| Lanza, F | 1 |
| Galajda, P | 1 |
| Gurney, D | 1 |
| Moog, S | 1 |
| Robinson, N | 1 |
| Golledge, P | 1 |
| Timmis, A | 1 |
| Anderson, HV | 1 |
| McNatt, J | 1 |
| Clubb, FJ | 1 |
| Herman, M | 1 |
| Maffrand, JP | 1 |
| DeClerck, F | 1 |
| Ahn, C | 1 |
| Buja, LM | 1 |
| Willerson, JT | 1 |
| Brown, JB | 1 |
| Delea, TE | 1 |
| Nichols, GA | 1 |
| Edelsberg, J | 1 |
| Elmer, PJ | 1 |
| Oster, G | 1 |
| Spieker, LE | 1 |
| Noll, G | 1 |
| Lettino, M | 1 |
| Cantù, F | 1 |
| Mariani, M | 1 |
| Moons, AH | 1 |
| Levi, M | 1 |
| Peters, RJ | 1 |
| Syvänne, M | 1 |
| Ostbye, T | 2 |
| Muhlbaier, LH | 2 |
| Chen, A | 2 |
| LaPointe, NA | 1 |
| Hammill, BG | 2 |
| McCants, CB | 2 |
| Taubes, G | 1 |
| Rupprecht, HJ | 1 |
| Espinola-Klein, C | 1 |
| Meyer, J | 1 |
| Nickolaus, MJ | 1 |
| Momplaisir, T | 1 |
| Miller, L | 1 |
| Bertolet, BD | 1 |
| Pang, Y | 1 |
| Liang, H | 1 |
| Yu, S | 1 |
| Liu, X | 1 |
| Takkouche, B | 1 |
| Etminan, M | 1 |
| Caamaño, F | 1 |
| Rochon, PA | 1 |
| Ghosh, S | 1 |
| Ziesmer, V | 1 |
| Massel, D | 1 |
| Cruickshank, MK | 1 |
| Rush, JE | 1 |
| Sanderink, G | 1 |
| Ball, SP | 1 |
| Juliard, JM | 1 |
| Himbert, D | 1 |
| Verstraete, M | 1 |
| Manson, JE | 1 |
| Hennekens, CH | 1 |
| Malaia, LT | 1 |
| Ladnyĭ, AI | 1 |
| Aoyama, T | 1 |
| Yui, Y | 1 |
| Hattori, R | 1 |
| Kawai, C | 1 |
| Nye, ER | 1 |
| Ablett, MB | 1 |
| Robertson, MC | 1 |
| Ilsley, CD | 1 |
| Sutherland, WH | 1 |
| Berge, PG | 1 |
| Höpp, HW | 1 |
| Maseri, A | 1 |
| Xu, YS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation[NCT01813435] | Phase 3 | 15,991 participants (Actual) | Interventional | 2013-07-01 | Completed | ||
| [NCT02513810] | 3,020 participants (Anticipated) | Interventional | 2015-12-02 | Active, not recruiting | |||
| A head-to Head Comparison of the Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease[NCT01852175] | 110 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| The Effect of Cocoa on Platelet Function Profiles in Patients With Stable Coronary Artery Disease in Trinidad and Tobago: The ECLAIR Study[NCT04554901] | 25 participants (Actual) | Interventional | 2020-09-01 | Completed | |||
| A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ti[NCT01991795] | Phase 3 | 19,271 participants (Actual) | Interventional | 2014-02-10 | Completed | ||
| A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424] | Phase 3 | 27,395 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| HELicobacter Pylori Screening to Prevent Gastrointestinal Bleeding in Patients With Acute Myocardial Infarction Trial Based on the SWEDEHEART Registry (HELP-SWEDEHEART)[NCT05024864] | 22,000 participants (Anticipated) | Interventional | 2021-11-17 | Recruiting | |||
| A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938] | Phase 4 | 25,682 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Int[NCT02415400] | Phase 4 | 4,614 participants (Actual) | Interventional | 2015-06-04 | Completed | ||
| A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared With Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation TiCAB- Ticagrelor in CABG[NCT01755520] | Phase 3 | 1,893 participants (Actual) | Interventional | 2013-04-24 | Terminated (stopped due to DSMB Interim Analyses) | ||
| Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy[NCT04059679] | Phase 4 | 30 participants (Anticipated) | Interventional | 2020-01-30 | Recruiting | ||
| A Prospective Randomised, Open Label, Blinded Endpoint (PROBE) Study to Evaluate DUAL Antithrombotic Therapy With Dabigatran Etexilate (110mg and 150mg b.i.d.) Plus Clopidogrel or Ticagrelor vs. Triple Therapy Strategy With Warfarin (INR 2.0 - 3.0) Plus C[NCT02164864] | Phase 3 | 2,725 participants (Actual) | Interventional | 2014-07-22 | Completed | ||
| STable Coronary Artery Diseases RegisTry[NCT03796741] | 5,070 participants (Actual) | Observational | 2016-03-17 | Completed | |||
| COmparison of Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation for Prevention of Gastrointestinal Injury Evaluated by Ankon Magnetically Controlled Capsule Endoscopy[NCT03198741] | Phase 4 | 783 participants (Actual) | Interventional | 2017-07-13 | Completed | ||
| A Randomized Phase 1 Dose-Escalation Study in Healthy Volunteers and Subjects on Aspirin With Stable Coronary Artery Disease to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RUC-4[NCT03844191] | Phase 1 | 44 participants (Actual) | Interventional | 2019-02-18 | Completed | ||
| Intensified Antiplatelet Therapy in Post-PCI Patients With High On-treatment Platelet Reactivity: the OPTIMA-2 Trial[NCT01955200] | Phase 4 | 1,724 participants (Actual) | Interventional | 2013-10-05 | Completed | ||
| Uninterrupted Direct-acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures[NCT05292846] | Phase 4 | 200 participants (Anticipated) | Interventional | 2022-01-20 | Recruiting | ||
| ASET Clinical Investigational Plan Acetyl Salicylic Elimination Trial: The ASET Pilot Study[NCT03469856] | 200 participants (Anticipated) | Interventional | 2018-02-22 | Recruiting | |||
| Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG[NCT04045665] | Phase 3 | 3,200 participants (Anticipated) | Interventional | 2019-12-13 | Recruiting | ||
| Comparison Between P2Y12 Antagonist MonotHerapy and Dual Antiplatelet Therapy in Patients UndergOing Implantation of Coronary Drug-Eluting Stents[NCT02079194] | 3,000 participants (Actual) | Interventional | 2014-03-18 | Active, not recruiting | |||
| Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study)[NCT02642419] | Phase 4 | 2,200 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242] | Phase 4 | 9,006 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Efficacy and Safety of Clopidogrel for Primary Prevention in Patients With Subclinical Coronary Atherosclerosis Identified on Imaging[NCT05845489] | Phase 4 | 9,930 participants (Anticipated) | Interventional | 2023-03-09 | Recruiting | ||
| Comparison of Clopidogrel vs. Aspirin Monotherapy Beyond Two Year After Drug-eluting Stent Implantation[NCT02044250] | Phase 4 | 5,530 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| HOST-EXAM-Ex : Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - EXtended Antiplatelet Monotherapy - EXtended Follow up[NCT05567536] | 5,530 participants (Actual) | Observational | 2014-03-01 | Active, not recruiting | |||
| PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286] | Phase 4 | 1,700 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| Randomized 2x2 Factorial Trial Comparing the Cre8 Amphilimus-sirolimus Eluting Stent vs. the Synergy Everolimus-eluting Stent and a Personalized vs. Standard Duration of Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary Int[NCT04135989] | Phase 4 | 2,106 participants (Anticipated) | Interventional | 2020-01-01 | Active, not recruiting | ||
| Nobori Dual Antiplatelet Therapy as Appropriate Duration.[NCT01514227] | Phase 4 | 3,773 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Effects of High-dose Statin Treatments on Patients With Aspirin Mono Antiplatelet Therapy 12-months After Drug-eluting Stents Implantation: a Randomized Controlled Study[NCT01557075] | Phase 4 | 2,000 participants (Anticipated) | Interventional | 2010-07-31 | Recruiting | ||
| Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423] | Phase 2 | 113 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| OCT Evaluation of Early Vascular Repair in Patients With Non ST Elevation Acute Coronary Syndrome (NSTE-ACS)[NCT04375319] | 60 participants (Anticipated) | Interventional | 2019-10-28 | Recruiting | |||
| Influence of Rivaroxaban 2.5 mg Two Times a Day for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic Peripheral Arterial Disease (PAD) - a Randomised Controlled Trial[NCT04305028] | 100 participants (Anticipated) | Observational | 2021-03-10 | Not yet recruiting | |||
| Effects of Edoxaban on Platelet Aggregation in Patients With Stable Coronary Artery Disease[NCT05122455] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | ||
| Clopidogrel or Ticagrelor in Acute Coronary Syndrome Patients Treated With Newer-Generation Drug-Eluting Stents: CHANGE DAPT[NCT03197298] | 2,062 participants (Actual) | Observational [Patient Registry] | 2012-12-21 | Completed | |||
| Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Chronic Coronary Syndromes[NCT04347200] | 2,000 participants (Anticipated) | Observational [Patient Registry] | 2015-01-15 | Recruiting | |||
| Plaque Erosion: A New in Vivo Diagnosis and Paradigm Shift in the Treatment of Patients With Acute Coronary Syndrome[NCT02041650] | Phase 4 | 250 participants (Anticipated) | Interventional | 2014-08-31 | Completed | ||
| A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation[NCT00412984] | Phase 3 | 20,976 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis (TARGET Trial): Does Ticagrelor Improve Graft Patency After Coronary Bypass?[NCT02053909] | Phase 4 | 250 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen[NCT00346216] | Phase 4 | 24,081 participants (Actual) | Interventional | 2006-10-04 | Completed | ||
| Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events[NCT02616497] | Phase 4 | 1,220 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794] | 8,575 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268] | Phase 4 | 72 participants (Actual) | Interventional | 2019-04-24 | Completed | ||
| PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET Trial A Drug Reduction Study for Patients With Acute Coronary Syndrome in the Unified Health System[NCT04360720] | Phase 3 | 3,400 participants (Anticipated) | Interventional | 2020-10-15 | Recruiting | ||
| Efficacy and Safety of Sequential Monotherapy of Ticagrelor and Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention With Acute Coronary Syndrome[NCT04937699] | Phase 4 | 2,690 participants (Anticipated) | Interventional | 2023-03-28 | Recruiting | ||
| A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum C[NCT02605447] | Phase 4 | 2,009 participants (Actual) | Interventional | 2016-02-16 | Completed | ||
| PROspective Multicenter Imaging Study for Evaluation of Chest Pain - The PROMISE Trial[NCT01174550] | 10,003 participants (Actual) | Interventional | 2010-07-31 | Completed | |||
| [NCT02101437] | 175 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
| A Randomized, Double-Blind, Placebo-Controlled Trial Investigating The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery (The POPular CABG Study)[NCT02352402] | Phase 3 | 487 participants (Anticipated) | Interventional | 2015-03-31 | Active, not recruiting | ||
| Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial[NCT04696120] | Phase 2 | 200 participants (Anticipated) | Interventional | 2021-03-02 | Not yet recruiting | ||
| A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban With Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Diseas[NCT01877915] | Phase 3 | 5,081 participants (Actual) | Interventional | 2013-09-10 | Completed | ||
| Associations of the Pharmacogenetic and Pharmacokinetic Factors With Clopidogrel Low Response and Clinical Outcome in Patients With Coronary Stent Implantation: a Registration Study[NCT01968499] | 1,805 participants (Actual) | Observational [Patient Registry] | 2011-03-31 | Completed | |||
| Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting[NCT04694248] | 172 participants (Anticipated) | Interventional | 2021-11-03 | Recruiting | |||
| The Effect of Training Given to Coronary Artery Patients on Disease Management[NCT04556006] | 58 participants (Actual) | Interventional | 2019-03-01 | Completed | |||
| The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Aspirin-treated Subjects With Stable Coronary Artery Disease[NCT01260584] | Phase 4 | 110 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet [NCT01267734] | Phase 4 | 3,750 participants (Anticipated) | Interventional | 2010-06-30 | Recruiting | ||
| Optimal Duration of Clopidogrel Therapy After Drug-Eluting Stent Implantation to Reduce Late Coronary Arterial Thrombotic Events[NCT01186146] | Phase 4 | 5,000 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor Zotarolimus - Eluting Stent in the Real World Clinical Practice - Optimize Trial[NCT01113372] | Phase 4 | 3,119 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture[NCT02475187] | 33 participants (Anticipated) | Observational | 2015-09-30 | Terminated | |||
| Relationship Between Level of Glycosylated Hemoglobin and Platelet Function in Patients Undergoing Coronary Artery Bypass Grafting[NCT02711124] | 130 participants (Anticipated) | Observational [Patient Registry] | 2014-02-28 | Recruiting | |||
| A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure[NCT03088072] | Phase 4 | 75 participants (Anticipated) | Interventional | 2017-03-23 | Recruiting | ||
| Intracoronary Stenting and Antithrombotic Regimen: Testing of a Six-week Versus a Six-month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-eluting Stenting[NCT00776633] | Phase 4 | 614 participants (Actual) | Interventional | 2008-09-30 | Active, not recruiting | ||
| Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting[NCT01159639] | Phase 4 | 200 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Multi-Analyte, Genetic, and Thrombogenic Markers of Atherosclerosis (The MAGMA STUDY)[NCT01276678] | 1,300 participants (Anticipated) | Observational | 2010-06-30 | Recruiting | |||
| A Randomised, Double-Blind, Parallel Group, Asian, Multicenter Study, to Assess Pharmacokinetic and Pharmacodynamic Profile of 2 Doses of Ticagrelor on Top of Low Dose Acetyl Salicylic Acid (ASA) Therapy on Platelet Aggregation in Japanese and Asian Patie[NCT01118325] | Phase 2 | 146 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and a Interruption Versus Continuation of Double Antiplatelet Therapy, One Year After Stenting[NCT00827411] | Phase 4 | 2,500 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Impact of Preoperative FFR on Arterial Bypass Graft Functionality: Towards a New CABG Paradigm[NCT02527044] | 120 participants (Anticipated) | Interventional | 2015-11-30 | Active, not recruiting | |||
| Is a Reduced Biochemical Response to Aspirin Associated With Increased Cardiovascular Morbidity and Mortality in High Risk Patients With Coronary Artery Disease?[NCT01383304] | 906 participants (Actual) | Observational | 2007-11-30 | Active, not recruiting | |||
| Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry[NCT01515345] | Phase 3 | 1,008 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Evaluation of Late Clinical Events After Drug-eluting Versus Bare-metal Stents in Patients at Risk: BAsel Stent Kosten Effektivitäts Trial - PROspective Validation Examination Part II (BASKET-PROVE II)[NCT01166685] | Phase 4 | 2,291 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| Is There A LIfe for DES After Discontinuation of Clopidogrel:The ITALIC PLUS Trial[NCT01476020] | 1,240 participants (Anticipated) | Observational | 2011-11-30 | Not yet recruiting | |||
| COronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter Registry[NCT01443637] | 34,000 participants (Actual) | Observational | 2003-06-30 | Completed | |||
| Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study[NCT01385319] | Phase 3 | 1,606 participants (Actual) | Interventional | 2011-06-30 | Active, not recruiting | ||
| Impact of Hybrid Coronary Revascularization on Antiplatelet Effect of Aspirin and Clopidogrel[NCT02293928] | 40 participants (Actual) | Observational | 2010-10-31 | Completed | |||
| Effects of Selective and Nonselective Beta-blockade on Platelet Aggregation in Patients With Acute Coronary Syndrome[NCT02809820] | Phase 4 | 100 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention[NCT02334254] | Phase 4 | 420 participants (Anticipated) | Interventional | 2013-08-31 | Recruiting | ||
| Endothelial Function Guided Therapy in Patients With Non-obstructive Coronary Artery Disease (EndoFIND Study)[NCT04013204] | 1,000 participants (Anticipated) | Interventional | 2019-08-15 | Recruiting | |||
| A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease[NCT01523392] | Phase 4 | 50 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery (CABG)[NCT01373411] | Phase 4 | 70 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes - the TC4 Comparative Effectiveness Study[NCT04057300] | Phase 4 | 1,038 participants (Actual) | Interventional | 2018-10-01 | Completed | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562] | Phase 3 | 21,379 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery[NCT04951128] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-08-01 | Not yet recruiting | ||
| Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial[NCT03364491] | Phase 3 | 11,000 participants (Actual) | Interventional | 2018-03-15 | Completed | ||
| Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma. A Double-blind, Placebo-controlled, Multicentre, Randomized Controlled Clinical Trial[NCT03582293] | Phase 3 | 140 participants (Anticipated) | Interventional | 2018-06-19 | Recruiting | ||
| DEPOSITION: Pilot Study Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery[NCT03376061] | Phase 4 | 97 participants (Actual) | Interventional | 2017-12-21 | Completed | ||
| Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery (DEPOSITION) Study[NCT03954314] | Phase 3 | 3,242 participants (Actual) | Interventional | 2019-09-17 | Terminated (stopped due to Upon the Data Safety Monitoring Board review of the interim analysis (75% of participants have finished their follow-up) on November 17, 2023, they made a recommendation to stop recruitment into the trial.) | ||
| Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Percutaneous Coronary Intervention: The PL-PLATELET Randomized Trial[NCT03078465] | Phase 3 | 0 participants (Actual) | Interventional | 2017-06-20 | Withdrawn (stopped due to Competitive studies were conducted at the same time, and enrollment was suspended.) | ||
| Aspirin DesensitizAtion in PatienTs With Coronary artEry Disease: Results of a Multi Center Registry: the ADAPTED Registry[NCT02848339] | 330 participants (Actual) | Observational [Patient Registry] | 2010-05-31 | Completed | |||
| Non-steroidal Anti-inflammatory Drugs Impair the Platelet Inhibiting Effect of Acetylsalicylic Acid in Coronary Artery Disease Patients[NCT01402804] | 85 participants (Actual) | Observational | 2011-07-31 | Completed | |||
| TIGRIS: Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable Coronary Artery dISease in Post Myocardial Infarction Patients[NCT01866904] | 9,284 participants (Actual) | Observational | 2013-06-19 | Terminated (stopped due to Study was terminated in order to secure the data quality of the study in terms of follow-up rates and data completeness.) | |||
| "Prospective Registry of Patients Over 75 Years Old Treated With Xience Sierra Stents. Sierra 75 Study"[NCT03567733] | 1,000 participants (Actual) | Observational [Patient Registry] | 2018-06-18 | Completed | |||
| Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction Treated With Percutaneous Coronary Intervention - The Dan-DAPT Trial[NCT05262803] | Phase 4 | 2,808 participants (Anticipated) | Interventional | 2022-06-17 | Recruiting | ||
| The Predictive Value of PRECISE DAPT Score in Patients With ST Segment Elevation Myocardial Infarction (STEMI) After Primary Percutaneous Coronary Intervention (PPCI)[NCT04549766] | 150 participants (Anticipated) | Observational | 2020-09-30 | Not yet recruiting | |||
| Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733] | Phase 4 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Optimization of Antiplatelet Therapy With Clopidogrel on the Basis of the Extent of Platelet Inhibition in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy Undergoing PCI With Stent Implantation[NCT00774475] | Phase 3 | 442 participants (Anticipated) | Interventional | 2008-11-30 | Not yet recruiting | ||
| EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia[NCT01515241] | Phase 2 | 10 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome[NCT01201837] | Phase 2 | 507 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)[NCT01412034] | Phase 2 | 23 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| PPD Trial Pilot Study: Plavix, Prasugrel and Drug Eluting Stents[NCT01103843] | 1,000 participants (Anticipated) | Interventional | 2010-04-30 | Recruiting | |||
| Assessment of Platelet-dependent Thrombosis in Patients With Acute Coronary Syndromes Using an ex Vivo Arterial Injury Model[NCT00728286] | 90 participants (Actual) | Observational | 2008-10-31 | Completed | |||
| Assessment of Platelet-dependent Thrombosis by an ex Vivo Arterial Injury Model: a Placebo Controlled Trial of Clopidogrel as Antiplatelet Therapy in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease[NCT00728156] | Phase 4 | 90 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Clopidogrel and Proton Pump Inhibitors: A Propensity Score Adjusted Cohort Study to Examine a Possible Interaction: A CALIBER Study[NCT01231867] | 24,471 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| [NCT01032668] | Phase 3 | 192 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention[NCT00111566] | Phase 4 | 624 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent[NCT00331578] | Phase 4 | 2,077 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel[NCT00398463] | Phase 4 | 263 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Randomized, Multicenter, Double-Blind, Study to Evaluate the Efficacy of Tirofiban HCl Versus Placebo in the Setting of Standard Therapies Among Subjects Undergoing Percutaneous Coronary Intervention[NCT01245725] | Phase 3 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to Study was not initiated, change in clinical development) | |||
| Customized Choice of P2Y12 Oral Receptor Blocker Based on Phenotype Assessment Via Point of Care Testing[NCT01477775] | Phase 4 | 4,000 participants (Anticipated) | Interventional | 2012-01-31 | Recruiting | ||
| What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing[NCT00769938] | Phase 4 | 573 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Pharmacodynamic Effect of Loading And Maintenance Doses Of Clopidogrel Versus Half Doses of Ticagrelor In Healthy Subjects[NCT02086903] | Phase 3 | 12 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| A Multi-centre Randomised, Double-blind, Double-dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects of Ticagrelor Compared With Clopidogrel and Placebo With Aspirin as Background Therapy in Patients With Stable Coronary Artery Disea[NCT00528411] | Phase 2 | 123 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Efficacy of Intracoronary Infusion of Different Medicine With Targeted Perfusion Catheter on Myocardial Perfusion in Patients With STEMI Undergoing Primary PCI:an Open,Prospective,Randomized,Multicenter Trial.[NCT03252665] | Phase 4 | 600 participants (Anticipated) | Interventional | 2017-09-01 | Not yet recruiting | ||
| Comparison of Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI Undergoing PPCI Evaluated by SPECT[NCT02233790] | Phase 4 | 600 participants (Anticipated) | Interventional | 2014-12-31 | Not yet recruiting | ||
| Cangrelor vs. Ticagrelor for Early Platelet Inhibition in ST-elevation Myocardial Infarction[NCT03182855] | Phase 4 | 80 participants (Anticipated) | Interventional | 2018-09-01 | Not yet recruiting | ||
| Prospective Observational Clinical Study：The Impact of Early rhBNP on Myocardial Remodeling and Reperfusion in Patients With ST-segment Elevation Myocardial Infarction After Percutaneous Coronary Intervention[NCT04033861] | Phase 4 | 352 participants (Anticipated) | Interventional | 2019-06-19 | Recruiting | ||
| An Open-label Study Evaluating the Acute Efficacy of Treatment With Ticagrelor Versus Clopidogrel on Myocardial Tissue-level Perfusion Assessed by TMPFC and MRI in Patients With High-risk NSTE-ACS Undergoing Early PCI（EARLY-MYO II）[NCT02201667] | Phase 4 | 444 participants (Anticipated) | Interventional | 2014-08-31 | Not yet recruiting | ||
| Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor[NCT03039205] | Phase 2 | 90 participants (Actual) | Interventional | 2017-11-07 | Completed | ||
| Comparison of Antiplatelet Therapy With Clopidogrel and Ticagrelor in Patients After Cardiac Arrest Treated With Therapeutic Hypothermia[NCT02224274] | Phase 4 | 57 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| "Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing One-stop Hybrid Coronary Revascularization"[NCT02513004] | Phase 4 | 60 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| Ticagrelor vs. Tirofiban, Comparison of Anti-platelet Effects in Patients With Non-ST Elevation Acute Coronary Syndrome(TE-CLOT Trial : Ticagrelor's Effect for CLOT Prevention) ; A Single Center, Open-label Randomized Controlled Study[NCT01660373] | Phase 3 | 100 participants (Anticipated) | Interventional | 2012-08-31 | Recruiting | ||
| Intracoronary Infusion of Alprostadil and Nitroglycerin With Targeted Perfusion Microcatheter in STEMI Patients With Coronary Slow Flow Phenomenon[NCT03296670] | Phase 4 | 57 participants (Actual) | Interventional | 2015-08-01 | Completed | ||
| Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)[NCT02428374] | Phase 4 | 300 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| Perioperative Blood Pressure and In-hospital Morbidity After Coronary Artery Bypass Surgery[NCT05192005] | 1,220 participants (Anticipated) | Observational | 2023-04-15 | Not yet recruiting | |||
| Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II[NCT05702463] | Phase 1 | 30 participants (Anticipated) | Interventional | 2023-06-13 | Recruiting | ||
| Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes: APPEASED Study Phase 1[NCT05105919] | Early Phase 1 | 50 participants (Anticipated) | Interventional | 2021-08-26 | Recruiting | ||
| Platelet Reactivity in Patients With Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared to a High-maintenance Dose of Clopidogrel[NCT01328470] | Phase 4 | 85 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Stent-Assisted Coiling Followed by Ticagrelor Monotherapy Instead of Dual Antiplatelet Therapy in Endovascular Treatment of Unruptured Intracranial Aneurysm (SAC-TIDE) ---a Pilot Study[NCT06015477] | 180 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | |||
| Effect of Fluvastatin on Top of Clopidogrel and Aspirin in Patients After DES Implantation on Platelet Aggregation[NCT00465322] | 100 participants | Observational | Completed | ||||
| A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease[NCT00557921] | Phase 3 | 5,000 participants (Anticipated) | Interventional | 2007-12-31 | Terminated (stopped due to Terminated by Sponsor) | ||
| The Efficacy and Safety of Proton Pump Inhibitor ( in Patients With Moderate Bleeding Risk and Coronary Artery Disease Undergoing Percutaneous Coronary: A Randomised, Open ,Compared With Control[NCT05820048] | Phase 4 | 300 participants (Anticipated) | Interventional | 2023-05-01 | Not yet recruiting | ||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| [NCT00776477] | Phase 3 | 300 participants (Anticipated) | Interventional | 2007-12-31 | Recruiting | ||
| A Randomised, Double-Blind, Outpatient, Crossover Study of the Anti-platelet Effects of Ticagrelor Compared With Clopidogrel in Patients With Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND][NCT00642811] | Phase 2 | 98 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions[NCT00180310] | Phase 3 | 300 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| SPIRIT III: A Clinical Evaluation of the Investigational Device XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) in the Treatment of Subjects With de Novo Native Coronary Artery Lesions[NCT00180479] | Phase 3 | 1,002 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| A Multicenter, Open-labeled, Randomized Controlled Trial Comparing Three 2nd Generation Drug-Eluting Stents in Real-World Practice[NCT01397175] | 1,960 participants (Actual) | Interventional | 2013-01-16 | Terminated (stopped due to Slow enrollment) | |||
| The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| A Pharmacodynamic Comparison of Prasugrel (LY640315) Versus High Dose Clopidogrel in Subjects With Type 2 Diabetes Mellitus and Coronary Artery Disease.[NCT00642174] | Phase 2 | 35 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease[NCT01201785] | Phase 4 | 20 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Comparison of Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent Implantation For Long Coronary Lesions[NCT00589927] | Phase 4 | 486 participants (Anticipated) | Interventional | 2007-12-31 | Completed | ||
| Risk Informed Intervention Development and Implementation of Safe Ambulatory Care[NCT01247454] | 7,000 participants (Actual) | Interventional | 2009-07-31 | Completed | |||
| PILOT-EBM: Patient Focused Intervention to Improve Long-term Adherence to Evidence Based Medications[NCT00323258] | 143 participants (Actual) | Interventional | 2006-06-30 | Completed | |||
| Aspirin Resistance in Obstructive Sleep Apnea Patients (ARISA Trial)[NCT03930875] | 63 participants (Actual) | Observational | 2017-12-12 | Completed | |||
| Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Ischemic Heart Disease Refractory to Medical and Surgical Treatment: Randomized, Triple-blind Clinical Trial[NCT03660657] | Phase 2/Phase 3 | 1 participants (Actual) | Interventional | 2020-02-26 | Terminated (stopped due to Very low recruitment. During COVID-19 pandemic these are patients of high risk.) | ||
| Effects of Ozone Autohemotherapy on Patients With Post-ischemic Stroke Insomnia[NCT05508113] | 60 participants (Anticipated) | Interventional | 2022-08-26 | Not yet recruiting | |||
| Comparison of Antiplatelet and Anti-inflammatory Effects of High Dose Statin Monotherapy Versus Moderate Dose Statin Plus Ezetimibe[NCT00474123] | 78 participants (Actual) | Interventional | 2006-01-31 | Completed | |||
| ABSORB II RANDOMIZED CONTROLLED TRIAL A Clinical Evaluation to Compare the Safety, Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System Against XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Sub[NCT01425281] | 501 participants (Actual) | Interventional | 2011-11-30 | Completed | |||
| French Observatory Evaluating the Use of Intracoronary Prosthesis ABSORB BVS[NCT02238054] | 2,072 participants (Actual) | Observational [Patient Registry] | 2014-09-30 | Completed | |||
| Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary An[NCT00433966] | Phase 3 | 3,602 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Randomized Clinical Comparative Study of the Nobori and the Cypher Stents in Unselected Subjects With Ischemic Heart Disease[NCT01254981] | Phase 4 | 2,504 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Comparison of the Everolimus Eluting (XIENCE-V®, XIENCE-Prime® or PROMUS® Stent) With the Biolimus A9 Eluting NOBORI® Stent in All-comers: a Randomized Open Label Study[NCT01233453] | Phase 4 | 2,700 participants (Anticipated) | Interventional | 2009-01-31 | Active, not recruiting | ||
| Vessel Injury in Relation With Strut Thickness Assessed by OCT (VISTA): A Comparison of Vascular Injury Induced by a Polymer Free Sirolimus and Probucol Eluting Stent and a Biodegradable-polymer Biolimus-eluting Stent[NCT03026465] | Phase 4 | 50 participants (Actual) | Interventional | 2017-02-16 | Completed | ||
| Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261] | Phase 4 | 1,001 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Prospective Pilot Study- Does Mean Platelet Volume Change With Clopidogrel in Patients With Stable Angina Undergoing Percutaneous Coronary Intervention?[NCT02550301] | 100 participants (Anticipated) | Observational | 2015-09-30 | Not yet recruiting | |||
| Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE)[NCT00298428] | 159 participants (Actual) | Interventional | 2006-05-31 | Completed | |||
| Platelet Function in Resuscitated Patients[NCT02914795] | 99 participants (Actual) | Observational | 2015-06-30 | Completed | |||
| Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI[NCT00889044] | Phase 3 | 30 participants (Anticipated) | Interventional | 2009-04-30 | Recruiting | ||
| Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel[NCT01643031] | Phase 4 | 500 participants (Anticipated) | Interventional | 2012-08-31 | Not yet recruiting | ||
| A Prospective, Multicentre, Randomized, Open Label, Blinded Endpoint, Phase 3 Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular E[NCT02989558] | Phase 3 | 90 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435] | 889 participants (Actual) | Interventional | 2013-06-30 | Terminated (stopped due to Ethics Committe decision) | |||
| A Prospective, Double-blinded, Randomised Study to Evaluate the Effects of Different Doses of Statin Treatment on Plaque Volume and Composition in Coronary Disease Determined by Virtual Histology Using Intravascular Ultrasound[NCT01200056] | Phase 4 | 40 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Abciximab And Bivalirudin in Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Interventions (ISAR-REACT-4)[NCT00373451] | Phase 4 | 1,721 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Maintenance of an Antiaggregation by Acetylsalicylic Acid, Less or Equal to 250mg While a Extracorporeal Lithotripsy (ECL) Session on a Kidney Stone is Perfomed: Comparative Unicentric Prospective Study[NCT03437057] | 300 participants (Anticipated) | Interventional | 2018-01-08 | Recruiting | |||
| A Multi-center, Open-label, Randomized, Study to Assess the Onset of Platelet Aggregation Inhibition After a Single Subcutaneous Injection of ACT-246475 in Adults With Acute Myocardial Infarction[NCT03487445] | Phase 2 | 48 participants (Actual) | Interventional | 2018-07-10 | Completed | ||
| Phase IV Study of the Effects of Clopidogrel on Soluble CD40 Ligand, Endothelial Function and Blood Pressure[NCT01112137] | Phase 4 | 46 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Antiplatelet Activity of Aspirin in Infants After Aortopulmonary and Cavopulmonary Shunts[NCT01656993] | 25 participants (Actual) | Observational | 2012-11-30 | Completed | |||
| Must Aspirin be Discontinued Prior to TURBT: a Prospective, Randomized, Non-inferiority Trial Comparing Peri-operative Aspirin Continuation Versus Discontinuation.[NCT02350543] | Phase 4 | 50 participants (Actual) | Interventional | 2015-02-28 | Terminated (stopped due to Insufficient recruitment.) | ||
| Trial of Pulse Steroid Therapy in Kawasaki Disease (A Trial Conducted by the Pediatric Heart Network)[NCT00132080] | Phase 3 | 199 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Infliximab (Remicade®) Plus Intravenous Immunoglobulin (IVIG) for the Primary Treatment of Patients With Acute Kawasaki Disease[NCT00760435] | Phase 3 | 196 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Low-dose Colchicine Intervention in Patients With Type 2 Diabetes Mellitus and Microalbuminuria: Chongqing Study[NCT02035891] | 160 participants (Actual) | Interventional | 2013-12-31 | Active, not recruiting | |||
| Optimized Antiplatelet Therapy With Aspirin and Clopidogrel Improves Mortality Compared to Standard Treatment.[NCT01796691] | 600 participants (Actual) | Observational | 2009-01-31 | Completed | |||
| Optimizing Therapy With Aspirin and Clopidogrel. The BOchum CLopidogrel and Aspirin Plan to Improve Dual Antiplatelet Therapy.[NCT01212302] | 500 participants (Actual) | Interventional | 2008-10-31 | Completed | |||
| [NCT00000490] | Phase 3 | 0 participants | Interventional | 1973-06-30 | Completed | ||
| A Comprehensive Care Plan for Pediatric Patients With Vaso-Occlusive Crises[NCT02698761] | 3 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to Standard of care changed) | |||
| Renal and Cardiovascular Impairment in WTC Responders: Implications for Diagnosis and Treatment[NCT02246101] | 406 participants (Actual) | Observational | 2014-07-31 | Completed | |||
| [NCT00000500] | Phase 3 | 0 participants | Interventional | 1981-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"BARC definition. We only considered BARC 3 or 5 for this secondary safety endpoint.~Type 3: Clinical, laboratory, and/or imaging evidence of bleeding with:~Type 3a:~Overt bleeding + Hb drop of 3 to < 5 g/dL (provided Hb drop is related to bleed)~Any transfusion with overt bleeding~Type 3b:~Overt bleeding + Hb drop ≥5 g/dL (provided Hb drop is related to bleed)~Cardiac tamponade~Bleeding requiring surgical intervention (excluding dental/nasal/skin/haemorrhoid)~Bleeding requiring intravenous vasoactive agents~Type 3c:~Intracranial haemorrhage (does not include microbleeds or haemorrhagic transformation, does include intraspinal)~Subcategories confirmed by autopsy or imaging or lumbar puncture~Intraocular bleed compromising vision. Type 5: Fatal bleeding~Type 5a:~• Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious~Type 5b:~Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation" (NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 163 |
| Reference Treatment Strategy | 169 |
Number of Participants with a composite of all-cause mortality or non-fatal new Q-wave MI up to 2 years post randomisation. (NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 304 |
| Reference Treatment Strategy | 349 |
shown are the first event per event type for each patient only. Multiple events of the same type within the same patient are disregarded (NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 362 |
| Reference Treatment Strategy | 416 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 64 |
| Reference Treatment Strategy | 64 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 739 |
| Reference Treatment Strategy | 793 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 80 |
| Reference Treatment Strategy | 82 |
(NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 224 |
| Reference Treatment Strategy | 253 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 248 |
| Reference Treatment Strategy | 250 |
(NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 83 |
| Reference Treatment Strategy | 103 |
The primary end-point of the study was the comparison in the platelet reactivity index (PRI%) determined by vasodilator-stimulated phosphoprotein (VASP) at 1 week between prasugrel and ticagrelor. (NCT01852175)
Timeframe: 1 week
| Intervention | PRI% (Least Squares Mean) |
|---|---|
| Prasugrel | 32.1 |
| Ticagrelor | 32.6 |
A secondary outcome was the comparison between groups of platelet reactivity index (PRI) measured by vasodilator-stimulated phosphoprotein (VASP) at 2 hours after loading dose. (NCT01852175)
Timeframe: 2 hours
| Intervention | PRI% (Least Squares Mean) |
|---|---|
| Prasugrel | 13.4 |
| Ticagrelor | 15.6 |
A secondary outcome was the comparison between groups of platelet reactivity index (PRI) measured by vasodilator-stimulated phosphoprotein (VASP) at 24 hours after loading dose. (NCT01852175)
Timeframe: 24 hours
| Intervention | PRI% (Least Squares Mean) |
|---|---|
| Prasugrel | 14.2 |
| Ticagrelor | 26.4 |
Participants with all-cause death. If no event, censoring occurs at the earliest of PACD and last endpoint assessment date. Includes deaths based on publically available vital status data in patients who have withdrawn consent. (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 579 |
| Ticagrelor Placebo | 592 |
Participants with Cardiovascular (CV) death, myocardial infarction (MI) or stroke. If no event, censoring occurs at the earliest of PACD, last endpoint assessment date and non-CV death date. (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 736 |
| Ticagrelor Placebo | 818 |
Participants with Cardiovascular (CV) death. If no event, censoring occurs at the earliest of PACD, last endpoint assessment date and non-CV death date. (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 364 |
| Ticagrelor Placebo | 357 |
Participants with ischaemic stroke. If no event, censoring occurs at the earliest of PACD, last endpoint assessment date and death date. (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 152 |
| Ticagrelor Placebo | 191 |
Participants with myocardial infarction. If no event, censoring occurs at the earliest of primary analysis censoring date (PACD), last endpoint assessment date and death date (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 274 |
| Ticagrelor Placebo | 328 |
Participants with permanent discontinuation of study medication due to any bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and the date of last dose of study medication (NCT01991795)
Timeframe: From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 466 |
| Ticagrelor Placebo | 125 |
Participants with PLATO major bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and 7 days following the date of last dose of study medication (NCT01991795)
Timeframe: From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 310 |
| Ticagrelor Placebo | 145 |
Participants with TIMI major bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and 7 days following the date of last dose of study medication (NCT01991795)
Timeframe: From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 206 |
| Ticagrelor Placebo | 100 |
Participants with TIMI major or minor bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and 7 days following the date of last dose of study medication (NCT01991795)
Timeframe: From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 285 |
| Ticagrelor Placebo | 129 |
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 313 |
| Rivaroxaban 5mg + Aspirin Placebo | 366 |
| Rivaroxaban Placebo + Aspirin 100mg | 378 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 282 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 389 |
| Rivaroxaban 5mg + Aspirin Placebo | 453 |
| Rivaroxaban Placebo + Aspirin 100mg | 516 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 329 |
| Rivaroxaban 5mg + Aspirin Placebo | 397 |
| Rivaroxaban Placebo + Aspirin 100mg | 450 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 379 |
| Rivaroxaban 5mg + Aspirin Placebo | 448 |
| Rivaroxaban Placebo + Aspirin 100mg | 496 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 353 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 288 |
| Rivaroxaban 5mg + Aspirin Placebo | 255 |
| Rivaroxaban Placebo + Aspirin 100mg | 170 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 138 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 1.70 |
| Propensity-matched BMS | 2.61 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.69 |
| DES 12-month DAPT | 1.45 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.40 |
| DES 12-month DAPT | 1.35 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.03 |
| BMS 12-month DAPT | 0.90 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.09 |
| BMS 12-month DAPT | 1.05 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.74 |
| DES 12-month DAPT | 1.88 |
The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.53 |
| DES 12-month DAPT | 1.57 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 11.37 |
| Propensity-matched BMS | 13.24 |
(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.04 |
| BMS 12-month DAPT | 4.69 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.68 |
| BMS 12-month DAPT | 5.48 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 5.62 |
| DES 12-month DAPT | 6.49 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 4.34 |
| DES 12-month DAPT | 5.92 |
"Time to first occurrence during the time the participants were treated with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 24.66 |
| Vitamin K Antagonist | 35.79 |
"Time to first death or ischenic event during the 6-month treatment period with aspirin or placebo.~N is the number of participants treated with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with death or ischemic events in each treatment group during the 6-month treatment period.~Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Acetylsalicylic Acid Film Coated Tablet | 15.28 |
| Placebo Matching Acetylsalicylic Acid Film Coated Tablet | 17.73 |
"Time to first all-cause death or all-cause hospitalization during the during the 6-month treatment period with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 57.24 |
| Vitamin K Antagonist | 69.19 |
"Time to first all-cause death or all-cause hospitalization during the 6-month period of treatment with aspirin or placebo.~N is the number of participants treated with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Acetylsalicylic Acid Film Coated Tablet | 65.72 |
| Placebo Matching Acetylsalicylic Acid Film Coated Tablet | 60.56 |
"Time to first ISTH major or CRNM bleeding during the 6-month period of treatment with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with major or CRNM bleeding divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 24.66 |
| Vitamin K Antagonist | 35.79 |
"Time to first ISTH major or CRNM bleeding during the treatment period of 6 months with aspirin or placebo.~N is the number of participants with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Acetylsalicylic Acid Film Coated Tablet | 40.51 |
| Placebo Matching Acetylsalicylic Acid Film Coated Tablet | 21.03 |
"Time to first occurrence during the 6-month treatment period with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with death or ischemic events in each treatment group during the during the 6-month period of treatment.~Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 15.85 |
| Vitamin K Antagonist | 17.17 |
Time to event analysis of patients with adjudicated all cause death. The number of observed patients with adjudicated all cause death was reported. All cause death is defined as the death from any cause included CV death, non-CV death, and undetermined cause of death. (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 55 |
| Dabigatran Etexilate 150mg | 30 |
| Warfarin | 48 |
| Warfarin (Excluding Elder Patients Outside USA) | 35 |
"Time to event analysis of patients with adjudicated Cardiovascular (CV) death. The number of observed patients with adjudicated Cardiovascular (CV) death was reported.~CV death included death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, death due to stroke, death due to CV procedures, death due to CV haemorrhage, and death due to other CV causes." (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 37 |
| Dabigatran Etexilate 150mg | 21 |
| Warfarin | 31 |
| Warfarin (Excluding Elder Patients Outside USA) | 24 |
"Time to event analysis of patients with adjudicated Non-cardiovascular (Non-CV). The number of observed patients with adjudicated Non-CV was reported.~Non-CV death was defined as any death with a specific cause that was not thought to be CV. These were possible examples of non-CV causes of death: Pulmonary, Renal, Gastrointestinal, Hepatobiliary, Pancreatic Infection(included sepsis), Inflammatory (e.g. systemic inflammatory response syndrome) or immune (including autoimmune), Haemorrhage that was neither CV bleeding nor a stroke, Non-CV procedure or surgery, Trauma, Suicide, Non-prescription drug reaction or overdose, Prescription drug reaction or overdose, Neurological (non-CV), Malignancy, Other non-CV" (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 14 |
| Dabigatran Etexilate 150mg | 4 |
| Warfarin | 13 |
| Warfarin (Excluding Elder Patients Outside USA) | 8 |
"Time to event analysis of patients with adjudicated Undetermined cause of death. The number of observed patients with adjudicated Undetermined cause of death was reported.~This is referred to a death not attributable to cardiovascular (CV) death or to a non-cardiovascular (non-CV) cause. Inability to classify the cause of death may have been due to lack of information (e.g. the only available information was patient died) or when there was insufficient supporting information or detail to assign the cause of death." (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 4 |
| Dabigatran Etexilate 150mg | 5 |
| Warfarin | 4 |
| Warfarin (Excluding Elder Patients Outside USA) | 3 |
Time to event analysis of patients with the composite endpoint of death + myocardial infarction (MI) + stroke. The number of observed patients with the composite endpoint of death + myocardial infarction (MI) + stroke was reported. (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 107 |
| Dabigatran Etexilate 150mg | 60 |
| Warfarin | 80 |
| Warfarin (Excluding Elder Patients Outside USA) | 57 |
Time to event analysis of patients with composite endpoint of death or first thrombotic event (all death, myocardial infarction (MI), stroke/systemic embolism (SE)). The number of observed patients with composite endpoint of death or thrombotic event (all death, MI, stroke/SE). (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 108 |
| Dabigatran Etexilate 150mg | 60 |
| Warfarin | 83 |
| Warfarin (Excluding Elder Patients Outside USA | 60 |
| All Dabigatran Etexilate | 168 |
Time to event analysis of patients with death or thrombotic event (all death, myocardial infarction, stroke/systemic embolism) or unplanned revascularisation by Percutaneous Coronary Intervention/Coronary Artery Bypass Graft. The number of observed patients with death or first thrombotic event or unplanned revascularisation by PCI/CABG was reported. (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 149 |
| Dabigatran Etexilate 150mg | 90 |
| Warfarin | 131 |
| Warfarin (Excluding Elder Patients Outside USA) | 98 |
| All Dabigatran Etexilate | 239 |
"Time to event analysis of patients with first adjudicated International Society of Thrombosis and Haemostasis (ISTH) Major Bleeding Event (MBE) or Clinically Relevant Non Major Bleeding Event (CRNMBE). The number of observed patients with adjudicated ISTH MBE or CRNMBE was reported.~Full analysis set (FAS): All consenting patients randomised were analysed in the treatment group to which they were randomised regardless of whether they took trial medication. The start date of the observation period for this analysis set was the date of randomisation. Patients who discontinued trial medication were followed until the end of the trial.~Patients who were lost to follow-up for vital status were censored for the primary endpoint at the time of their last known vital status.~Intention to treat period: The observation period for these analysis was the so called 'intention to treat period'." (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 151 |
| Dabigatran Etexilate 150mg | 154 |
| Warfarin | 264 |
| Warfarin (Excluding Elder Patients Outside USA) | 196 |
Time to event analysis of patients with first adjudicated Myocardial Infarction (MI). The number of observed patients with adjudicated MI was reported (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 44 |
| Dabigatran Etexilate 150mg | 26 |
| Warfarin | 29 |
| Warfarin (Excluding Elder Patients Outside USA) | 22 |
"Time to event analysis of patients with first adjudicated Systemic embolism (SE). The number of observed patients with adjudicated SE was reported.~SE is an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts) and had to be documented by angiography, surgery, scintigraphy, or autopsy." (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 3 |
| Dabigatran Etexilate 150mg | 1 |
| Warfarin | 3 |
| Warfarin (Excluding Elder Patients Outside USA) | 3 |
Time to event analysis of patients with first adjudicated Stent Thrombosis (ST). The number of observed patients with adjudicated ST was reported. (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 15 |
| Dabigatran Etexilate 150mg | 7 |
| Warfarin | 8 |
| Warfarin (Excluding Elder Patients Outside USA) | 7 |
"Time to event analysis of patients with first adjudicated Stroke. The number of observed patients with adjudicated Stroke was reported.~Stroke was defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction" (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 17 |
| Dabigatran Etexilate 150mg | 9 |
| Warfarin | 13 |
| Warfarin (Excluding Elder Patients Outside USA) | 8 |
Time to event analysis of patients with adjudicated unplanned revascularisation by Percutaneous Coronary Intervention (PCI)/Coronary Artery Bypass Graft (CABG). The number of observed patients with adjudicated unplanned revascularisation by PCI/CABG was reported. (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 76 |
| Dabigatran Etexilate 150mg | 51 |
| Warfarin | 69 |
| Warfarin (Excluding Elder Patients Outside USA) | 52 |
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 141 |
| Aspirin + Ticagrelor | 250 |
Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 135 |
| Aspirin + Ticagrelor | 137 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 4 |
| Placebo | 5 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 1 |
| Placebo | 0 |
Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery
| Intervention | percentage (Number) |
|---|---|
| 75mg Clopidogrel | 94.3 |
| Placebo | 93.2 |
IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery
| Intervention | mm (Mean) |
|---|---|
| 75mg Clopidogrel | 4.1 |
| Placebo | 4.5 |
All bleeding events include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding. Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding. Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 2356 |
| Warfarin | 3060 |
ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more, and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 327 |
| Warfarin | 462 |
Death was defined as all-cause mortality. All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided. Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, myocardial infarction (MI), sudden death, heart failure, other cardiovascular, and unobserved deaths. Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death). (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 603 |
| Warfarin | 669 |
Major bleeding=bleeding that is clinically overt and that either resulted in a decrease in hemoglobin of 2 g/dL or more over a 24-hour period, led to a transfusion of 2 or more units of packed red blood cells, occurred in a critical site, or led to death. CRNM bleeding=bleeding that is clinically overt, that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event, that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 613 |
| Warfarin | 877 |
Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 459 |
| Warfarin | 608 |
For descriptions of Stroke and SE, see Outcome Measure 1. For description of Major bleeding, see Outcome Measure 3. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 229 |
| Warfarin | 285 |
All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided. Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, MI, sudden death, heart failure, other cardiovascular, and unobserved deaths. Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death). (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 3.52 |
| Warfarin | 3.94 |
Rate=number of adjudicated major (ISTH) bleed events per 100 patient years. ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 2.13 |
| Warfarin | 3.09 |
Rate=Number of adjudicated stroke or SE events per 100 patient years. Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 1.27 |
| Warfarin | 1.60 |
"Rate=number of all bleeding events per 100 patient years. All bleeding events include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding. Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding. Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death." (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 18.08 |
| Warfarin | 25.82 |
(NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 3.21 |
| Warfarin | 4.06 |
Rate=number of major or CRNM bleed events per 100 patient years. Major=clinically overt and either 1) resulted in a decrease in hemoglobin of 2 g/dL or more, or 2) led to a transfusion of 2 or more units of packed red blood cells, or 3) occurred in a critical site, or 4) led to death. CRNM bleeding=clinically overt, but satisfied no additional criteria required to be adjudicated as a major bleeding event, and led to either 1) hospital admission for bleeding or 2) physician guided medical or surgical treatment for bleeding or 3) a change in antithrombotic therapy. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | number of events / 100 patient years (Number) |
|---|---|
| Apixaban | 4.07 |
| Warfarin | 6.01 |
Rate=number of events of net-clinical benefit per 100 patient years. Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 3.01 |
| Warfarin | 4.09 |
AE: all SAEs or AEs with onset from first dose through 2 days (AEs) or 30 days (SAEs) after the last dose of blinded study drug (BSD). SAE: all SAEs with onset from first dose through 30 days after the last dose of BSD. Bleeding AE: all serious or non-serious bleeding-related AEs with onset from first dose through 2 days after the last dose of BSD. Discontinuations due to AE: all SAEs or AEs with onset from first dose of BSD and with action taken=drug discontinued. Deaths: all deaths occurring from first dose through 30 days after the last dose of BSD. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| AE | SAE | Bleeding AE | Discontinuations due to AE | Deaths | |
| Apixaban | 7406 | 3182 | 2288 | 688 | 429 |
| Warfarin | 7521 | 3302 | 2961 | 758 | 468 |
All suspected efficacy events were adjudicated by the Central Events Committee (CEC). Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing. (NCT00412984)
Timeframe: "Time to first event in Intended Treatment Period: started on day of randomization, ended at efficacy cut-off date (date target number of primary efficacy events [448] was expected to have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | participants (Number) | ||
|---|---|---|---|
| Ischemic or Unspecified Stroke | Hemorrhagic Stroke | Systemic Embolism | |
| Apixaban | 159 | 38 | 15 |
| Warfarin | 173 | 76 | 16 |
Rate=number of adjudicated GUSTO bleeding events per 100 patient years. GUSTO Bleeding Criteria: GUSTO severe (or life-threatening) bleeding: either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention. GUSTO moderate bleeding: bleeding that requires blood transfusion but does not result in hemodynamic compromise. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | Number of events per 100 patient years (Number) | |
|---|---|---|
| Severe (n=80, 172)) | Severe or Moderate (n=199, 328) | |
| Apixaban | 0.52 | 1.29 |
| Warfarin | 1.13 | 2.18 |
Rate=number of adjudicated TIMI bleeding events per 100 patient years. TIMI Bleeding Criteria: Major bleeding=Intracranial bleeding and/or clinically overt bleeding associated with ≥5 gm/dL fall in Hgb or 15% fall in hematocrit (Hct) from baseline, accounting for transfusions. Minor bleeding=Clinically overt bleeding associated with ≥3 gm/dL fall in Hgb or a ≥10% fall in Hct from baseline, accounting for transfusions. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | Number of events per 100 patient years (Number) | |
|---|---|---|
| Major (n=148, 256) | Major or Minor (n=239, 370) | |
| Apixaban | 0.96 | 1.55 |
| Warfarin | 1.69 | 2.46 |
Diagnosis for an acute or evolving MI=elevation of creatine kinase-MB isoenzyme (CK-MB) or Troponin T or I ≥ 2 × the upper limit of normal (ULN), or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads. For descriptions of Stroke and SE, see Outcome Measure 1. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) | |||
|---|---|---|---|---|
| Ischemic or Unspecified Stroke (n=162, 175) | Hemorrhagic Stroke (n=40, 78) | Systemic Embolism (n=15, 17) | Myocardial Infarction (n=90, 102) | |
| Apixaban | 0.97 | 0.24 | 0.09 | 0.53 |
| Warfarin | 1.05 | 0.47 | 0.10 | 0.61 |
Diagnosis for an acute or evolving MI=elevation of CK-MB or Troponin T or I ≥ 2 × the ULN, or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads. For descriptions of Stroke and SE, see Outcome Measure 1. For description of ACD, see Outcome Measure 5. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Stroke / SE / Major Bleeding (n=521, 666) | Stroke / SE / All-Cause Death (ACD) (n=752, 837) | Stroke / SE / Major Bleeding / ACD (n=1009, 1168) | Stroke / SE / MI / ACD (n=810, 906) | Ischemic or Unspecified Stroke / ACD (n=725, 796) | Hemorrhagic Stroke / ACD (n=622, 703) | SE / ACD (n=613, 679) | MI / ACD (n=663, 740) | |
| Apixaban | 3.17 | 4.49 | 6.13 | 4.85 | 4.32 | 3.68 | 3.63 | 3.93 |
| Warfarin | 4.11 | 5.04 | 7.20 | 5.49 | 4.78 | 4.20 | 4.05 | 4.43 |
The primary objective of this clinical trial will be to evaluate whether, as compared to usual aspirin treatment, ticagrelor early after CABG prevents saphenous vein graft occlusion 1 year after surgery, as assessed by computed tomography (CT) coronary angiography. (NCT02053909)
Timeframe: 1 year after surgery
| Intervention | percentage of veins occluded (Number) |
|---|---|
| Aspirin | 17.4 |
| Ticagrelor | 13.2 |
The secondary objective of this clinical trial will be to evaluate whether, as compared to usual aspirin treatment, ticagrelor early after CABG prevents saphenous vein graft stenosis, defined as >50% narrowing of the graft, 1 year after surgery, as assessed by computed tomography (CT) coronary angiography. (NCT02053909)
Timeframe: 1 year after surgery
| Intervention | percentage of veins stenosed (Number) |
|---|---|
| Aspirin | 4.1 |
| Ticagrelor | 4.2 |
"VAS question How much pain do you have was graded on a scale from 0 to 100 with 0 indicating No pain and 100 indicating Worst possible pain." (NCT00346216)
Timeframe: ITT and MITT Population - Baseline to 42 months
| Intervention | Number of participants (Mean) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (ITT) N= 8014, 8001, 7928 | Change-Baseline to Mon1 (ITT) N=7382, 7379, 7325 | Change-Baseline to Mon2 (ITT) N=7180, 7090, 7149 | Change-Baseline to Mon4 (ITT) N=6777, 6696, 6740 | Change-Baseline to Mon8 (ITT) N=6230, 6137, 6159 | Change-Baseline to Mon12 (ITT) N=5792, 5696, 5846 | Change-Baseline to Mon18 (ITT) N=5310, 5181. 5246 | Change-Baseline to Mon24 (ITT) N=4818, 4776, 4785 | Change-Baseline to Mon30 (ITT) N=4140, 4069, 4086 | Change-Baseline to Mon36 (ITT) N=3692, 3627, 3635 | Change-Baseline to Mon42 (ITT) N=3469, 3406, 3439 | Baseline (MITT) N=7974, 7954, 7894 | Change-Baseline to Mon1 MITT N=7372, 7367, 7321 | Change-Baseline to Mon2 MITT N=7170, 7078, 7142 | Change-Baseline to Mon4 MITT N=6772, 6686, 6732 | Change-Baseline to Mon8 MITT N=6224, 6128, 6155 | Change-Baseline to Mon12 MITT N=5787, 5689, 5844 | Change-Baseline to Mon18 MITT N=5305, 5175, 5242 | Change-Baseline to Mon24 MITT N=4815, 4769, 4782 | Change-Baseline to Mon30 MITT N=4139, 4067, 4085 | Change-Baseline to Mon36 MITT N=3691, 3623, 3635 | Change-Baseline to Mon42 MITT N=3468, 3404, 3438 | |
| Celecoxib | 54.0 | -8.2 | -10.5 | -11.4 | -11.7 | -11.0 | -11.3 | -11.3 | -10.5 | -10.1 | -11.4 | 54.0 | -8.2 | -10.5 | -11.4 | -11.7 | -11.0 | -11.3 | -11.4 | -10.5 | -10.2 | -11.4 |
| Ibuprofen | 54.1 | -9.0 | -10.6 | -11.7 | -12.1 | -11.6 | -11.3 | -11.5 | -11.2 | -10.7 | -11.1 | 54.1 | -9.0 | -10.6 | -11.7 | -12.1 | -11.6 | -11.3 | -11.5 | -11.2 | -10.7 | -11.1 |
| Naproxen | 54.1 | -9.9 | -11.1 | -12.3 | -12.1 | -11.9 | -11.7 | -11.4 | -11.3 | -11.6 | -12.1 | 54.1 | -9.9 | -11.1 | -12.3 | -12.1 | -11.9 | -11.7 | -11.3 | -11.3 | -11.6 | -12.1 |
MACE defined as the composite of CV death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 4.2 | 3.1 |
| Ibuprofen | 4.8 | 3.6 |
| Naproxen | 4.3 | 3.2 |
APTC events are defined as a composite of any of the following events: Death due to CV causes (including cardiac, cerebrovascular, venous thromboembolic, haemorrhagic, other vascular, or unknown cause); Non-fatal MI; Non-fatal stroke (including intracranial hemorrhages, stroke of ischemic or unknown etiology). (NCT00346216)
Timeframe: Intent to Treat (ITT) Population - 30 months; Modified ITT (MITT) Population - 42 months
| Intervention | Percentage of Partcipants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 2.3 | 1.7 |
| Ibuprofen | 2.7 | 1.9 |
| Naproxen | 2.5 | 1.8 |
CSGIE include: Gastroduodenal (GD) hemorrhage, Gastric outlet obstruction, Gastroduodenal, small bowel or large bowel perforation, Large bowel hemorrhage, Small bowel hemorrhage, Acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage, Symptomatic gastric or duodenal ulcer (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 0.7 | 0.3 |
| Ibuprofen | 0.9 | 0.7 |
| Naproxen | 0.7 | 0.7 |
Rate of death or myocardial infarction (NCT02605447)
Timeframe: 3 to 15 months
| Intervention | Participants (Count of Participants) |
|---|---|
| SYNERGY Stent + 3 Month DAPT | 84 |
"Rate of Bleeding, per Bleeding Academic Consortium definition (BARC2, 3a, 3b, 3c, 4, 5a and 5b)~Type 0: No Bleeding~Type 1: Bleeding that is not actionable and does not cause the patient to seek treatment~Type 2: Any clinically overt sign of hemorrhage that is actionable and requires diagnostic studies, hospitalization, or treatment by a health care professional~Type 3a: Overt bleeding plus hemoglobin drop of 3 to < 5 g/dL (provided hemoglobin drop is related to bleed); transfusion with overt bleeding~Type 3b: Overt bleeding plus hemoglobin drop ≥5 g/dL (provided hemoglobin drop is related to bleed); cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage confirmed by autopsy, imaging, or lumbar puncture; intraocular bleed compromising vision~Type 4: CABG-related bleeding within 48 hours~Type 5a: Probable fatal bleeding~Type 5b: Definite fatal bleeding" (NCT02605447)
Timeframe: 3 to 15 months
| Intervention | Participants (Count of Participants) |
|---|---|
| SYNERGY Stent + 3 Month DAPT | 103 |
"Rate of stent thrombosis: definite + probable, using the Academic Research Consortium (ARC) definition Confirmed/Definite (is considered either angiographic confirmed or pathologic confirmed) Probable~Clinical definition of probable stent thrombosis is considered to have occurred in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure and MI in the absence of any obvious cause which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis Possible Clinical definition of possible stent thrombosis is considered to have occurred with any unexplained death beyond 30 days." (NCT02605447)
Timeframe: 3 to 15 months
| Intervention | Participants (Count of Participants) |
|---|---|
| SYNERGY Stent + 3 Month DAPT | 3 |
Cumulative radiation exposure from all cardiovascular diagnostic tests and procedures performed within 90 days after randomization. (NCT01174550)
Timeframe: 90 days
| Intervention | milliSievert (mSv) (Median) |
|---|---|
| Anatomic Diagnostic Test | 10.0 |
| Functional Diagnostic Tests | 11.3 |
Percentage of Invasive Cardiac Catheterization Events Without Obstructive Coronary Artery Disease (CAD)Within 90 Days Following Participant Randomization (NCT01174550)
Timeframe: Up to 90 days following participant randomization
| Intervention | Percentage of events (Mean) |
|---|---|
| Anatomic Diagnostic Test | 3.4 |
| Functional Diagnostic Tests | 4.3 |
Assess and compare total medical cost for the two diagnostic testing arms by intention to treat at both 90 days and 3 years cumulative. (NCT01174550)
Timeframe: 90 days and 3 years cumulative
| Intervention | Per participant cost in US dollars (Mean) | |
|---|---|---|
| 90 days | 3 years cumulative | |
| Anatomic Diagnostic Test | 2494 | 7213 |
| Functional Diagnostic Tests | 2240 | 6586 |
Percentage of participants with improvement in Quality of Life as measured by complete resolution of the symptoms that led to initial testing (NCT01174550)
Timeframe: 6 month, 12 month 24 month
| Intervention | % of participants (Number) | ||
|---|---|---|---|
| 6 months | 12 months | 24 months | |
| Anatomic Diagnostic Test | 43.3 | 47.3 | 52.1 |
| Functional Diagnostic Tests | 46.5 | 48.8 | 54.3 |
Participant score in Quality of Life as measured by Duke Activity Status Index (DASI). DASI measures a person's functional capacity based on a 12-item questionnaire that correlates with peak O2 uptake during exercise testing. The DASI is a self-administered questionnaire that measures a patient's functional capacity. It can be used to get a rough estimate of a patient's peak oxygen uptake. The maximum score for the DASI is 58.2 (better functional ability/capacity) and the minimum score is 0 (worse functional ability/capacity). (NCT01174550)
Timeframe: Baseline, 6 months, 12 months 24 months
| Intervention | participant score (Median) | |||
|---|---|---|---|---|
| Baseline | 6 months | 12 months | 24 months | |
| Anatomic Diagnostic Test | 21.5 | 30.5 | 29.2 | 31.5 |
| Functional Diagnostic Tests | 22.9 | 30.2 | 31.2 | 31.2 |
Participant score Quality of Life measured by Seattle Angina Scale Anginal Frequency Subscale utilizing the Seattle Angina Questionnaire (SAQ). SAQ: 19-item, 5-6-point Likert, questionnaire measuring 5 dimensions of coronary artery disease: Anginal Stability: whether symptoms are changing. Anginal Frequency: how often patient having symptoms Physical Limitation: how much condition hampers ability to do what he wants.Treatment Satisfaction: how well patient understands care. Disease Perception: impact of condition on interpersonal relationships. Each dimension assigns response an value, beginning with 1 for response at the lowest level of functioning & summing across items within each of the 5 scales. Scale scores transformed to 0-100 range by subtracting the lowest scale. Higher score suggest symptoms more stable & less frequent, condition has less impact on activities, increased satisfaction with treatment, & perception of disease has less impact on interpersonal relationships. (NCT01174550)
Timeframe: Baseline, 6 month, 12 month, 24 month
| Intervention | participant score (Median) | |||
|---|---|---|---|---|
| Baseline | 6 month | 12 month | 24 month | |
| Anatomic Diagnostic Test | 70 | 100 | 100 | 100 |
| Functional Diagnostic Tests | 80 | 100 | 100 | 100 |
Participant score Quality of Life measured by Seattle Angina Scale Anginal Frequency Subscale utilizing the Seattle Angina Questionnaire (SAQ). SAQ: 19-item, 5-6-point Likert, questionnaire measuring 5 dimensions of coronary artery disease: Anginal Stability: whether symptoms are changing. Anginal Frequency: how often patient having symptoms Physical Limitation: how much condition hampers ability to do what he wants.Treatment Satisfaction: how well patient understands care. Disease Perception: impact of condition on interpersonal relationships. Each dimension assigns response an value, beginning with 1 for response at the lowest level of functioning & summing across items within each of the 5 scales. Scale scores transformed to 0-100 range by subtracting the lowest scale. Higher score suggest symptoms more stable & less frequent, condition has less impact on activities, increased satisfaction with treatment, & perception of disease has less impact on interpersonal relationships. (NCT01174550)
Timeframe: Baseline, 6 months, 12 months, 24 months
| Intervention | participant score (Median) | |||
|---|---|---|---|---|
| Baseline | 6 month | 12 month | 24 month | |
| Anatomic Diagnostic Test | 58.3 | 83.3 | 83.3 | 91.7 |
| Functional Diagnostic Tests | 58.3 | 83.3 | 91.7 | 91.7 |
Time to this secondary endpoint as defined as a composite of death and myocardial infarction (MI). The Kaplan-Meier events rates (cumulative percentage of participants with an event) were estimated for the anatomic and functional diagnostic test groups. (NCT01174550)
Timeframe: 90 days, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months
| Intervention | Percentage of participants with an event (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| 90 Days | 6 months | 12 months | 18 months | 24 months | 30 months | 36 months | 42 months | |
| Anatomic Diagnostic Test | 0.3 | 0.4 | 0.8 | 1.3 | 1.7 | 2.2 | 3.3 | 3.9 |
| Functional Diagnostic Tests | 0.6 | 0.9 | 1.2 | 1.8 | 2.0 | 2.7 | 3.0 | 4.2 |
Time to primary endpoint as defined as a composite of death, myocardial infarction (MI), major complications from cardiovascular (CV) procedures or testing, unstable angina hospitalization, and no coronary artery disease (CAD). The Kaplan-Meier events rates (cumulative percentage of participants with an event) were estimated for the anatomic and functional diagnostic test groups. (NCT01174550)
Timeframe: 90 days, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months
| Intervention | Percentage of participants with an event (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| 90 days | 6 months | 12 months | 18 months | 24 months | 30 months | 36 months | 42 months | |
| Anatomic Diagnostic Test | 4.4 | 4.6 | 5.2 | 5.9 | 6.3 | 6.9 | 8.0 | 8.7 |
| Functional Diagnostic Tests | 5.2 | 5.6 | 6.1 | 6.7 | 6.9 | 7.6 | 7.9 | 9.1 |
Time to this secondary endpoint as defined as a composite of death, myocardial infarction (MI), and unstable angina hospitalization. The Kaplan-Meier events rates (cumulative percentage of participants with an event) were estimated for the anatomic and functional diagnostic test groups. (NCT01174550)
Timeframe: 90 days, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months
| Intervention | Percentage of participants with an event (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| 90 day | 6 month | 12 month | 18 month | 24 month | 30 month | 36 month | 42 month | |
| Anatomic Diagnostic Test | 0.9 | 1.2 | 1.8 | 2.5 | 2.9 | 3.5 | 4.6 | 5.2 |
| Functional Diagnostic Tests | 1.0 | 1.4 | 1.9 | 2.5 | 2.8 | 3.4 | 3.7 | 5.1 |
Time to this secondary endpoint as defined as a composite of major complications from cardiovascular procedures and testing (stroke, bleeding, anaphylaxis, renal failure). The Kaplan-Meier events rates (cumulative percentage of participants with an event) were estimated for the anatomic and functional diagnostic test groups. (NCT01174550)
Timeframe: 90 days, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months
| Intervention | Percentage of participants with an event (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| 90 day | 6 month | 12 month | 18 month | 24 month | 30 month | 36 month | 42 month | |
| Anatomic Diagnostic Test | 0.1 | 0.2 | 0.5 | 1.0 | 1.2 | 1.7 | 2.6 | 3.1 |
| Functional Diagnostic Tests | 0.3 | 0.5 | 0.8 | 1.1 | 1.4 | 1.9 | 2.2 | 3.2 |
Time to primary endpoint as defined as a composite of death, myocardial infarction (MI), major complications from cardiovascular (CV) procedures or testing, and unstable angina hospitalization. The Kaplan-Meier events rates (cumulative percentage of participants with an event) were estimated for the anatomic and functional diagnostic test groups. (NCT01174550)
Timeframe: 90 days, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months
| Intervention | Percentage of participants with an event (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| 90 days | 6 months | 12 months | 18 months | 24 months | 30 months | 36 months | 42 months | |
| Anatomic Diagnostic Test | 1.0 | 1.2 | 1.8 | 2.5 | 2.9 | 3.5 | 4.6 | 5.3 |
| Functional Diagnostic Tests | 1.1 | 1.4 | 1.9 | 2.6 | 2.8 | 3.5 | 3.8 | 5.1 |
"miRNA-365-3p measure by Roche miRNA kits; PRP(platelet riched plasma) isolated miRNA by isolation Kit, then havest in cDNA synthesis Kit; then perform RT PCR.~." (NCT02101437)
Timeframe: 7 days
| Intervention | fold of change (Mean) |
|---|---|
| Control | -8.14 |
| Clopidogrel | -3.46 |
| Ticagrelor | -7.54 |
| Clopidogrel+Cilostazol | -3.97 |
Event rate of all-Cause Mortality (ACM) or re-Hospitalization for worsening heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 24.84 |
| Placebo | 24.57 |
Event Rate of all-cause mortality (ACM), MI, or stroke were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 patient [pt]-year [yr]) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 13.44 |
| Placebo | 14.27 |
Event rate of bleeding events and required Hospitalization were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 1.52 |
| Placebo | 1.16 |
Event rate of cardio vascular death were assessed. CV death included deaths due to spontaneous bleeding, MI, stroke, worsening HF and arrhythmias, death due to CV procedures and sudden death. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 9.46 |
| Placebo | 9.96 |
Event rate of cardio vascular (CV) death or re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 23.32 |
| Placebo | 23.46 |
Event rate of ISTH major bleeding event were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 2.04 |
| Placebo | 1.21 |
Event rate due to cardio vascular events were assessed. Hospitalization for a CV Event required that participants be hospitalized (in-patient or emergency department) for greater than 24 hours and must have met the following criterion:Discharge summary with primary reason for admission listed as CV in nature (example, bleeding, arrhythmia, ACS, MI) other than HF which was captured in the HF re-hospitalization. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 13.30 |
| Placebo | 14.04 |
Event rate of re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 17.24 |
| Placebo | 17.45 |
Event rate of either fatal bleeding or bleeding into critical space with potential for permanent disability were assessed. Fatal bleeding event was death within 7 days after a bleeding event which required hospitalization or met International Society on Thrombosis and Haemostasis(ISTH) major bleeding definition criteria. Fatal bleeding events included those met criteria in 3 categories: 1: Any ISTH major bleeding event consider primary cause of death by investigator; 2: Any ISTH major bleeding event not considered to be primary cause of death by investigator but resulted in death within 7 days;3: Any bleeding event resulted in hospital stay and death within 7 days. Bleeding into critical space with potential for permanent disability included 7 critical spaces: intracranial, intraspinal, intraocular. Event rate estimated based on time to first occurrence of event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks
| Intervention | Event rate per 100 patient-year (Number) | |
|---|---|---|
| Fatal Bleeding | Critical Space Bleeding with Permanent Disability | |
| Placebo | 0.22 | 0.48 |
| Rivaroxaban | 0.22 | 0.32 |
"Day 10 occurs in each treatment period at which time data collections are made. 12.1.4. Responders and Poor Responders~Numerous studies have established an association between high on-treatment platelet reactivity with clopidogrel and an increased risk for post-PCI ischemic events. In this study, the percentages of responders and poor responders following treatment with prasugrel and clopidogrel were compared. Poor responders were defined based on an Accumetrics VerifyNow PRU >235 and a VASP PRI >50%, as assessed 24 hours after the 9th maintenance dose." (NCT01260584)
Timeframe: Day 10 for Active Treatment Periods 1 and 2
| Intervention | P2Y12 reaction unit (Least Squares Mean) |
|---|---|
| Prasugrel Smokers | 85.1 |
| Prasugrel Non-Smokers | 106.3 |
| Clopidogrel Smokers | 178.9 |
| Clopidogrel Non-Smokers | 215.1 |
"Day 10 occurs in each treatment period at which time data collections are made. Numerous studies have established an association between high on-treatment platelet reactivity with clopidogrel and an increased risk for post-PCI ischemic events. In this study, the percentages of responders and poor responders following treatment with prasugrel and clopidogrel were compared. Poor responders were defined based on an Accumetrics VerifyNow PRU >235 and a VASP PRI >50%, as assessed 24 hours after the 9th maintenance dose." (NCT01260584)
Timeframe: Day 10 for Active Treatment Periods 1 and 2
| Intervention | % vasodilator stimulated phosphoprotein (Least Squares Mean) |
|---|---|
| Prasugrel Smokers | 25.4 |
| Prasugrel Non-Smokers | 31.2 |
| Clopidogrel Smokers | 48.1 |
| Clopidogrel Non-Smokers | 55.7 |
Blood samples for determination of plasma concentrations of the prasugrel active metabolite, clopidogrel active metabolite, and clopidogrel inactive metabolite will be collected following the administration of the 10th (last) maintenance dose of each of the 2 Active Treatment Periods at 0.5, 1, 2, 4, and 6 hours post-dose. (NCT01260584)
Timeframe: After dose on Day 10 of Active Treatment Periods 1 and 2
| Intervention | hr*ng/mL (Geometric Mean) |
|---|---|
| Prasugrel Smokers | 53.7 |
| Prasugrel Non-Smokers | 48.1 |
| Clopidogrel Smokers | 19.9 |
| Clopidogrel Non-Smokers | 16.2 |
(NCT01260584)
Timeframe: After dose on Day 10 of Active Treatment Periods 1 and 2
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Prasugrel Smokers | 42.9 |
| Prasugrel Non-Smokers | 35.9 |
| Clopidogrel Smokers | 14.1 |
| Clopidogrel Non-Smokers | 10.8 |
IPA will be measured by the Accumetrics P2Y12 Assay Device. Response will be assessed in P2Y12 Reaction Units and as Platelet Reactivity Index (vasodilator-stimulated phosphoprotein assay). (NCT01260584)
Timeframe: Baseline to day 10 for Active Treatment Periods 1 and 2
| Intervention | percentage of device derived inhibition (Least Squares Mean) |
|---|---|
| Prasugrel Smokers | 70.3 |
| Prasugrel Non-Smokers | 65.6 |
| Clopidogrel Smokers | 38.6 |
| Clopidogrel Non-Smokers | 30.9 |
(NCT01260584)
Timeframe: Day 10 for Active Treatment Periods 1 and 2
| Intervention | % participants with PRU <=235 (Number) |
|---|---|
| Prasugrel Smokers | 98.0 |
| Prasugrel Non-Smokers | 96.2 |
| Clopidogrel Smokers | 76.6 |
| Clopidogrel Non-Smokers | 61.1 |
"Numerous studies have established an association between high on-treatment platelet reactivity with clopidogrel and an increased risk for post-PCI ischemic events. In this study, the percentages of responders and poor responders following treatment with prasugrel and clopidogrel were compared. Poor responders were defined based on an Accumetrics VerifyNow PRU >235 and a VASP PRI >50%, as assessed 24 hours after the 9th maintenance dose." (NCT01260584)
Timeframe: Day 10 for Active Treatment Periods 1 and 2
| Intervention | % participants with PRI <=50% (Number) |
|---|---|
| Prasugrel Smokers | 96.0 |
| Prasugrel Non-Smokers | 82.7 |
| Clopidogrel Smokers | 51.1 |
| Clopidogrel Non-Smokers | 44.4 |
Area under the plasma concentration curve of AZD6140 drug metabolite AR-C124910XX from time zero to dosing interval (NCT01118325)
Timeframe: Week 4
| Intervention | ng.h/mL (Geometric Mean) |
|---|---|
| AZD6140 45 mg bd in Japanese Patients | 1180 |
| AZD6140 45 mg bd in Non-Japanese Patients | 954 |
| AZD6140 90 mg bd in Japanese Patients | 2720 |
| AZD6140 90 mg bd in Non-Japanese Patients | 3380 |
Maximum plasma concentration of AZD6140 drug metabolite AR-C124910XX (NCT01118325)
Timeframe: Week 4
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| AZD6140 45 mg bd in Japanese Patients | 135 |
| AZD6140 45mg bd in Non-Jpanese Patients | 101 |
| AZD6140 90 mg bd in Japanese Patients | 326 |
| AZD6140 90 mg bd in Non-Jpanese Patients | 381 |
Time to reach peak or maximum concentration of AZD6140 drug metabolite AR-C124910XX following AZD6140 administration (NCT01118325)
Timeframe: Week 4
| Intervention | hour (Median) |
|---|---|
| AZD6140 45 mg bd in Japanese Patients | 4.0 |
| AZD6140 45 mg bd in Non-Japanese Patients | 4.0 |
| AZD6140 90 mg bd in Japanese Patients | 2.1 |
| AZD6140 90 mg bd in Non-Japanese Patients | 2.0 |
Area under the plasma concentration curve of AZD6140 from time zero to dosing interval (NCT01118325)
Timeframe: Week 4
| Intervention | ng.h/mL (Geometric Mean) |
|---|---|
| AZD6140 45 mg bd in Japanese Patients | 3050 |
| AZD6140 45 mg bd in Non-Japanese Patients | 2930 |
| AZD6140 90 mg bd in Japanese Patients | 6080 |
| AZD6140 90 mg bd in Non-Japanese Patients | 10900 |
Maximum plasma AZD6140 concentration (NCT01118325)
Timeframe: Week 4
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| AZD6140 45 mg bd in Japanese Patients | 422 |
| AZD6140 45 mg bd in Non-Japanese Patients | 341 |
| AZD6140 90 mg bd in Japanese Patients | 931 |
| AZD6140 90 mg bd in Non-Japanese Patients | 1380 |
Time to reach peak or maximum concentration of AZD6140 following AZD6140 administration (NCT01118325)
Timeframe: Week 4
| Intervention | hour (Median) |
|---|---|
| AZD6140 45 mg bd in Japanese Patients | 2.0 |
| AZD6140 45 mg bd in Non-Japanese Patients | 4.0 |
| AZD6140 90 mg bd in Japanese Patients | 2.0 |
| AZD6140 90 mg bd in Non-Japanese Patients | 4.0 |
"Final extent IPA from pre-dose baseline was calculated using the following formula for Adenosine Diphosphate (ADP)-induced platelet aggregation:~Percentage Inhibition = 100% x (PAs - PA) / (PAs) Platelet Aggregation (PA) was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit." (NCT01118325)
Timeframe: Week 4
| Intervention | percentage inhibition (Mean) |
|---|---|
| AZD6140 45 mg bd | 64.5 |
| AZD6140 90 mg bd | 73.0 |
| Clopidogrel 75 mg od | 38.9 |
"Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation:~Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit." (NCT01118325)
Timeframe: Week 4
| Intervention | percentage inhibition (Mean) |
|---|---|
| Arm 1 - AZD6140 45 mg bd | 56.9 |
| AZD6140 90 mg bd | 66.8 |
| Clopidogrel 75 mg od | 41.8 |
"Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation:~Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit." (NCT01118325)
Timeframe: Week 4
| Intervention | percentage inhibition (Mean) |
|---|---|
| AZD6140 45 mg bd | 46.2 |
| AZD6140 90 mg bd | 59.1 |
| Clopidogrel 75 mg od | 38.0 |
"Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation:~Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit." (NCT01118325)
Timeframe: Week 4
| Intervention | percentage inhibition (Mean) |
|---|---|
| AZD6140 45 mg bd | 67.3 |
| AZD6140 90 mg bd | 73.2 |
| Clopidogrel 75 mg od | 43.7 |
"Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation:~Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit." (NCT01118325)
Timeframe: Week 4
| Intervention | percentage inhibition (Mean) |
|---|---|
| AZD6140 45 mg bd | 62.7 |
| AZD6140 90 mg bd | 68.6 |
| Clopidogrel 75 mg od | 42.5 |
"Bleeding classified by the TIMI hemorrhage classification scheme:~Minor: any clinically overt sign of hemorrhage (including imaging) that is associated with a hemoglobin drop of 3 to < 5 g/dL~Major: (1) if it is intracranial, or (2) clinically significant overt signs of hemorrhage associated with a drop inhemoglobin of > 5 g/dL" (NCT01515345)
Timeframe: 30days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 17 |
| Individualized Therapy | 9 |
"The angiographic or pathological confirmation of stent thrombosis is called definite stent thrombosis" (NCT01515345)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 1 |
| Individualized Therapy | 0 |
"Probable stent thrombosis is considered to have occurred in case of~any unexplained death within the first 30 days.~any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause, irrespective of the time after the index procedure" (NCT01515345)
Timeframe: 30days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 2 |
| Individualized Therapy | 0 |
(NCT01523392)
Timeframe: At 2 hours after the loading dose
| Intervention | PRU (Least Squares Mean) |
|---|---|
| Ticagrelor | 27.6 |
| Clopidogrel | 211.2 |
The standard deviation (SD) is the geometric SD (NCT01523392)
Timeframe: Predose, 0.5 hour, 2 hours, 8 hours from loading dose and 0, 2 hours, 8 hours and 12 hours from last dose
| Intervention | ng/mL (Geometric Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline (0 pre-dose hours) | 0.5 hours after the loading dose | 2 hours after the loading dose | 8 hours after the loading dose - Period 1 N=19 | 0 hours after multiple doses - Period 1 N=18 | 2 hours after multiple doses - Period 1 N=18 | 8 hours after multiple doses - Period 1 N=18 | End of dosing interval on Day 8 - Period 1 N=18 | |
| Ticagrelor (Treatment Period 1) | 1.0 | 9.8 | 222.6 | 119.0 | 93.2 | 136.7 | 89.8 | 140.8 |
| Ticagrelor (Treatment Period 2) | 1.0 | 2.3 | 150.9 | 54.8 | 74.5 | 172.3 | 112.6 | 110.3 |
(NCT01523392)
Timeframe: At 0.5 hour and 8 hours after the loading dose
| Intervention | PRU (Least Squares Mean) | |
|---|---|---|
| 0.5 hours | 8 hours (N=28 ticagrelor, N=27 clopidogrel) | |
| Clopidogrel | 270.1 | 192.6 |
| Ticagrelor | 166.3 | 27.2 |
(NCT01523392)
Timeframe: At 2 hours and 8 hours on Day 7 after multiple doses and at end of dosing interval on Day 8
| Intervention | PRU (Least Squares Mean) | ||
|---|---|---|---|
| 2 hours on Day 7 (N=27 for clopidogrel) | 8 hours on Day 7 | End of dosing interval on Day 8 | |
| Clopidogrel | 157.8 | 146.5 | 172.7 |
| Ticagrelor | 22.9 | 28.5 | 39.3 |
The standard deviation (SD) is the geometric SD (NCT01523392)
Timeframe: Predose, 0.5 hour, 2 hours, 8 hours from loading dose; 0, 2 hours, 8 hours and 12 hours from last dose
| Intervention | ng/mL (Geometric Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline (0 pre-dose hours) | 0.5 hours after the loading dose | 2 hours after the loading dose | 8 hours after the loading dose - Period 1 N=19 | 0 hours after multiple doses - Period 1 N=18 | 2 hours after multiple doses - Period 1 N=18 | 8 hours after multiple doses - Period 1 N=18 | End of dosing interval on Day 8 - Period 1 N=18 | |
| Ticagrelor (Treatment Period 1) | 1.0 | 206.6 | 1167.3 | 395.9 | 168.4 | 324.6 | 179.2 | 284.9 |
| Ticagrelor (Treatment Period 2) | 1.2 | 33.7 | 756.9 | 141.9 | 187.4 | 608.8 | 311.3 | 295.7 |
Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 5.1 |
| Ticagrelor 60 mg | 4.7 |
| Placebo | 5.2 |
A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.6 |
| Ticagrelor 60 mg | 2.3 |
| Placebo | 1.1 |
Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.9 |
| Ticagrelor 60 mg | 2.9 |
| Placebo | 3.4 |
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 7.8 |
| Ticagrelor 60 mg | 7.8 |
| Placebo | 9.0 |
[Key secondary outcome] Change in hemoglobin from the most recent measured before delivery to lowest measured in the 48 hours after delivery (NCT03364491)
Timeframe: from 4 weeks before delivery to 48 hours postpartum
| Intervention | grams per deciliter (Mean) |
|---|---|
| Tranexamic Acid | -1.8 |
| Placebo | -1.9 |
Mother's length of stay from delivery to discharge (NCT03364491)
Timeframe: Until hospital discharge, an average of 3 days
| Intervention | days (Median) |
|---|---|
| Tranexamic Acid | 3 |
| Placebo | 3 |
(NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 35 |
| Placebo | 32 |
This is the number of mothers who were treated with any amount of open-label TXA (not blinded study drug) or another antifibrinolytic (eg., Amicar) (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 108 |
| Placebo | 109 |
This is the number of mothers who required any of the following types of surgical procedures to control bleeding: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 233 |
| Placebo | 231 |
[Key secondary outcome] This is the number of mothers who received treatments and interventions to control bleeding such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 892 |
| Placebo | 986 |
Participants were categorized according to the amount of packed red blood cells or whole blood transfused, either as 0 to 3 units, or 4 or more units (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 20 |
| Placebo | 19 |
This is the number of mothers who received during the first 7 days after delivery a transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets, or received any factor concentrates (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 29 |
| Placebo | 31 |
This is the number of mothers who were treated with uterotonics such as prostaglandins or methergine, but excluding oxytocin, from delivery through 48 hours after delivery. (NCT03364491)
Timeframe: within 48 hours postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 649 |
| Placebo | 732 |
[Key secondary outcome] This is the number of mothers who experienced a thromboembolic event, ischemic stroke, or myocardial infarction during the 6 weeks after delivery. (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 12 |
| Placebo | 13 |
[Major secondary outcome] The surgeon or anesthesiologist estimated the blood loss during the delivery in milliliters, which was recorded in the anesthesia record and/or operative report (NCT03364491)
Timeframe: From skin incision to transfer from operating room, average of 1 hour
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 339 |
| Placebo | 368 |
Participants were monitored from delivery until hospital discharge or 7 days after delivery (postpartum), whichever is sooner. This is the number of mothers who died for any reason, or had a blood transfusion of 1 or more units (of packed red blood cells, including whole blood or cell saver). (NCT03364491)
Timeframe: by hospital discharge or by 7 days postpartum, whichever is sooner
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 201 |
| Placebo | 233 |
[Key Secondary Outcome] This is the number of mothers who experienced any of the following infectious complications in the 6 weeks after delivery: endometritis, surgical site infection, pelvic abscess (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 162 |
| Placebo | 125 |
This is the number of mothers who experienced seizure activity, confirmed by central review, whose onset is after enrollment (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 2 |
| Placebo | 0 |
Plasma TxA concentrations measured from blood samples taken upon arrival in the ICU (NCT03376061)
Timeframe: on arrival in ICU within 3 hours
| Intervention | microgram per milliliter per kilogram (Mean) |
|---|---|
| Topical TxA (Intervention) | 0.58 |
| Intravenous TxA (Control) | 1.10 |
Number of hours participants spent in the intensive care unit (ICU) (NCT03376061)
Timeframe: Number of hours spent in ICU from arrival to exit (collected at the Post-Operative Visit).
| Intervention | hours (Median) |
|---|---|
| Topical TxA (Intervention) | 23 |
| Intravenous TxA (Control) | 26 |
Cumulative volume (mL) of fluid collected from mediastinal drainage tubes 24 hours after the surgical procedure (NCT03376061)
Timeframe: Fluid collected in the first 24 hours after the surgical procedure
| Intervention | mL (Median) |
|---|---|
| Topical TxA (Intervention) | 500 |
| Intravenous TxA (Control) | 540 |
The occurrence of death due to any cause (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 1 |
| Intravenous TxA (Control) | 1 |
Patients requiring a red blood cell transfusion (NCT03376061)
Timeframe: Intra-operative and post-operative RBC transfusions
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 19 |
| Intravenous TxA (Control) | 23 |
Occurrence of re-operation for the purpose of bleeding or cardiac tamponade (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 0 |
| Intravenous TxA (Control) | 1 |
Patients experiencing a post-operative seizure (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 0 |
| Intravenous TxA (Control) | 1 |
SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin. (NCT00528411)
Timeframe: Baseline
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 96.59 |
| Clopidogrel | 96.78 |
| Placebo | 97.58 |
EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle. (NCT00528411)
Timeframe: Baseline
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 57.96 |
| Clopidogrel | 61.91 |
| Placebo | 59.92 |
FEV1 is measured by Spirometry, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 2.79 |
| Clopidogrel | 2.71 |
| Placebo | 2.94 |
FVC is measured by Spirometry, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 3.72 |
| Clopidogrel | 3.73 |
| Placebo | 4.03 |
FRC is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 2.79 |
| Clopidogrel | 2.89 |
| Placebo | 2.91 |
FEF25-75 is measured by Spirometry, the unit is Liter/Second. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter/second (Mean) |
|---|---|
| Ticagrelor | 2.88 |
| Clopidogrel | 2.70 |
| Placebo | 2.50 |
VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute (NCT00528411)
Timeframe: Baseline
| Intervention | Liter/minute (Mean) |
|---|---|
| Ticagrelor | 12.92 |
| Clopidogrel | 12.17 |
| Placebo | 12.06 |
NT-proBNP is measured by clinical lab, the unit is pg/mL. (NCT00528411)
Timeframe: Baseline
| Intervention | pg/ml (Mean) |
|---|---|
| Ticagrelor | 163.34 |
| Clopidogrel | 185.98 |
| Placebo | 145.41 |
FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio. (NCT00528411)
Timeframe: Baseline
| Intervention | Ratio (Mean) |
|---|---|
| Ticagrelor | 75.01 |
| Clopidogrel | 73.04 |
| Placebo | 73.13 |
RV is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 1.94 |
| Clopidogrel | 2.01 |
| Placebo | 1.91 |
RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute. (NCT00528411)
Timeframe: Baseline
| Intervention | Breaths/minute (Mean) |
|---|---|
| Ticagrelor | 14.79 |
| Clopidogrel | 14.15 |
| Placebo | 15.5 |
DLCOSB is measured by Body Box Plethysmography, the unit is Percent. (NCT00528411)
Timeframe: Baseline
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 17.00 |
| Clopidogrel | 17.29 |
| Placebo | 15.83 |
VT is measured by Body Box Plethysmography, the unit is Liter/Minute. (NCT00528411)
Timeframe: Baseline
| Intervention | Liters/minute (Mean) |
|---|---|
| Ticagrelor | 0.96 |
| Clopidogrel | 0.89 |
| Placebo | 0.89 |
TLC is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 5.78 |
| Clopidogrel | 5.83 |
| Placebo | 6.10 |
FEV1 is measured by Spirometry, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 2.77 |
| Clopidogrel | 2.74 |
| Placebo | 2.95 |
FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Ratio (Mean) |
|---|---|
| Ticagrelor | 74.71 |
| Clopidogrel | 72.84 |
| Placebo | 74.27 |
FVC is measured by Spirometry, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 3.70 |
| Clopidogrel | 3.78 |
| Placebo | 3.98 |
DLCOSB is measured by Body Box Plethysmography, the unit is Percent. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 16.38 |
| Clopidogrel | 16.53 |
| Placebo | 16.09 |
EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 60.70 |
| Clopidogrel | 62.38 |
| Placebo | 60.73 |
FEF25-75 is measured by Spirometry, the unit is Liter/Second. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter/second (Mean) |
|---|---|
| Ticagrelor | 2.77 |
| Clopidogrel | 2.67 |
| Placebo | 2.91 |
FRC is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 2.73 |
| Clopidogrel | 2.79 |
| Placebo | 2.75 |
NT-proBNP is measured by clinical lab, the unit is pg/mL. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | pg/ml (Mean) |
|---|---|
| Ticagrelor | 139.88 |
| Clopidogrel | 214.43 |
| Placebo | 140.68 |
RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Breaths/minute (Mean) |
|---|---|
| Ticagrelor | 15.21 |
| Clopidogrel | 15.10 |
| Placebo | 14.91 |
RV is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 1.88 |
| Clopidogrel | 1.97 |
| Placebo | 1.90 |
SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Percentage (Mean) |
|---|---|
| Ticagrelor | 97.73 |
| Clopidogrel | 97.35 |
| Placebo | 98.56 |
TLC is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 5.70 |
| Clopidogrel | 5.85 |
| Placebo | 5.96 |
VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter/minute (Mean) |
|---|---|
| Ticagrelor | 13.69 |
| Clopidogrel | 13.14 |
| Placebo | 11.45 |
VT is measured by Body Box Plethysmography, the unit is Liter/Minute. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liters/minute (Mean) |
|---|---|
| Ticagrelor | 0.92 |
| Clopidogrel | 0.93 |
| Placebo | 0.83 |
IPA(%)=(PAb-PAt)/PAb*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: At 2 hours after first dose of study drug
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 93.15 |
| Clopidogrel | 31.05 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 0 hour before last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 74.53 |
| Clopidogrel | 51.75 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 0.5 hours after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 45.39 |
| Clopidogrel | 4.71 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 1 hour after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 86.71 |
| Clopidogrel | 15.83 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 120 hours - Day 5 after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 0.0 |
| Clopidogrel | 21.15 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference of baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 168 hours - Day 7 after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 0.0 |
| Clopidogrel | 6.32 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 2 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 91.49 |
| Clopidogrel | 62.96 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 24 hours after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 87.29 |
| Clopidogrel | 49.64 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 24 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 55.18 |
| Clopidogrel | 53.91 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 240 hours - Day 10 after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 1.64 |
| Clopidogrel | 0.98 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 4 hours after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 98.39 |
| Clopidogrel | 40.87 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 4 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 96.10 |
| Clopidogrel | 61.80 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 48 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 30.94 |
| Clopidogrel | 45.79 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 72 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 11.76 |
| Clopidogrel | 21.09 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 8 hours after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 96.99 |
| Clopidogrel | 46.90 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 8 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 88.31 |
| Clopidogrel | 61.31 |
IPA(%)=(PAb-PAt)/PAb*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. The unit for the slope of IPA curve is percent/hour. (NCT00528411)
Timeframe: 4 to 72 Hours after last dose of study drug
| Intervention | Percentage/Hour (Least Squares Mean) |
|---|---|
| Ticagrelor | -1.037 |
| Clopidogrel | -0.482 |
"Platelet activation by adenosine diphosphate (ADP) expressed in arbitrary aggregation units (U). P2Y12 inhibitors block ADP receptors and decrease platelet activation by ADP. Higher values mean less effect of P2Y12 inhibitors, lower values mean more effect of P2Y12 inhibitors on platelets.~High on-treatment platelet reactivity was defined as >46 U." (NCT02224274)
Timeframe: 12 hours after P2Y12 inhibitor loading
| Intervention | U (Mean) |
|---|---|
| Clopidogrel | 28 |
| Ticagrelor | 15 |
% inhibition reflects P2Y12 inhibitor effect regarding basal platelet reactivity (defined as: (1- (platelet reactivity/basal platelet reactivity)) x 100). Higher values mean better P2Y12 inhibition response. High on-treatment platelet reactivity was defined as <11% inhibition. (NCT02224274)
Timeframe: 12 hours after P2Y12 inhibitor loading
| Intervention | % inhibition (Mean) |
|---|---|
| Clopidogrel | 4 |
| Ticagrelor | 55 |
Platelet reactivity reflects P2Y12 inhibitor effect. Higher values mean normal platelet reactivity due to low P2Y12 inhibition response, while lower values mean decreased platelet reactivity due to the effect of a P2Y12 inhibitor. High on-treatment platelet reactivity was defined as >208 PRU. (NCT02224274)
Timeframe: 12 h after P2Y12 inhibitor loading
| Intervention | PRU (Mean) |
|---|---|
| Clopidogrel | 238 |
| Ticagrelor | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
IPA(%)=(PAb-PAt)/PAb*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered. (NCT00642811)
Timeframe: Day 15, 4 hrs post switching
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Responder: Ticagrelor | 95.0 |
| Responder: Clopidogrel | 48.5 |
IPA(%)=(PAb-PAt)/PAb*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered. (NCT00642811)
Timeframe: 4 hrs post first dose on day 28
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Responder: Ticagrelor | 77.4 |
| Responder: Clopidogrel | 60.8 |
IPA(%)=(PAb-PAt)/PAb*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered. (NCT00642811)
Timeframe: Day 15, 4 hrs post switching
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Responder: Ticagrelor | 66.7 |
| Responder: Clopidogrel | 65.3 |
IPA(%)=(PAb-PAt)/PAb*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered. (NCT00642811)
Timeframe: 4 hrs post first dose on day 28
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Responder: Ticagrelor | 91.0 |
| Responder: Clopidogrel | 61.2 |
The secondary definition of response to treatment is IPA >50% post treatment. The response is reported as percentage of participants of each treatment. Please refer to the protocol section for details about the interventions administered. IPA(%)=(PAb-PAt)/PAb*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00642811)
Timeframe: Day 14, and day 28, 4 hours post dose
| Intervention | Percent of participants (Number) |
|---|---|
| Non-responder: Ticagrelor | 81.3 |
| Non-responder: Clopidogrel | 25.0 |
The primary definition of response to treatment is IPA >10% post treatment. The response is reported as percentage of participants of each treatment. Please refer to the protocol section for details about the interventions administered. IPA(%)=(PAb-PAt)/PAb*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00642811)
Timeframe: Day 14 and Day 28, 4 Hrs Post Dose.
| Intervention | Percent of Participants (Number) |
|---|---|
| Non-responder: Ticagrelor | 100 |
| Non-responder: Clopidogrel | 93.8 |
Defined as stent intimal hyperplasia and calculated as 100*(Stent Volume - Lumen Volume)/Stent Volume by IVUS. (NCT00180479)
Timeframe: at 240 days
| Intervention | percent of volume obstruction (Mean) |
|---|---|
| XIENCE V® EECSS | 6.91 |
| TAXUS® EXPRESS2™ ECSS | 11.21 |
Successful delivery and deployment of 1st implanted study stent/s @ the intended target lesion and successful withdrawal of the stent delivery system with final residual stenosis < 50%. (NCT00180479)
Timeframe: In-hospital
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 98.3 |
| TAXUS® EXPRESS2™ ECSS | 98.7 |
Successful delivery and deployment of study stent/s @ the intended target lesion and successful withdrawal of the stent delivery system with final residual stenosis < 50%. (NCT00180479)
Timeframe: In-hospital
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 98.5 |
| TAXUS® EXPRESS2™ ECSS | 97.3 |
Distal MLD post-procedure minus distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to stent placement) (NCT00180479)
Timeframe: 240 days
| Intervention | millimeters (Mean) |
|---|---|
| XIENCE V® EECSS | 0.09 |
| TAXUS® EXPRESS2™ ECSS | 0.10 |
Percent of subjects with a follow-up in-segment percent diameter stenosis of ≥ 50% per QCA (NCT00180479)
Timeframe: 240 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 4.7 |
| TAXUS® EXPRESS2™ ECSS | 8.9 |
Within the margins of the stent, 5 mm proximal and 5 mm distal to the stent, the value calculated as 100 * (1 - in-segment MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA. (NCT00180479)
Timeframe: 240 days
| Intervention | percent of in-segment diameter stenosis (Mean) |
|---|---|
| XIENCE V® EECSS | 18.77 |
| TAXUS® EXPRESS2™ ECSS | 22.82 |
Percent of subjects with a follow-up in-stent percent diameter stenosis of ≥ 50% per quantitative coronary angiography (QCA) (NCT00180479)
Timeframe: at 240 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 2.3 |
| TAXUS® EXPRESS2™ ECSS | 5.7 |
In-stent: Within the margins of the stent, the value calculated as 100 * (1 - in-stent MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA. (NCT00180479)
Timeframe: at 240 days
| Intervention | percent diameter stenosis (Mean) |
|---|---|
| XIENCE V® EECSS | 5.92 |
| TAXUS® EXPRESS2™ ECSS | 10.30 |
In-stent MLD post-procedure minus in-stent MLD at follow-up (in-stent defined as within the margins of the stent) (NCT00180479)
Timeframe: at 240 days
| Intervention | millimeters (Mean) |
|---|---|
| XIENCE V® EECSS | 0.16 |
| TAXUS® EXPRESS2™ ECSS | 0.30 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 6.0 |
| TAXUS® EXPRESS2™ ECSS | 10.3 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 180 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 2.9 |
| TAXUS® EXPRESS2™ ECSS | 5.2 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 270 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 5.0 |
| TAXUS® EXPRESS2™ ECSS | 8.8 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 3 year
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 9.7 |
| TAXUS® EXPRESS2™ ECSS | 16.4 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 1.3 |
| TAXUS® EXPRESS2™ ECSS | 3.0 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 4 year
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 12.8 |
| TAXUS® EXPRESS2™ ECSS | 18.5 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 14.4 |
| TAXUS® EXPRESS2™ ECSS | 22.0 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 7.7 |
| TAXUS® EXPRESS2™ ECSS | 13.8 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 1 years
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 3.4 |
| TAXUS® EXPRESS2™ ECSS | 5.6 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 180 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 1.5 |
| TAXUS® EXPRESS2™ ECSS | 2.1 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 5.7 |
| TAXUS® EXPRESS2™ ECSS | 9.2 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 270 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 2.7 |
| TAXUS® EXPRESS2™ ECSS | 5.0 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 3 year
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 5.7 |
| TAXUS® EXPRESS2™ ECSS | 9.2 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 0.4 |
| TAXUS® EXPRESS2™ ECSS | 0.3 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 4 year
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 8.0 |
| TAXUS® EXPRESS2™ ECSS | 10.6 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 8.9 |
| TAXUS® EXPRESS2™ ECSS | 12.9 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 3.1 |
| TAXUS® EXPRESS2™ ECSS | 4.7 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 180 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 1.2 |
| TAXUS® EXPRESS2™ ECSS | 1.8 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 4.9 |
| TAXUS® EXPRESS2™ ECSS | 6.6 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 270 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 2.9 |
| TAXUS® EXPRESS2™ ECSS | 4.1 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 6.7 |
| TAXUS® EXPRESS2™ ECSS | 8.9 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 0.3 |
| TAXUS® EXPRESS2™ ECSS | 0.9 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 4 years
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 7.8 |
| TAXUS® EXPRESS2™ ECSS | 9.6 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 8.8 |
| TAXUS® EXPRESS2™ ECSS | 11.9 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 270 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 7.2 |
| TAXUS® EXPRESS2™ ECSS | 9.0 |
"Incomplete Apposition (Persisting & Late acquired): Failure to completely appose vessel wall w/ ≥1 strut separated from vessel wall w/ blood behind strut per ultrasound. Aneurysm: Abnormal vessel expansion ≥ 1.5 of reference vessel diameter. Thrombus: Protocol & ARC definition.~Persisting dissection @ follow-up, present post-procedure." (NCT00180479)
Timeframe: at 240 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 24.4 |
| TAXUS® EXPRESS2™ ECSS | 14.0 |
In-segment minimal lumen diameter (MLD) post-procedure minus (-) in segment MLD at 240 day follow-up and 5 mm proximal and 5mm distal to the stent equals Late Loss. MLD defined: The average of two orthogonal views (when possible) of the narrowest point within the area of assessment. (NCT00180479)
Timeframe: 240 days
| Intervention | millimeters (Mean) |
|---|---|
| XIENCE V® EECSS | 0.14 |
| TAXUS® EXPRESS2™ ECSS | 0.28 |
Proximal Minimum Lumen Diameter (MLD) post-procedure minus proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to stent placement) (NCT00180479)
Timeframe: at 240 days
| Intervention | millimeters (Mean) |
|---|---|
| XIENCE V® EECSS | 0.12 |
| TAXUS® EXPRESS2™ ECSS | 0.20 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 8.6 |
| TAXUS® EXPRESS2™ ECSS | 11.6 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 180 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 4.1 |
| TAXUS® EXPRESS2™ ECSS | 5.5 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 2 year
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 11.3 |
| TAXUS® EXPRESS2™ ECSS | 16.4 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 3 year
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 14.3 |
| TAXUS® EXPRESS2™ ECSS | 20.0 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 1.6 |
| TAXUS® EXPRESS2™ ECSS | 3.3 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 4 year
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 18.5 |
| TAXUS® EXPRESS2™ ECSS | 22.5 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 20.3 |
| TAXUS® EXPRESS2™ ECSS | 26.6 |
The inhibition of platelet aggregation 4 hours after the loading dose was administered was assessed using the Accumetrics VerifyNow™ P2Y12 assay. Percentage inhibition, as reported by VerifyNow™ P2Y12, was calculated from P2Y12 Reaction Unit (PRU) (rate and extent of adenosine diphosphate [ADP]-stimulated platelet aggregation) and BASE (estimate of baseline platelet reactivity independent of P2Y12 receptor inhibition [reference values]: rate and extent of Thrombin Receptor-Activated Peptide-stimulated platelet aggregation) values as follows: Percentage (%) inhibition = (1-PRU/BASE) x 100. (NCT00642174)
Timeframe: 4 hours after loading dose
| Intervention | percent inhibition (Least Squares Mean) | |
|---|---|---|
| Baseline | 4 Hours After Loading Dose | |
| Clopidogrel | 9.3 | 27.7 |
| Prasugrel | 9.4 | 89.3 |
Inhibition of platelet aggregation 1- and 24-hours after loading dose and 24-hours after last maintenance dose was administered was assessed using Accumetrics VerifyNow™ P2Y12 assay. Percentage inhibition, as reported by VerifyNow™ P2Y12, was calculated from PRU (rate and extent of ADP-stimulated platelet aggregation) and BASE (estimate of baseline platelet reactivity independent of P2Y12 receptor inhibition [reference values]: rate and extent of Thrombin Receptor-Activated Peptide-stimulated platelet aggregation) values as follows: Percentage (%) inhibition = (1-PRU/BASE) x 100. (NCT00642174)
Timeframe: 1 hour and 24 hours after the loading dose (LD) and 24 hours after the last maintenance dose (LMD)
| Intervention | percent inhibition (Least Squares Mean) | ||
|---|---|---|---|
| 1 Hour After Loading Dose | 24 Hours After Loading Dose | 24 Hours After Last Maintenance Dose | |
| Clopidogrel | 13.4 | 29.3 | 44.2 |
| Prasugrel | 49.9 | 87.1 | 61.8 |
Thromboelastography (TEG) platelet mapping (MP) maximum amplitude (MA) - Adenosine Diphosphate (ADP) millimeters (mm) at each time point. The TEG-MP MA measures strength of clot formation in whole blood. MA-ADP is the maximal amplitude resulting from fibrin and platelets not blocked by ADP-receptor inhibiting drugs. Fibrin strands in blood sample link a rotating sample cup with a stationary pin suspended by a torsion wire. The degree of platelet contribution to the MA through platelet-fibrin bonding directly influences the magnitude of pin movement and ultimately the amplitude of the tracing. (NCT00642174)
Timeframe: Baseline, 1 Hour, 4 Hours, and 24 Hours after loading dose, and 24 Hours after last maintenance dose
| Intervention | millimeters (mm) (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Baseline | 1 Hour After Loading Dose | 4 Hours After Loading Dose | 24 Hours After Loading Dose | 24 Hours After Last Maintenance Dose | |
| Clopidogrel | 58.1 | 54.8 | 48.1 | 49.2 | 46.8 |
| Prasugrel | 56.8 | 38.5 | 24.2 | 29.3 | 44.2 |
Mean platelet aggregation (MPA) to 5 and 20 µM adenosine diphosphate (ADP) was assessed by light transmittance aggregometry (LTA). Platelet aggregation was monitored for a total of 7 minutes after addition of ADP. Maximum platelet aggregation was the maximal aggregation value achieved during the 7-minute observation period following addition of agonists. (NCT00642174)
Timeframe: Baseline, 1 Hour, 4 Hours, and 24 Hours after loading dose, and 24 Hours after last maintenance dose
| Intervention | percent platelet aggregation (Least Squares Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (5 μM ADP) | 1 Hour After Loading Dose (5 μM ADP) | 4 Hours After Loading Dose (5 μM ADP) | 24 Hours After Loading Dose (5 μM ADP) | 24 Hours After Last Maintenance Dose (5 μM ADP) | Baseline (20 μM ADP) | 1 Hour After Loading Dose (20 μM ADP) | 4 Hours After Loading Dose (20 μM ADP) | 24 Hours After Loading Dose (20 μM ADP) | 24 Hours After Last Maintenance Dose (20 μM ADP) | |
| Clopidogrel | 65.7 | 56.7 | 44.6 | 45.6 | 38.3 | 76.9 | 69.8 | 57.5 | 58.4 | 50.7 |
| Prasugrel | 64.9 | 33.7 | 18.0 | 22.3 | 29.6 | 77.1 | 44.7 | 22.4 | 27.4 | 38.3 |
Data from the Vasodilator-associated stimulated phosphoprotein assay were reported as the platelet reactivity index (PRI) which was calculated from corrected mean fluorescence intensity (cMFI) following incubation of platelets with either prostaglandin E1 (PGE1) alone or PGE1 plus ADP: Platelet Reactivity Index (%) = [1-(cMFI PGEI+ADP/cMFI PGEI)] x 100. Lower PRI values indicate greater platelet P2Y12 inhibition. (NCT00642174)
Timeframe: Baseline, 1 Hour, 4 Hours, and 24 Hours after loading dose, and 24 Hours after last maintenance dose
| Intervention | percent inhibition (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Baseline | 1 Hour After Loading Dose | 4 Hours After Loading Dose | 24 Hours After Loading Dose | 24 Hours After Last Maintenance Dose | |
| Clopidogrel | 80.6 | 76.2 | 67.5 | 58.5 | 42.3 |
| Prasugrel | 83.5 | 40.0 | 14.5 | 15.7 | 27.4 |
Collagen induced aggregation using light transmittance aggregometry (NCT01201785)
Timeframe: after 1 -week of treatment
| Intervention | percentage of platelet aggregation (Mean) |
|---|---|
| Aspirin Dose Range | 32 |
Number of patients who died in each treatment group prior to the 6 month follow-up time point. (NCT00323258)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Intervention | 1 |
| Usual Care | 2 |
Percent of patients in each group adherent to triple therapy (aspirin/antiplatelet; beta blocker; and statin) 6 months after discharge as assessed by medication history obtained during a follow-up phone call by a blinded pharmacist (NCT00323258)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Intervention | 91 |
| Usual Care | 94 |
Percent of patients in each group adherent to beta-blocker and statin for 6 months after discharge as assessed by refill records from the patient's pharmacy (NCT00323258)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Intervention | 53 |
| Usual Care | 38 |
"According to the local pharmacy records, the patient has had a supply of beta-blocker for at least 75% of the days from the day of discharge to 180 days after the discharge date. Refill records from 90 days prior to index admission will be taken into account.~% adherence = (days of available drug supply in the first 180 days/180)*100 If % adherence = or > 75, then adherence = yes" (NCT00323258)
Timeframe: 6 months
| Intervention | percentage of patients with PDC >or=75% (Number) |
|---|---|
| Intervention | 71 |
| Usual Care | 49 |
"According to the local pharmacy records, the patient has had a supply of statin for at least 75% of the days from the day of discharge to 180 days after the discharge date. Refill records from 90 days prior to index admission will be taken into account.~% adherence = (days of available drug supply in the first 180 days/180)*100 If % adherence = or > 75, then adherence = yes" (NCT00323258)
Timeframe: 6 months
| Intervention | percentage of patients with >or=75% (Number) |
|---|---|
| Intervention | 58 |
| Usual Care | 49 |
Serum was separated by centrifugation from the blood samples. For high-sensitivity C-Reactive Protein measurement, whole venous blood was collected in tubes without anticoagulant and centrifuged at room temperature. Serum C-Reactive Protein was assessed with a high-sensitivity, latex microparticle-enhanced immunoturbidimetric assay (Behring Nephelometer Analyzer System; Behring Diagnostics, Somerville, NJ). (NCT00474123)
Timeframe: Change from baseline at 6 weeks
| Intervention | Percentage (Median) |
|---|---|
| Simvastatin 80 mg | -16 |
| Simvastatin 20mg/Ezetimibe 10 mg | -11 |
Endothelial progenitor cells were evaluated by flow cytometry. Selected cells were positive for CD31, CD34 and VEGFR receptors. (NCT00474123)
Timeframe: Fasting venous blood samples were drawn immediately after randomization and at the conclusions of the six week study period.
| Intervention | percentage (Mean) |
|---|---|
| Simvastatin 80 mg | 0.4 |
| Simvastatin 20mg/Ezetimibe 10 mg | 0.1 |
A commercial ELISA assay detecting IL-6 (Siemens, USA) was applied. (NCT00474123)
Timeframe: Fasting venous blood samples were drawn immediately after randomization and after at the conclusions of the six weeks study period.
| Intervention | percentage (Median) |
|---|---|
| Simvastatin 80 mg | 0 |
| Simvastatin 20mg/Ezetimibe 10 mg | 0 |
(NCT00474123)
Timeframe: Fasting venous blood samples were drawn immediately after randomization and at the conclusions of the six week study period.
| Intervention | percentage (Mean) |
|---|---|
| Simvastatin 80 mg | -28 |
| Simvastatin 20mg/Ezetimibe 10 mg | -29 |
Serum samples were stored at -70°C and were determined simultaneously by ELISA in order to avoid variation of assay conditions. Commercial ELISA assays detecting MCP-1/ICAM-1 (R&D Systems, Europe, Abingdon, UK). (NCT00474123)
Timeframe: Change from baseline at 6 weeks
| Intervention | percentage (Mean) |
|---|---|
| Simvastatin 80 mg | 11 |
| Simvastatin 20mg/Ezetimibe 10 mg | 10 |
Serum samples were stored at -70°C and were determined simultaneously by ELISA in order to avoid variation of assay conditions. Commercial ELISA assays detecting oxLDL (Mercodia, USA) were applied. (NCT00474123)
Timeframe: Change from baseline at 6 weeks
| Intervention | Percentage (Mean) |
|---|---|
| Simvastatin 80 mg | -18 |
| Simvastatin 20mg/Ezetimibe 10 mg | -15 |
Samples were collected in 3.8% sodium citrate (buffered, pH 5.5, Vacutainer, Becton Dickinson, Plymouth, UK) for platelet function tests. Platelet function assays were processed within 2 hours of blood collection. The PFA-100 records the closure time (CT), witch means the time in seconds (s) from the start of the test until the platelet plug occludes the aperture. (NCT00474123)
Timeframe: Change from baseline at 6 weeks
| Intervention | Percentage (Mean) |
|---|---|
| Simvastatin 80 mg | 27 |
| Simvastatin 20mg/Ezetimibe 10 mg | 8 |
A commercial ELISA assay detecting sCD40L (R&D Systems, USA) was applied. Detection limits and intra-assay variability was respectively, as follows: sCD-40L 15.6 pg/mL (intra-assay variability not available). (NCT00474123)
Timeframe: Fasting venous blood samples were drawn immediately after randomization and after at the conclusions of the six weeks study period.
| Intervention | percentage (Mean) |
|---|---|
| Simvastatin 80 mg | 6 |
| Simvastatin 20mg/Ezetimibe 10 mg | 6 |
serum samples were stored at -70°C and were determined simultaneously by ELISA in order to avoid variation of assay conditions. Commercial ELISA assays detecting MCP-1/ICAM-1 (R&D Systems, Europe, Abingdon, UK) (NCT00474123)
Timeframe: Change from baseline at 6 weeks
| Intervention | percentage (Mean) |
|---|---|
| Simvastatin 80 mg | 10 |
| Simvastatin 20mg/Ezetimibe 10 mg | 10 |
(NCT00474123)
Timeframe: Fasting venous blood samples were drawn immediately after randomization and at the conclusions of the six week study period.
| Intervention | percentage (Mean) |
|---|---|
| Simvastatin 80 mg | -4 |
| Simvastatin 20mg/Ezetimibe 10 mg | -14 |
In-scaffold:Within the margins of the scaffold. (NCT01425281)
Timeframe: 3 years
| Intervention | mm (Mean) |
|---|---|
| Absorb BVS™ | 0.05 |
| XIENCE™ | 0.06 |
In-scaffold:Within the margins of the scaffold. (NCT01425281)
Timeframe: 3 years
| Intervention | mm (Mean) |
|---|---|
| Absorb BVS™ | -0.37 |
| XIENCE™ | -0.25 |
Successful delivery and deployment of the first study scaffold/stent the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 50% by quantitative coronary angiography (QCA). (NCT01425281)
Timeframe: From the start of index procedure to end of index procedure
| Intervention | Percentage of lesions (Number) |
|---|---|
| Absorb BVS™ | 99.5 |
| XIENCE™ | 100 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 0 |
| XIENCE™ | 1 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT01425281)
Timeframe: 180 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 0 |
| XIENCE™ | 1 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 4 |
| XIENCE™ | 1 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 8 |
| XIENCE™ | 6 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 0 |
| XIENCE™ | 0 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 11 |
| XIENCE™ | 7 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 13 |
| XIENCE™ | 7 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 0 |
| XIENCE™ | 0 |
"All deaths includes~• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.~Myocardial Infarction (MI)~Q wave MI Development of new, pathological Q wave on the ECG.~Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 14 |
| XIENCE™ | 3 |
"All deaths includes~• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.~Myocardial Infarction (MI)~Q wave MI Development of new, pathological Q wave on the ECG.~Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 14 |
| XIENCE™ | 2 |
"All deaths includes~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 35 |
| XIENCE™ | 12 |
"All deaths includes~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 22 |
| XIENCE™ | 5 |
"All deaths includes~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 33 |
| XIENCE™ | 11 |
"All deaths includes~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI)~Q wave MI Development of new, pathological Q wave on the ECG.~Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 37 |
| XIENCE™ | 13 |
"All deaths includes~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.~Myocardial Infarction (MI) Q wave MI Development of new, pathological Q wave on the ECG. Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 13 |
| XIENCE™ | 2 |
"All deaths includes~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 15 |
| XIENCE™ | 3 |
"Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 29 |
| XIENCE™ | 9 |
"Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 29 |
| XIENCE™ | 10 |
"Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves" (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 13 |
| XIENCE™ | 2 |
"Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 15 |
| XIENCE™ | 2 |
"Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 14 |
| XIENCE™ | 2 |
"Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 20 |
| XIENCE™ | 4 |
"Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 28 |
| XIENCE™ | 8 |
"Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 14 |
| XIENCE™ | 2 |
"Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.~-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 15 |
| XIENCE™ | 2 |
"Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.~-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 14 |
| XIENCE™ | 2 |
"Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.~-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 19 |
| XIENCE™ | 4 |
"Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.~-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 27 |
| XIENCE™ | 5 |
"Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.~-Non-Q wave MI: Elevation of Creatine kinase (CK) levels to ≥ two times the upper limit of normal (ULN) with elevated Creatine kinase-MB (CK-MB) in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 14 |
| XIENCE™ | 2 |
"Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.~-Non-Q wave MI: Elevation of Creatine kinase (CK) levels to ≥ two times the upper limit of normal (ULN) with elevated Creatine kinase-MB (CK-MB) in the absence of new pathological Q waves." (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 13 |
| XIENCE™ | 2 |
"Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 27 |
| XIENCE™ | 5 |
"Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 27 |
| XIENCE™ | 6 |
"Revascularization:~Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.~Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.~Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.~Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel." (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 12 |
| XIENCE™ | 12 |
"Revascularization:~Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.~Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.~Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.~Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel." (NCT01425281)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 7 |
| XIENCE™ | 6 |
"Revascularization:~Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.~Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.~Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.~Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel." (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 22 |
| XIENCE™ | 18 |
"Revascularization:~Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.~Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.~Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.~Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel." (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 49 |
| XIENCE™ | 33 |
"Revascularization:~Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.~Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.~Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.~Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel." (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 2 |
| XIENCE™ | 2 |
"Revascularization:~Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.~Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.~Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.~Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel." (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 57 |
| XIENCE™ | 34 |
"Revascularization:~Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.~Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.~Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.~Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel." (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 1 |
| XIENCE™ | 0 |
Revascularization: Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold. Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion. Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion. Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 59 |
| XIENCE™ | 34 |
DMR is the composite of All Death, All MI, All Revascularization (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 76 |
| XIENCE™ | 40 |
DMR is the composite of All Death, All MI, All Revascularization (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 80 |
| XIENCE™ | 41 |
DMR is the composite of All Death, All MI, All Revascularization (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 13 |
| XIENCE™ | 2 |
DMR is the composite of All Death, All MI, All Revascularization. (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 24 |
| XIENCE™ | 15 |
DMR is the composite of All Death, All MI, All Revascularization. (NCT01425281)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 19 |
| XIENCE™ | 9 |
DMR is the composite of All Death, All MI, All Revascularization. (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 38 |
| XIENCE™ | 21 |
DMR is the composite of All Death, All MI, All Revascularization. (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 68 |
| XIENCE™ | 39 |
DMR is the composite of All Death, All MI, All Revascularization. (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 14 |
| XIENCE™ | 4 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 17 |
| XIENCE™ | 5 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). (NCT01425281)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 14 |
| XIENCE™ | 3 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 25 |
| XIENCE™ | 7 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 38 |
| XIENCE™ | 11 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 14 |
| XIENCE™ | 2 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 40 |
| XIENCE™ | 12 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 41 |
| XIENCE™ | 13 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 13 |
| XIENCE™ | 2 |
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 6 |
| XIENCE™ | 6 |
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 4 |
| XIENCE™ | 3 |
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 10 |
| XIENCE™ | 11 |
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 22 |
| XIENCE™ | 19 |
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 1 |
| XIENCE™ | 0 |
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 29 |
| XIENCE™ | 20 |
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 0 |
| XIENCE™ | 0 |
Non Target Vessel Revascularization (Non-TVR) is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 30 |
| XIENCE™ | 20 |
Achievement of final in-scaffold/stent residual stenosis of less than 50% by QCA with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay. (NCT01425281)
Timeframe: From the start of index procedure to end of index procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 322 |
| XIENCE™ | 164 |
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 13 |
| XIENCE™ | 2 |
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 16 |
| XIENCE™ | 5 |
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 13 |
| XIENCE™ | 3 |
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 23 |
| XIENCE™ | 5 |
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 34 |
| XIENCE™ | 8 |
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 37 |
| XIENCE™ | 9 |
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 38 |
| XIENCE™ | 9 |
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 12 |
| XIENCE™ | 2 |
"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated (CI) or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 2 |
| XIENCE™ | 0 |
"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated (CI) or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 1 |
| XIENCE™ | 0 |
"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 4 |
| XIENCE™ | 3 |
"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 2 |
| XIENCE™ | 1 |
"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 9 |
| XIENCE™ | 3 |
"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 24 |
| XIENCE™ | 8 |
"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 27 |
| XIENCE™ | 8 |
"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 28 |
| XIENCE™ | 8 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR) (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 45 |
| XIENCE™ | 21 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR) (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 47 |
| XIENCE™ | 22 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 18 |
| XIENCE™ | 8 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT01425281)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 15 |
| XIENCE™ | 5 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 28 |
| XIENCE™ | 11 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 41 |
| XIENCE™ | 20 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 14 |
| XIENCE™ | 3 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 13 |
| XIENCE™ | 2 |
Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 8 |
| XIENCE™ | 8 |
Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. (NCT01425281)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 4 |
| XIENCE™ | 4 |
Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 15 |
| XIENCE™ | 9 |
Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 33 |
| XIENCE™ | 19 |
Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 2 |
| XIENCE™ | 2 |
Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 38 |
| XIENCE™ | 19 |
Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 41 |
| XIENCE™ | 19 |
Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 1 |
| XIENCE™ | 0 |
"Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points.~Timings:~Acute:0-24 hours;Subacute:>24 hours-30 days;Late:30 days-1 year;Very late:>1 year.~Definite stent thrombosis occurred by either angiographic/pathologic confirmation.~Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&presence of at least 1 of the following criteria within a 48-hour time window~-Acute onset of ischemic symptoms at rest;New ischemic ECG changes;Typical rise&fall in cardiac biomarkers;Nonocclusive/Occlusive thrombus~Pathological confirmation:Evidence of recent thrombus.~Probable stent thrombosis may occur after intracoronary stenting due to:~Unexplained death within first 30 days~Any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&in the absence of any other obvious cause." (NCT01425281)
Timeframe: <=1 day
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Definite | Probable | |
| Absorb BVS™ | 1 | 0 |
| XIENCE™ | 0 | 0 |
"Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points.~Timings:~Acute:0-24 hours;Subacute:>24 hours-30 days;Late:30 days-1 year;Very late:>1 year.~Definite stent thrombosis occurred by either angiographic/pathologic confirmation.~Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&presence of at least 1 of the following criteria within a 48-hour time window~-Acute onset of ischemic symptoms at rest;New ischemic ECG changes;Typical rise&fall in cardiac biomarkers;Nonocclusive/Occlusive thrombus~Pathological confirmation:Evidence of recent thrombus.~Probable stent thrombosis may occur after intracoronary stenting due to:~Unexplained death within first 30 days~Any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&in the absence of any other obvious cause." (NCT01425281)
Timeframe: 0-30 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Definite | Probable | |
| Absorb BVS™ | 2 | 0 |
| XIENCE™ | 0 | 0 |
"Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points.~Timings:~Acute:0-24 hours;Subacute:>24 hours-30 days;Late:30 days-1 year;Very late:>1 year.~Definite stent thrombosis occurred by either angiographic/pathologic confirmation.~Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&presence of at least 1 of the following criteria within a 48-hour time window~-Acute onset of ischemic symptoms at rest;New ischemic ECG changes;Typical rise&fall in cardiac biomarkers;Nonocclusive/Occlusive thrombus~Pathological confirmation:Evidence of recent thrombus.~Probable stent thrombosis may occur after intracoronary stenting due to:~Unexplained death within first 30 days~Any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&in the absence of any other obvious cause." (NCT01425281)
Timeframe: 0-1853 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Definite | Probable | |
| Absorb BVS™ | 8 | 1 |
| XIENCE™ | 0 | 0 |
"Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points.~Timings:~Acute:0-24 hours;Subacute:>24 hours-30 days;Late:30 days-1 year;Very late:>1 year.~Definite stent thrombosis occurred by either angiographic/pathologic confirmation.~Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&presence of at least 1 of the following criteria within a 48-hour time window~-Acute onset of ischemic symptoms at rest;New ischemic ECG changes;Typical rise&fall in cardiac biomarkers;Nonocclusive/Occlusive thrombus~Pathological confirmation:Evidence of recent thrombus.~Probable stent thrombosis may occur after intracoronary stenting due to:~Unexplained death within first 30 days~Any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&in the absence of any other obvious cause." (NCT01425281)
Timeframe: 31-365 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Definite | Probable | |
| Absorb BVS™ | 0 | 1 |
| XIENCE™ | 0 | 0 |
"Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points.~Timings:~Acute:0-24 hours;Subacute:>24 hours-30 days;Late:30 days-1 year;Very late:>1 year.~Definite stent thrombosis occurred by either angiographic/pathologic confirmation.~Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&presence of at least 1 of the following criteria within a 48-hour time window~-Acute onset of ischemic symptoms at rest;New ischemic ECG changes;Typical rise&fall in cardiac biomarkers;Nonocclusive/Occlusive thrombus~Pathological confirmation:Evidence of recent thrombus.~Probable stent thrombosis may occur after intracoronary stenting due to:~Unexplained death within first 30 days~Any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&in the absence of any other obvious cause." (NCT01425281)
Timeframe: > 1-30 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Definite | Probable | |
| Absorb BVS™ | 1 | 0 |
| XIENCE™ | 0 | 0 |
"Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points.~Timings:~Acute:0-24 hours;Subacute:>24 hours-30 days;Late:30 days-1 year;Very late:>1 year.~Definite stent thrombosis occurred by either angiographic/pathologic confirmation.~Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&presence of at least 1 of the following criteria within a 48-hour time window~-Acute onset of ischemic symptoms at rest;New ischemic ECG changes;Typical rise&fall in cardiac biomarkers;Nonocclusive/Occlusive thrombus~Pathological confirmation:Evidence of recent thrombus.~Probable stent thrombosis may occur after intracoronary stenting due to:~Unexplained death within first 30 days~Any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&in the absence of any other obvious cause." (NCT01425281)
Timeframe: > 365 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Definite | Probable | |
| Absorb BVS™ | 6 | 0 |
| XIENCE™ | 0 | 0 |
Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) (NCT00433966)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Pharmacology Arm - Bivalirudin | 379 |
| Pharmacology Arm - Unfractionated Heparin | 377 |
Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) (NCT00433966)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Pharmacology Arm - Bivalirudin | 98 |
| Pharmacology Arm - Unfractionated Heparin | 99 |
Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) and major bleeding (bleeding adjudicated as not related to coronary artery bypass grafting). (NCT00433966)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Pharmacology Arm - Bivalirudin | 166 |
| Pharmacology Arm - Unfractionated Heparin | 218 |
Number of participants with major bleeding (bleeding adjudicated as not related to coronary artery bypass grafting) (NCT00433966)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Pharmacology Arm - Bivalirudin | 89 |
| Pharmacology Arm - Unfractionated Heparin | 149 |
Number of Participants With Death, Reinfarction, Stroke, or Stent Thrombosis (NCT00433966)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Stent Arm - Paclitaxel-Eluting Stent | 181 |
| Stent Arm - Bare Metal Stent | 59 |
Number of Participants With Ischemic Target Lesion Revascularization (NCT00433966)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Stent Arm - Paclitaxel-Eluting Stent | 98 |
| Stent Arm - Bare Metal Stent | 54 |
Number of Participants With Segment Binary Angiographic Restenosis (13-month Angiographic Subset). (NCT00433966)
Timeframe: 13 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Stent Arm - Paclitaxel-Eluting Stent | 102 |
| Stent Arm - Bare Metal Stent | 76 |
(NCT02914795)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Non-resuscitated Myocardial Infarction | 0 |
| Resuscitated Myocardial Infarction | 3 |
Median (Inter-Quartile Range) Collagen AUC values on Day 3 measured with optical aggregometry The more light signal is detected, the better thrombocyte function is. (NCT02914795)
Timeframe: day 3
| Intervention | AU*min (Median) |
|---|---|
| Non-resuscitated Myocardial Infarction | 109 |
| Resuscitated Myocardial Infarction | 253.8 |
"The Cmax is the peak concentration of selatogrel in the plasma after subcutaneous injection.~The pharmacokinetic parameters of selatogrel (ACT-246475) were derived by non-compartmental analyses of the plasma concentration-time profiles." (NCT03487445)
Timeframe: pre-dose, 15, 30 and 60 minutes and 8 hours after the administration of the subcutaneous injection
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Selatogrel 8 mg | 390.1 |
| Selatogrel 16 mg | 672.6 |
The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting at 30 minutes post-dose was counted as a participant that had a pharmacodynamic response. (NCT03487445)
Timeframe: 30 minutes after the administration of the subcutaneous injection
| Intervention | Count of participants (Number) |
|---|---|
| Selatogrel 8 mg | 18 |
| Selatogrel 16 mg | 19 |
The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using the VerifyNow® assay. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU).The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU less than 100 at 30 minutes post-dose was counted as a participant that had a pharmacodynamic response. (NCT03487445)
Timeframe: 30 minutes after the administration of the subcutaneous injection
| Intervention | Count of participants (Number) |
|---|---|
| Selatogrel 8 mg | 21 |
| Selatogrel 16 mg | 21 |
Time after subcutaneous injection to reach the maximum observed selatogrel plasma concentration (Cmax). (NCT03487445)
Timeframe: pre-dose, 15, 30 and 60 minutes and 8 hours after the administration of the subcutaneous injection
| Intervention | hours (Median) |
|---|---|
| Selatogrel 8 mg | 1.00 |
| Selatogrel 16 mg | 0.97 |
The pharmacodynamic response assessed by the inhibition of adenosine diphosphate (ADP)-mediated platelet aggregation was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test. The results are expressed as P2Y12 reaction units (PRU). (NCT03487445)
Timeframe: pre-dose, 15, 30 and 60 minutes after administration of the subcutaneous injection
| Intervention | P2Y12 reaction units (PRU) (Median) | |||
|---|---|---|---|---|
| pre-dose | 15 minutes post-dose | 30 minutes post-dose | 60 minutes post-dose | |
| Selatogrel 16 mg | 181 | 9 | 9 | 7 |
| Selatogrel 8 mg | 194 | 51 | 59 | 9 |
The purpose of this supportive analysis was to assess the effect when relaxing the time of a PRU < 100, i.e., considering as a response a PRU < 100 at 15, 30 or 60 min. post injection. The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using the VerifyNow® assay. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU).The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU less than 100 post-dose was counted as a participant that had a pharmacodynamic response. (NCT03487445)
Timeframe: pre-dose, 15, 30 and 60 minutes after the administration of the subcutaneous injection
| Intervention | Count of participants (Number) | |||
|---|---|---|---|---|
| pre-dose | 15 minutes post-dose | 30 minutes post-dose | 60 minutes post-dose | |
| Selatogrel 16 mg | 0 | 21 | 21 | 22 |
| Selatogrel 8 mg | 1 | 18 | 21 | 18 |
The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting at 30 minutes post-dose was counted as a participant that had a pharmacodynamic response. (NCT03487445)
Timeframe: 30 minutes after the administration of the subcutaneous injection
| Intervention | Count of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age less than 55 years old | Age 55 years and older | Male | Female | Body Mass Index less than 25 | Body Mass Index less than 25 and up to 30 | Body Mass Index greater than 30 | Diabetes mellitus at baseline | No diabetes mellitus at baseline | No Chronic kidney disease at baseline | STEMI at baseline | NSTEMI at baseline | |
| Selatogrel 8 mg | 3 | 18 | 14 | 7 | 5 | 8 | 8 | 8 | 13 | 21 | 14 | 7 |
The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting at 30 minutes post-dose was counted as a participant that had a pharmacodynamic response. (NCT03487445)
Timeframe: 30 minutes after the administration of the subcutaneous injection
| Intervention | Count of participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age less than 55 years old | Age 55 years and older | Male | Female | Body Mass Index less than 25 | Body Mass Index less than 25 and up to 30 | Body Mass Index greater than 30 | Diabetes mellitus at baseline | No diabetes mellitus at baseline | Chronic kidney disease at baseline | No Chronic kidney disease at baseline | STEMI at baseline | NSTEMI at baseline | |
| Selatogrel 16 mg | 4 | 17 | 17 | 4 | 8 | 9 | 4 | 5 | 16 | 3 | 18 | 11 | 10 |
left anterior descending coronary artery Z-score; a Z score is the coronary artery adjusted for body surface area (NCT00760435)
Timeframe: 2 weeks
| Intervention | Z-score (Mean) |
|---|---|
| Infliximab | -0.605 |
| Placebo | -0.313 |
(NCT00760435)
Timeframe: 24 hours
| Intervention | mg/dL (Mean) |
|---|---|
| Infliximab | -6.6 |
| Placebo | -3.6 |
(NCT00760435)
Timeframe: up to 6 weeks
| Intervention | days (Median) |
|---|---|
| Infliximab | 1 |
| Placebo | 2 |
(NCT00760435)
Timeframe: 10 weeks
| Intervention | participants (Number) |
|---|---|
| Infliximab | 11 |
| Placebo | 11 |
"In patients treated with aspirin and clopidogrel aggregometry was performed and depending on the results the patients were either responder or low-responder of antiplatelet therapy.~The following definitions were used for clopidogrel low response (CLR: >5 ohm when stimulated with adenosine diphosphate (ADP) 5 μM) and ASA low response (ALR: >0 ohm;stimulated with arachidonic acid 10 μM) with the ChronoLog 590 aggregometer. In the case of low-response alternative antiplatelet therapy was modified according to the study plan (see protocol section)." (NCT01212302)
Timeframe: 2 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel Low Response | 155 |
205 reviews available for aspirin and Coronary Artery Disease
| Article | Year |
|---|---|
Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease.
Topics: Adult; Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibi | 2022 |
Extended, standard, or De-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention? A trial-sequential, bivariate, influential, and network meta-analysis.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Hemorrhage; Humans; Network Meta-Analysis; Percutaneo | 2022 |
Association of Genetic Polymorphisms in Kawasaki Disease with the Response to Intravenous Immunoglobulin Therapy.
Topics: Aspirin; Child, Preschool; Coronary Artery Disease; Humans; Immunoglobulins, Intravenous; Infant; Mu | 2023 |
Antiplatelet therapy for coronary artery disease in 2023: current status and future prospects.
Topics: Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Per | 2023 |
Personalised antiplatelet therapies for coronary artery disease: what the future holds.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Hemorrhage; Humans; Myocardial Infarction | 2023 |
P2Y
Topics: Aspirin; Coronary Artery Disease; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary I | 2023 |
Comparison of Different Chronic Maintenance Antithrombotic Strategies in Patients with Coronary Artery Disease: A Systematic Review and Network Meta-Analysis.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Fibrinolytic Agents; Humans; Ischemic Stroke; Network | 2023 |
Tailoring antiplatelet therapy in older patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Dual Ant | 2023 |
Management of Antiplatelet Agents in Patients with History of Coronary Artery Disease in Various Medical Conditions.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Humans; Myocardial Ischemia; Platelet Agg | 2019 |
Association among PlA1/A2 gene polymorphism, laboratory aspirin resistance and clinical outcomes in patients with coronary artery disease: An updated meta-analysis.
Topics: Antigens, Human Platelet; Aspirin; Coronary Artery Disease; Drug Resistance; Genotype; Humans; Integ | 2019 |
Update on Antithrombotic Therapy after Percutaneous Coronary Intervention.
Topics: Administration, Oral; Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; H | 2020 |
A Meta-Analysis Comparing Aspirin Alone Versus Dual Antiplatelet Therapy for the Prevention of Venous Graft Failure Following Coronary Artery Bypass Surgery.
Topics: Aged; Aspirin; Bayes Theorem; Coronary Artery Bypass; Coronary Artery Disease; Dual Anti-Platelet Th | 2020 |
Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Chronic Disease; Coronary Artery Dis | 2019 |
Omitting aspirin in PCI patients: Myth or reality?
Topics: Aspirin; Clinical Decision-Making; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; H | 2019 |
Direct Oral Anticoagulants and Coronary Artery Disease: The Debacle of the Aspirin Era?
Topics: Administration, Oral; Animals; Aspirin; Blood Coagulation; Coronary Artery Disease; Coronary Thrombo | 2020 |
[Treatment of coronary artery disease in renal insufficiency].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Aspirin; Cardiovascular Diseases; Cor | 2020 |
[Short dual antiplatelet therapy: how, when and why].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Dual Anti-Platelet Therapy; H | 2020 |
Aspirin for Primary Prevention of Coronary Artery Disease.
Topics: Aspirin; Coronary Artery Disease; Humans; Primary Prevention; Randomized Controlled Trials as Topic | 2021 |
Complexity of Antiplatelet Therapy in Coronary Artery Disease Patients.
Topics: Aspirin; Coronary Artery Disease; Hemorrhage; Humans; Multiple Chronic Conditions; Platelet Aggregat | 2021 |
Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition.
Topics: Aspirin; Chronic Disease; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; | 2020 |
The COMPASS trial: practical considerations for application after coronary artery bypass surgery.
Topics: Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Drug Therapy, Combination; Humans; Platele | 2020 |
An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Disease; Diabetes Complications; Drug Therapy, Co | 2020 |
The Role of Aspirin After High-Risk Percutaneous Coronary Intervention: The Ticagrelor with Aspirin or Alone in High-Risk Patients After Coronary Intervention Clinical Trial Experience.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; H | 2020 |
A systematic review of guidelines for dual antiplatelet therapy in coronary artery bypass graft.
Topics: Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Deprescriptions; Dual Anti-Platelet Therap | 2021 |
Dual antiplatelet therapy duration after percutaneous coronary intervention with drug-eluting stents: how short can we go?
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Percutaneo | 2020 |
Management of Patients with Acute Coronary Syndrome and Cancer.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Humans; Neoplasms; Platelet Aggregation I | 2020 |
Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review.
Topics: Acute-Phase Reaction; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Child; | 2021 |
Aspirin in Primary Prevention: What Changed? A Critical Appraisal of Current Evidence.
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Evidence-Based Medicine; Heart Disease Ri | 2021 |
Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2017 |
Aspirin challenge and desensitization: how, when and why.
Topics: Aspirin; Asthma, Aspirin-Induced; Coronary Artery Disease; Desensitization, Immunologic; Humans; Rhi | 2017 |
Antithrombotic regimens in patients with atrial fibrillation and coronary artery disease after percutaneous coronary intervention: A focused review.
Topics: Aspirin; Atrial Fibrillation; Coronary Artery Disease; Drug Therapy, Combination; Fibrinolytic Agent | 2017 |
Usefulness of PA32540 in Protecting the Gastric Layer While Providing Secondary Prevention for Coronary Artery Disease.
Topics: Administration, Oral; Aspirin; Coronary Artery Disease; Double-Blind Method; Drug Combinations; Gast | 2017 |
Thirty days only double antiplatelet therapy after drug-eluting stenting: could a 'short-term' treatment be advantageous?
Topics: Aspirin; Clinical Decision-Making; Coronary Artery Disease; Coronary Thrombosis; Drug Administration | 2018 |
What dose of aspirin should be used in the initial treatment of Kawasaki disease?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Coronary Artery Disease; Humans; Mucocutane | 2017 |
The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Disease; Fibrinolytic Agents; Hemorrhage; Humans; | 2018 |
Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; DNA; Drug Therapy, Combination; Facto | 2018 |
Aspirin Hypersensitivity in Patients Undergoing Percutaneous Coronary Intervention. What Should We be Doing?
Topics: Algorithms; Animals; Aspirin; Clinical Decision-Making; Coronary Artery Disease; Decision Support Te | 2019 |
Aspirin hypersensitivity in patients with coronary artery disease: linking pathophysiology to clinical practice.
Topics: Aspirin; Coronary Artery Disease; Desensitization, Immunologic; Drug Hypersensitivity; Drug Toleranc | 2018 |
Dual versus single antiplatelet therapy after coronary artery bypass graft surgery: An updated meta-analysis.
Topics: Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Hum | 2018 |
Dual versus triple therapy in patients on oral anticoagulants and undergoing coronary stent implantation: A systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; D | 2018 |
Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Humans; Observational Studies as Topic; P | 2018 |
Optimal duration of dual antiplatelet therapy after PCI: integrating procedural complexity, bleeding risk and the acuteness of clinical presentation.
Topics: Aspirin; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug-Elut | 2018 |
Triple therapy: A review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Combined Modality Therapy; Coron | 2019 |
Aspirin to Prevent Sudden Cardiac Death in Athletes with High Coronary Artery Calcium Scores.
Topics: Aspirin; Athletes; Coronary Artery Disease; Death, Sudden, Cardiac; Humans | 2019 |
Short-term versus long-term triple antithrombotic therapy for patients with coronary stents and requiring oral anticoagulation: a meta-analysis of randomized clinical trials.
Topics: Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; He | 2019 |
Omission of aspirin in patients taking oral anticoagulation after percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Age Factors; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Coronary Artery Disease; Dru | 2019 |
Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease?
Topics: Acute Coronary Syndrome; Aged; Algorithms; Aspirin; Cardiovascular Diseases; Coronary Artery Disease | 2019 |
Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease.
Topics: Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Humans; Percuta | 2019 |
How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?
Topics: Aged; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Hum | 2019 |
Aspirin Versus Clopidogrel Monotherapy for the Treatment of Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; | 2019 |
Antithrombotics: From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5).
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Drug Th | 2019 |
Total Thrombus-Formation Analysis System (T-TAS): Clinical Application of Quantitative Analysis of Thrombus Formation in Cardiovascular Disease.
Topics: Anticoagulants; Area Under Curve; Aspirin; Blood Platelets; Cardiovascular Diseases; Catheter Ablati | 2019 |
The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Coronary Artery Disease; Cost of Illn | 2013 |
Monitoring aspirin and clopidogrel response: testing controversies and recommendations.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Interv | 2013 |
Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis.
Topics: Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinatio | 2013 |
Perioperative management of antiplatelet therapy in patients with a coronary stent who need noncardiac surgery: a systematic review of clinical practice guidelines.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Elective Surgical Procedures; Hemorrhage; Humans; Met | 2013 |
Antiplatelet therapy in patients undergoing percutaneous coronary intervention: economic considerations.
Topics: Aspirin; Coronary Artery Disease; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Percutan | 2013 |
Kawasaki disease: part II. Complications and treatment.
Topics: Adrenal Cortex Hormones; Aspirin; Child; Child, Preschool; Coronary Aneurysm; Coronary Artery Diseas | 2013 |
Use of antiplatelet agents in patients with atherosclerotic disease.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Atherosclerosis; Clopidogrel; Coronary Artery Dis | 2013 |
Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Coronary Artery Disease; Drug Therapy, Combination; | 2013 |
Perioperative management of antiplatelet therapy.
Topics: Aspirin; Blood Coagulation; Coronary Artery Disease; Humans; Perioperative Care; Platelet Activation | 2013 |
Combining antiplatelet and antithrombotic therapy (triple therapy): what are the risks and benefits?
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibri | 2014 |
Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Humans; Pla | 2014 |
Pharmacogenomics of oral antiplatelet drugs.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Meta-Analysis as To | 2014 |
Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen-Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oraL anticoagulant therapy following drug-Eluting stenting (ISAR-
Topics: Administration, Oral; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Dru | 2014 |
Who might benefit from early aspirin after coronary artery surgery?
Topics: Aged; Aspirin; Benchmarking; Coronary Artery Bypass; Coronary Artery Disease; Coronary Thrombosis; D | 2014 |
Antithrombotics in atrial fibrillation and coronary disease.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Coronary Artery D | 2014 |
Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; | 2014 |
Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2014 |
Dual antiplatelet therapy for coronary artery disease.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Platelet Aggregati | 2015 |
Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials.
Topics: Aspirin; Combined Modality Therapy; Coronary Artery Disease; Drug Administration Schedule; Drug Ther | 2015 |
Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Pressur | 2015 |
Aspirin desensitization for cardiovascular disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Artery Disease; Desensitization, Immunolo | 2015 |
Bleeding versus thrombosis: role of short DAPT in complex lesions.
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans | 2015 |
Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Diabetes Mellitu | 2015 |
Acetylsalicylic acid desensitization in patients with coronary artery disease: A comprehensive overview of currently available protocols.
Topics: Aspirin; Coronary Artery Disease; Drug Hypersensitivity; Humans; Platelet Aggregation Inhibitors; Se | 2016 |
Kawasaki disease: a comprehensive review of treatment options.
Topics: Aspirin; Coronary Artery Disease; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; In | 2015 |
Efficacy and Safety of Available Protocols for Aspirin Hypersensitivity for Patients Undergoing Percutaneous Coronary Intervention: A Survey and Systematic Review.
Topics: Aspirin; Clinical Protocols; Coronary Artery Disease; Drug Hypersensitivity; Humans; Incidence; Perc | 2016 |
Platelets and Antiplatelet Therapy in Patients with Coronary Artery Disease and Diabetes.
Topics: Aspirin; Blood Coagulation; Blood Platelets; Coronary Artery Disease; Diabetes Mellitus, Type 2; Hum | 2016 |
Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Assoc
Topics: Advisory Committees; American Heart Association; Aspirin; Cardiology; Coronary Artery Disease; Drug | 2016 |
[Coronary microvascular dysfunction : Clinical aspects, diagnosis and therapy].
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Cardiology; Coronary Angiography; Co | 2016 |
Effect of aspirin in addition to oral anticoagulants in stable coronary artery disease outpatients with an indication for anticoagulation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Humans; | 2016 |
The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; | 2016 |
[Dual antiplatelet therapy for treatment and secondary prevention of coronary artery disease: indications, modalities and duration].
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregatio | 2016 |
Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews.
Topics: Aspirin; Blood Pressure; Cardiovascular Diseases; Coronary Artery Disease; Humans; Hydroxymethylglut | 2016 |
Adverse clinical outcomes associated with a low dose and a high dose of aspirin following percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Aspirin; Coronary Artery Disease; Global Health; Humans; Incidence; Percutaneous Coronary Interventi | 2016 |
Aspirin, Plavix, and Other Antiplatelet Medications: What the Oral and Maxillofacial Surgeon Needs to Know.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Humans; Medication Therapy Management; Oral Surgical | 2016 |
Clinical outcomes associated with per-operative discontinuation of aspirin in patients with coronary artery disease: A systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiac Surgical Procedures; Chi-Square Distribution; Coronary Art | 2017 |
What is the impact of preoperative aspirin administration on patients undergoing coronary artery bypass grafting?
Topics: Aged; Aspirin; Blood Transfusion; Coronary Artery Bypass; Coronary Artery Disease; Humans; Myocardia | 2017 |
Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy; Fibrinolytic Agents; He | 2016 |
Clinical Therapeutic Effects of Aspirin in Combination with Fufang Danshen Diwan, a Traditional Chinese Medicine Formula, on Coronary Heart Disease: A Systematic Review and Meta-Analysis.
Topics: Angina Pectoris; Aspirin; Cardiotonic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Di | 2016 |
Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease.
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Gastrointestinal Diseases; Gastrointestin | 2017 |
Perioperative Aspirin in Cardiac and Noncardiac Surgery.
Topics: Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Humans; Perioperative Care; Postoperative | 2017 |
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
Topics: Acute Coronary Syndrome; Analysis of Variance; Aspirin; Blood Vessel Prosthesis Implantation; Clopid | 2017 |
Aspirin Use Prior to Coronary Artery Bypass Grafting Surgery: a Systematic Review.
Topics: Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Humans; Meta-Analysis as Topic; Myocardial | 2017 |
Cardiovascular Disease Update: Care of Patients After Coronary Artery Bypass Graft.
Topics: Adrenergic beta-Antagonists; Aspirin; Cardiac Rehabilitation; Coronary Artery Bypass; Coronary Arter | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
The hazards of discontinuing acetylsalicylic acid therapy in those at risk of coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Artery Di | 2008 |
Clopidogrel and aspirin in cardiovascular medicine: responders or not--current best available evidence.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disea | 2008 |
Aspirin and clopidogrel response variability: review of the published literature.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Resistance; Humans; Platelet | 2008 |
Role of antiplatelet therapy across the spectrum of patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disea | 2009 |
Prevention and management of coronary artery disease in patients with diabetes mellitus.
Topics: Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzy | 2009 |
Variability in platelet response to the antiplatelet agents aspirin and clopidogrel: mechanisms, measurement, and clinical relevance.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, | 2009 |
Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2009 |
Significant gastrointestinal bleeding in patients at risk of coronary stent thrombosis.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Anti-Bacterial Agents; Aspirin; Clopidogrel; Coro | 2009 |
New antiplatelet drugs: beyond aspirin and clopidogrel.
Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery | 2009 |
Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Platel | 2009 |
Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Drug | 2008 |
Platelet resistance to antiplatelet drugs.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug | 2009 |
Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Platelet Ag | 2009 |
Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Humans; | 2009 |
Dual antiplatelet therapy in coronary artery disease: a case-based approach.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery | 2009 |
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Huma | 2009 |
Recent advances in cardiology.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiac Pacing | 2010 |
The role of antiplatelet therapy in the secondary prevention of coronary artery disease.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combinati | 2010 |
Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coro | 2010 |
Conventional and novel drug therapeutics to relief myocardial ischemia.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors | 2010 |
[Antiplatelet therapy in coronary heart disease. Some problems and achivements].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; A | 2010 |
[Dilemma between gastroprotection and cardiovascular prevention].
Topics: Alleles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; | 2010 |
Antiplatelet drug therapy: role of pharmacodynamic and genetic testing.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combina | 2011 |
Oral antiplatelet therapy for acute coronary syndromes: aspirin, P2Y12 inhibition and thrombin receptor antagonists.
Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Aspirin; Coronary Artery Disease; Humans; Mo | 2011 |
Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Design; Drug Interactio | 2012 |
Antiplatelet therapy in the era of percutaneous coronary intervention with drug-eluting balloons.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Bioco | 2011 |
Recent advances in the treatment of Kawasaki disease.
Topics: Adrenal Cortex Hormones; Aspirin; Coronary Artery Disease; Hydroxymethylglutaryl-CoA Reductase Inhib | 2011 |
Atherothrombosis in von Willebrand disease: an analysis of the literature and implications for clinical management.
Topics: Adult; Aged; Aspirin; Atherosclerosis; Cardiac Surgical Procedures; Coronary Artery Disease; Hemophi | 2012 |
The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Confidence Intervals; Coronary Art | 2012 |
[Stable coronary artery disease--invasive treatment does not replace secondary prevention].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Bloc | 2012 |
Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease.
Topics: Aspirin; Blood Glucose; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Ty | 2012 |
Aspirin resistance: current status and role of tailored therapy.
Topics: Aspirin; Blood Platelets; Coronary Artery Disease; Drug Resistance; Humans; Patient Selection; Plate | 2012 |
Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary A | 2012 |
[Acetylsalicylic acid in patients with planned (elective) interventions on the coronary arteries. Risks and benefits].
Topics: Aspirin; Blood Loss, Surgical; Blood Transfusion; Coronary Artery Bypass; Coronary Artery Disease; H | 2012 |
Clopidogrel in coronary artery disease: update 2012.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocard | 2012 |
[Kawasaki disease: what you need to know].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Aspirin; | 2012 |
Antiplatelet effect of aspirin in patients with coronary artery disease.
Topics: Aspirin; Blood Platelets; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Humans; Med | 2012 |
Long-term clinical experience with zofenopril.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aspirin; Captopril; Coro | 2012 |
Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Cost Savings; Drug Monitoring; Drug Resistance; Drug | 2013 |
Aspirin and aspirin resistance in coronary artery disease.
Topics: Aspirin; Coronary Artery Disease; Drug Resistance; Fibrinolytic Agents; Humans; Platelet Aggregation | 2013 |
[Secondary and primary prevention of coronary heart disease: platelet aggregation inhibitors and anticoagulants].
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Respon | 2002 |
C-reactive protein: the pawn has been promoted to queen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; C-Reactive Protein; Coronary Artery Di | 2003 |
Oral anticoagulants in patients with coronary artery disease.
Topics: Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Int | 2003 |
Oral anticoagulants in patients with coronary artery disease: an inexpensive and effective strategy.
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Artery Disease; Humans; Treatment Outcom | 2003 |
Current concepts of cardiovascular diseases in diabetes mellitus.
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus | 2003 |
[Clopidogrel: background information and use in clinical practice].
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibrinol | 2003 |
[Primary and secondary prevention of coronary artery disease].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Aspir | 2003 |
Aggressive treatment of atherosclerosis: the time is now.
Topics: Aspirin; Coronary Artery Disease; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhib | 2003 |
Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases.
Topics: Adjuvants, Immunologic; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Ster | 2003 |
[Antiplatelet drugs in prevention and treatment of coronary heart disease: aspirin is obligatory, quite sufficient, and safe].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Intera | 2003 |
[Antiplatelet drugs in prevention of complications of arteriosclerotic diseases: it is necessary to move beyond aspirin].
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Drug Therapy, Combination; Hu | 2003 |
Coronary artery disease and stroke in HIV-infected patients: prevention and pharmacological therapy.
Topics: Anticoagulants; Antiretroviral Therapy, Highly Active; Aspirin; Cardiomyopathies; Comorbidity; Coron | 2003 |
The expanding role of antiplatelet agents in coronary artery disease. A current review of aspirin, glycoprotein IIb/IIIa inhibitors, and the thienopyridines.
Topics: Aspirin; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPI | 2003 |
Aspirin and thrombinogenesis.
Topics: Animals; Anticoagulants; Aspirin; Blood Coagulation; Coronary Artery Disease; Drug Resistance; Human | 2003 |
Role of antiplatelet drugs in the prevention of cardiovascular events.
Topics: Aspirin; Benzamidines; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Oximes; | 2003 |
Silent acute myocardial infarction following a wasp sting.
Topics: Aged; Animals; Aspirin; Coronary Angiography; Coronary Artery Disease; Echocardiography; Electrocard | 2003 |
Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice.
Topics: Aspirin; Blood Coagulation; Coronary Artery Disease; Coronary Thrombosis; Fibrinolytic Agents; Human | 2004 |
Long-term statin safety and efficacy in secondary prevention: can combination therapy improve outcomes?
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Aspirin; Coronary Artery Disease | 2003 |
Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemor | 2004 |
Clopidogrel: how good is it and how does it work?
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; | 2004 |
Current concepts in the antithrombotic management of non-ST-elevation acute coronary syndromes.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Artery Disease; Heparin, Low-Molecular | 2004 |
Oral anticoagulant therapy in patients with coronary artery disease.
Topics: Administration, Oral; Anticoagulants; Aspirin; Coronary Artery Disease; Humans; International Normal | 2003 |
Approach to "aspirin allergy" in cardiovascular patients.
Topics: Anaphylaxis; Aspirin; Coronary Artery Disease; Drug Hypersensitivity; Humans; Platelet Aggregation I | 2004 |
[Risk management of coronary artery disease--pharmacological therapy].
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Coronary Arte | 2004 |
Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Antithrombins; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery D | 2004 |
Prevention of cardiovascular complications of diabetes mellitus by aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; | 2004 |
Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Topics: Administration, Oral; Angina Pectoris; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopido | 2004 |
Aspirin and coronary artery disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Blood Platelets; Clinical Tria | 2004 |
Aspirin sensitivity: implications for patients with coronary artery disease.
Topics: Algorithms; Anaphylaxis; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Coron | 2004 |
Cardiac medical therapy in patients after undergoing coronary artery bypass graft surgery: a review of randomized controlled trials.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Bloc | 2005 |
What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis.
Topics: Aged; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Blood Vessel Prost | 2005 |
Late thrombosis associated with drug-eluting stents.
Topics: Aspirin; Cell Proliferation; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug | 2005 |
Long-term anticoagulant therapy in patients with coronary artery disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Artery Disease; Drug Combina | 2006 |
Gastrointestinal complications of dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, | 2006 |
[Acute coronary syndrome risk management].
Topics: Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Artery Disease; Humans | 2006 |
Aspirin resistance, an emerging, often overlooked, factor in the management of patients with coronary artery disease.
Topics: Aspirin; Coronary Artery Disease; Drug Resistance; Humans; Platelet Aggregation Inhibitors | 2006 |
Antiplatelet resistance with aspirin and clopidogrel: is it real and does it matter?
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Platelet Aggregation Inhibit | 2006 |
Intravascular ultrasound in cardiovascular medicine.
Topics: Adult; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA | 2006 |
A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease.
Topics: Aspirin; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Risk Factors; Treatment R | 2006 |
To statin or to non-statin in coronary disease--considering absolute risk is the answer.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Cholesterol, LDL; Coronary Artery Disease; Diet; | 2007 |
Role of clopidogrel in managing atherothrombotic cardiovascular disease.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Dr | 2007 |
Preventing cardiovascular disease in women: an update.
Topics: Aspirin; Coronary Artery Disease; Female; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase In | 2008 |
Monitoring of the antiplatelet drugs effect in patients with coronary artery disease: what is the real clinical impact?
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Monitoring; Drug Resistance; Humans; Platelet Ag | 2007 |
Platelet function monitoring in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Disease; Drug Resis | 2007 |
Aspirin combined with clopidogrel (Plavix) decreases cardiovascular events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Evidence-B | 2007 |
Increased incidence of in-stent thrombosis related to cocaine use: case series and review of literature.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cocaine; Cocaine-Related Disorders; Cor | 2007 |
Update on antiplatelet agents, including MATCH, CHARISMA, and ESPRIT.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Dipyridamole; Female; Humans; Ischemi | 2008 |
Aspirin resistance in atherosclerosis.
Topics: Aspirin; Blood Platelets; Coronary Artery Disease; Coronary Thrombosis; Cyclooxygenase Inhibitors; D | 2008 |
Coronary atherothrombotic disease: progress in antiplatelet therapy.
Topics: Aspirin; Blood Platelets; Coronary Artery Disease; Coronary Thrombosis; Humans; Platelet Aggregation | 2008 |
Atherothrombotic insights into secondary prevention after acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agent | 1993 |
[Blood platelet aggregation inhibitors in the treatment of heart diseases].
Topics: Angina, Unstable; Aspirin; Coronary Artery Disease; Coronary Disease; Dipyridamole; Humans; Platelet | 1993 |
Unmet therapeutic needs in the management of acute ischemia.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Fibrinolytic Agents; Humans; Myo | 1997 |
Long-term management--the way forward?
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Dalteparin; Drug Therapy, Combin | 2000 |
Contemporary diagnosis and management of unstable angina.
Topics: Abciximab; Acute Disease; Algorithms; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, | 2000 |
Post-hospitalization management of high-risk coronary patients.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiotonic Agents; Coronary Artery Bypass; Coronary Artery | 2000 |
Advances in the pharmacology of acute coronary syndrome. Platelet inhibition.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Combined Modality Therapy; Corona | 2000 |
Current strategies and perspectives for correcting endothelial dysfunction in atherosclerosis.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2001 |
Cyclo-oxygenase-1 and cyclo-oxygenase-2 and cardiovascular system.
Topics: Aspirin; Cell Adhesion Molecules; Coronary Artery Disease; Cyclooxygenase 1; Cyclooxygenase 2; Cyclo | 2001 |
Tissue factor and coronary artery disease.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Angiotensin II; Angiotensin Receptor Antagonists; Ang | 2002 |
[Treatment of coronary artery disease in a patient with adult-onset diabetes mellitus].
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 1999 |
[Modern therapy in acute coronary syndrome].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Di | 2002 |
Interaction between aspirin and ACE Inhibitors: resolving discrepancies using a meta-analysis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Artery Disease; Drug Interactions; Drug | 2002 |
Enoxaparin in acute coronary syndromes: evidence for superiority over placebo or untreated control.
Topics: Anticoagulants; Aspirin; Confidence Intervals; Coronary Artery Disease; Coronary Thrombosis; Drug Th | 2002 |
Aspirin beyond platelet inhibition.
Topics: Abciximab; Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; As | 2002 |
[Can coronary "restenosis" after percutaneous angioplasty be prevented?].
Topics: Adrenal Cortex Hormones; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Disease; Coronary | 1992 |
Risk factors, interventions and therapeutic agents in the prevention of atherosclerosis-related ischaemic diseases.
Topics: Aspirin; Coronary Artery Disease; Coronary Disease; Humans; Male; Myocardial Infarction; Platelet Ag | 1991 |
[Prevention of obliterating arterial diseases with acetylsalicylic acid].
Topics: Arteriosclerosis Obliterans; Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction | 1990 |
[Platelet and coronary disease].
Topics: Animals; Aspirin; Blood Platelet Disorders; Coronary Artery Disease; Coronary Disease; Humans | 1987 |
278 trials available for aspirin and Coronary Artery Disease
| Article | Year |
|---|---|
Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Dual An | 2021 |
Optimal medical therapy in patients with stable coronary artery disease in Poland: the ISCHEMIA trial experience.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cholester | 2021 |
Influence of cardiopulmonary exercise test on platelet function in patients with coronary artery diseases on antiplatelet therapy.
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Exercise Test; Female; Humans; Male; Mi | 2022 |
Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; D | 2022 |
Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial.
Topics: Aspirin; Coronary Artery Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Humans; Percutan | 2022 |
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry.
Topics: Aged; Aspirin; Coronary Artery Disease; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Peri | 2022 |
Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial.
Topics: Asian People; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Perip | 2022 |
Cilostazol treatment for preventing adverse cardiovascular events in patients with type 2 diabetes and coronary atherosclerosis: Long-term follow-up of the ESCAPE study.
Topics: Aspirin; Cilostazol; Coronary Artery Disease; Coronary Stenosis; Diabetes Mellitus, Type 2; Drug The | 2022 |
Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Di | 2022 |
Effect of cocoa (
Topics: Aspirin; Cacao; Chocolate; Clopidogrel; Coronary Artery Disease; Humans; Pilot Projects; Platelet Ag | 2022 |
External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Hea
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Myocardial Infarction; Outcome | 2023 |
Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial.
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Human | 2023 |
Rationale and design of the TUXEDO-2 India study: Ultra-Thin strUt Supraflex Cruz versus XiencE in a Diabetic pOpulation with multi-vessel disease-2.
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus; Everolimus; Humans; Myocardial Infarction; Perc | 2023 |
Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority ra
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Gastrointestinal Diseases; | 2023 |
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.
Topics: Aged; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; Coronary Artery Disease; Cyclooxygena | 2020 |
Validation of the DAPT score in real-world patients undergoing coronary stent implantation.
Topics: Aged; Aged, 80 and over; Aspirin; Cohort Studies; Coronary Artery Disease; Drug-Eluting Stents; Dual | 2020 |
Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
Topics: Aged; Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy | 2019 |
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.
Topics: Aged; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastroin | 2019 |
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.
Topics: Aged; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastroin | 2019 |
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.
Topics: Aged; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastroin | 2019 |
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.
Topics: Aged; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastroin | 2019 |
Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin.
Topics: Aged; Aspirin; Coronary Artery Disease; Drug Combinations; Factor Xa Inhibitors; Female; Hemorrhage; | 2019 |
Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2 | 2020 |
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.
Topics: Aged; Anticoagulants; Aspirin; Chronic Disease; Coronary Artery Disease; Double-Blind Method; Drug T | 2020 |
Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual Antiplatelet Therapy Study).
Topics: Aged; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Artery Disease; Dual Anti-P | 2019 |
Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial.
Topics: Aged; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hem | 2020 |
Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Coronary Thrombosis; Factor X | 2020 |
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2019 |
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2019 |
Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy.
Topics: Aged; Aspirin; Biomarkers; Blood Coagulation; Coronary Artery Disease; Drug Therapy, Combination; Fa | 2020 |
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; C | 2020 |
Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
Topics: Aged; Aged, 80 and over; Aspirin; Comorbidity; Coronary Artery Disease; Double-Blind Method; Drug Ad | 2021 |
Influence of lipoproteins and antiplatelet agents on vein graft patency 1 year after coronary artery bypass grafting.
Topics: Aged; Aspirin; Biomarkers; China; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; | 2022 |
Optimal antiplatelet therapy for prevention of gastrointestinal injury evaluated by ANKON magnetically controlled capsule endoscopy: Rationale and design of the OPT-PEACE trial.
Topics: Adult; Aspirin; Capsule Endoscopy; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Doubl | 2020 |
First Human Use of RUC-4: A Nonactivating Second-Generation Small-Molecule Platelet Glycoprotein IIb/IIIa (Integrin αIIbβ3) Inhibitor Designed for Subcutaneous Point-of-Care Treatment of ST-Segment-Elevation Myocardial Infarction.
Topics: Adult; Aged; Aspirin; Case-Control Studies; Coronary Artery Disease; Female; Humans; Injections, Sub | 2020 |
Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD: The ASET Pilot Study.
Topics: Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; P | 2020 |
Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD: The ASET Pilot Study.
Topics: Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; P | 2020 |
Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD: The ASET Pilot Study.
Topics: Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; P | 2020 |
Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD: The ASET Pilot Study.
Topics: Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; P | 2020 |
Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Dabigatran; Drug Therapy, Com | 2021 |
New-Onset Atrial Fibrillation After Coronary Artery Bypass Grafting and Long-Term Outcome: A Population-Based Nationwide Study From the SWEDEHEART Registry.
Topics: Aged; Aspirin; Atrial Fibrillation; Coronary Artery Bypass; Coronary Artery Disease; Factor Xa Inhib | 2021 |
Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial.
Topics: Aged; Aspirin; Biodegradable Plastics; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Dr | 2021 |
Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Factor Xa Inhibitors; Fema | 2021 |
Ticagrelor or Aspirin After Coronary Artery Bypass in Patients With Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Meth | 2022 |
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial.
Topics: Aspirin; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Humans; Percutaneous Corona | 2021 |
Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials.
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Foll | 2021 |
Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial.
Topics: Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Female; Glo | 2021 |
Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Midd | 2021 |
Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Midd | 2021 |
Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Midd | 2021 |
Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Midd | 2021 |
Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Midd | 2021 |
Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Midd | 2021 |
Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Midd | 2021 |
Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Midd | 2021 |
Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Midd | 2021 |
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease.
Topics: Aged; Aspirin; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Factor Xa Inhi | 2021 |
Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosis.
Topics: Aged; Aspirin; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Administration Schedu | 2021 |
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Coronary Artery Bypass; Coronary Artery Disease; | 2017 |
Impact of dual antiplatelet therapy after coronary artery bypass surgery on 1-year outcomes in the Arterial Revascularization Trial.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Dose-Response Relationship, D | 2017 |
Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; D | 2017 |
6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedu | 2017 |
High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study.
Topics: Aspirin; Atorvastatin; Coronary Artery Disease; Drug-Eluting Stents; Female; Graft Occlusion, Vascul | 2018 |
Eight-year follow-up of the Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) trial.
Topics: Aged; Aspirin; Clopidogrel; Computed Tomography Angiography; Coronary Angiography; Coronary Artery B | 2018 |
Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy.
Topics: Aged; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Dr | 2018 |
Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial.
Topics: Adenosine; Aspirin; Clinical Protocols; Coronary Artery Disease; Drug Therapy, Combination; England; | 2017 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Effect of Sustained Use of Aspirin until the Time of Surgery on Outcomes following Coronary Artery Bypass Grafting: A Randomized Clinical Trial.
Topics: Aged; Aspirin; Blood Loss, Surgical; Cardiovascular Agents; Coronary Artery Bypass; Coronary Artery | 2018 |
Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREA
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Double-Blind Method | 2018 |
Guanxinning tablet for patients who switch from dual antiplatelet therapy to aspirin alone after percutaneous coronary intervention: study protocol for a cluster randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; China; Coronary Artery Di | 2018 |
Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Drug Monitoring; Female | 2018 |
Vascular response to biolimus A-9 eluting stent in patients with shorter and prolonged dual antiplatelet therapy: optical coherence tomography sub-study of the NIPPON trial.
Topics: Aged; Aspirin; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Drug The | 2018 |
Impact of ticagrelor versus aspirin on graft patency after CABG: Rationale and design of the TARGET (ticagrelor antiplatelet therapy to reduce graft events and thrombosis) randomized controlled trial (NCT02053909).
Topics: Aftercare; Aged; Aspirin; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Cor | 2018 |
Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Coronary Artery Disease; Drug The | 2018 |
Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial.
Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Cyclooxygenase Inhibitors; Female; Greece; H | 2019 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention.
Topics: Aged; Aspirin; Brazil; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug | 2018 |
Aspirin in coronary artery surgery: 1-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial.
Topics: Aged; Antifibrinolytic Agents; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Coronary Th | 2019 |
Tranexamic acid in coronary artery surgery: One-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial.
Topics: Activities of Daily Living; Aged; Antifibrinolytic Agents; Aspirin; Coronary Artery Bypass; Coronary | 2019 |
The effect of acetylsalicylic acid dosed at bedtime on the anti-aggregation effect in patients with coronary heart disease and arterial hypertension: A randomized, controlled trial.
Topics: Aged; Arterial Pressure; Aspirin; Coronary Artery Disease; Drug Chronotherapy; Female; Humans; Hyper | 2019 |
Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease: Insights from the PROMISE trial.
Topics: Aspirin; Cardiac Catheterization; Computed Tomography Angiography; Coronary Angiography; Coronary Ar | 2019 |
Stroke Outcomes in the COMPASS Trial.
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Female; Follow | 2019 |
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Chronic Disease; Corona | 2019 |
Platelet MicroRNA 365-3p Expression Correlates with High On-treatment Platelet Reactivity in Coronary Artery Disease Patients.
Topics: Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Coronary Artery Disease; Drug Resistance; D | 2019 |
Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study.
Topics: Aged; Aspirin; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Diabetes Mellitus, Type | 2019 |
Effects of Rosuvastatin and Aspirin on Retinal Vascular Structures in Hypercholesterolemic Patients with Low-to-Moderate Risk of Coronary Artery Disease.
Topics: Arterioles; Asian People; Aspirin; Atherosclerosis; C-Reactive Protein; Coronary Artery Disease; Fem | 2019 |
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fib | 2019 |
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY).
Topics: Aspirin; Coronary Artery Disease; Drug Administration Routes; Drug Therapy, Combination; Endpoint De | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial.
Topics: Aged; Aspirin; Coronary Artery Disease; Correlation of Data; Double-Blind Method; Drug Therapy, Comb | 2019 |
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combinat | 2019 |
Genetic variation at the coronary artery disease risk locus GUCY1A3 modifies cardiovascular disease prevention effects of aspirin.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Female; G | 2019 |
Effectiveness of antiplatelet therapy in atherosclerotic disease: comparing the ASA low-response prevalence in CVD, CAD and PAD.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Female; Humans; Male; Middle Aged; | 2014 |
The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studi | 2013 |
Low-dose acetylsalicylic acid therapy monitored with ultra high performance liquid chromatography.
Topics: Adult; Aspirin; Calibration; Case-Control Studies; Chromatography, High Pressure Liquid; Coronary Ar | 2013 |
Current medical management of stable coronary artery disease before and after elective percutaneous coronary intervention.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Clopidogrel; Coloring Agents; Coronary Angiography; Coro | 2013 |
Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study.
Topics: Adult; Arachidonic Acid; Aspirin; Blood Platelets; Collagen; Coronary Artery Disease; Diabetes Melli | 2013 |
Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery D | 2014 |
Aspirin dose increase from 75 to 150 mg suppresses red blood cell contribution to suboptimal platelet response to aspirin in patients with CAD.
Topics: Adult; Aspirin; C-Reactive Protein; Coronary Artery Disease; Cross-Over Studies; Erythrocyte Count; | 2013 |
Thromboxane A(2) generation, in the absence of platelet COX-1 activity, in patients with and without atherothrombotic myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Creatinine; Cyclooxygenase 1; Cyclooxygenas | 2013 |
Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-plate
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, | 2013 |
Comparison of dual versus triple antiplatelet therapy after drug-eluting stent according to stent length (from the pooled analysis of DECLARE trials).
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Diabetes Compl | 2013 |
Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Arte | 2014 |
Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
Topics: Aspirin; Biomarkers; Blood Platelets; Body Mass Index; Cell Adhesion Molecules; Clopidogrel; Coronar | 2014 |
Aspirin inhibits release of platelet-derived sphingosine-1-phosphate in acute myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Humans; Injections, Intravenous; Lysophosph | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Atorvastatin; Clopidogrel; Coronary Artery Disease; Cross-Sectiona | 2014 |
Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; | 2014 |
Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Croatia; Dose-Response | 2014 |
Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease.
Topics: Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P- | 2014 |
Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Coronary Artery Disea | 2014 |
Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
Topics: Aged; Angina, Stable; Aspirin; Belgium; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coron | 2014 |
Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study.
Topics: Adult; Aged; Anti-Ulcer Agents; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; | 2014 |
Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial.
Topics: Adolescent; Adult; Aged; Aspirin; Coronary Artery Disease; Drug Administration Schedule; Drug Therap | 2014 |
Dual antiplatelet therapy in patients with stable coronary artery disease in modern practice: prevalence, correlates, and impact on prognosis (from the Suivi d'une cohorte de patients COROnariens stables en region NORd-Pas-de-Calais study).
Topics: Aged; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Female; Follow-Up Studies; France | 2014 |
Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome tria
Topics: Absorbable Implants; Aged; Anti-Inflammatory Agents; Aspirin; Coronary Artery Disease; Drug-Eluting | 2015 |
6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Drug-Elu | 2015 |
Comparison of the antiplatelet effect of clopidogrel hydrogenosulfate and clopidogrel besylate in patients with stable coronary artery disease.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug | 2015 |
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinat | 2015 |
Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.
Topics: Aged; Aged, 80 and over; Aspirin; Biocompatible Materials; Clopidogrel; Coronary Angiography; Corona | 2015 |
Reduced Effect of Aspirin and Clopidogrel Following Hybrid Coronary Revascularization.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Female; Follow-Up Studi | 2015 |
Prevention of dipyrone (metamizole) induced inhibition of aspirin antiplatelet effects.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Aspirin; Biomarkers; Blood Platelets; Chro | 2015 |
Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention.
Topics: Adenosine; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug | 2015 |
The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin.
Topics: Aged; Aspirin; Blood Platelets; Cohort Studies; Coronary Artery Disease; Diabetes Complications; Dia | 2015 |
Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study.
Topics: Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2015 |
Postoperative Atrial Fibrillation Is Associated With High On-Aspirin Platelet Reactivity.
Topics: Aged; Aspirin; Atrial Fibrillation; Blood Platelets; Coronary Artery Bypass; Coronary Artery Disease | 2015 |
Stopping antiplatelet medication before coronary artery bypass graft surgery: is there an optimal timing to minimize bleeding?
Topics: Aged; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; D | 2015 |
Temporal variability in the antiplatelet effects of clopidogrel and aspirin after elective drug-eluting stent implantation. An ADAPT-DES substudy.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Vessel Prosthesis Implantation; Clopid | 2015 |
Effects of CYP2C19 Polymorphism on Endothelial Function, Arterial Stiffness and Inflammation in Coronary Artery Disease Patients Under Clopidogrel Treatment.
Topics: Aged; Aged, 80 and over; Aspirin; Brachial Artery; Clopidogrel; Coronary Artery Disease; Cytochrome | 2015 |
Comparative effect on platelet function of a fixed-dose aspirin and clopidogrel combination versus separate formulations in patients with coronary artery disease: A phase IV, multicenter, prospective, 4-week non-inferiority trial.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Combinations; Drug-Eluting Stents; Female; Human | 2016 |
Antiplatelet Efficacy of Fixed-Dose Aspirin-Clopidogrel Combination in Patients with Stable Coronary Artery Disease Treated with Drug-Eluting Stent Implantation.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Combinations; Dr | 2015 |
Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Clopidogrel | 2016 |
Effect of Preoperative Aspirin Replacement With Enoxaparin in Patients Undergoing Primary Isolated On-Pump Coronary Artery Bypass Grafting.
Topics: Aged; Anticoagulants; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Dose-Response Relati | 2016 |
Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.
Topics: Aged; Aspirin; Cardiovascular Agents; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Met | 2016 |
Ticagrelor and aspirin for the prevention of cardiovascular events after coronary artery bypass graft surgery.
Topics: Adenosine; Aged; Aspirin; British Columbia; Chi-Square Distribution; Computed Tomography Angiography | 2016 |
Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dru | 2016 |
Comparison of dual antiplatelet therapy prescribed as one-pill versus two-pill regimen. A pooled analysis of individual patient data from the three MR-CAPCIS trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Combinations; Drug-Eluting Stents; Female; | 2016 |
Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease.
Topics: Adenosine; Aged; Area Under Curve; Asian People; Aspirin; Blood Platelets; Coronary Artery Disease; | 2016 |
Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study.
Topics: Aged; Anemia; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinat | 2016 |
Comparison of the antiplatelet effect of clopidogrel benzene sulfonate and clopidogrel hydrogen sulfate in stable coronary heart disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-4 | 2016 |
Rationale and design of a randomized cluster trial to improve guideline-adherence of secondary preventive drugs prescription after coronary artery bypass grafting in China: Measurement and Improvement Studies of Surgical Coronary Revascularization: Second
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2016 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; D | 2016 |
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; C | 2016 |
Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease: A Subgroup Analysis of the PRODIGY Randomized Clinical Trial.
Topics: Aged; Aspirin; Composite Resins; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; | 2016 |
Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Artery Disease; Double-Blin | 2016 |
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm
Topics: Adenosine; Aged; Aspirin; Coronary Artery Disease; Female; Hemorrhage; Humans; Intracranial Hemorrha | 2016 |
A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Investig
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Bypass; Coronary Artery Disease; | 2016 |
Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Dose-Response Relations | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Effect of sarpogrelate, a selective 5-HT
Topics: Adult; Aged; Ankle Brachial Index; Anti-Inflammatory Agents; Aspirin; Biomarkers; Computed Tomograph | 2017 |
Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
Topics: Aspirin; Cilostazol; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Corona | 2017 |
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Cross-Ove | 2008 |
Pharmacotherapy in patients with stable coronary artery disease treated on an outpatient basis in Poland. Results of the multicentre RECENT study.
Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care Facilities; Angiotensin-Converting Enzyme Inhibit | 2008 |
Monitoring aspirin therapy with the Platelet Function Analyzer-100.
Topics: Adult; Arachidonic Acid; Aspirin; Coronary Artery Disease; Female; Health; Humans; Male; Middle Aged | 2008 |
Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Ther | 2008 |
Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; Drug Resista | 2008 |
Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
Topics: Aged; Aspirin; Cell Size; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; F | 2008 |
Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; | 2008 |
Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque.
Topics: Aged; Aspirin; Cardiotonic Agents; Cholesterol, HDL; Coronary Artery Disease; Female; Fibrinolytic A | 2008 |
Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque.
Topics: Aged; Aspirin; Cardiotonic Agents; Cholesterol, HDL; Coronary Artery Disease; Female; Fibrinolytic A | 2008 |
Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque.
Topics: Aged; Aspirin; Cardiotonic Agents; Cholesterol, HDL; Coronary Artery Disease; Female; Fibrinolytic A | 2008 |
Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque.
Topics: Aged; Aspirin; Cardiotonic Agents; Cholesterol, HDL; Coronary Artery Disease; Female; Fibrinolytic A | 2008 |
Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque.
Topics: Aged; Aspirin; Cardiotonic Agents; Cholesterol, HDL; Coronary Artery Disease; Female; Fibrinolytic A | 2008 |
Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque.
Topics: Aged; Aspirin; Cardiotonic Agents; Cholesterol, HDL; Coronary Artery Disease; Female; Fibrinolytic A | 2008 |
Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque.
Topics: Aged; Aspirin; Cardiotonic Agents; Cholesterol, HDL; Coronary Artery Disease; Female; Fibrinolytic A | 2008 |
Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque.
Topics: Aged; Aspirin; Cardiotonic Agents; Cholesterol, HDL; Coronary Artery Disease; Female; Fibrinolytic A | 2008 |
Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque.
Topics: Aged; Aspirin; Cardiotonic Agents; Cholesterol, HDL; Coronary Artery Disease; Female; Fibrinolytic A | 2008 |
ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Comorbidity; Coronary Artery Dis | 2008 |
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.
Topics: Adult; Aspirin; Biomarkers; Blood Platelets; Cell Communication; Clopidogrel; Coronary Artery Diseas | 2008 |
Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease | 2008 |
Comparison of laboratory detection methods of aspirin resistance in coronary artery disease patients.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clinical Laboratory Techniques; Clopidogrel; Coronary Arter | 2010 |
Comparison of collagen versus adenosine diphosphate in detecting antiplatelet effect in patients with coronary artery disease.
Topics: Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Collagen; Coronary Artery Disease; Drug Resistanc | 2009 |
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Fe | 2008 |
Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, C | 2009 |
Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox".
Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Aspirin; Body Mass Index; Cell Adhesion Molecules | 2009 |
Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel | 2008 |
The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease | 2008 |
Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Blood Platelets; C | 2008 |
Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.
Topics: Aged; Angioplasty, Balloon, Coronary; Asia; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Mate | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin.
Topics: Aspirin; Biomarkers; CD40 Ligand; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule | 2009 |
Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coron | 2009 |
The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients.
Topics: Adenosine Diphosphate; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon | 2010 |
Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoag | 2009 |
Design and rationale of the WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST).
Topics: Administration, Oral; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Arter | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thromb | 2010 |
Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation.
Topics: Aged; Aspirin; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Resistance; Drug Ther | 2010 |
In-hospital outcomes of contemporary percutaneous coronary intervention in patients with chronic total occlusion insights from the J-CTO Registry (Multicenter CTO Registry in Japan).
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disea | 2010 |
Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease.
Topics: Adult; Aspirin; Coronary Artery Disease; Cyclooxygenase Inhibitors; Female; Genetic Heterogeneity; H | 2011 |
Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease.
Topics: Adult; Aspirin; Coronary Artery Disease; Cyclooxygenase Inhibitors; Female; Genetic Heterogeneity; H | 2011 |
Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease.
Topics: Adult; Aspirin; Coronary Artery Disease; Cyclooxygenase Inhibitors; Female; Genetic Heterogeneity; H | 2011 |
Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease.
Topics: Adult; Aspirin; Coronary Artery Disease; Cyclooxygenase Inhibitors; Female; Genetic Heterogeneity; H | 2011 |
Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) st
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Blood Proteins; Cell Adhesi | 2010 |
Pantoprazole does not influence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2010 |
Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting.
Topics: Adenosine Diphosphate; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square D | 2010 |
A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atorvastatin; Chi-Square Distribution; Clopidogrel; C | 2010 |
Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy.
Topics: Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Drug-Elutin | 2010 |
Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes.
Topics: Adult; Aged; Aspirin; Blood Platelets; Chemoprevention; Coronary Artery Disease; Diabetes Mellitus; | 2010 |
Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Coronary | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial.
Topics: Administration, Oral; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary A | 2010 |
First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
Topics: Adenosine; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytoc | 2010 |
First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
Topics: Adenosine; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytoc | 2010 |
First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
Topics: Adenosine; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytoc | 2010 |
First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
Topics: Adenosine; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytoc | 2010 |
Effect of omeprazole on the concentration of interleukin-6 and transforming growth factor-β1 in patients receiving dual antiplatelet therapy after percutaneous coronary intervention.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Biomarkers; Clopidogrel; Coronary Angiography; Coronary Artery Dis | 2010 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Dr | 2010 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Dr | 2010 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Dr | 2010 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Dr | 2010 |
Comparison of the racial/ethnic prevalence of regular aspirin use for the primary prevention of coronary heart disease from the multi-ethnic study of atherosclerosis.
Topics: Aged; Aged, 80 and over; Asian; Aspirin; Black or African American; Cohort Studies; Coronary Artery | 2011 |
Secondary prevention after coronary artery bypass graft surgery: findings of a national randomized controlled trial and sustained society-led incorporation into practice.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Female; | 2011 |
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes | 2011 |
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes | 2011 |
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes | 2011 |
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes | 2011 |
Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study.
Topics: Acute Coronary Syndrome; Administration, Cutaneous; Age Factors; Aged; Angioplasty, Balloon, Coronar | 2011 |
Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease.
Topics: Aged; Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Respo | 2011 |
A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Sten
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Double-Blind M | 2011 |
Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot).
Topics: Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Coagulation; | 2011 |
Reconsidering low-dose aspirin therapy for cardiovascular disease: a study protocol for physician and patient behavioral change.
Topics: Aspirin; Cardiovascular Diseases; Clinical Protocols; Colorado; Coronary Artery Disease; Decision Su | 2011 |
Effect of polymorphism and type II diabetes on aspirin resistance in patients with unstable coronary artery disease.
Topics: Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type | 2011 |
The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies.
Topics: Adenosine; Administration, Oral; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Stu | 2011 |
Influence of renal function and platelet turnover on the antiplatelet effect of aspirin.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Female; Glomerular Filtration Rate; Humans; | 2012 |
Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel.
Topics: Aged; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Diabe | 2011 |
Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Double-B | 2012 |
Description of response to aspirin and clopidogrel in outpatients with coronary artery disease using multiple electrode impedance aggregometry.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Place | 2012 |
Monocyte gene expression signature of patients with early onset coronary artery disease.
Topics: Adult; Aspirin; Case-Control Studies; Coronary Artery Disease; Gene Expression Profiling; Gene Expre | 2012 |
Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
Topics: Anti-Inflammatory Agents; Aspirin; Child, Preschool; Coronary Artery Disease; Coronary Vessel Anomal | 2012 |
Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.
Topics: Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Coronary Artery Disease; Cross-Over Studies | 2013 |
Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.
Topics: Adenosine Diphosphate; Aspirin; Atorvastatin; Calcium Channel Blockers; Clopidogrel; Coronary Artery | 2012 |
Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial.
Topics: Adrenergic Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Artery Disease; C | 2012 |
Effects on platelet function of a direct acting antagonist of coagulation factor Xa.
Topics: Adenosine Monophosphate; Aged; Anticoagulants; Aspirin; Blood Platelets; Coronary Artery Disease; Cr | 2012 |
Effects of preoperative aspirin in coronary artery bypass grafting: a double-blind, placebo-controlled, randomized trial.
Topics: Aged; Aspirin; Chi-Square Distribution; Coronary Artery Bypass; Coronary Artery Disease; Double-Blin | 2012 |
Polyunsaturated omega-3 fatty acids improve responsiveness to clopidogrel after percutaneous coronary intervention in patients with cytochrome P450 2C19 loss-of-function polymorphism.
Topics: Administration, Cutaneous; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Arter | 2012 |
Markers of endothelial and platelet activation are associated with high on-aspirin platelet reactivity in patients with stable coronary artery disease.
Topics: Adult; Aged; Aspirin; Biomarkers; Blood Coagulation Factors; Coronary Artery Disease; Dose-Response | 2012 |
Effects of ozone therapy on haemostatic and oxidative stress index in coronary artery disease.
Topics: Aged; Aged, 80 and over; Antioxidants; Aspirin; Biomarkers; Coronary Artery Disease; Fatty Alcohols; | 2012 |
Effects of ozone therapy on haemostatic and oxidative stress index in coronary artery disease.
Topics: Aged; Aged, 80 and over; Antioxidants; Aspirin; Biomarkers; Coronary Artery Disease; Fatty Alcohols; | 2012 |
Effects of ozone therapy on haemostatic and oxidative stress index in coronary artery disease.
Topics: Aged; Aged, 80 and over; Antioxidants; Aspirin; Biomarkers; Coronary Artery Disease; Fatty Alcohols; | 2012 |
Effects of ozone therapy on haemostatic and oxidative stress index in coronary artery disease.
Topics: Aged; Aged, 80 and over; Antioxidants; Aspirin; Biomarkers; Coronary Artery Disease; Fatty Alcohols; | 2012 |
Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin.
Topics: Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Mi | 2012 |
Renal function and aspirin resistance in patients with coronary artery disease.
Topics: Aspirin; Coronary Artery Disease; Drug Resistance; Female; Glomerular Filtration Rate; Humans; Kidne | 2012 |
Cardiovascular therapy, diagnostic procedures, and control of risk factors in patients with diabetes or coronary artery disease in Poland: the Kardia‑Pol registry.
Topics: Aged; Aged, 80 and over; Aspirin; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Female; H | 2012 |
Tranexamic Acid in on-pump coronary artery bypass grafting without clopidogrel and aspirin cessation: randomized trial and 1-year follow-up.
Topics: Antifibrinolytic Agents; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Coronar | 2013 |
Inflammation and circulating endothelial progenitor cells in patients with coronary artery disease and residual platelet reactivity.
Topics: Aged; Aspirin; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Endothelial Cells; Female; H | 2012 |
Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease.
Topics: Analysis of Variance; Arachidonic Acid; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over St | 2012 |
ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatm
Topics: Absorbable Implants; Adult; Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary T | 2012 |
ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatm
Topics: Absorbable Implants; Adult; Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary T | 2012 |
ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatm
Topics: Absorbable Implants; Adult; Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary T | 2012 |
ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatm
Topics: Absorbable Implants; Adult; Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary T | 2012 |
Optimized duration of clopidogrel therapy following treatment with the Endeavor zotarolimus-eluting stent in real-world clinical practice (OPTIMIZE) trial: rationale and design of a large-scale, randomized, multicenter study.
Topics: Adult; Aspirin; Brazil; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Co | 2012 |
Benefit of long-term dual anti-platelet therapy in patients treated with drug-eluting stents: from the NHLBI dynamic registry.
Topics: Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Rela | 2013 |
Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial.
Topics: Aged; Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy | 2014 |
Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial.
Topics: Aspirin; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stent | 2013 |
Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aspirin; Coated Materials, Biocompatible; Corona | 2013 |
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
Topics: Absorbable Implants; Aspirin; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Thr | 2013 |
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
Topics: Absorbable Implants; Aspirin; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Thr | 2013 |
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
Topics: Absorbable Implants; Aspirin; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Thr | 2013 |
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
Topics: Absorbable Implants; Aspirin; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Thr | 2013 |
Effect of antioxidant probucol for preventing stent restenosis.
Topics: Aged; Antioxidants; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Angiography; Coronary Ar | 2002 |
Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Coronary Artery Disease; Drug Resistance; F | 2002 |
Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease.
Topics: Adult; Antigens, CD; Aspirin; Coronary Artery Disease; Female; Flow Cytometry; Humans; Integrin alph | 2003 |
A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents.
Topics: Aged; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Artery Disease; Drug Ther | 2003 |
Sarpogrelate treatment reduces restenosis after coronary stenting.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Cell Division; Coronary Angiography; | 2003 |
Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin.
Topics: Acetylcholine; Aged; Aspirin; Coronary Artery Disease; Cyclooxygenase Inhibitors; Double-Blind Metho | 2003 |
Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Coronary Artery Di | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Effects of aspirin (325 mg/day) on serum high-sensitivity C-reactive protein, cytokines, and adhesion molecules in healthy volunteers.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; Cell Adhesion Molecules | 2003 |
Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease.
Topics: Aspirin; Biomarkers; Brachial Artery; Coronary Artery Disease; Cyclooxygenase Inhibitors; Double-Bli | 2003 |
Alabama coronary artery bypass grafting project: results from phase II of a statewide quality improvement initiative.
Topics: Adrenergic beta-Antagonists; Aged; Alabama; Aspirin; Benchmarking; Cardiology Service, Hospital; Cor | 2004 |
The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy.
Topics: Aspirin; Biomarkers; Chronic Disease; Coronary Artery Disease; Humans; P-Selectin; Platelet Activati | 2003 |
Reduction of daily life ischaemia by aspirin in patients with angina: underlying link between thromboxane A2 and macrophage colony stimulating factor.
Topics: Adult; Aged; Aspirin; Biomarkers; Cohort Studies; Coronary Artery Disease; Cross-Over Studies; Doubl | 2004 |
Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Aspirin; Blood Coagulation; Cohort Studies; Coronary Artery Dis | 2005 |
Beneficial effect of aspirin on renal function in patients with renal insufficiency postcardiac surgery.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiopulmonary Bypass; Coronary Arte | 2004 |
What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis.
Topics: Aged; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Blood Vessel Prost | 2005 |
Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial.
Topics: Aged; alpha-Tocopherol; Antioxidants; Ascorbic Acid; Aspirin; Atorvastatin; Calcinosis; Coronary Art | 2005 |
Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Genotype; Humans; Integrin beta3; Ma | 2005 |
Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination.
Topics: Adenosine Diphosphate; Antigens, Human Platelet; Aspirin; Blood Platelets; Clopidogrel; Collagen; Co | 2006 |
Effects of angiotensin-converting enzyme inhibitors or an angiotensin receptor blocker in combination with aspirin and cilostazol on in-stent restenosis.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; | 2006 |
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Human | 2006 |
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Human | 2006 |
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Human | 2006 |
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Human | 2006 |
Antithrombotic effects of aspirin based on PLA1/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease.
Topics: Alleles; Aspirin; Bleeding Time; Coronary Artery Disease; Cyclooxygenase Inhibitors; Homozygote; Hum | 2007 |
Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects.
Topics: Acetylcholine; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants | 2006 |
Evaluation of platelet function in aspirin treated patients with CAD.
Topics: Aged; Aspirin; Blood Platelets; Case-Control Studies; Coronary Artery Disease; Female; Humans; Male; | 2006 |
Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; | 2006 |
Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'.
Topics: Adenosine Diphosphate; Adult; Aspirin; Bayes Theorem; Blood Platelets; Clopidogrel; Coronary Artery | 2007 |
The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Follow-Up | 2006 |
Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG.
Topics: Acetylcholine; Aged; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Mellitus, Ty | 2007 |
Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA-100 system in patients with coronary artery disease.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Female; Fibrinolytic Agents; Humans; Male; | 2006 |
Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR).
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Artery Disease; Death; Drug Resistance; Female | 2007 |
Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Child, Preschool; Coronary Artery Disease; | 2007 |
Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Child, Preschool; Coronary Artery Disease; | 2007 |
Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Child, Preschool; Coronary Artery Disease; | 2007 |
Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Child, Preschool; Coronary Artery Disease; | 2007 |
Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease.
Topics: Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Colchicine; Coronary Angiography; Coronary Ar | 2007 |
Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Cre | 2008 |
The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Biomarkers; Case-Control Studies; Clopidogrel; Coronary | 2007 |
C-reactive protein levels increase after exercise testing in patients with increased platelet reactivity.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Coronary Artery Disease; Exercise Test; Female; | 2007 |
Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Collagen; Coronary Artery | 2007 |
Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE trial).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2007 |
Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial).
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Vess | 2007 |
TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug-Elutin | 2007 |
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Mal | 2008 |
Alternative splicing of platelet cyclooxygenase-2 mRNA in patients after coronary artery bypass grafting.
Topics: Administration, Oral; Alternative Splicing; Animals; Aspirin; Base Sequence; Blood Platelets; Chloro | 2007 |
Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; C-Reactive Protein; CD40 Ligand; Clopidogrel; | 2007 |
[Effects of intensive antiplatelet therapy in patients with high platelet aggregability after percutaneous coronary intervention].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; | 2007 |
Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest | 2008 |
Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events.
Topics: Age Factors; Aged; Anti-Inflammatory Agents; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel | 2008 |
Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest | 2008 |
Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study.
Topics: Aged; Aged, 80 and over; Aspirin; Cohort Studies; Coronary Artery Disease; Drug Resistance; Female; | 2008 |
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.
Topics: Aged; Antidotes; Aptamers, Nucleotide; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind M | 2008 |
Effect of aspirin use on death and recurrent myocardial infarction in current and former cigarette smokers. Program on the Surgical Control of the Hyperlipidemias Group.
Topics: Aspirin; Cohort Studies; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hypercholestero | 1995 |
Combined antiplatelet therapy with ticlopidine and aspirin. A simplified approach to intracoronary stent management.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Coronary Artery Disea | 1996 |
Is there something more behind atherosclerotic plaque inflammation?
Topics: Antibodies, Bacterial; Aspirin; Chlamydia Infections; Chlamydophila pneumoniae; Coronary Artery Dise | 1998 |
Long-term management--the way forward?
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Dalteparin; Drug Therapy, Combin | 2000 |
Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Double-Blind | 2000 |
Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Double-Blind | 2000 |
Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Double-Blind | 2000 |
Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Double-Blind | 2000 |
Oral anticoagulant therapy during and after coronary angioplasty the intensity and duration of anticoagulation are essential to reduce thrombotic complications.
Topics: Administration, Oral; Aneurysm, False; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cere | 2001 |
Paradoxical activation of major platelet receptors in the methadone-maintained patients after single pill of aspirin.
Topics: Adult; Aspirin; Coronary Artery Disease; Drug Interactions; Female; Humans; Male; Methadone; Middle | 2001 |
Use of clopidogrel loading, enoxaparin, and double-bolus eptifibatide in the setting of early percutaneous coronary intervention for acute coronary syndromes.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Arter | 2002 |
The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from the Physicians' Health Study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Coronary Artery Disease; Co | 1991 |
Effect of eicosapentaenoic acid on restenosis rate, clinical course and blood lipids in patients after percutaneous transluminal coronary angioplasty.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Disease; Dipyridamole; Drug Th | 1990 |
[Prevention of obliterating arterial diseases with acetylsalicylic acid].
Topics: Arteriosclerosis Obliterans; Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction | 1990 |
722 other studies available for aspirin and Coronary Artery Disease
| Article | Year |
|---|---|
Platelet reactivity and clinical outcomes following percutaneous coronary intervention in complex higher-risk patients.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Myocardial Infarction; Pe | 2022 |
In-hospital Bleeding Outcomes of Oral Anticoagulant and Dual Antiplatelet Therapy During Percutaneous Coronary Intervention: An Analysis From the Japanese Nationwide Registry.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Dual Anti-Platelet Therapy | 2021 |
Third-Generation Hydroxyethyl Starch Causes Dose-Dependent Coagulopathy in Patients Undergoing Off-Pump Coronary Artery Bypass with Continuation of Preoperative Aspirin.
Topics: Aged; Aspirin; Blood Coagulation; Blood Coagulation Disorders; Coronary Artery Bypass, Off-Pump; Cor | 2021 |
Chinese expert consensus statement on dual antiplatelet therapy in patients with coronary artery disease.
Topics: Aspirin; China; Coronary Artery Disease; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Huma | 2022 |
Impact of Calcium Channel Blockers on Aspirin Reactivity in Patients with Coronary Artery Disease.
Topics: Aspirin; Blood Platelets; Calcium Channel Blockers; Coronary Artery Disease; Female; Humans; Male; P | 2022 |
Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cy | 2022 |
Evaluation of efficacy and safety of rivaroxaban combined with aspirin in patients with chronic coronary artery disease: A protocol for systematic review and meta-analysis.
Topics: Aspirin; Coronary Artery Disease; Humans; Meta-Analysis as Topic; Myocardial Ischemia; Research Desi | 2022 |
Clopidogrel Monotherapy More Effective Than Aspirin to Prevent Coronary Events After PCI With Drug-Eluting Stents.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Human | 2022 |
Prediction of Low-Dose Aspirin-Induced Gastric Toxicity Using Nuclear Magnetic Resonance Spectroscopy-Based Pharmacometabolomics in Rats.
Topics: Animals; Aspirin; Coronary Artery Disease; Humans; Magnetic Resonance Spectroscopy; Male; Metabolomi | 2022 |
Association of steroid administration with larger coronary artery abnormalities in patients with Kawasaki disease.
Topics: Aspirin; Child, Preschool; Coronary Artery Disease; Humans; Immunoglobulins, Intravenous; Infant; Ma | 2023 |
The Effect of Off-Pump Coronary Artery Bypass Grafting in Patients on Aspirin Therapy until Surgery Day.
Topics: Aspirin; Coronary Artery Bypass; Coronary Artery Bypass, Off-Pump; Coronary Artery Disease; Humans; | 2022 |
Potent antithrombotic treatments in Asian vs. non-Asian patients.
Topics: Aspirin; Coronary Artery Disease; Fibrinolytic Agents; Humans; Peripheral Arterial Disease; Rivaroxa | 2022 |
Dual Antiplatelet Therapy Is Associated with Increased Risk of Bleeding and Decreased Risk of Stroke Following Carotid Endarterectomy.
Topics: Aspirin; Carotid Stenosis; Coronary Artery Disease; Endarterectomy, Carotid; Humans; Platelet Aggreg | 2023 |
Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Cholesterol; Clopidogrel; Cohort Studies; Coronary Ar | 2022 |
Rivaroxaban, a New Molecule with Potential to Balance Bleeding Risk and Ischemic Events in Patients with Chronic Coronary Syndrome.
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Periphera | 2022 |
Clinical Practice Variations in the Management of Ischemia With No Obstructive Coronary Artery Disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel | 2022 |
Cost-effectiveness analysis of screening for peripheral artery disease in patients with coronary artery disease in China: A Markov model.
Topics: Aged; Aspirin; China; Coronary Artery Disease; Cost-Benefit Analysis; Cost-Effectiveness Analysis; H | 2023 |
Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease: A retrospective observational study.
Topics: Aspirin; Constriction, Pathologic; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, | 2022 |
Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease: A retrospective observational study.
Topics: Aspirin; Constriction, Pathologic; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, | 2022 |
Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease: A retrospective observational study.
Topics: Aspirin; Constriction, Pathologic; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, | 2022 |
Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease: A retrospective observational study.
Topics: Aspirin; Constriction, Pathologic; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, | 2022 |
[ANMCO Position paper: Evidence and practical indications for the use of low-dose rivaroxaban in stable coronary artery disease and peripheral artery disease].
Topics: Aspirin; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Peripheral Arterial Di | 2022 |
[ANMCO Position paper: Evidence and practical indications for the use of low-dose rivaroxaban in stable coronary artery disease and peripheral artery disease].
Topics: Aspirin; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Peripheral Arterial Di | 2022 |
[ANMCO Position paper: Evidence and practical indications for the use of low-dose rivaroxaban in stable coronary artery disease and peripheral artery disease].
Topics: Aspirin; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Peripheral Arterial Di | 2022 |
[ANMCO Position paper: Evidence and practical indications for the use of low-dose rivaroxaban in stable coronary artery disease and peripheral artery disease].
Topics: Aspirin; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Peripheral Arterial Di | 2022 |
Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study.
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Human | 2022 |
Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study.
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Human | 2022 |
Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study.
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Human | 2022 |
Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study.
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Human | 2022 |
Family history of premature myocardial infarction and the effect of aspirin.
Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; | 2023 |
Family history of premature myocardial infarction and the effect of aspirin.
Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; | 2023 |
Family history of premature myocardial infarction and the effect of aspirin.
Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; | 2023 |
Family history of premature myocardial infarction and the effect of aspirin.
Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; | 2023 |
Dual Pathway Inhibition with Rivaroxaban and Aspirin Reduces Inflammatory Biomarkers in Atherosclerosis.
Topics: Aged; Aspirin; Atherosclerosis; Biomarkers; Coronary Artery Disease; Drug Therapy, Combination; Fact | 2023 |
Antiplatelet therapy after complex percutaneous coronary intervention and in left main coronary disease. Not all lesions are the same.
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervent | 2023 |
De-escalation in intensity or duration of dual antiplatelet therapy in patients with coronary artery disease: More than alternative treatment options.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Hu | 2023 |
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneou
Topics: Aspirin; Cardiology; Clopidogrel; Coronary Artery Disease; Fibrinolytic Agents; Hemorrhage; Humans; | 2023 |
Antithrombotic therapies in Canadian atrial fibrillation patients with concomitant coronary artery disease: Insights from the CONNECT AF + PCI-II program.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Canada; Coronary Artery Disease; Fibrinolytic Ag | 2023 |
[Debate on antiplatelet monotherapy: P2Y12 inhibitor monotherapy in patients with coronary artery disease].
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervent | 2023 |
[Debate on dual pathway inhibition: Antiplatelet therapy in patients with peripheral artery disease: old but gold?]
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Peripheral Arteria | 2023 |
Immature platelets and cardiovascular events in patients with stable coronary artery disease.
Topics: Aspirin; Blood Platelets; Coronary Artery Disease; Humans; Ischemic Stroke; Myocardial Infarction; P | 2023 |
The Optimal Antiplatelet Agent for Secondary Prevention of Coronary Artery Disease: Ring Out the Old?
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutan | 2023 |
[Comparison of Various Regimens of Antithrombotic Therapy in Patients With Valvular Heart Disease and Coronary Artery Disease After Surgical and Interventional Interventions].
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Fibrinolytic Agents; Heart Va | 2023 |
Myocardial Dysfunction and Coronary Artery Disease as Therapeutic Targets in Heart Failure.
Topics: Aspirin; Coronary Artery Disease; Heart Failure; Humans; Peripheral Arterial Disease; Rivaroxaban | 2019 |
Higher-starting-dose protocols in patients with coronary artery disease and aspirin hypersensitivity.
Topics: Aged; Aspirin; Coronary Artery Disease; Desensitization, Immunologic; Drug Hypersensitivity; Female; | 2019 |
Understanding the Effects of NOAC Combined with Antiplatelet Therapy on Clot Kinetics.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Dimaprit; Humans; Kinetics; Platelet | 2020 |
Risk stratification of non-obstructive coronary artery disease for guidance of preventive medical therapy.
Topics: Aged; Aspirin; Clinical Decision-Making; Computed Tomography Angiography; Coronary Angiography; Coro | 2019 |
Timing Strategy of Preoperative Aspirin and Its Impact on Early Outcomes in Patients Undergoing Coronary Artery Bypass Grafting: A Propensity Score Matching Analysis.
Topics: Aged; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Female; Hospital Mortality; Humans; | 2020 |
Central cardiovascular calcifications: supplementation with Pycnogenol® and Centellicum®: variations over 12 months.
Topics: Aspirin; Cardiovascular Diseases; Centella; Coronary Artery Disease; Dietary Supplements; Disease Ma | 2020 |
Enhanced Platelet Reactivity under Aspirin Medication and Major Adverse Cardiac and Cerebrovascular Events in Patients with Coronary Artery Disease.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Coronary Artery Disease; Female; Humans; Male; My | 2020 |
Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischemic risk compared with 75-100 mg aspirin daily in coronary artery disease patients: insights from the TIFU (Ticagrelor in Fuwai Hospital) study.
Topics: Aspirin; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregatio | 2020 |
Impact of high on-treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT-DES substudy.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Dual | 2020 |
Interaction Between Diabetes Mellitus and Platelet Reactivity in Determining Long-Term Outcomes Following Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Diabetes Mellitus; Drug Re | 2020 |
Imbalance between Fibrin Clot Formation and Fibrinolysis Predicts Cardiovascular Events in Patients with Stable Coronary Artery Disease.
Topics: Aged; Aspirin; Blood Coagulation; Coronary Artery Disease; Fibrin; Fibrinolysis; Follow-Up Studies; | 2020 |
Ticagrelor monotherapy versus aspirin in patients undergoing multiple arterial or single arterial coronary artery bypass grafting: insights from the TiCAB trial.
Topics: Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Humans; Myocardial Infarction; Stroke; Tic | 2020 |
Long-Term Efficacy of Extended Dual Antiplatelet Therapy After Left Main Coronary Artery Bifurcation Stenting.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Drug-Eluting | 2020 |
Determinants of aspirin resistance in patients with type 2 diabetes.
Topics: Aged; Arachidonic Acid; Aspirin; C-Reactive Protein; Coronary Artery Disease; Diabetes Mellitus, Typ | 2020 |
Relation of Hypoalbuminemia to Response to Aspirin in Patients With Stable Coronary Artery Disease.
Topics: Aged; Aspirin; Biomarkers; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hypoalbuminem | 2020 |
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease.
Topics: Aspirin; Coronary Artery Disease; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Fact | 2020 |
Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Child, Preschool; Coronary Arte | 2020 |
Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percut
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cor | 2020 |
Effect of Elevated Calcium Score on Normal Myocardial Perfusion Study on Clinician Management of Coronary Artery Disease Risk Factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Cohort Studies; Coronary Artery Di | 2020 |
In stable CAD with type 2 diabetes, adding ticagrelor to aspirin reduced CV events but increased major bleeding.
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Hemorrhage; Humans; Ticagrelor | 2020 |
Impact of Anemia on the Risk of Bleeding Following Percutaneous Coronary Interventions in Patients ≥75 Years of Age.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anemia; Angina, Unstable; Anticoagulants; Antithro | 2020 |
Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis).
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Decision-Making; Computed Tomography Angiography; Coronar | 2020 |
Ischemic Versus Bleeding Outcomes After Percutaneous Coronary Interventions in Patients With High Bleeding Risk.
Topics: Aged; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Artery Disease; Dual Anti-Platelet | 2020 |
Coronary stent embolism to the right posterior cerebral artery.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Atropine; Clopidogrel; Coronary Angiography; Coronary Arter | 2020 |
Cilostazol for Chinese Patients with Aspirin Intolerance after Coronary Drug-Eluting Stent Implantation.
Topics: Aspirin; China; Cilostazol; Coronary Artery Disease; Drug-Eluting Stents; Dual Anti-Platelet Therapy | 2020 |
Early dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass surgery: survival and safety outcomes.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Dual Anti-Platelet Ther | 2020 |
COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: insights from the START registry.
Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Registries; Rivaroxaban | 2021 |
Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Coronary Artery Disease; Dual An | 2020 |
Nonusefulness of Antithrombotic Therapy After Surgical Bioprosthetic Aortic Valve Replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aortic Valve; Aortic Valve Insufficiency; Aortic Val | 2020 |
The role of rivaroxaban for patients with atherosclerotic vascular disease in the modern era.
Topics: Aspirin; Atherosclerosis; Coronary Artery Disease; Factor Xa Inhibitors; Humans; Rivaroxaban; Treatm | 2021 |
Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease.
Topics: Aspirin; Brain Ischemia; Coronary Artery Disease; Diabetes Mellitus; Humans; Percutaneous Coronary I | 2021 |
Aspirin protects human coronary artery endothelial cells by inducing autophagy.
Topics: Angiotensin II; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Autophagy; Cells, Cultured; Corona | 2020 |
Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry.
Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug | 2020 |
Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases.
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Cost-Benefit Analysis; Do | 2021 |
Serum uric acid level negatively correlated with the prevalence of clopidogrel low response in patients undergoing antiplatelet treatment with aspirin and clopidogrel.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Cross-Sectional | 2020 |
Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease.
Topics: Aged; Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Dual An | 2021 |
Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease.
Topics: Adult; Aspirin; Atherosclerosis; Cohort Studies; Coronary Artery Disease; Coronary Disease; Eye Hemo | 2021 |
Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) After Percutaneous Coronary Intervention in High-Risk Patients With Diabetes Mellitus.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Dual | 2021 |
Impact of Preoperative Aspirin on Long-Term Outcomes in Diabetic Patients Following Coronary Artery Bypass Grafting: a Propensity Score Matched Study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; D | 2020 |
Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease.
Topics: Aged; Aspirin; China; Coronary Artery Disease; COVID-19; Female; Hospital Mortality; Hospitalization | 2021 |
A Pathophysiologic Primary Prevention Review of Aspirin Administration to Prevent Cardiovascular Thrombosis.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Humans; Plaque, Atherosclerotic; Pr | 2020 |
Early stent thrombosis confirmed in a cancer patient receiving regorafenib, despite triple antithrombotic therapy: a case report.
Topics: Aged; Angiogenesis Inhibitors; Aspirin; Colorectal Neoplasms; Coronary Artery Disease; Coronary Thro | 2021 |
CARDIOVASCULAR EVENT ASSESSMENT IN PATIENTS WITH NONOBSTRUCTIVE CORONARY ARTERY DISEASE UNDERGOING DUAL ANTIPLATELET TREATMENT.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Percutaneous Coronary | 2020 |
Assessment of The High risk and unmEt Need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource use, cost, and burden of illness in a commercially insured population.
Topics: Aspirin; Coronary Artery Disease; Cost of Illness; Delivery of Health Care; Diabetes Mellitus, Type | 2021 |
Traditional Chinese Medicine for Patients of Coronary Artery Disease: Savior or Troublemaker? A Cohort Study About the Adherence to Antiplatelet Therapy.
Topics: Aspirin; Cohort Studies; Coronary Artery Disease; Drug Therapy, Combination; Humans; Medicine, Chine | 2022 |
The expression profile of platelet-derived miRNA in coronary artery disease patients with clopidogrel resistance.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Clopidogrel; Cohort Studies; Coron | 2021 |
Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy.
Topics: Aged; Aspirin; Coronary Artery Disease; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hu | 2021 |
Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey.
Topics: Age Distribution; Antirheumatic Agents; Aspirin; C-Reactive Protein; Child; Child, Preschool; Corona | 2021 |
Sex Differences in Coronary Arterial Calcification in Symptomatic Patients.
Topics: Adult; Aspirin; Chest Pain; Cohort Studies; Computed Tomography Angiography; Coronary Angiography; C | 2021 |
Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19.
Topics: Adenosine Monophosphate; Adult; Aged; Alanine; Antiviral Agents; Aspirin; Blood Platelets; Coronary | 2021 |
Association of Aspirin Treatment With Cardiac Allograft Vasculopathy Progression and Adverse Outcomes After Heart Transplantation.
Topics: Allografts; Aspirin; Coronary Angiography; Coronary Artery Disease; Heart Failure; Heart Transplanta | 2021 |
The Association between Multi-Vessel Coronary Artery Disease and High On-Aspirin Platelet Reactivity.
Topics: Aspirin; Blood Platelets; Coronary Artery Disease; Female; Humans; Male; Platelet Aggregation Inhibi | 2022 |
Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Registry.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Cohort Studies; Coronary Artery Disease; Denmark; | 2022 |
Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery.
Topics: Aspirin; Beijing; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Dual Anti-Platelet T | 2021 |
A retrospective study of antithrombotic therapy use in an outpatient haemodialysis unit.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Drug Utilization; Du | 2021 |
Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events.
Topics: Acute Coronary Syndrome; Aspirin; Cerebrovascular Disorders; Coronary Artery Disease; Humans; Intrac | 2021 |
Effect of diabetic kidney disease on therapeutic strategies for coronary artery disease: ten year follow-up.
Topics: Aged; Aspirin; Calcium Channel Blockers; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabeti | 2021 |
Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry.
Topics: Aged; Aspirin; Coronary Artery Disease; Coronary Thrombosis; Diabetes Mellitus; Drug Administration | 2017 |
Restless legs syndrome/Willis-Ekbom disease in type 2 diabetes as the initial manifestation of Parkinson's disease and major cardiovascular disease.
Topics: Aged; Amines; Analgesics; Anticonvulsants; Antihypertensive Agents; Antiparkinson Agents; Aspirin; B | 2017 |
Optimal secondary prevention medication use in acute myocardial infarction patients with nonobstructive coronary artery disease is modified by management strategy: insights from the TRIUMPH Registry.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2017 |
Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Ar | 2017 |
Total Thrombus-formation Analysis System Predicts Periprocedural Bleeding Events in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Artery Disease; Fem | 2017 |
Changes in cardiovascular medication after coronary artery calcium scanning and normal single photon emission computed tomography myocardial perfusion imaging in symptomatic patients.
Topics: Aspirin; Calcinosis; Coronary Artery Disease; Coronary Vessels; Female; Fibrinolytic Agents; Humans; | 2017 |
Validation of aspirin response-related transcripts in patients with coronary artery disease and preliminary investigation on CMTM5 function.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Cell Movement; Cell Proliferation; Chemokines; Cluster | 2017 |
Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events.
Topics: Aged; Aspirin; Chi-Square Distribution; Coronary Artery Disease; Female; Humans; Male; Middle Aged; | 2017 |
Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Coronary A | 2017 |
Platelet distribution width as the prognostic marker in coronary bifurcation treatment.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; H | 2017 |
Impact of mean platelet aggregation degree on long-term clinical outcomes among patients undergoing a complex percutaneous coronary intervention.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Monitoring; Drug | 2017 |
Patients With Diabetes Without Significant Angiographic Coronary Artery Disease Have the Same Risk of Myocardial Infarction as Patients Without Diabetes in a Real-World Population Receiving Appropriate Prophylactic Treatment.
Topics: Aged; Aspirin; Cohort Studies; Comorbidity; Coronary Angiography; Coronary Artery Disease; Denmark; | 2017 |
[A novel protein peptide associated with ischemic heart disease: dermcidin].
Topics: Aspirin; Coronary Artery Disease; Dermcidins; Humans; Peptides; Platelet Aggregation | 2017 |
Computed Tomography Angiography Images of Coronary Artery Stenosis Provide a Better Prediction of Risk Than Traditional Risk Factors in Asymptomatic Individuals With Type 2 Diabetes: A Long-term Study of Clinical Outcomes.
Topics: Aged; Aspirin; Cholesterol; Computed Tomography Angiography; Coronary Angiography; Coronary Artery D | 2017 |
Efficacy and Safety of Triple Therapy and Dual Therapy With Direct Oral Anticoagulants Compared to Warfarin.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Coronary Artery Disease; Dose-Response Relation | 2017 |
Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study).
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combi | 2017 |
MMP-2, MMP-9, and TIMP-4 and Response to Aspirin in Diabetic and Nondiabetic Patients with Stable Coronary Artery Disease: A Pilot Study.
Topics: Aspirin; Blood Platelets; Coronary Artery Disease; Diabetes Mellitus; Female; Humans; Male; Matrix M | 2017 |
Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Follow-Up St | 2017 |
Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease.
Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Female | 2017 |
Early aspirin use and the development of cardiac allograft vasculopathy.
Topics: Adult; Allografts; Aspirin; Biopsy; Cause of Death; Coronary Angiography; Coronary Artery Disease; F | 2017 |
Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Female; Humans; | 2017 |
My Approach to the patient with CAD and aspirin resistance.
Topics: Aspirin; Clinical Decision-Making; Coronary Artery Disease; Drug Interactions; Drug Resistance; Drug | 2017 |
Cardiovascular events associated with proton pump inhibitors.
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Heart Failure; Humans; Mortality; Myocard | 2017 |
Cardiac Society of Australia and New Zealand position statement executive summary: coronary artery calcium scoring.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asymptomatic Diseases; Coronary Artery Disea | 2017 |
Impact of Long-Term Dual Antiplatelet Therapy on Immature Platelet Count and Platelet Reactivity.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2018 |
Over-expression of cyclooxygenase-2 in increased reticulated platelets leads to aspirin resistance after elective off-pump coronary artery bypass surgery.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Bypass, Off-Pump; Coronary Artery Disease; Cyclooxyg | 2017 |
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery D | 2017 |
Lower gastrointestinal bleeding in patients with coronary artery disease on antithrombotics and subsequent mortality risk.
Topics: Aged; Anticoagulants; Aspirin; Cohort Studies; Coronary Artery Disease; Drug Therapy; Female; Fibrin | 2018 |
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
Topics: Aged; Aspirin; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Factor Xa Inhibitors; F | 2018 |
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
Topics: Aged; Aspirin; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Factor Xa Inhibitors; F | 2018 |
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
Topics: Aged; Aspirin; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Factor Xa Inhibitors; F | 2018 |
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
Topics: Aged; Aspirin; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Factor Xa Inhibitors; F | 2018 |
Prevention: Rivaroxaban plus aspirin in CAD or PAD.
Topics: Aspirin; Coronary Artery Disease; Double-Blind Method; Factor Xa Inhibitors; Humans; Platelet Aggreg | 2018 |
Factors associated with advanced cardiac care in prehospital chest pain patients.
Topics: Age Distribution; Aged; Aspirin; Cardiac Catheterization; Chest Pain; Coronary Artery Bypass; Corona | 2018 |
EROSION Study (Effective Anti-Thrombotic Therapy Without Stenting: Intravascular Optical Coherence Tomography-Based Management in Plaque Erosion): A 1-Year Follow-Up Report.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aspirin; Coronary Angiography; Coronary Artery Disease; C | 2017 |
Glycaemic control and cardiovascular risk factor management in patients with diabetes with and without coronary artery disease: insights from the diabetes mellitus status in Canada survey.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Glu | 2016 |
Sustained sex-based treatment differences in acute coronary syndrome care: Insights from the American Heart Association Get With The Guidelines Coronary Artery Disease Registry.
Topics: Acute Coronary Syndrome; Age Factors; Aged; American Heart Association; Aspirin; Chi-Square Distribu | 2018 |
Duration of high-dose aspirin therapy does not affect long-term coronary artery outcomes in Kawasaki disease.
Topics: Aspirin; Child; Child, Preschool; Coronary Aneurysm; Coronary Artery Disease; Coronary Vessels; Drug | 2018 |
Novel assay demonstrates that coronary artery disease patients have heightened procoagulant platelet response.
Topics: Aged; Arsenicals; Aspirin; Biomarkers; Blood Coagulation; Blood Platelets; Case-Control Studies; Clo | 2018 |
Impact of Depressive Disorder on Access and Quality of Care in Veterans With Prevalent Cardiovascular Disease.
Topics: Age Distribution; Aged; Angina Pectoris; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; | 2018 |
Utilization of aspirin and statin in management of coronary artery disease in patients with cirrhosis undergoing liver transplant evaluation.
Topics: Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Drug Utiliz | 2018 |
Platelet Inhibition and Bleeding in Patients Undergoing Non-Cardiac Surgery-The BIANCA Observational Study.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Blood Platelets; Cell Adhesion Molecules; Cl | 2018 |
Do practice gaps exist in evidence-based medication prescription at hospital discharge in patients undergoing coronary artery bypass surgery & coronary angioplasty?
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angioplasty; Angioplasty, Balloon, Coro | 2017 |
Role of Dipyrone in the High On-Treatment Platelet Reactivity amongst Acetylsalicylic Acid-Treated Patients Undergoing Peripheral Artery Revascularisation.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Catheter | 2018 |
Asprin and statin use for management of atherosclerotic cardiovascular disease in liver transplant candidates: Are we missing the mark?
Topics: Aspirin; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Cirr | 2018 |
[High On-Treatment Platelet Reactivity Determinants on Dual Antiplatelet Therapy in Patients With Ischemic Heart Disease Before Elective Percutaneous Coronary Intervention].
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Middle Ag | 2018 |
Poor Compliance With Carrying Nitroglycerin and Aspirin in Patients With Coronary Artery Disease.
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans | 2018 |
[ANMCO/ANCE/ARCA/GICR-IACPR intersociety consensus document: long-term antiplatelet therapy in patients with coronary artery disease].
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Ho | 2018 |
Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Female; H | 2019 |
Effect of Physical Exercise on Platelet Reactivity in Patients with Dual Antiplatelet Therapy.
Topics: Adenosine Diphosphate; Aspirin; Chromogranin A; Clopidogrel; Coronary Artery Disease; Electrocardiog | 2018 |
Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Dr | 2018 |
Predictors of coronary stent thrombosis: a case-control study.
Topics: Aged; Aspirin; Brazil; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Coronary Thrombos | 2018 |
[Optical Coherence Tomography in ST-Elevation Myocardial Infarction].
Topics: Aged, 80 and over; Aspirin; Coronary Angiography; Coronary Artery Disease; Diagnosis, Differential; | 2018 |
Real clinical experiences of dual versus triple antithrombotic therapy after percutaneous coronary intervention.
Topics: Absorbable Implants; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Coronar | 2018 |
High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Substitution; Female; Hum | 2019 |
A case of Henoch-Schonlein Purpura with dilated coronary arteries.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Aspirin; Child; Coronary Artery Disea | 2018 |
Dose reduction, oral application, and order of intake to preserve aspirin antiplatelet effects in dipyrone co-medicated chronic artery disease patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic | 2019 |
Diabetes and Platelet Response to Low-Dose Aspirin.
Topics: Adult; Aspirin; Blood Platelets; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dose-Response R | 2018 |
Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease.
Topics: Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Coronar | 2018 |
Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Decision Support Technique | 2018 |
Prestroke Aspirin Use is Associated with Clinical Outcomes in Ischemic Stroke Patients with Atherothrombosis, Small Artery Disease, and Cardioembolic Stroke.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Biomarkers; Brain Ischemia; | 2019 |
Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Aspirin; Blood Component Remov | 2019 |
Stopping Versus Continuing Aspirin Before Coronary Artery Surgery for Desensitized Cardiac Patients.
Topics: Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; S | 2019 |
Effect of P2Y
Topics: Adenosine Monophosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Femal | 2019 |
Variable gender-dependent platelet responses to combined antiplatelet therapy in patients with stable coronary-artery disease.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle A | 2018 |
Intravenous Antiplatelet Therapy Bridging in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Administration, Intravenous; Aged; Aspirin; Cardiac Surgical Procedures; Cl | 2019 |
Aspirin on Top of Anticoagulation in Patients With Concomitant Stable Coronary Artery Disease and Atrial Fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Humans; Platelet Aggregation | 2019 |
Impact of dual antiplatelet therapy with adjusted-dose prasugrel on mid-term vascular response in patients undergoing elective percutaneous coronary intervention with everolimus-eluting stents.
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug-Eluting St | 2019 |
Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention.
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Co | 2019 |
Non-vitamin K antagonist oral anticoagulants in the treatment of coronary and peripheral atherosclerosis.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiology; Coronary Artery Disease; | 2019 |
The ABO locus is associated with increased platelet aggregation in patients with stable coronary artery disease.
Topics: ABO Blood-Group System; Administration, Oral; Aged; Aspirin; Coronary Artery Disease; Dose-Response | 2019 |
Impact of long-term therapy with acetylsalicylic acid on immature platelet count: a single-centre cohort study.
Topics: Aged; Aspirin; Blood Platelets; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Cr | 2019 |
Management of aspirin intolerance in patients undergoing percutaneous coronary intervention. The role of mono-antiplatelet therapy: a retrospective, multicenter, study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Dru | 2019 |
External applicability of the COMPASS trial: the Western Denmark Heart Registry.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Clinical Decision-Making; Coronary Angiography; Coronary A | 2019 |
Dual platelet antiaggregation therapy after myocardial revascularization surgery.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Graft Occlusion, Vascular; Hu | 2019 |
Do Statins Have a Positive Impact on Patients with Coronary Microvascular Dysfunction on Long-Term Clinical Outcome? A Large Retrospective Cohort Study.
Topics: Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus; Drug-Related Side E | 2019 |
Impact of Platelet Endothelial Aggregation Receptor-1 Genotypes on Platelet Reactivity and Early Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention and Treated With Aspirin and Clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Clopidogrel; Coronary Artery Disease; Drug Resistance | 2019 |
Genetic influences on aspirin response in patients undergoing percutaneous coronary intervention.
Topics: Aspirin; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation I | 2019 |
Association between High Platelet Reactivity Following Dual Antiplatelet Therapy and Ischemic Events in Japanese Patients with Coronary Artery Disease Undergoing Stent Implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Japan; Male; Middle Aged; Myoca | 2020 |
Omalizumab for the Treatment of Persistent Drug Induced Urticaria Elicited by Thienopyridines: A Case Report.
Topics: Aged; Anti-Allergic Agents; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug | 2020 |
Navigating the treacherous waters of antithrombotic therapies in patients with atrial fibrillation and coronary artery disease: Lessons from AUGUSTUS.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Drug Therapy, Combination; Fi | 2019 |
Anticoagulation and antiplatelet therapy in stable coronary artery disease: A multicenter survey.
Topics: Anticoagulants; Aspirin; Coronary Artery Disease; Health Care Surveys; Humans; Platelet Aggregation | 2019 |
Course of platelet miRNAs after cessation of P2Y12 antagonists.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; MicroRNA | 2019 |
Aspirin Resistance Incidence and Associations Between Aspirin Effect and Outcomes in Cardiac Surgery.
Topics: Aged; Aspirin; Cardiac Surgical Procedures; Coronary Artery Disease; Drug Resistance; Female; Follow | 2019 |
[The Pathways to Increase the Efficacy of Drug Therapy in Patients with Ischemic Heart Disease after Coronary Artery Bypass Grafting].
Topics: Aged; Angina Pectoris; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Mellitus, | 2019 |
Critical appraisal of the AUGUSTUS trial.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Fact | 2019 |
Variability in aspirin efficacy: all in the genes?
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Genetic Variation; Humans; Platelet Aggre | 2019 |
Lymphocyte Hydrogen Sulfide Production Predicts Coronary Artery Lesions in Children with Kawasaki Disease: A Preliminary, Single-Center Study.
Topics: Aspirin; Biomarkers; Case-Control Studies; Child; Child, Preschool; Coronary Artery Disease; Coronar | 2020 |
Impact of platelet turnover on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Diseas | 2019 |
Relationship between drug application and mortality rate in Chinese older coronary artery disease/chronic heart failure patients with and without low glomerular filtration rate.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin- | 2019 |
Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Drug-Eluting Stents; Europe; Female | 2019 |
The association of P2Y
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Extracellular Vesicles; Female; Humans; Male; M | 2020 |
Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; C-Reactive Protein; Coronary Artery Disease; Cross-Secti | 2013 |
Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
Topics: Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; | 2013 |
Invited commentary.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Humans; Male; Ticlopidine; Tr | 2013 |
Hypertension as a risk factor for aspirin and clopidogrel resistance in patients with stable coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Humans; Hyperte | 2014 |
Aspirin hydrolysis in plasma is a variable function of butyrylcholinesterase and platelet-activating factor acetylhydrolase 1b2 (PAFAH1b2).
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aspirin; Blood Platelets; Butyrylcholinesterase; Cor | 2013 |
Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: a novel cytoprotective role of aspirin in acute myocardial infarction.
Topics: Aged; Apoptosis; Aspirin; Base Sequence; Cardiovascular Agents; Case-Control Studies; Cell Survival; | 2013 |
Intractable intraoperative bleeding requiring platelet transfusion during emergent cholecystectomy in a patient with dual antiplatelet therapy after drug-eluting coronary stent implantation (with video).
Topics: Aged; Aspirin; Blood Loss, Surgical; Cholecystectomy; Coronary Artery Disease; Drug-Eluting Stents; | 2013 |
Soluble P-selectin level correlates with acetylsalicylic acid but not with clopidogrel response in patients with stable coronary artery disease after a percutaneous coronary intervention.
Topics: Aged; Anti-Inflammatory Agents; Aryl Hydrocarbon Hydroxylases; Aspirin; CD40 Ligand; Cell Adhesion M | 2013 |
Association of plasma concentrations of salicylic acid and high on ASA platelet reactivity in type 2 diabetes patients.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Chromatography, High Pressure Liquid; Coronary Artery Di | 2013 |
Relation of aspirin response to age in patients with stable coronary artery disease.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Cross-Sectional Studi | 2013 |
Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; ATP Binding Cassette Tran | 2013 |
Changes in preventive medical therapies and CV risk factors after CT angiography.
Topics: Adult; Aged; Antihypertensive Agents; Aspirin; Biomarkers; Blood Pressure; Chi-Square Distribution; | 2013 |
Association of PON1 genotype and haplotype with susceptibility to coronary artery disease and clinical outcomes in dual antiplatelet-treated Han Chinese patients.
Topics: Aged; Aryldialkylphosphatase; Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Female; G | 2013 |
Cytochrome P450 2B6 and 2C9 genotype polymorphism--a possible cause of prasugrel low responsiveness.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Biomarkers, Pharmacological; Blood Platelets; Clopidogrel; C | 2013 |
Aspirin desensitisation for Chinese patients with coronary artery disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Angiography; Coronary | 2013 |
Perioperative management of a neurosurgical patient with a meningioma and recent coronary artery stent.
Topics: Aged; Aspirin; Blood Loss, Surgical; Clopidogrel; Contraindications; Coronary Artery Disease; Drug T | 2013 |
Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
Topics: Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery | 2013 |
Pharmacogenomics of anti-platelet therapy focused on peripheral blood cells of coronary arterial disease patients.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; | 2013 |
The place of newer oral anticoagulants in the treatment of patients with non-valvular atrial fibrillation and coronary artery disease.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Dis | 2013 |
Associations between aspirin and other non-steroidal anti-inflammatory drugs and aortic valve or coronary artery calcification: the Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aortic Valve Stenosis; Aspirin; Ca | 2013 |
Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Results of an in vitro pilot investigation.
Topics: Adenosine Diphosphate; Aged; Aspirin; Cell Adhesion Molecules; Coronary Artery Disease; Drug Dosage | 2013 |
The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease.
Topics: Aged; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Drug Combi | 2013 |
Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 | 2013 |
Dipyrone (metamizole) can nullify the antiplatelet effect of aspirin in patients with coronary artery disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Artery Disease; Dipyrone; Drug Inte | 2013 |
Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Blood Coagulation; Clopidogrel; Co | 2014 |
Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure.
Topics: Aged; Aspirin; Blood Coagulation; Blood Platelets; C-Reactive Protein; Coronary Artery Disease; Fema | 2013 |
The clinical outcomes of percutaneous coronary intervention performed without pre-procedural aspirin.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Artery Disease; Drug Utilization; F | 2013 |
Culprit segments identified by optical coherence tomography in patients with acute myocardial infarction: two case reports.
Topics: Aged; Anticoagulants; Aspirin; Cardiac Catheterization; Chest Pain; Coronary Angiography; Coronary A | 2012 |
Letter by Mangiacapra and Barbato regarding article, "Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease".
Topics: Aspirin; Coronary Artery Disease; Endothelium, Vascular; Female; Humans; Male; Platelet Aggregation; | 2013 |
Response to letter regarding article, "Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease".
Topics: Aspirin; Coronary Artery Disease; Endothelium, Vascular; Female; Humans; Male; Platelet Aggregation; | 2013 |
Rapid evaluation of platelet function using the Multiplate® Analyzer.
Topics: Aged; Aspirin; Coronary Artery Disease; Female; Humans; Male; Platelet Activation; Platelet Aggregat | 2014 |
Rapid evaluation of platelet function using the Multiplate® Analyzer.
Topics: Aged; Aspirin; Coronary Artery Disease; Female; Humans; Male; Platelet Activation; Platelet Aggregat | 2014 |
Rapid evaluation of platelet function using the Multiplate® Analyzer.
Topics: Aged; Aspirin; Coronary Artery Disease; Female; Humans; Male; Platelet Activation; Platelet Aggregat | 2014 |
Rapid evaluation of platelet function using the Multiplate® Analyzer.
Topics: Aged; Aspirin; Coronary Artery Disease; Female; Humans; Male; Platelet Activation; Platelet Aggregat | 2014 |
Antiplatelet therapy: DAPT for 3 months is sufficient.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male | 2014 |
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clopidogrel; Coronary Artery Diseas | 2013 |
Spontaneous chest wall hematoma with dual antiplatelet therapy.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Follow-Up Studies; H | 2014 |
Definition of acetylsalicylic acid resistance using whole blood impedance aggregometry in patients undergoing coronary artery surgery.
Topics: Aged; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Drug Resistance; Female; Humans; Mal | 2013 |
Haemodialysis impairs clopidogrel but not aspirin responsiveness in patients with end-stage renal disease. Results of a pilot study.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Hum | 2014 |
Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Thera | 2014 |
Predictors of successful acetylsalicylic acid resistance suppression after percutaneous coronary revascularisation.
Topics: Aspirin; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Resistance; Female; Humans; | 2013 |
Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty.
Topics: Adenosine Diphosphate; Aged; Angioplasty; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; | 2014 |
Association of thrombin generation potential with platelet PAR-1 regulation and P-selectin expression in patients on dual antiplatelet therapy.
Topics: Adult; Aged; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Arter | 2014 |
Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies; | 2014 |
Prevalence of aspirin resistance in Asian-Indian patients with stable coronary artery disease.
Topics: Adult; Aged; Asian People; Aspirin; Coronary Angiography; Coronary Artery Disease; Drug Resistance; | 2016 |
Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease.
Topics: Adult; Aged; Amino Acid Substitution; Aspirin; Clopidogrel; Coronary Artery Disease; Factor XIII; Fe | 2014 |
Breakage of floppy wire during coronary stenting and long-term outcome.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheters; Coronary Angiography; Coronary Artery Di | 2013 |
Nitric oxide from mononuclear cells may be involved in platelet responsiveness to aspirin.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Drug Resistance; Female; Humans; Interleuki | 2014 |
Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 | 2014 |
A case of right atrial appendage aneurysm in a 62-year-old man.
Topics: Aspirin; Atrial Appendage; Coronary Artery Disease; Diagnosis, Differential; Echocardiography; Heart | 2014 |
Evolving antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: results from a survey among US cardiologists.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Fibrino | 2014 |
Triple versus dual antiplatelet therapy after percutaneous coronary intervention for coronary bifurcation lesions: results from the COBIS (COronary BIfurcation Stent) II Registry.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2015 |
Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Corona | 2014 |
Dual antiplatelet therapy after stent implantation.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male | 2014 |
Dual antiplatelet therapy after stent implantation--reply.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male | 2014 |
Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Coronary Artery Disease; Diabetes Mellitus, Type 2; Fema | 2015 |
Successful multidisciplinary treatment of hilar cholangiocarcinoma in a patient with complicated new-onset coronary artery disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bile Duct Neoplasms; Bile Ducts, Intr | 2014 |
Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin.
Topics: Aged; Aspirin; Biomarkers; Blood Coagulation; Chi-Square Distribution; Coronary Artery Disease; Dose | 2014 |
Effects of eicosapentaenoic acid on platelet function in patients taking long-term aspirin following coronary stent implantation.
Topics: Administration, Oral; Aspirin; Blood Platelets; Coronary Artery Disease; Dose-Response Relationship, | 2014 |
Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregati | 2014 |
Antiplatelet therapy during perioperative period: double-edged sword.
Topics: Aspirin; Coronary Artery Disease; Hemorrhage; Humans; Percutaneous Coronary Intervention; Perioperat | 2014 |
Low dose aspirin is associated with plasma chemerin levels and may reduce adipose tissue inflammation.
Topics: Adipocytes; Adipose Tissue; Aspirin; Biomarkers; Case-Control Studies; Cell Line; Chemokines; Corona | 2014 |
Posttreatment platelet reactivity on clopidogrel is associated with the risk of adverse events after off-pump coronary artery bypass.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Bypass, Off-Pump; Coron | 2014 |
Coronary artery disease detected by coronary computed tomographic angiography is associated with intensification of preventive medical therapy and lower low-density lipoprotein cholesterol.
Topics: Aspirin; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Female; Follow-Up Studies; | 2014 |
Demographic and clinical characteristics of patients with stable coronary artery disease: results from the CLARIFY registry in Spain.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Coronary Artery Disease; Female; Humans; Hypolipidemic A | 2014 |
Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects.
Topics: Adult; Arachidonic Acid; Aspirin; Blood Platelets; Cohort Studies; Coronary Artery Disease; Dose-Res | 2014 |
[Clinical impact of dual antiplatelet therapy on peptic ulcer disease].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Angiography; Coronary | 2014 |
Kounis syndrome and acetylsalicylic acid desensitization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Artery Disease; Drug Hypersensitivity; Fe | 2014 |
The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease.
Topics: Aged; Aspirin; Blood Coagulation Tests; C-Reactive Protein; Case-Control Studies; Complement C3; Cor | 2014 |
Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
[Does dual antiplatelet therapy increase the risk of peptic ulcer disease?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Huma | 2014 |
Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients.
Topics: Aged; Aspirin; Cardiac Catheterization; Chi-Square Distribution; Clopidogrel; Cohort Studies; Corona | 2014 |
Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Ma | 2015 |
Genetic determinants of on-aspirin platelet reactivity: focus on the influence of PEAR1.
Topics: Aged; Aspirin; Coronary Artery Disease; Cyclooxygenase 1; Female; Genotype; Humans; Male; Platelet A | 2014 |
[Antithrombotic treatment in patients with stable coronary artery disease. Which drugs and for how long?].
Topics: Aspirin; Atrial Fibrillation; Cardiovascular Surgical Procedures; Coronary Artery Disease; Drug Admi | 2014 |
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; | 2014 |
Influence of dual antiplatelet therapy on mean platelet volume in patients with coronary artery disease undergoing percutaneous coronary intervention.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Monitoring; Drug Therapy, | 2016 |
Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting E | 2015 |
Impact of aspirin according to type of stable coronary artery disease: insights from a large international cohort.
Topics: Aged; Aspirin; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction; My | 2015 |
Letter by Sardar et al regarding article, "optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial".
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Female; Human | 2014 |
Response to letter regarding article, "optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial".
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Female; Human | 2014 |
Prognostic and therapeutic implications of statin and aspirin therapy in individuals with nonobstructive coronary artery disease: results from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter registry) re
Topics: Adult; Aged; Asia; Aspirin; Canada; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis | 2015 |
Dual antiplatelet therapy in patients with a long coronary artery lesion over 30 mm: Determinants and impact on prognosis.
Topics: Administration, Inhalation; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration | 2015 |
An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort.
Topics: Aged; Aged, 80 and over; American Heart Association; Antihypertensive Agents; Aspirin; Calibration; | 2015 |
Effect of preoperatively continued aspirin use on early and mid-term outcomes in off-pump coronary bypass surgery: a propensity score-matched study of 1418 patients.
Topics: Aged; Aspirin; Coronary Artery Bypass, Off-Pump; Coronary Artery Disease; Female; Humans; Male; Midd | 2015 |
Homocysteine Levels Influence Platelet Reactivity in Coronary Artery Disease Patients Treated With Acetylsalicylic Acid.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Coronary Artery Disease; Female; Homo | 2015 |
Dual Antiplatelet Therapy Duration Following Coronary Stenting. [Corrected].
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Hem | 2015 |
Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy.
Topics: Adenosine; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Coronary Artery Disease; Drug Ther | 2015 |
Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Chi-Square Distributi | 2015 |
Close encounters with errors of the second kind: evaluating risks and benefits of long-term dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Female; Humans; Male; Platelet Aggregatio | 2015 |
Whatever will be, will be: spontaneous chest wall hematoma with regular use of low-dose acetylsalicylic Acid.
Topics: Aspirin; Coronary Artery Disease; Hematoma; Humans; Male; Platelet Aggregation Inhibitors; Thoracic | 2015 |
Neurologic symptom severity after a recent noncardioembolic stroke and recurrent vascular risk.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Double-Blind Method; Female; Fibri | 2015 |
Influence of Different β-Blockers on Platelet Aggregation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aspirin; Bisoprolol; Carbazoles; Carvedilol; Clopidog | 2016 |
Primary prevention of coronary artery disease by aspirin.
Topics: Aspirin; Coronary Artery Disease; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Primary Preve | 2015 |
Dual or triple therapy in patients with atrial fibrillation and drug-eluting stents?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Female; Fibrinolytic Agents; | 2015 |
Calprotectin and platelet aggregation in patients with stable coronary artery disease.
Topics: Aged; Aspirin; C-Reactive Protein; Coronary Artery Disease; Cross-Sectional Studies; Female; Humans; | 2015 |
Trends in pharmacological therapy of patients referred for coronary artery bypass grafting between 2004 and 2008: a single-centre study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Co | 2015 |
Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease.
Topics: Aged; Aspirin; Body Mass Index; Coronary Artery Disease; Cross-Sectional Studies; Diabetes Mellitus, | 2015 |
Aspirin desensitization in a patient with NSAID-induced delayed angioedema.
Topics: Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Artery Disease; Desensitizati | 2015 |
Should all stent patients have prolonged dual antiplatelet therapy?
Topics: Aspirin; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, C | 2015 |
Association between Aspirin Therapy and Clinical Outcomes in Patients with Non-Obstructive Coronary Artery Disease: A Cohort Study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cohort Studies; Coronary Ang | 2015 |
Antiplatelet therapy: Defining the optimal duration of DAPT after PCI with DES.
Topics: Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; P | 2015 |
Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Dis | 2015 |
Comparison between urinary 11-dehydrothromboxane B2 detection and platelet Light Transmission Aggregometry (LTA) assays for evaluating aspirin response in elderly patients with coronary artery disease.
Topics: Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Blood Platelets; Coronary Artery Disease; Female | 2015 |
Impact of Antithrombotic Therapy in Atrial Fibrillation on the Presentation of Coronary Artery Disease.
Topics: Aged; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Female; Fibrinolytic Agents; Hong Kong; | 2015 |
Assessing the optimal strategy for dual antiplatelet therapy.
Topics: Aspirin; Coronary Artery Disease; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Pyridines; Ri | 2015 |
Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease.
Topics: Aged; Alleles; Antigens, Human Platelet; Aspirin; Case-Control Studies; Clopidogrel; Cohort Studies; | 2015 |
Optical coherence tomography analysis of the stent strut and prediction of resolved strut malapposition at 3 months after 2nd-generation drug-eluting stent implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Everolim | 2016 |
Low platelet activity predicts 30 days mortality in patients undergoing heart surgery.
Topics: Adenosine Diphosphate; Aged; Aortic Valve; Arachidonic Acid; Area Under Curve; Aspirin; Blood Platel | 2016 |
Strategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative--Effectiveness M
Topics: Adult; Aged; Aspirin; C-Reactive Protein; Calcium; Cholesterol; Coronary Artery Disease; Coronary Ve | 2015 |
Recurrent myocardial infarctions and premature coronary atherosclerosis in a 23-year-old man with antiphospholipid syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Coronary Angiography; Coronary Artery Disease; H | 2016 |
Management of coronary artery disease patients in Latvia compared with practice in Central-Eastern Europe and globally: analysis of the CLARIFY registry.
Topics: Aged; Aspirin; Body Mass Index; Coronary Artery Disease; Evidence-Based Practice; Female; Humans; La | 2015 |
Platelet Larger Cell Ratio and High-on Treatment Platelet Reactivity During Dual Antiplatelet Therapy.
Topics: Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Mal | 2015 |
Coronary artery disease risk reduction in HIV-infected persons: a comparative analysis.
Topics: Adult; Aspirin; Case-Control Studies; Coronary Artery Disease; Drug Prescriptions; Female; HIV Infec | 2016 |
Duration of dual antiplatelet therapy after coronary stenting.
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Graft Occlusion, Vascular; Humans; Plat | 2016 |
Successful Prasugrel Therapy for Recurrent Left Main Stent Thrombosis in a Clopidogrel Hyporesponder.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug Resis | 2015 |
Low miR-19b-1-5p expression in isolated platelets after aspirin use is related to aspirin insensitivity.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Blood Plate | 2016 |
Relationship between high on aspirin platelet reactivity and oxidative stress in coronary artery by-pass grafted patients.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Platelets; Collagen; Coronary Artery B | 2016 |
Changes in Medical Management after Coronary CT Angiography.
Topics: Aged; Anticholesteremic Agents; Aspirin; Cholesterol; Clinical Decision-Making; Coronary Angiography | 2015 |
Platelet aggregation in response to ADP is highly variable in normal donors and patients on anti-platelet medication.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Case-Control Studies; Coronary Artery Disease | 2016 |
The monitoring of antiaggregation effect of acetylsalicylic acid therapy by measuring serum thromboxane B2 in patients with coronary artery bypass grafting.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Case-Control Studies; Coronary Artery Bypa | 2016 |
Impact of Anemia and Dual Antiplatelet Therapy on Mortality in Patients Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents.
Topics: Aged; Anemia; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Female; Follow-Up Studies; Glom | 2015 |
Association between low-dose acetylsalicylic acid reinitiation and the risk of myocardial infarction or coronary heart disease death.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Coronary Artery Disease; Dose-Response Relationshi | 2016 |
Does high serum uric acid level cause aspirin resistance?
Topics: Aged; Angina Pectoris; Aspirin; Biomarkers; Blood Cell Count; Blood Glucose; C-Reactive Protein; Cor | 2016 |
[Association between CMTM5 gene rs723840 single nucleotide polymorphism and high on asprin platelet reactivity].
Topics: Aspirin; Blood Platelets; Case-Control Studies; Chemokines; Coronary Artery Disease; Gene Frequency; | 2015 |
[Correlation between the level of the urinary 11-dehydrothromboxane B2 and the clinical efficacy of aspirin in patients with type 2 diabetes and coronary artery disease].
Topics: Aspirin; Beijing; Blood Platelets; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Plate | 2015 |
[Influence of coronary CT angiography findings on prevention strategies of coronary artery disease].
Topics: Aspirin; Cholesterol; Coronary Angiography; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-C | 2015 |
[Evaluation of treatment and management of Kawasaki coronary artery disease based on clinical severity classification].
Topics: Aspirin; Child; Child, Preschool; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Dise | 2015 |
Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy.
Topics: Aged; Area Under Curve; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Sectio | 2016 |
Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Endovascular Procedures; F | 2016 |
Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; | 2016 |
Value of Coronary Computed Tomography Angiography in Tailoring Aspirin Therapy for Primary Prevention of Atherosclerotic Events in Patients at High Risk With Diabetes Mellitus.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Coronary Angiography; Coron | 2016 |
Prevalence and risk factors of clopidogrel non-response among Saudi patients undergoing coronary angiography.
Topics: Adult; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Artery Disease; C | 2016 |
Laboratory assessment of anti-thrombotic therapy in heart failure, atrial fibrillation and coronary artery disease: insights using thrombelastography and a micro-titre plate assay of thrombogenesis and fibrinolysis.
Topics: Aspirin; Atrial Fibrillation; Clinical Laboratory Techniques; Coronary Artery Disease; Fibrinolysis; | 2016 |
The lack of aspirin resistance in patients with coronary artery disease.
Topics: Acetylation; Adult; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Coronary Artery Disease; Cyc | 2016 |
Effects of Arnica comp.-Heel® on reducing cardiovascular events in patients with stable coronary disease.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Aspirin; Clopidogrel; Coronary Artery Disease; Dr | 2016 |
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Topics: Algorithms; Aspirin; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Purinergic P2 | 2016 |
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Topics: Algorithms; Aspirin; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Purinergic P2 | 2016 |
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Topics: Algorithms; Aspirin; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Purinergic P2 | 2016 |
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Topics: Algorithms; Aspirin; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Purinergic P2 | 2016 |
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Topics: Algorithms; Aspirin; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Purinergic P2 | 2016 |
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Topics: Algorithms; Aspirin; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Purinergic P2 | 2016 |
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Topics: Algorithms; Aspirin; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Purinergic P2 | 2016 |
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Topics: Algorithms; Aspirin; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Purinergic P2 | 2016 |
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Topics: Algorithms; Aspirin; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Purinergic P2 | 2016 |
Soluble sortilin is released by activated platelets and its circulating levels are associated with cardiovascular risk factors.
Topics: Adaptor Proteins, Vesicular Transport; Adult; Aged; Aged, 80 and over; Animals; Aspirin; Blood Plate | 2016 |
Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; C | 2016 |
Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trial.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Female; Humans; Lactones; Mal | 2016 |
Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Chi-Square Distribution; Clopidogrel; | 2016 |
Frequency of Use of Statins and Aspirin in Patients With Previous Coronary Artery Bypass Grafting.
Topics: Aged; Aspirin; Cardiac Catheterization; Coronary Angiography; Coronary Artery Bypass; Coronary Arter | 2016 |
Utility of the HAS-BLED Score in Risk Stratifying Patients on Dual Antiplatelet Therapy Post 12 Months After Drug-Eluting Stent Placement.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug Administration Schedu | 2017 |
Cardiac assessment prior to non-cardiac surgery.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Australia; Comorbidity; Coronary Artery Disease; Drug Th | 2016 |
Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity.
Topics: Adult; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C1 | 2016 |
[Comment on “Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review”].
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors | 2016 |
Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2017 |
Topics: Aspirin; Atherosclerosis; Brazil; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitu | 2014 |
[The incidence, clinical characteristics and risk factors of upper gastrointestinal bleeding in patients taking dual antiplatelet therapy after percutaneous coronary intervention in south China].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Coronary Artery Disease; Femal | 2016 |
Rapid Desensitization to Aspirin in Patients With Coronary Artery Disease: A Single Center Experience.
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Desensitization, Immunologic; Drug Hypers | 2016 |
Early Clinical Experience with a Polymer-Free Biolimus A9 Drug-Coated Stent in DES-Type Patients Who Are Poor Candidates for Prolonged Dual Anti-Platelet Therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting S | 2016 |
The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2016 |
Impact of aspirin on the prognosis in patients with coronary spasm without significant atherosclerotic stenosis.
Topics: Aged; Aspirin; Cohort Studies; Coronary Artery Disease; Coronary Vasospasm; Female; Follow-Up Studie | 2016 |
A study into the genetic basis of aspirin resistance in Pakistani patients with coronary artery disease.
Topics: Aged; Aspirin; Coronary Artery Disease; Cyclooxygenase 1; Drug Resistance; Female; Humans; Integrin | 2016 |
Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience.
Topics: Acenocoumarol; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebra | 2016 |
Changes in response to clopidogrel therapy in patients after percutaneous coronary interventions as assessed by different platelet function tests.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Percutaneous | 2016 |
About Rapid Aspirin Desensitization in Coronary Artery Disease Patients.
Topics: Aspirin; Coronary Artery Disease; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Plate | 2016 |
Risk of bleeding after hospitalization for a serious coronary event: a retrospective cohort study with nested case-control analyses.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Confidence Intervals; Coronary A | 2016 |
About Rapid Aspirin Desensitization in Coronary Artery Disease Patients. Response.
Topics: Aspirin; Coronary Artery Disease; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Plate | 2016 |
Combined aspirin and anticoagulant therapy in patients with atrial fibrillation.
Topics: Academic Medical Centers; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Diseas | 2017 |
Changes in Medical Therapy and Lifestyle After Anatomical or Functional Testing for Coronary Artery Disease.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2016 |
Single versus double antiplatelet therapy in patients undergoing coronary artery bypass grafting with coronary endarterectomy: mid-term results and clinical implications.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Drug Therapy, Combinati | 2017 |
Oxidative stress reflected by increased F
Topics: Aged; Aspirin; Coronary Artery Disease; Cross-Sectional Studies; Cyclooxygenase 1; Dinoprost; F2-Iso | 2016 |
Perioperative antiplatelet therapy and cardiovascular outcomes in patients undergoing joint and spine surgery.
Topics: Aged; Aspirin; Blood Loss, Surgical; Coronary Artery Disease; Erythrocyte Transfusion; Female; Human | 2016 |
High platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; F | 2016 |
Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy.
Topics: Aged; Aspirin; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; D | 2016 |
Residual thromboxane activity and oxidative stress: influence on mortality in patients with stable coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Cause of Death; Coronary Artery Disease; Cycloo | 2017 |
Cardiac arrest at high elevation with a favorable outcome.
Topics: Adult; Air Ambulances; Altitude; Aspirin; Computed Tomography Angiography; Coronary Angiography; Cor | 2017 |
Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients.
Topics: Alleles; Aryldialkylphosphatase; Aspirin; ATP Binding Cassette Transporter, Subfamily B; Blood Plate | 2017 |
Acute Coronary Syndrome
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Coronary Artery Disease; Coronary Thrombosis; Earl | 2017 |
The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Gene Frequenc | 2017 |
Platelet reactivity in patients carrying the e-NOS G894T polymorphism after a loading dose of aspirin plus clopidogrel.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Humans; Nitric Oxide; Nitric Oxide S | 2017 |
Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis.
Topics: Aged; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Ther | 2017 |
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2017 |
Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease).
Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Desensitizati | 2017 |
Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary Artery Disease.
Topics: Aspirin; Coronary Artery Disease; Desensitization, Immunologic; Drug Hypersensitivity; Humans | 2017 |
Long-Term Comparative Outcomes of Patients With Peripheral Artery Disease With and Without Concomitant Coronary Artery Disease.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; California; Coronary Artery Disease; Diabetes Mellitus; | 2017 |
Analgesic medication with dipyrone in patients with coronary artery disease: Relation to MACCE.
Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Aspirin; Chest Pain; Coronary Artery Disease; Dip | 2017 |
Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease (TIGRIS) observational study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Femal | 2017 |
Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies.
Topics: Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Case-Control Studie | 2017 |
Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2017 |
[Ability to Overcome the Thrombocyte Resistance to Acetylsalicylic Acid in Patients With Coronary Artery Disease After Myocardial Revascularization With Coronary Stenting].
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Disease; Drug Resi | 2016 |
Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study.
Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combinati | 2017 |
A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability.
Topics: Adult; Aged; Aspirin; Black or African American; Coronary Artery Disease; Female; Genetic Predisposi | 2008 |
Five-year follow-up of drug utilization for secondary prevention in coronary artery disease.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cohort Studies | 2008 |
The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Evidence-Based Medicine; F | 2008 |
Clopidogrel but not Aspirin prevents acute smoking-induced platelet aggregation in patients with stable coronary artery disease.
Topics: Adult; Aspirin; Clopidogrel; Coronary Artery Disease; Humans; Male; Middle Aged; Platelet Aggregatio | 2009 |
Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease.
Topics: Aged; Aspirin; Baltimore; Biomarkers; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Femal | 2008 |
Secondary prevention of coronary artery disease in urban Indian primary care.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Artery Dise | 2009 |
The use of an anesthesia information system to identify and trend gender disparities in outpatient medical management of patients with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anesthesia; Aspirin; Coronary Artery Disease; Female; Huma | 2008 |
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensiv | 2008 |
Aspirin: expectations and limitations.
Topics: Asia, Western; Aspirin; Coronary Artery Disease; Cross-Sectional Studies; Cyclooxygenase Inhibitors; | 2008 |
Aspirin resistance an underestimated risk in patients with drug-eluting stents?
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug-Eluting Stents; Graft Occlusion | 2008 |
Heart rate variability in patients with stable coronary artery disease and aspirin resistance.
Topics: Adult; Aged; Aspirin; Circadian Rhythm; Coronary Artery Disease; Cyclooxygenase Inhibitors; Drug Res | 2008 |
Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients.
Topics: Aspirin; Chronic Disease; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; Middle Age | 2008 |
Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease.
Topics: Adenosine Diphosphate; Aged; Aspirin; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Dr | 2008 |
Unprotected left main coronary artery bifurcation stenosis: impact of plaque debulking prior to single sirolimus-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Vessel | 2008 |
The presence of coronary artery disease increases platelet-dependent thrombosis in patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; | 2008 |
The presence of coronary artery disease increases platelet-dependent thrombosis in patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; | 2008 |
The presence of coronary artery disease increases platelet-dependent thrombosis in patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; | 2008 |
The presence of coronary artery disease increases platelet-dependent thrombosis in patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; | 2008 |
Adrenoreceptors, platelet reactivity and clopidogrel resistance.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combi | 2008 |
Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adrenergic alpha-Antagonists; Aged; Aspirin; Blood P | 2008 |
Measurement of the platelet retention rate in a column of collagen-coated beads is useful for the assessment of efficacy of antiplatelet therapy.
Topics: Aged; Aspirin; Blood Platelets; Cell Separation; Clopidogrel; Collagen; Coronary Artery Disease; Fem | 2009 |
In-stent late total occlusion following left main coronary artery stenting.
Topics: Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; A | 2008 |
Status of drug-eluting coronary stents.
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Consensus; Coronary Arte | 2008 |
Gemcitabine-induced acute coronary syndrome: a case report.
Topics: Antimetabolites, Antineoplastic; Aspirin; Bundle-Branch Block; Clopidogrel; Coronary Artery Disease; | 2009 |
The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Antiplatyhelmintic Agents; Aspirin; Cell Adhesion Molecules; C | 2009 |
Safety and effectiveness of combining carotid artery stenting with cardiac surgery: preliminary results of a single-center experience.
Topics: Aged; Aged, 80 and over; Angioplasty; Anticoagulants; Aspirin; Carotid Artery Diseases; Coronary Art | 2009 |
Leukocyte count is associated with increased platelet reactivity and diminished response to aspirin in healthy individuals with a family history of coronary artery disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Artery Disease; Cytokines; Drug To | 2009 |
Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration.
Topics: Adult; Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Dose-Response Relationship, Drug; Fe | 2009 |
Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Dinoprost; Drug Resistance; Female; Humans; | 2010 |
Evaluation of the platelet count drop method for assessment of platelet function in comparison with "gold standard" light transmission aggregometry.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel; Coronary Arter | 2009 |
Prolonged dual antiplatelet therapy improves clinical outcomes in high-risk patients implanted with sirolimus-eluting stents.
Topics: Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; | 2009 |
Accelerated atherosclerosis in systemic lupus erythematosus: perspectives towards decreasing cardiovascular morbidity and mortality.
Topics: Aspirin; Azetidines; Clinical Trials as Topic; Coronary Artery Disease; Drug Therapy, Combination; E | 2009 |
Report: frequency of aspirin resistance in patients with coronory artery disease in Pakistan.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Cross-Sectional Studies; Drug Resi | 2009 |
Does the Holy Grail escape us again?
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Platelet Fun | 2009 |
Treatment of multilesion coronary artery disease with simultaneous drug-eluting and bare-metal stent implantation: clinical follow up and angiographic mid-term results.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; A | 2009 |
Spontaneous coronary artery dissection and severe hypothyroidism.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Aspirin; Clopi | 2009 |
Clopidogrel and proton pump inhibitors: gastric protection at expense of vascular benefit?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Aspi | 2009 |
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary | 2009 |
Native platelet aggregation and response to aspirin in persons with the metabolic syndrome and its components.
Topics: Adult; Arachidonic Acid; Aspirin; Collagen; Coronary Artery Disease; Female; Guidelines as Topic; Hu | 2009 |
A study of aspirin resistance in type 2 diabetes.
Topics: Aspirin; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies | 2008 |
Incidence of stent thrombosis in patients with drug eluting stents and short-term dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clop | 2009 |
Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Male; Mi | 2010 |
The preventive and therapeutic impact of antiplatelet agents: past and present.
Topics: Adult; Aged; Aspirin; Coronary Artery Disease; Female; Fibrinolytic Agents; History, 19th Century; H | 2009 |
Combined carotid stenting and urgent coronary artery surgery in unstable angina patients with severe carotid stenosis.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon; Anticoagulants; Aspirin; Carotid St | 2009 |
Mean platelet volume and the extent of coronary artery disease: results from a large prospective study.
Topics: Aspirin; Blood Platelets; Carotid Arteries; Cell Size; Coronary Angiography; Coronary Artery Disease | 2009 |
Antiplatelet effects of n-3 polyunsaturated fatty acids compared with aspirin: a pilot study with whole-blood aggregometry.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Cardiovascular Diseases; Co | 2009 |
Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiogra | 2008 |
The excel stent: a good DES, but can we really stop clopidogrel after 6 months?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Bioco | 2009 |
1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; | 2009 |
Heterogeneous arterial healing in patients following paclitaxel-eluting stent implantation: comparison with sirolimus-eluting stents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Aspirin; Coronary Angiography; Co | 2009 |
Coronary artery disease: Platelet activity: an obstacle for successful PCI.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combina | 2009 |
Profile of cardiovascular risk factors and mortality in patients with symptomatic peripheral arterial disease.
Topics: Aged; Aspirin; Brazil; Coronary Artery Disease; Female; Humans; Hypertension; Kaplan-Meier Estimate; | 2009 |
Development and validation of a risk scoring model to predict net adverse cardiovascular outcomes after primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: rationale and design of the RISK-PCI study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Di | 2009 |
Coronary embolism causing acute myocardial infarction in a patient with mitral valve prosthesis: successful management with angioplasty.
Topics: Adrenergic beta-Antagonists; Adult; Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; A | 2009 |
Relationship between elevated serum gamma-glutamyltransferase activity and slow coronary flow.
Topics: Adrenergic beta-Agonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Body Mass Index; | 2009 |
The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Synergism; Fe | 2009 |
Aspirin resistance after CABG.
Topics: Aged; Aspirin; Biomarkers; Blood Urea Nitrogen; C-Reactive Protein; Coronary Artery Bypass; Coronary | 2009 |
Evaluation of aspirin response by Multiplate whole blood aggregometry and light transmission aggregometry.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Coronary Artery Dise | 2009 |
Prevalence and risk factors for aspirin and clopidogrel resistance in patients with coronary artery disease or ischemic cerebrovascular disease.
Topics: Aged; Aspirin; Blood Pressure; Cerebral Arterial Diseases; Clopidogrel; Coronary Artery Disease; Dru | 2009 |
Challenge. What is your diagnosis? Answer. Primary nodal diffuse large B-cell lymphoma with secondary cutaneous involvement.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; C | 2009 |
Incomplete (atypical) Kawasaki disease in a young infant with remarkable paucity of signs.
Topics: Aneurysm; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Coronary Artery Disease; Cor | 2010 |
One-year follow-up of nonrandomized comparison between coronary artery bypass grafting surgery and drug-eluting stent for the treatment of unprotected left main coronary artery disease in elderly patients (aged >or=75 years).
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Confi | 2009 |
Impact of coronary computed tomographic angiography findings on the medical treatment and control of coronary artery disease and its risk factors.
Topics: Adult; Aged; Ambulatory Care; Antihypertensive Agents; Aspirin; Cholesterol, LDL; Cohort Studies; Co | 2009 |
Induced cardiovascular procedural costs and resource consumption patterns after coronary artery calcium screening: results from the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) study.
Topics: Aged; Aspirin; Calcinosis; Cardiovascular Diseases; Coronary Angiography; Coronary Artery Disease; C | 2009 |
Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions.
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disea | 2010 |
[Use of aspirin for primary prevention of cardiovascular events in diabetic patients--is it justified?].
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus | 2009 |
Prevalence of unresponsiveness to aspirin and/or clopidogrel in patients with stable coronary heart disease.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregati | 2009 |
[Basic examination before clinical examination. That is why it is worthwhile to return to the laboratory].
Topics: Aspirin; Biomarkers; Blood Coagulation; CD40 Ligand; Clopidogrel; Coronary Artery Disease; Drug Ther | 2009 |
Do systemic risk factors impact invasive findings from virtual histology? Insights from the international virtual histology registry.
Topics: Aged; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Diabetic Angiopathies; Dyslipidemias | 2010 |
Platelet-bound P-selectin expression in patients with coronary artery disease: impact on clinical presentation and myocardial necrosis, and effect of diabetes mellitus and anti-platelet medication.
Topics: Acute Coronary Syndrome; Angina Pectoris; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Coronar | 2010 |
The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease.
Topics: Aged; Aspirin; Biomarkers; Case-Control Studies; Coronary Artery Disease; Drug Interactions; Female; | 2010 |
Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; | 2010 |
There is no place like home after successful percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Ar | 2009 |
Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.
Topics: Adult; Aspirin; Blood Platelets; Cardiac Catheterization; Collagen; Coronary Artery Disease; Cycloox | 2009 |
Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2010 |
Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2010 |
Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2010 |
Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2010 |
Trends in the use of evidence-based treatments for coronary artery disease among women and the elderly: findings from the get with the guidelines quality-improvement program.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Bl | 2009 |
Neutrophilia predicts death and heart failure after myocardial infarction: a community-based study.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Body Mass Index; Cell Count; Cohort Studies; Coronary Ar | 2009 |
Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome.
Topics: Aspirin; Child; Child, Preschool; Cohort Studies; Comorbidity; Coronary Artery Disease; Drug Resista | 2010 |
Receipt of cardiac medications upon discharge among men and women with acute coronary syndrome and nonobstructive coronary artery disease.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Age Factors; Angiotensin-Converting Enzyme Inh | 2010 |
Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Age Factors; Aged; Alcohol Drinking; Antichol | 2010 |
Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Combi | 2010 |
Very late drug-eluting stent thrombosis in the perioperative period of endoscopic choledocholithotomy.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; | 2009 |
The GPIIIa PlA polymorphism and the platelet hyperactivity in Tunisian patients with stable coronary artery disease treated with aspirin.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Female; Genotype; Humans; Integrin beta3; M | 2010 |
Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cor | 2010 |
Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry).
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combin | 2010 |
Triple therapy: triple safety or triple danger?
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary | 2010 |
Axillary cellulitis as a manifestation of Kawasaki disease.
Topics: Aspirin; Axilla; C-Reactive Protein; Cellulitis; Child, Preschool; Conjunctivitis; Coronary Artery D | 2010 |
Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel.
Topics: Adenosine Diphosphate; Administration, Oral; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary | 2010 |
Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Laser-Assisted; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Ther | 2010 |
Evaluation of antiplatelet effects of a modified protocol by platelet aggregation in patients undergoing "one-stop" hybrid coronary revascularization.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; Clopidogrel; Combi | 2010 |
Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Dis | 2010 |
Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Sectional Studies; Diabe | 2010 |
Long-term aspirin for coronary artery disease: are we being deceived by a biased presentation of the evidence?
Topics: Aspirin; Coronary Artery Disease; Drug Industry; Humans; Myocardial Infarction; Platelet Aggregation | 2010 |
A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease.
Topics: Arachidonic Acid; Aspirin; Blood Platelets; Cells, Cultured; Collagen; Coronary Artery Disease; Cycl | 2010 |
Coronary artery calcium in relation to initiation and continuation of cardiovascular preventive medications: The Multi-Ethnic Study of Atherosclerosis (MESA).
Topics: Aged; Antihypertensive Agents; Aspirin; Atherosclerosis; Biomarkers; Calcium; Coronary Artery Diseas | 2010 |
Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Di | 2010 |
Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery | 2010 |
Aspirin can stimulate luminol-enhanced chemiluminescence of activated platelets.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Female; Humans; Luminescent Measurements; L | 2010 |
Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus.
Topics: Aged; Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged | 2010 |
Rotablation in the drug eluting era: immediate and long-term results from a single center experience.
Topics: Aged; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Aspirin; Atherectomy, Co | 2010 |
Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Glucose; C-Reactive Protein; Clopid | 2010 |
A combined genome-wide linkage and association approach to find susceptibility loci for platelet function phenotypes in European American and African American families with coronary artery disease.
Topics: Adult; Aspirin; Black or African American; Blood Platelets; Chromosomes, Human, Pair 5; Coronary Art | 2010 |
Successful use of endothelial progenitor cell capture stents in a coronary artery disease patient with aspirin hypersensitivity who failed initial aspirin desensitization.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Hy | 2011 |
Comparison of symptoms, treatment, and outcomes of coronary artery disease among rheumatoid arthritis and matched subjects undergoing percutaneous coronary intervention.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Arthritis, Rhe | 2010 |
2-arachidonyl glycerol activates platelets via conversion to arachidonic acid and not by direct activation of cannabinoid receptors.
Topics: Adolescent; Adult; Aged; Arachidonic Acids; Aspirin; Blood Platelets; Cannabinoid Receptor Antagonis | 2010 |
Letter by Violi et al regarding article, "Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization".
Topics: Aspirin; Blood Platelets; Cardiac Catheterization; Coronary Artery Disease; Cyclooxygenase 1; Cycloo | 2010 |
Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Ch | 2010 |
Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon; Aspirin; Blood Platelets; C-Reactive Protein; C | 2010 |
Aspirin and coronary artery disease.
Topics: Aspirin; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibitors | 2010 |
Platelet glycoprotein IIIa (platelet antigen 1/platelet antigen 2) polymorphism and 1-year outcome in patients with stable coronary artery disease.
Topics: Age Factors; Aged; Aspirin; Coronary Artery Disease; Endpoint Determination; Female; Genotype; Human | 2010 |
Intracoronary shear-related up-regulation of platelet P-selectin and platelet-monocyte aggregation despite the use of aspirin and clopidogrel.
Topics: Aged; Aspirin; Blood Platelets; CD11b Antigen; Clopidogrel; Coronary Artery Disease; Coronary Stenos | 2011 |
Increased plasma levels of CATS mRNA but not CATB mRNA in patients with coronary atherosclerosis.
Topics: Aged; Aspirin; Cathepsin B; Cathepsins; Coronary Artery Disease; Female; Fibrinolytic Agents; Humans | 2010 |
Determination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various platelet-function tests.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug Therapy, Comb | 2010 |
Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2010 |
Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Biomarkers; Blood Platelets; Case-Control St | 2011 |
Hybrid revascularization, comprising coronary artery bypass graft with exclusive arterial conduits followed by early drug-eluting stent implantation, in multivessel coronary artery disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Chi-Square Distribution; Clopid | 2010 |
Why an aspirin a day no longer keeps the doctor away ….
Topics: Arachidonic Acid; Aspirin; Blood Platelets; Coronary Artery Disease; Drug Administration Schedule; D | 2011 |
24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease.
Topics: Aged; Arachidonic Acid; Aspirin; Blood Platelets; Chi-Square Distribution; Coronary Artery Disease; | 2011 |
Do you need aspirin therapy? Your risks of heart attack and stroke based upon your current and past medical history must be weighed against the chances of internal bleeding.
Topics: Aspirin; Coronary Artery Disease; Health Knowledge, Attitudes, Practice; Hemorrhage; Humans; Platele | 2009 |
Measurement of platelet reactivity of patients with cardiovascular disease on-treatment with acetyl salicylic acid: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Aspirin; Chi-Square Distribution; Clopidogrel; | 2011 |
Frequency and location of yellow and disrupted coronary plaques in patients as detected by angioscopy.
Topics: Acute Coronary Syndrome; Aged; Angioscopy; Aspirin; Clopidogrel; Coronary Artery Disease; Disease Pr | 2011 |
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confidence | 2010 |
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confidence | 2010 |
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confidence | 2010 |
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confidence | 2010 |
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confidence | 2010 |
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confidence | 2010 |
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confidence | 2010 |
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confidence | 2010 |
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confidence | 2010 |
Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chronic Disease; Clopidogrel; Cohort Studies; Coronar | 2011 |
Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary A | 2011 |
The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Clopi | 2011 |
Genetic determinants of response to aspirin: appraisal of 4 candidate genes.
Topics: Aged; Aspirin; Coronary Artery Disease; Cyclooxygenase 1; Female; Follow-Up Studies; Genotype; Human | 2011 |
Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on
Topics: Aspirin; Blood Loss, Surgical; Cardiovascular Surgical Procedures; Clopidogrel; Contraindications; C | 2011 |
A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent.
Topics: Aged; Angioplasty, Balloon, Coronary; Anterior Wall Myocardial Infarction; Aryl Hydrocarbon Hydroxyl | 2012 |
Reasons for aspirin resistance.
Topics: Aspirin; Blood Platelets; Coronary Artery Disease; Female; Humans; Male; Platelet Aggregation; Plate | 2011 |
Left main stent thrombosis complicated by eptifibatide-induced acute thrombocytopenia.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Clopidogrel; Corona | 2011 |
Further ex vivo evidence supporting higher aspirin dosing in patients with coronary artery disease and diabetes.
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Re | 2011 |
Simultaneous drug-eluting and bare-metal stent implantation: long-term clinical outcome and findings of clinically indicated coronary angiography.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Confidence Intervals; Coronary Angiography; Co | 2011 |
Acetylsalicylate reduces endothelial and platelet-derived microparticles in patients with coronary artery disease.
Topics: Aspirin; Blood Platelets; Cell-Derived Microparticles; Coronary Artery Disease; Cyclooxygenase 2 Inh | 2011 |
Coagulation status in patients with coronary artery disease taking 100 mg aspirin and healthy volunteers using PFA-100® and ROTEM®.
Topics: Adult; Aged; Aging; Aspirin; Blood Coagulation; Body Mass Index; Coronary Artery Disease; Female; Hu | 2011 |
Poor aspirin response in diabetic patients presenting with acute coronary syndromes: results using a near patient test.
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Male; Platelet Activati | 2011 |
Feasibility and safety of 7-Fr radial approach for complex PCI.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Arter | 2011 |
High on treatment platelet reactivity and stent thrombosis.
Topics: Adult; Aged; Angioplasty; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middl | 2011 |
Impact of coronary computed tomographic angiography results on patient and physician behavior in a low-risk population.
Topics: Acute Disease; Adult; Aged; Aspirin; Baltimore; Cardiovascular Agents; Case-Control Studies; Confoun | 2011 |
Non-adherence to aspirin in patients undergoing coronary stenting: negative impact of comorbid conditions and implications for clinical management.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Comorbidity; Coronary Artery Disease; Female; France; | 2011 |
Ischemic stroke in patients receiving aspirin.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Argentina; Aspirin; Brain Ischemia; Chi-Square Dis | 2012 |
A complex case of angulated and bifurcated lesion facilitated by excimer laser coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Stenosis; Hu | 2011 |
Effects of additional treatment of sarpogrelate to aspirin therapy on platelet aggregation and plasma plasminogen activator inhibitor activity in patients with stable effort angina.
Topics: Adult; Aged; Angina, Stable; Aspirin; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Pl | 2011 |
Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2012 |
Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use.
Topics: Aged; Alleles; Aspirin; Blood Platelets; Coronary Angiography; Coronary Artery Disease; DNA; Dose-Re | 2011 |
Low-dose versus high-dose aspirin after percutaneous coronary intervention: analysis from the guthrie health off-label StenT (GHOST) registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cohort Studies; Coronary Artery Disease; Delivery of | 2011 |
Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression.
Topics: Alleles; Aspirin; Black People; Blood Platelets; Cell Line; Coronary Artery Disease; Gene Expression | 2011 |
Letter by Gasparovic et al regarding article, "Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) trial".
Topics: Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Artery Disease; Dr | 2011 |
Letter by Bisdas et al regarding article, "Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) trial".
Topics: Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary | 2011 |
Hospital variability in the rate of finding obstructive coronary artery disease at elective, diagnostic coronary angiography.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aspirin; Coronary Angiography; Coronary Artery Diseas | 2011 |
Letter by Santos et al regarding article, "Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease".
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; | 2011 |
Differences in the mode of presentation for acute coronary syndrome by pre-hospitalization medication, in relation to coronary risk factors, East-Osaka acute coronary syndrome (EACS) registry.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Coronary Arte | 2011 |
Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspir | 2011 |
Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Annexin A5; Aspirin; Baltimore; Clopido | 2012 |
Comparison of venous and arterial blood sampling for the assessment of platelet aggregation with whole blood impedance aggregometry.
Topics: Adenosine Diphosphate; Arachidonic Acid; Area Under Curve; Arteries; Aspirin; Blood Platelets; Clopi | 2011 |
Optical coherence tomography findings during "evolving" stent thrombosis.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cardiopulmonary Resuscitation; Clopidogr | 2011 |
Platelet aggregation is dependent on platelet count in patients with coronary artery disease.
Topics: Adult; Aged; Arachidonic Acid; Aspirin; Case-Control Studies; Chi-Square Distribution; Collagen; Cor | 2012 |
Effects of P2Y(1) receptor antagonism on the reactivity of platelets from patients with stable coronary artery disease using aspirin and clopidogrel.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Collagen; Coronary Artery Diseas | 2012 |
Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: a retrospective study.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child, Preschool; Combined Modality | 2011 |
Coronary artery stents and antiplatelet therapy in patients with cirrhosis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Fatty Liver; Female; Follow-Up Studies; Gastroi | 2012 |
Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2012 |
[Kawasaki disease in children and adolescents].
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Coronary Artery Disease; Humans | 2011 |
Effect of timing of chronic preoperative aspirin discontinuation on morbidity and mortality in patients having combined coronary artery bypass grafting and valve surgery.
Topics: Aged; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Female; Fibrinolytic Agents; Follow- | 2012 |
Assessment of platelet function by whole blood impedance aggregometry in coronary artery bypass grafting patients on acetylsalicylic acid treatment may prompt a switch to dual antiplatelet therapy.
Topics: Adult; Aspirin; Blood Platelets; Coronary Artery Bypass; Coronary Artery Disease; Drug Therapy, Comb | 2013 |
Potential implications of coronary artery calcium testing for guiding aspirin use among asymptomatic individuals with diabetes.
Topics: Adult; Aged; Aspirin; Calcinosis; Coronary Artery Disease; Diabetes Mellitus; Female; Humans; Male; | 2012 |
Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cause of Death; Coronary Artery Disease; Co | 2012 |
[Aspirin response and related factors in aged patients].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Coronary Artery Disease | 2011 |
Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; In Vitro Techn | 2012 |
Simultaneous left anterior descending and right coronary stent thrombosis after aspirin withdrawal.
Topics: Aged; Aspirin; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stent | 2012 |
[The frequency of aspirin resistance by a modified thrombelastography method and its relationship with clinical and laboratory parameters in patients with stable coronary artery disease].
Topics: Aspirin; Coronary Artery Disease; Drug Administration Schedule; Drug Resistance; Female; Humans; Mal | 2012 |
Cardiology patient page: Aspirin.
Topics: Aspirin; Blood Coagulation; Cardiovascular Diseases; Coronary Artery Disease; Drug Therapy, Combinat | 2012 |
Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Di | 2012 |
Comparison of additional versus no additional heparin during therapeutic oral anticoagulation in patients undergoing percutaneous coronary intervention.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrilla | 2012 |
Effects of PPIs and an H2 blocker on the antiplatelet function of clopidogrel in Japanese patients under dual antiplatelet therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Asian People; Aspirin; Case-Control Studies; Clopidog | 2012 |
Effect of timing of chronic preoperative aspirin discontinuation on morbidity and mortality in patients having combined coronary artery bypass grafting and valve surgery.
Topics: Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Female; Heart Valve Diseases; Heart Valve | 2012 |
Increased platelet aggregation and serum thromboxane levels in aspirin-treated patients with prior myocardial infarction.
Topics: Aged; Aspirin; Coronary Artery Disease; Disease Progression; Drug Resistance; Female; Humans; Male; | 2012 |
P2RY1 and P2RY12 polymorphisms and on-aspirin platelet reactivity in patients with coronary artery disease.
Topics: Aged; Aspirin; Coronary Artery Disease; Female; Gene Frequency; Genotype; Humans; Logistic Models; M | 2012 |
Influence of patients' coronary artery calcium on subsequent medication use patterns.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Calcinosis; Coronary Artery Diseas | 2012 |
Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Cohort Studies; | 2012 |
CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 | 2012 |
Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary "real-world" practice.
Topics: Aged; Analysis of Variance; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Fema | 2012 |
Effect of hypoglycemic drugs on aspirin resistance in patients with diabetes mellitus.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Chi-S | 2012 |
Medium to long-term clinical outcomes with everolimus-eluting stents in real-life percutaneous coronary intervention.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Arter | 2012 |
Complex coronary lesions and rotational atherectomy: one hospital's experience.
Topics: Aged; Angiography; Aspirin; Atherectomy, Coronary; Cardiology; Clopidogrel; Comorbidity; Coronary Ar | 2012 |
Aspirin sensitivity and coronary artery disease: implications for the practicing cardiologist.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Asthma; Chronic Disease; Coronary Artery Disease; Cyclooxyg | 2012 |
Impact of proton pump inhibitors or famotidine on the antiplatelet actions during dual-antiplatelet therapy in Japanese patients.
Topics: Aged; Asian People; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Interaction | 2013 |
Early and late outcome associated with bleeding events in the setting of dual antiplatelet therapy following stent placement.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Hem | 2012 |
Less may be more: insights on dual antiplatelet therapy duration after drug-eluting stent implantation from the MATRIX registry.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Hum | 2012 |
Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study.
Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Cor | 2013 |
EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arachidonic Acid; Aspirin; Coronary Artery Disease; Diabete | 2012 |
Femoral pseudoaneurysm with a communicating arteriovenous fistula: a complication after percutaneous coronary intervention.
Topics: Aneurysm, False; Angioplasty, Balloon, Coronary; Arteriovenous Fistula; Aspirin; Clopidogrel; Comorb | 2012 |
Dual antiplatelet therapy after drug-eluting stent implantation: is it time to slacken the reins?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Stenosis; Dr | 2012 |
Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response R | 2012 |
Secondary prevention therapies for coronary heart disease in patients with type 2 diabetes: an audit.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2012 |
Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cor | 2012 |
Dual antiplatelet agent-induced spontaneous liver hematoma.
Topics: Aged; Aspirin; Chemical and Drug Induced Liver Injury; Clopidogrel; Coronary Artery Disease; Drug Th | 2012 |
Variable on treatment platelet reactivity in coronary artery bypass grafting patients suggests the need for perioperative platelet function testing.
Topics: Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Female; Humans; Male; Platelet Aggregation | 2012 |
[Expert answer. Coronary artery patients with atrial fibrillation on anticoagulation treatment may need antithrombotic treatment. What kind is there?].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2012 |
A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.
Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; China; Clopidogrel; Coronary Artery Disea | 2012 |
Pharmacologic treatment in dialysis patients hospitalized for cardiovascular reasons: do we follow the guidelines?
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2013 |
Vascular and platelet responses to aspirin in patients with coronary artery disease.
Topics: Aged; Analysis of Variance; Aspirin; Blood Platelets; Case-Control Studies; Coronary Artery Disease; | 2013 |
The membrane expression of P-selectin, but not monocyte-platelet aggregates, is influenced by variability in response to aspirin in patients with coronary artery disease.
Topics: Aspirin; Blood Platelets; Coronary Artery Disease; Humans; Monocytes; P-Selectin; Platelet Adhesiven | 2014 |
Triple antiplatelet therapy with cilostazol: hitting the "sweet-spot".
Topics: Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Te | 2013 |
Decreased plasma IL-35 levels are related to the left ventricular ejection fraction in coronary artery diseases.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Cytokines; Female; Humans; Interleukins; Male; Middle | 2012 |
Prevalence of high platelet reactivity in aspirin-treated patients referred for coronary angiography.
Topics: Aged; Aspirin; Collagen; Coronary Angiography; Coronary Artery Disease; Drug Resistance; Female; Hum | 2013 |
Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; | 2013 |
Risk factors for upper gastrointestinal bleeding in coronary artery disease patients receiving both aspirin and clopidogrel.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Gastrointestinal Hem | 2013 |
Characterization of aspirin allergies in patients with coronary artery disease.
Topics: Aged; Aged, 80 and over; Aspirin; California; Cardiovascular Diseases; Clopidogrel; Coronary Artery | 2013 |
A case of in-stent thrombosis in a patient with drug eluting stents during perioperative management with glycoprotein IIb/IIIa inhibitors.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug | 2013 |
Low molecular weight heparin: a bridge over troubled water.
Topics: Anticoagulants; Aspirin; Coronary Artery Disease; Dalteparin; Heparin, Low-Molecular-Weight; Humans; | 2002 |
Association of aortic stenosis with platelet hyperaggregability and impaired responsiveness to nitric oxide.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Cardiovascula | 2002 |
[ASA therapy or not?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Artery Disease; Dose-Response Relationshi | 2002 |
On changing a long-term clinical trial midstream.
Topics: Aspirin; beta Carotene; Clinical Trials Data Monitoring Committees; Coronary Artery Disease; Data In | 2002 |
Aspirin--first the good news...
Topics: Anticoagulants; Aspirin; Coronary Artery Disease; Humans; Thromboxanes | 2002 |
Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome.
Topics: Aspirin; Child; Child, Preschool; Coronary Artery Disease; Coronary Vessel Anomalies; Fever; Humans; | 2002 |
Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate.
Topics: Adenosine Diphosphate; Aged; Angina Pectoris; Aspirin; Blood Platelets; Case-Control Studies; Corona | 2002 |
Aspirin for the primary prevention of cardiovascular events.
Topics: Aspirin; Coronary Artery Disease; Evidence-Based Medicine; Humans; Male; Middle Aged; Myocardial Inf | 2002 |
Coronary artery spasm associated with a moderately severe atherosclerotic stenosis in the proximal LAD.
Topics: Adult; Aspirin; Atorvastatin; Cardiac Catheterization; Coronary Angiography; Coronary Artery Disease | 2002 |
Secondary prevention following myocardial infarction: evidence from an audit in South Wales that the National Service Framework for coronary heart disease does not address all the issues.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2002 |
Aspirin use after bypass surgery may save lives.
Topics: Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Humans | 2002 |
Anti-thrombin action of low-dose acetylsalicylic acid.
Topics: Aged; Antithrombin III; Aspirin; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Adm | 2003 |
The underutilization of cardiac medications of proven benefit, 1990 to 2002.
Topics: Adrenergic beta-Antagonists; Ambulatory Care; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atr | 2003 |
Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease.
Topics: Aged; Aspirin; Coronary Artery Disease; Drug Resistance; Exercise Test; Female; Humans; In Vitro Tec | 2002 |
Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Case-Control Studies; Clopidogrel; Coronar | 2003 |
ATP diphosphohydrolase in human platelets from patients with coronary arteries heart disease.
Topics: Acute Disease; Adult; Aged; Apyrase; Aspirin; Blood Glucose; Blood Platelets; Case-Control Studies; | 2003 |
Suppression of oxidative stress as a mechanism of reduction of hypercholesterolemic atherosclerosis by aspirin.
Topics: Animals; Aorta; Aspirin; Cholesterol; Cholesterol, Dietary; Coronary Artery Disease; Cyclooxygenase | 2003 |
Cocaine-associated chest pain in the emergency department.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzodiazepines; Chest Pain; Co | 2003 |
Percutaneous interventions in radial artery grafts: clinical and angiographic outcomes.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enz | 2003 |
[Effects of antiaggregants on concentration of plasma cytokines in patients with acute coronary syndrome].
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cytokines; Female | 2003 |
The discharge.
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Artery Disease; Fibrinolytic Agents; Humans; Myocardi | 2003 |
Percutaneous intervention a winner--even in patients with stable, single-vessel disease.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Congresses as Topic; Contraindications; Coronary Artery Dis | 2003 |
The effect of salicylate on the serum lipids and lipoproteins in coronary artery disease.
Topics: Aspirin; Coronary Artery Disease; Coronary Disease; Humans; Lipids; Lipoproteins; Salicylates | 1959 |
[Sudden edema and pain in the knee].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactio | 2003 |
[Myocardial infarction after influenza vaccination].
Topics: Adrenergic beta-Antagonists; Adult; Aspirin; Coronary Artery Disease; Cortisone; Diagnosis, Differen | 2003 |
Beta brachytherapy of an old degenerated saphenous vein graft with occlusive in-stent restenosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Beta Particles; Blood Vessel Prosthesis; Brachytherap | 2003 |
Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA.
Topics: Aspirin; Coronary Artery Disease; Drug Resistance; Female; Hematocrit; Humans; Incidence; Logistic M | 2003 |
Cyclooxygenase inhibition in patients with coronary artery disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Artery Disease; Cyclooxygenase 1; Cycloox | 2004 |
Secondary prevention for coronary artery disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cholesterol; Coronary Artery Disease; Drug | 2004 |
[Cardiovascular risk stratification in general practice].
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Pressure; Cholesterol; Coronar | 2004 |
[Pharmacological aspects of secondary prevention post-MI].
Topics: Aftercare; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Clinical Trials | 2004 |
Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris.
Topics: Aged; Angina Pectoris; Anticoagulants; Aspirin; Biomarkers; Blood Proteins; C-Reactive Protein; Coro | 2004 |
Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Creatine Kinase | 2004 |
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Topics: Acute-Phase Reaction; Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Coronary spasm in a 59-yr-old woman with hyperventilation.
Topics: Alkalosis, Respiratory; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antihypertensive Ag | 2004 |
[Antiplatelet therapy in patients with peripheral arterial disease (PAD)].
Topics: Arterial Occlusive Diseases; Aspirin; Cause of Death; Cerebral Infarction; Clopidogrel; Coronary Art | 2004 |
The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2004 |
Evolution of spontaneous atherosclerotic plaque rupture with medical therapy: long-term follow-up with intravascular ultrasound.
Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Disease Progression; Female; Follow | 2004 |
[Patients with arterial occlusive disease die of myocardial infarct or stroke. The dangerous sisters: arterial occlusive disease and coronary heart disease].
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Cause of Death; Clinical Trials as Topic; Clopidogrel; C | 2004 |
Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery B | 2004 |
Concordance between clopidogrel use and prescribing guidelines.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Australia; Clopidogrel; Cohort Studies; Coronary Artery Dis | 2004 |
Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis.
Topics: Aged; Angina Pectoris; Aspirin; Coronary Artery Disease; Female; Fibrinolytic Agents; Graft Occlusio | 2005 |
Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Desensitization, Immu | 2005 |
Oral antiplatelet therapy.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; | 2005 |
Plaque instability frequently occurs days or weeks before occlusive coronary thrombosis: a pathological thrombectomy study in primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Combined Modality Therapy; Coronary A | 2005 |
Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
Topics: Acetylcysteine; Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; A | 2005 |
The use of anti-inflammatory analgesics in the patient with cardiovascular disease: what a pain.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Coronary Artery Disease; Cyclooxygenase | 2005 |
High frequency of aspirin resistance in patients with acute coronary syndrome.
Topics: Adult; Aged; Angiography; Aspirin; Blood Platelets; Cardiovascular Diseases; Cardiovascular System; | 2005 |
Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Coronary Artery Disea | 2005 |
Ask the doctors. My mother in her early 90s has been diagnosed with atherosclerosis, had a successful angioplasty a year ago for severe chest pain, takes clopidogrel and aspirin, and in general eats a low-fat diet, although she really likes melted ice cre
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Diet, Fat-Restricted; Exerci | 2005 |
Aspirin use in older patients with heart failure and coronary artery disease: national prescription patterns and relationship with outcomes.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Drug Prescriptions; Female; | 2005 |
Use of combination evidence-based medical therapy prior to acute myocardial infarction (from the National Registry of Myocardial Infarction-4).
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Arter | 2005 |
Antiplatelet therapy and the vascular tree.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Dis | 2006 |
[Primary prevention of coronary heart disease? What is cost effective in the clinical practice?].
Topics: Aspirin; Coronary Artery Disease; Cost-Benefit Analysis; Humans; Hydroxymethylglutaryl-CoA Reductase | 2005 |
A new definition of aspirin non-responsiveness by platelet function analyzer-100 and its predictors.
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus; Diet; Drug Resistance; Female; Humans; Male; Mi | 2006 |
Long-term adherence with cardiovascular drug regimens.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Arter | 2006 |
Imaging of a regressive coronary soft plaque under lipid lowering therapy by multi-slice computed tomography.
Topics: Aspirin; Atorvastatin; Carotid Stenosis; Coronary Artery Disease; Drug Therapy, Combination; Heptano | 2006 |
Infarct-related coronary artery patency and medication use prior to ST-segment elevation myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Angiography | 2006 |
Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Angiostatins; Apolipoproteins A; Aspirin; Atherosclerosi | 2006 |
Female sex: a protective role in suspected myocardial ischemia.
Topics: Aspirin; Coronary Artery Disease; Diagnostic Techniques, Cardiovascular; Female; Fibrinolytic Agents | 2006 |
[Level of C-reactive protein and efficacy of therapy with aspirin in patients with ischemic heart disease.].
Topics: Aspirin; C-Reactive Protein; Coronary Artery Disease; Humans; Myocardial Ischemia | 2006 |
Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients.
Topics: Adult; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Coronary Artery Disease; Cyclooxygenase 1 | 2006 |
Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Fema | 2006 |
[Postoperative antithrombotic treatment in diabetic patients].
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Mell | 2006 |
Differential antiplatelet effects of angiotensin converting enzyme inhibitors: comparison of ex vivo platelet aggregation in cardiovascular patients with ramipril, captopril and enalapril.
Topics: Adenosine Diphosphate; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Aspirin | 2006 |
Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; C-Reactive Protein; Cholesterol; | 2006 |
Non-calcified plaques of coronary arteries with obvious outward remodeling demonstrated by multislice computed tomography.
Topics: Aged; Aspirin; Calcinosis; Coronary Artery Disease; Fibrinolytic Agents; Humans; Hydroxymethylglutar | 2006 |
Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel.
Topics: Adenine; Alleles; Anticoagulants; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Ar | 2006 |
Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphism.
Topics: Antigens, Neoplasm; Aspirin; Blood Platelets; Coronary Artery Disease; Cyclooxygenase 1; Dinoprost; | 2006 |
Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease.
Topics: Aged; Aspirin; Body Mass Index; Comorbidity; Coronary Artery Disease; Dose-Response Relationship, Dr | 2006 |
Percutaneous stenting of the left main with drug eluting stents for in-stent restenosis: immediate- and long-term results.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary Res | 2006 |
Late in-stent thrombosis in a patient with systemic lupus erythematosus and hyperhomocysteinemia while on clopidogrel and aspirin.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Coagulation Disorders; Clopidogrel; Coronary Artery D | 2006 |
Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Clopidogrel; Coronary Artery Disease; Cyclooxygena | 2006 |
The aspirin resistance controversy: clinical entity or platelet heterogeneity?
Topics: Aspirin; Coronary Artery Disease; Cyclooxygenase 1; Cyclooxygenase 2; Dose-Response Relationship, Dr | 2006 |
[Combination of clopidogrel and aspirin was no better than aspirin alone for prevention of atherothrombotic events in stable patients. Results of CHARISMA].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug T | 2006 |
Viscosity, hemostasis and inflammation in atherosclerotic heart diseases.
Topics: Aged; Aspirin; Blood Viscosity; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Diabetes Compl | 2006 |
Aspirin resistance, an emerging, often overlooked, factor in the management of patients with coronary artery disease.
Topics: Aspirin; Coronary Artery Disease; Drug Resistance; Humans; Platelet Aggregation Inhibitors | 2006 |
Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population.
Topics: Adenosine Diphosphate; Adult; Arachidonic Acid; Aspirin; Coronary Artery Disease; Drug Resistance; F | 2006 |
Low-molecular-weight heparin in pregnant women with prosthetic heart valves.
Topics: Adult; Anticoagulants; Antifibrinolytic Agents; Aortic Valve; Aspirin; Biomarkers; Coronary Artery D | 2006 |
Aspirin reduces anticardiolipin antibodies in patients with coronary artery disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Anticardiolipin; Aspirin; Case-Control Studies; | 2006 |
Hymenoptera sting-induced Kounis syndrome: effects of aspirin and beta-blocker administration.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Animals; Anti-Inflammatory Agents, Non-Steroidal | 2007 |
Clinical trials update from the annual scientific session of the American College of Cardiology 2006.
Topics: Aspirin; Cardiac Catheterization; Cardiology; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2006 |
Combination antiplatelet therapy with aspirin and clopidogrel: the role of antecedent and concomitant doses of aspirin. An analysis of 711 patients.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug T | 2007 |
Prevalence and biologic profile of aspirin resistance in patients with angiographically proven coronary artery disease.
Topics: Aged; Apolipoproteins B; Aspirin; Blood Platelets; Coronary Artery Disease; Drug Resistance; Epineph | 2007 |
Determination of aspirin responsiveness by use of whole blood platelet aggregometry.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Blood Donors; Clopidogrel; Collagen; Coronary A | 2007 |
Acetylsalicylic acid resistance and clinical outcome--the Hobikoglu study is worth noting.
Topics: Acute Disease; Aspirin; Coronary Artery Disease; Drug Resistance; Humans; Platelet Aggregation Inhib | 2007 |
The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy.
Topics: Aged; Analysis of Variance; Aspirin; Biomarkers; Controlled Clinical Trials as Topic; Coronary Angio | 2007 |
Indices of platelet activation and the stability of coronary artery disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; CD40 Ligand; Coronary Artery Disease; Epinep | 2007 |
Self-reported use of complementary and alternative medicine in patients with previous acute coronary syndrome.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angina, Unstable; Aspirin; Complementary Th | 2007 |
Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction.
Topics: Aged; Aspirin; Case-Control Studies; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; | 2007 |
Increased incidence of stent thrombosis in patients with cocaine use.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cocaine-Related Disorders; Co | 2007 |
[Pathogenesis and prevention tactics of aspirin resistance].
Topics: Aspirin; Coronary Artery Disease; Diagnosis, Differential; Drug Resistance; Drug Therapy, Combinatio | 2007 |
A risk score to predict silent myocardial ischemia in patients with coronary artery disease under aspirin therapy presenting with upper gastrointestinal hemorrhage.
Topics: Aged; Aspirin; Coronary Artery Disease; Female; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Hu | 2007 |
Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative.
Topics: Acute Disease; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Dise | 2007 |
Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; | 2007 |
Screening for aspirin resistance in stable coronary artery patients by three different tests.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Bleeding Time; Blood Platelets; Coronary Artery Disease; Dr | 2007 |
Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; Corona | 2008 |
A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Coronary Artery Disease; Cyclooxygenase 1; | 2007 |
Management outcomes of patients with type 2 diabetes: targeting the 10-year absolute risk of coronary heart disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Pressure; Cholesterol; Cohort Studies; Coro | 2007 |
Aspirin-resistant platelet aggregation in a cohort of patients with coronary heart disease.
Topics: Aged; Aspirin; Cohort Studies; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; Middl | 2007 |
Prognostic value of ankle-brachial index and dobutamine stress echocardiography for cardiovascular morbidity and all-cause mortality in patients with peripheral arterial disease.
Topics: Aged; Ankle; Aspirin; Blood Pressure; Brachial Artery; Cardiovascular Diseases; Coronary Artery Dise | 2007 |
Aspirin resistance and adverse clinical events in patients with coronary artery disease.
Topics: Aged; Aspirin; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Resistance; Female; H | 2007 |
Evidence-based use of medications in patients with coronary artery disease in a rural Australian community.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 2007 |
Homocysteine (Hcy) follow-up study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Coronary Artery Disease; En | 2007 |
[Antiplatelet therapy can unmask an inherited bleeding disorder. Aspirin-like defect of platelets does not protect against atherosclerosis].
Topics: Aged; Aspirin; Blood Platelet Disorders; Coronary Artery Disease; Cyclooxygenase 1; Humans; Male; Pl | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk.
Topics: Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudden, Car | 2007 |
The CAPRIE-like subgroups of CHARISMA: a CAPRIEciously biased analysis of an unCHARISMAtic truth.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Ischemi | 2007 |
P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Genot | 2008 |
Are we ignoring the elephant in the room?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Artery Disease; Cyclooxygenase 2 Inhibito | 2007 |
Relationship between the serum sCD40L level and aspirin-resistant platelet aggregation in patients with stable coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; CD40 Ligand; Cohort Studies; Coronary Artery Disease; Drug | 2008 |
Coronary artery stenting in patients treated by clopidogrel without aspirin.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Agg | 2009 |
Outcomes associated with combined antiplatelet and anticoagulant therapy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disea | 2008 |
Secondary prevention following coronary artery bypass grafting has improved but remains sub-optimal: the need for targeted follow-up.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2008 |
I've heard that taking two baby aspirins provides as much or better protection against arterial disease as taking one adult aspirin, and that two baby aspirins are more than twice as effective as one baby aspirin. This seems contradictory to other studie
Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Th | 2007 |
[Acetylsalicylic acid hypersensitivity in a patient with coronary artery disease and insulin-dependent diabetes mellitus].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Artery Disease; Desensitizat | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
Rapid oral aspirin desensitization for patients with aspirin allergy requiring dual antiplatelet therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Hyperse | 2008 |
Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; | 2008 |
Calcified occlusion of the coronary arteries in a young woman diagnosed with Kawasaki disease.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Calcinosis; Cardiomyopathies; Coronary | 2008 |
[Medical therapy in revascularized coronary artery disease patients].
Topics: Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascu | 2008 |
Unilateral idiopathic adrenal hematomas with a preoperative diagnosis of indeterminate adrenal tumors.
Topics: Adrenal Gland Diseases; Adrenal Gland Neoplasms; Adrenalectomy; Aged; Anemia; Aspirin; Clopidogrel; | 2008 |
Acute stent thrombosis in a patient with giant cell arteritis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Di | 2008 |
Women tolerate drug therapy for coronary artery disease as well as men do, but are treated less frequently with aspirin, beta-blockers, or statins.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Arter | 2008 |
Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 2008 |
Aspirin resistance in patients with coronary artery disease - which test to use in routine management?
Topics: Aspirin; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance | 2008 |
[The relationship between aspirin resistance and endothelial dysfunction in patients with stable coronary artery disease].
Topics: Arm; Aspirin; Brachial Artery; Case-Control Studies; Coronary Artery Disease; Drug Resistance; Endot | 2008 |
Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry.
Topics: Adult; Aspirin; Blood Platelets; Case-Control Studies; Coronary Artery Disease; Drug Resistance; Fem | 2008 |
The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis.
Topics: Aged; Aspirin; Cholesterol, LDL; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Risk Fa | 1995 |
Long-term follow-up of coronary narrowing with spasm.
Topics: Angina Pectoris, Variant; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary Vasospasm | 1994 |
[Emergency intracoronary stent implantation: complications and experiences with 124 patients].
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Blood Coagulation Tests; Co | 1994 |
Intimal injury in a transiently occluded coronary artery increases myocardial necrosis. Effect of aspirin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bleeding Time; Blood Cell Count; Coronary | 1996 |
Effect of angiopeptin and aspirin on accelerated graft atherosclerosis in transplanted mouse heart.
Topics: Animals; Aspirin; Cardiovascular Agents; Coronary Artery Disease; Coronary Vessels; Heart; Heart Tra | 1999 |
Introduction: Expanding the horizons in unstable coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Coronary Thrombosis; Disease Man | 2000 |
Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coron | 2000 |
[Problems in the treatment of patients with ischemic heart disease].
Topics: Adrenergic beta-Antagonists; Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Ca | 2000 |
Successful management of intractable coronary spasm with a coronary stent.
Topics: Adult; Amlodipine; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Coronary Angiography; C | 2000 |
High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Biomarkers; C-Reactive P | 2000 |
Aspirin (5 mmol/L) inhibits leukocyte attack and triggered reactive cell proliferation in a 3D human coronary in vitro model.
Topics: Aspirin; Blotting, Northern; Bromodeoxyuridine; CD4-Positive T-Lymphocytes; Cell Adhesion; Cell Divi | 2001 |
Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP).
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cholesterol, L | 2001 |
UCLA's coronary artery disease initiative begins at the hospital with medication, lifestyle interventions.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cholesterol, LDL; Co | 2001 |
CAD initiative begins at the hospital with medication, lifestyle interventions.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Asp | 2001 |
Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis--the influence of aspirin and cigarette smoking.
Topics: Adenosine Diphosphate; Adult; Aged; Arteriosclerosis; Aspirin; beta-Thromboglobulin; Biomarkers; Cho | 2001 |
Coronary stent deployment in situs inversus.
Topics: Aged; Aspirin; Chest Pain; Clopidogrel; Coronary Artery Disease; Dextrocardia; Electrocardiography; | 2001 |
Platelet inhibition reduces cyclic flow variations and neointimal proliferation in normal and hypercholesterolemic-atherosclerotic canine coronary arteries.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Coagulation; Blood Flo | 2001 |
Use of oral antithrombotic agents among health maintenance organization members with atherosclerotic cardiovascular disease.
Topics: Administration, Oral; Aged; Arteriosclerosis; Aspirin; Comorbidity; Coronary Artery Disease; Drug Ut | 2002 |
Underuse of aspirin in a referral population with documented coronary artery disease.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Female; Follow-Up Stu | 2002 |
Cardiovascular disease. Does inflammation cut to the heart of the matter?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Biological Evol | 2002 |
Same-day transradial outpatient stenting with a 6-hr course of glycoprotein IIb/IIIa receptor blockade: a feasibility study.
Topics: Adult; Aged; Ambulatory Surgical Procedures; Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel P | 2002 |
Patient-reported frequency of taking aspirin in a population with coronary artery disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Coronary Artery Disease; Drug Hype | 2002 |
[Two platelet inhibitors after acute coronary syndrome. Many colleagues are not aware of this].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug T | 2002 |
[Dynamic study of platelets surface glycoprotein in Kawasaki disease].
Topics: Aspirin; Blood Platelets; Child; Child, Preschool; Coronary Artery Disease; Female; gamma-Globulins; | 2002 |
Underutilization of aspirin, beta blockers, angiotensin-converting enzyme inhibitors, and lipid-lowering drugs and overutilization of calcium channel blockers in older persons with coronary artery disease in an academic nursing home.
Topics: Academic Medical Centers; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converti | 2002 |
Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes.
Topics: Age Factors; Aged; Angina, Unstable; Area Under Curve; Aspirin; Biomarkers; Body Weight; Coronary Ar | 2002 |
[Pathogenetic and therapeutic significance of the angioprotective systems in patients with coronary arteriosclerosis].
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aspirin; Coronary Artery Disease; Depression, Chemical; Drug Th | 1990 |
[Ischemic heart disease and prostanoids: pathogenesis and its implications for treatment].
Topics: Arachidonic Acids; Aspirin; Coronary Artery Disease; Coronary Disease; Coronary Vasospasm; Cyclooxyg | 1990 |
Pathogenetic components of acute ischemic syndromes. Focus on acute ischemic stimuli.
Topics: Aspirin; Coronary Artery Disease; Coronary Disease; Coronary Thrombosis; Humans; Thromboxane A2 | 1990 |
[Unstable stenocardia: various problems of pathogenesis and treatment].
Topics: Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Constriction, Pathologic | 1989 |